Sentence,class,file
Eisai Inc. http://www.banzel.com/pdfs/BanzelPI.pdf (2013).,Non-OADS,/arxiv_data1/oa_pdf/01/96/40120_2016_Article_41.PMC4919131.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, providea link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/04/9b/40120_2016_Article_42.PMC4919132.pdf
2015. http://ms-coalition.org/cms/images/stories/ DMTfullpaper_2015update_ﬁnal.pdff .,Non-OADS,/arxiv_data1/oa_pdf/04/9b/40120_2016_Article_42.PMC4919132.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide alink to the Creative Commons license, and indicate if changes were made.REFERENCES 1.",Non-OADS,/arxiv_data1/oa_pdf/1c/41/40120_2016_Article_43.PMC4919133.pdf
Keywords: Medication guide; Meﬂoquine; Neurologic; Psychiatric; Side effectsEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/25D4 F0600B7DFC9C .,Non-OADS,/arxiv_data1/oa_pdf/d2/42/40120_2016_Article_45.PMC4919134.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/d2/42/40120_2016_Article_45.PMC4919134.pdf
"The interventions were targeted to patients/caregivers and/or doctors, with pharmacological and non-pharmacological measures.Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 66D4F060318369C4 .",Non-OADS,/arxiv_data1/oa_pdf/f1/0d/40120_2016_Article_46.PMC4919135.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, andindicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/f1/0d/40120_2016_Article_46.PMC4919135.pdf
"Blackwell, S.A. 2013.http://innovation.cms.gov/ﬁles/reports/mtm_ﬁnal_ report.pdf .",OADS,/arxiv_data1/oa_pdf/f1/0d/40120_2016_Article_46.PMC4919135.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/51/85/main.PMC4919251.pdf
Contents lists available at ScienceDirect International Journal for Parasitology: Drugs and Drug Resistance journal homepage: www.elsevier.com/locate/ijppaw http://dx.doi.org/10.1016/j.ijpddr.2016.01.001 2211-3207/ ©2016 Published by Elsevier Ltd on behalf of Australian Society for Parasitology.,Non-OADS,/arxiv_data1/oa_pdf/51/85/main.PMC4919251.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/52/90/main.PMC4919253.pdf
Contents lists available at ScienceDirect International Journal for Parasitology: Drugs and Drug Resistance journal homepage: www.elsevier.com/locate/ijppaw http://dx.doi.org/10.1016/j.ijpddr.2016.03.001 2211-3207/ ©2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/52/90/main.PMC4919253.pdf
The IH 1–24 hour slope differed from the IH 25–44 hour slope (p=0.001) and the  This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY- NC-ND) ( http://www.karger.com/Services/OpenAccessLicense ).,Non-OADS,/arxiv_data1/oa_pdf/94/5b/nihms780257.PMC4919278.pdf
Available from http://clinicaltrials.gov/ct2/show/NCT0082775 .,Non-OADS,/arxiv_data1/oa_pdf/94/5b/nihms780257.PMC4919278.pdf
Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious DiseasesThis is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) http://dx.doi.org/10.1016/j.nmni.2016.05.007,Non-OADS,/arxiv_data1/oa_pdf/09/fa/main.PMC4919280.pdf
nov. MALDI-TOF MS spectrum The MALDI-TOF MS spectrum of Haloferax massiliensis strain Arc-HrTis available at http://www.mediterranee-infection.com/ article.php?laref=256&titre=urms-database .,OADS,/arxiv_data1/oa_pdf/09/fa/main.PMC4919280.pdf
"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI ,12,9 6 –98 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/09/fa/main.PMC4919280.pdf
"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI ,12,9 6 –98 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/09/fa/main.PMC4919280.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/ 4.0/).,Non-OADS,/arxiv_data1/oa_pdf/fc/73/main.PMC4919281.pdf
http://dx.doi.org/10.1016/j.jdcr.2016.04.001 233,OADS,/arxiv_data1/oa_pdf/fc/73/main.PMC4919281.pdf
"The  Received: December 16, 2015 Accepted: January 13, 2016Published online in J-STAGE: February 5, 2016 ©2016 by the Society for Reproduction and Development Correspondence: P Tulay (e-mail: pintulay@gmail.com) This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Journal of Reproduction and Development, Vol.",Non-OADS,/arxiv_data1/oa_pdf/7e/4c/jrd-62-225.PMC4919285.pdf
"Copyright adapted with permission from “Development”, via DOI:- http://dev.biologists.org/content/138/9/1653.long/.",Non-OADS,/arxiv_data1/oa_pdf/7e/4c/jrd-62-225.PMC4919285.pdf
"Genes involved in nucleotide excision repair and miRNAs predicted to regulate these genes are shown (http://www.microrna.org/microrna/home.do, http://www.targetscan.org/, http://mirdb.org/miRDB/).",OADS,/arxiv_data1/oa_pdf/7e/4c/jrd-62-225.PMC4919285.pdf
"Genes involved in base excision repair and miRNAs predicted to regulate these genes are shown (http://www.microrna.org/microrna/home.do, http://www.targetscan.org/, http://mirdb.org/miRDB/).",OADS,/arxiv_data1/oa_pdf/7e/4c/jrd-62-225.PMC4919285.pdf
"Genes involved in a) non- homologous end joining and b) homologous recombination pathways, and miRNAs predicted to regulate these genes are shown (http://www.microrna.org/microrna/home.do, http://www.targetscan.org/, http://mirdb.org/miRDB/).",Non-OADS,/arxiv_data1/oa_pdf/7e/4c/jrd-62-225.PMC4919285.pdf
"Genes involved in mismatch repair and miRNAs predicted to regulate these genes are shown (http://www.microrna.org/microrna/home.do, http://www.targetscan.org/, http://mirdb.org/miRDB/).",OADS,/arxiv_data1/oa_pdf/7e/4c/jrd-62-225.PMC4919285.pdf
"This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Journal of Reproduction and Development, Vol.",Non-OADS,/arxiv_data1/oa_pdf/8d/07/jrd-62-235.PMC4919286.pdf
"LIM domains are  Received: December 8, 2015 Accepted: January 9, 2016Published online in J-STAGE: February 8, 2016 ©2016 by the Society for Reproduction and Development Correspondence: Y Kato (e-mail: yukato@isc.meiji.ac.jp) This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Journal of Reproduction and Development, Vol.",Non-OADS,/arxiv_data1/oa_pdf/3e/4d/jrd-62-241.PMC4919287.pdf
"Therefore, changes  Received: June 24, 2015 Accepted: January 21, 2016Published online in J-STAGE: February 9, 2016 ©2016 by the Society for Reproduction and Development Correspondences: D-B Koo (e-mail: dbkoo@daegu.ac.kr) and K-T Chang (e-mail: changkt@kribb.re.kr) This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Journal of Reproduction and Development, Vol.",Non-OADS,/arxiv_data1/oa_pdf/9d/b3/jrd-62-249.PMC4919288.pdf
"Materials and Methods All experiments were performed according to the Guiding Principles  for the Care and Use of Experimental Animals in the Field of Physiological Sciences (Physiological Society of Japan) and approved Received: October 23, 2015 Accepted: January 26, 2016Published online in J-STAGE: February 8, 2016 ©2016 by the Society for Reproduction and Development Correspondence: H Kadokawa (e-mail: hiroya@yamaguchi-u.ac.jp) This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Journal of Reproduction and Development, Vol.",Non-OADS,/arxiv_data1/oa_pdf/b1/85/jrd-62-257.PMC4919289.pdf
"This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Journal of Reproduction and Development, Vol.",Non-OADS,/arxiv_data1/oa_pdf/1d/d8/jrd-62-265.PMC4919290.pdf
"It is now well documented  that EGF, HGF and their receptors (EGFR and c-MET) are expressed  Received: December 1, 2015 Accepted: February 13, 2016Published online in J-STAGE: March 4, 2016 ©2016 by the Society for Reproduction and Development Correspondence: N Yamauchi (e-mail: ny0531@agr.kyushu-u.ac.jp) This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Journal of Reproduction and Development, Vol.",Non-OADS,/arxiv_data1/oa_pdf/80/52/jrd-62-271.PMC4919291.pdf
"This is an open‑access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by‑nc‑nd/4.0/>.Journal of Reproduction and Development, Vol.",Non-OADS,/arxiv_data1/oa_pdf/97/19/jrd-62-279.PMC4919292.pdf
Read mapping to the reference genome and sequencing quality  assessment The Ovis aries genome (http://www.livestockgenomics.csiro.,OADS,/arxiv_data1/oa_pdf/97/19/jrd-62-279.PMC4919292.pdf
au/sheep/oar2.0.php) and 20236 reference genes (http://www.live‑ stockgenomics.csiro.au/sheep/sheep.v4.gff.filter.chr.annot.gff3.gz)  were downloaded.,OADS,/arxiv_data1/oa_pdf/97/19/jrd-62-279.PMC4919292.pdf
"The high‑quality reads were mapped to the O. aries genome, and gene sequences were  annotated using the Short Oligonucleotide Analysis 2 (SOAP2)  software (http://soap.genomics.org.cn/).",OADS,/arxiv_data1/oa_pdf/97/19/jrd-62-279.PMC4919292.pdf
We used DA VID version 6.7 (http://david.abcc.ncifcrf.gov/) to perform functional annotations of biological processes  affected by IVO or IVP from the target gene list.,OADS,/arxiv_data1/oa_pdf/97/19/jrd-62-279.PMC4919292.pdf
"In addition, although β-carotene concentrations generally decline throughout the dry period, due to colostrum formation and decreased feed intake [14–16], lower concentrations are found in  Received: October 20, 2015 Accepted: February 17, 2016Published online in J-STAGE: March 3, 2016 ©2016 by the Society for Reproduction and Development Correspondence: C Kawashima (e-mail: kawasima@obihiro.ac.jp) This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Journal of Reproduction and Development, Vol.",Non-OADS,/arxiv_data1/oa_pdf/c7/5b/jrd-62-289.PMC4919293.pdf
"Therefore, parthenogenetic  Received: December 22, 2015 Accepted: February 21, 2016Published online in J-STAGE: March 13, 2016 ©2016 by the Society for Reproduction and Development Correspondence: X-S Cui (e-mail: xscui@chungbuk.ac.kr) and N-H Kim (e-mail: nhkim@chungbuk.ac.kr) This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Journal of Reproduction and Development, Vol.",Non-OADS,/arxiv_data1/oa_pdf/d3/5f/jrd-62-297.PMC4919294.pdf
"Received: February 6, 2016 Accepted: February 24, 2016Published online in J-STAGE: March 13, 2016 ©2016 by the Society for Reproduction and Development Correspondence: T Baba (e-mail: baba.tadashi.gf@u.tsukuba.ac.jp) This is an open-access article distributed under the terms of the Creative  Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Journal of Reproduction and Development, Vol.",Non-OADS,/arxiv_data1/oa_pdf/5a/d3/jrd-62-305.PMC4919295.pdf
"Received:	December	21,	2015 Accepted:	January	18,	2016Published	online	in	J-STAGE:	February	6,	2016 ©2016	by	the	Society	for	Reproduction	and	Development Correspondence:	A	Ogura	(e-mail:	ogura@rtc.riken.go.jp) This	is	an	open-access	article	distributed	under	the	terms	of	the	Creative 	 Commons	 Attribution	Non-Commercial	No	Derivatives	(by-nc-nd)	License 	 <http://creativecommons.org/licenses/by-nc-nd/4.0/>.Journal of Reproduction and Development, Vol.",Non-OADS,/arxiv_data1/oa_pdf/65/d9/jrd-62-311.PMC4919296.pdf
MALDI-TOF MS spectrum The MALDI-TOF MS spectrum of A. massiliensis is available at http://www.mediterraneeinfection.com/article.php?,Non-OADS,/arxiv_data1/oa_pdf/ec/ca/main.PMC4919311.pdf
Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) http://dx.doi.org/10.1016/j.nmni.2016.05.008,Non-OADS,/arxiv_data1/oa_pdf/ec/ca/main.PMC4919311.pdf
"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI ,12,9 9 –100 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/ec/ca/main.PMC4919311.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6d/11/main.PMC4919314.pdf
Tumour  size  is  both  measured  intra-  and  extrameatal http://dx.doi.org/10.1016/j.ejro.2016.05.005 2352-0477/© 2016  The  Authors.,Non-OADS,/arxiv_data1/oa_pdf/6d/11/main.PMC4919314.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.,Non-OADS,/arxiv_data1/oa_pdf/6d/11/main.PMC4919314.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/aa/33/main.PMC4919315.pdf
Contents lists available at ScienceDirect International Journal for Parasitology: Drugs and Drug Resistance journal homepage: www.elsevier.com /locate/ijppaw http://dx.doi.org/10.1016/j.ijpddr.2016.04.001 2211-3207/ ©2016 Published by Elsevier Ltd on behalf of Australian Society for Parasitology.,Non-OADS,/arxiv_data1/oa_pdf/aa/33/main.PMC4919315.pdf
"Bioinformatic identi ﬁcation of D. immitis ABC-B transporter genes All ABC-B transporter genes reported ( Sheps et al., 2004; Lespine et al., 2008 ) in the nematode model organism C.elegans (25 genes) were collected from WormBase ( http://www.wormbase.",OADS,/arxiv_data1/oa_pdf/aa/33/main.PMC4919315.pdf
org) and from GenBank NCBI ( http://www.ncbi.nlm.nih.gov/ ).,Non-OADS,/arxiv_data1/oa_pdf/aa/33/main.PMC4919315.pdf
"Also, based on the analysis of 15 genomic sequences that could predict ATP-binding cassette (ABC) systems in B. malayi (Ardelli et al., 2010 ), Pgp genes were identi ﬁed using NCBI Blast tool, BLASTN 2.3.1 þ(Zhang et al., 2000 ) and BLASTX 2.3.1 þ(Altschul et al., 1997 ) (http://blast.ncbi.nlm.nih.gov/Blast.cgi ).",OADS,/arxiv_data1/oa_pdf/aa/33/main.PMC4919315.pdf
"Additional Blast analysis on these 15 sequences was performed with the Broad Institute Blast tools ( http://www.broadinstitute.org/ ), to identify additional se- quences in ﬁlarial nematodes.",OADS,/arxiv_data1/oa_pdf/aa/33/main.PMC4919315.pdf
"These 69 sequences were used to interrogate the D.immitis genome nDi.2.2 (http://xyala.cap.ed.ac.uk/downloads/959nematodegenomes/ blast/ ﬁlareu.php ) with BLASTN 2.2.25 and TBLASTN 2.2.25 ( Altschul et al., 1997 ).",OADS,/arxiv_data1/oa_pdf/aa/33/main.PMC4919315.pdf
"Additionally, sequences annotated as nematode orthologs of Pgps in the nDi.2.2 genome browser ( http://salmo.bio.",OADS,/arxiv_data1/oa_pdf/aa/33/main.PMC4919315.pdf
"Simultaneously, open reading frame (ORF) ﬁnder from Geneious Pro.5.6.3 software ( http://www.geneious.com/ ;Kearse et al., 2012 ) was used to predict cDNA sequences.",OADS,/arxiv_data1/oa_pdf/aa/33/main.PMC4919315.pdf
"All the sequences ob- tained from the PCR amplicons were assembled and analysed using Geneious Pro.5.6.3, Sequencher®version 4.10 software (Gene Codes Corporation, Ann Arbor, MI, USA) and the nuclear genome assembly nDi.2.2 as D.immitis reference genome ( http://nematodes.org/ genomes/diro ﬁlaria_immitis/ ).",OADS,/arxiv_data1/oa_pdf/aa/33/main.PMC4919315.pdf
"Conserved Walker A and Walker B sites were located with NCBI server using BLASTP 2.3.1 þ(http://blast.st-va. ncbi.nlm.nih.gov/Blast.cgi )(Altschul et al., 1997 ).",OADS,/arxiv_data1/oa_pdf/aa/33/main.PMC4919315.pdf
The sequences were either collected on WormBase ( http://www.wormbase.org/#01-23-6 )o r GenBank NCBI ( http://www.ncbi.nlm.nih.gov/genbank/ ).,OADS,/arxiv_data1/oa_pdf/aa/33/main.PMC4919315.pdf
"Predictions of transmembrane domain, ATP-binding cassette, and of ABC transporter family signature, were performed using ScanProsite (released 20.123; http://prosite.expasy.org/scanprosite/ ).",OADS,/arxiv_data1/oa_pdf/aa/33/main.PMC4919315.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c0/08/main.PMC4919363.pdf
Contents lists available at ScienceDirect International Journal for Parasitology: Drugs and Drug Resistance journal homepage: www.elsevier.com/locate/ijppaw http://dx.doi.org/10.1016/j.ijpddr.2016.04.003 2211-3207/ ©2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c0/08/main.PMC4919363.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commercial use , distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Libyan J Med 2016, 11: 31576 - http://dx.doi.org/10.3402/ljm.v11.31576 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b1/12/LJM-11-31576.PMC4919366.pdf
"2 (page number not for citation purpose)Citation: Libyan Journal of Medicine 2016, 11: 31576 - http://dx.doi.org/10.3402/ljm.v11.31576",Non-OADS,/arxiv_data1/oa_pdf/b1/12/LJM-11-31576.PMC4919366.pdf
"Distribution of the genotypes in the study population Genotype HC n(%) All n(%) AG n(%) GC n(%) IL-1RN L/L 28 (87.50) 57 (72.15) 32 (82.05) 25 (62.50)2/L 04 (12.50) 19 (24.05) 04 (10.25) 15 (37.50)2/2 00 (00.00) 03 (03.79) 03 (07.69) 00 (00.00)2/L/C272/2 04 (12.50) 22 (27.84) 07 (17.94) 15 (37.50) IL-1B-511 C/C 18 (56.25) 28 (35.44) 09 (23.07) 19 (47.50)T/C 14 (43.75) 22 (27.84) 09 (23.07) 13 (32.50) T/T 00 (00.00) 29 (36.70) 21 (53.84) 08 (20.00) T/C/C27T/T 14 (43.75) 51 (64.55) 30 (76.92) 21 (52.50) IL-1B-31 T/T 17 (53.12) 24 (30.37) 14 (35.89) 10 (25.00)C/T 07 (21.87) 33 (41.77) 14 (35.89) 19 (47.50)C/C 08 (25.00) 22 (27.84) 11 (28.20) 11 (27.50)C/T/C27C/C 15 (46.87) 55 (69.62) 25 (64.10) 30 (75.00) AG: atrophic gastritis; GC: gastric carcinoma; All: atrophic gastritis and gastric carcinoma; HC: healthy controls; IL-1 b-31: cluster in gene encoding interleukin-1 bin the promoter region of TATA box at the -31 position; IL-1 b-511: cluster in gene encoding interleukin-1 bin the promoter region of TATA box at the /C28511 position; IL-1RN: gene encoding for the anti-inflammatory antagonist (interleukin-1ra); L: long genotype (more than three repetitions; alleles 1, 3, 4, 5); 2: short genotype (two repetitions;allele 2); C or T: single nucleotide polymorphisms.Effect of IL-1 band IL-1RN polymorphisms Citation: Libyan Journal of Medicine 2016, 11: 31576 - http://dx.doi.org/10.3402/ljm.v11.31576 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b1/12/LJM-11-31576.PMC4919366.pdf
"4 (page number not for citation purpose)Citation: Libyan Journal of Medicine 2016, 11: 31576 - http://dx.doi.org/10.3402/ljm.v11.31576",Non-OADS,/arxiv_data1/oa_pdf/b1/12/LJM-11-31576.PMC4919366.pdf
"AG: atrophic gastritis; GC: gastric carcinoma; HC: healthy controls; IL-1 b-31: cluster in gene encoding interleukin-1 bin the promoter region of TATA box at the /C2831 position; IL-1 b-511: cluster in gene encoding interleukin-1 bin the promoter region of TATA box at the /C28511 position; IL-1RN: gene encoding for the anti-inflammatory antagonist (interleukin-1ra); L: long genotype (more than three repetitions; alleles 1, 3, 4, 5); 2: short genotype (two repetitions; allele 2);C or T: single nucleotide polymorphisms.Effect of IL-1 band IL-1RN polymorphisms Citation: Libyan Journal of Medicine 2016, 11: 31576 - http://dx.doi.org/10.3402/ljm.v11.31576 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b1/12/LJM-11-31576.PMC4919366.pdf
"6 (page number not for citation purpose)Citation: Libyan Journal of Medicine 2016, 11: 31576 - http://dx.doi.org/10.3402/ljm.v11.31576",Non-OADS,/arxiv_data1/oa_pdf/b1/12/LJM-11-31576.PMC4919366.pdf
"2010; 10: 1 /C18.Effect of IL-1 band IL-1RN polymorphisms Citation: Libyan Journal of Medicine 2016, 11: 31576 - http://dx.doi.org/10.3402/ljm.v11.31576 7 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b1/12/LJM-11-31576.PMC4919366.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Single domain antibody Heavy chain antibody VHHNanobodyCancer Contents 1 .,Non-OADS,/arxiv_data1/oa_pdf/c1/a1/main.PMC4919472.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.04.028 2352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c1/a1/main.PMC4919472.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c1/a1/main.PMC4919472.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Inﬂammation DNA damageSLX4 complexendogenous retroelement Interferon Fanconi AnemiacGAS-STINGInnate immune sensingCytoplasmic DNA 1.,Non-OADS,/arxiv_data1/oa_pdf/da/8a/main.PMC4919473.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.05.0052352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/da/8a/main.PMC4919473.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/da/8a/main.PMC4919473.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: HIV-1 EradicationLatency reversal agentsElite suppressorsElite controllersCD8+ T cells 1.,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.04.019 2352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.1016/j.clim.,OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
"27, 29 –35.http://dx.doi.org/10.1097/QCO.0000000000000026 .",Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
"286 (1), 24 –34.http://dx.doi.org/10.1074/jbc.",Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.1128/JVI.02439-12 .,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.1038/nm.3489 .,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.1371/ journal.ppat.1005063 .,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.1371/journal.ppat.1000917 .,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.1371/journal.ppat.1005066 .,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.1371/journal.ppat.1004287 .,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.1002/ajh.23112 .,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.1172/ JCI80142 .,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.1093/nar/gks976 .,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.1038/ni.3161 .,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.1016/j.immuni.2008.10.010 .,OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
"Retrovirology 10, 152. http://dx.doi.org/10.1186/1742- 4690-10-152 .",Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.1016/j.immuni.2012.01.014 .,OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.1097/COH.0b013e328361eaca .,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
"35 (1), 87 –94.http://dx.doi.org/10.1016/j.leukres.2010.06.001 .",OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.1128/AAC.01077-15 .,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.1093/infdis/jiv022 .,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.1128/JVI.,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/90/54/main.PMC4919475.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Inﬂuenza Natural killer cells Antibody dependent cellular cytotoxicity NucleoproteinMatrix protein 1Hemagglutinin 1.,Non-OADS,/arxiv_data1/oa_pdf/a6/a6/main.PMC4919476.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.04.0292352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a6/a6/main.PMC4919476.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a6/a6/main.PMC4919476.pdf
In ﬂuenza (seasonal)Available at: http://www.who.int/ mediacentre/factsheets/fs211/en/ (Accessed February 5th) .,Non-OADS,/arxiv_data1/oa_pdf/a6/a6/main.PMC4919476.pdf
[J Adv Prosthodont 2016;8:167-71] KEY WORDS: Flexural strength; Halloysites nanotubes; Hardness; PMMA resin; Young’s modulushttp://dx.doi.org/10.4047/jap.2016.8.3.167 http://jap.or.kr J Adv Prosthodont 2016;8:167-71 INTRODUCTION Polymethyl methacrylate (PMMA) is considered to be the  most commonly used material in the field of  prosthodon-tics.,Non-OADS,/arxiv_data1/oa_pdf/ca/b8/jap-8-167.PMC4919485.pdf
"201224172781: e-mail, rehammohamedabdallah@gmail.comReceived July 25, 2015 / Last Revision December 2, 2015 / Accepted  January 12, 2016 © 2016  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ca/b8/jap-8-167.PMC4919485.pdf
ORCID Reham M. Abdallah  http://orcid.org/0000-0002-7095-9255 REfERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/ca/b8/jap-8-167.PMC4919485.pdf
"[J Adv Prosthodont  2016;8:172-80] KEY WORDS: Dendropanax morbifera Léveille; Antimicrobial activity; Antioxidant activity; Cytotoxicity; Denture  cleaning solution http://dx.doi.org/10.4047/jap.2016.8.3.172 http://jap.or.kr J Adv Prosthodont 2016;8:172-80 INTRODUCTION Dentate patients must exercise strict hygiene control through  the use of  oral hygiene products (toothbrush, mouthwash, etc.)",Non-OADS,/arxiv_data1/oa_pdf/07/be/jap-8-172.PMC4919486.pdf
"82622203825: e-mail, son0513@chosun.ac.krReceived September 1, 2015 / Last Revision November 26, 2015 /  Accepted December 14, 2015 © 2016  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/07/be/jap-8-172.PMC4919486.pdf
ORCID Ryeo-Woon Kim  http://orcid.org/0000-0003-0511-4595Sook-Young Lee  http://orcid.org/0000-0002-1944-1274Su-Gwan Kim  http://orcid.org/0000-0002-0424-9984Yu-Ri Heo  http://orcid.org/0000-0002-1806-3822Mee-Kyoung Son  http://orcid.org/0000-0001-9225-1744 REfERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/07/be/jap-8-172.PMC4919486.pdf
[J Adv Prosthodont 2016;8:181-6] KEY WORDS: Translucency; Contrast ratio; Colored zirconia; Monolithic zirconia; Grain sizehttp://dx.doi.org/10.4047/jap.2016.8.3.181 http://jap.or.kr J Adv Prosthodont 2016;8:181-6 INTRODUCTION  Metal-ceramic restorations have been used for a long time  in prosthodontics and constitute a reliable choice for restoring dentition.,Non-OADS,/arxiv_data1/oa_pdf/8f/8e/jap-8-181.PMC4919487.pdf
"905352152526: e-mail, isilbayramgurler@yahoo.comReceived September 1, 2015 / Last Revision January 14, 2016 / Accepted   February 15, 2016 © 2016  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/8f/8e/jap-8-181.PMC4919487.pdf
ORCID Işıl	Turp		http://orcid.org/0000-0002-3862-5781 REfERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/8f/8e/jap-8-181.PMC4919487.pdf
Available from: http://www.zirkon-zahn.com/en/prettau-zirconia/prettau-zirconia.,Non-OADS,/arxiv_data1/oa_pdf/8f/8e/jap-8-181.PMC4919487.pdf
Available from: http://www.zirkonzahn.com/assets/files/anleitungen-informationen-studien/INT- Data-sheet-Prettau-Zirconia.pdf.,OADS,/arxiv_data1/oa_pdf/8f/8e/jap-8-181.PMC4919487.pdf
[J Adv Prosthodont 2016;8:187-93] KEY WORDS: Power Spectral Density; Fast Fourier Transform; Brain activity; Geriatric; Electroencephalography;  Complete denturehttp://dx.doi.org/10.4047/jap.2016.8.3.187 http://jap.or.kr J Adv Prosthodont 2016;8:187-93 INTRODUCTION World Health Organization (WHO) and the National  Institute on Ageing (NIA) reported that tooth loss could be a risk for Alzheimer’s disease.,Non-OADS,/arxiv_data1/oa_pdf/b8/83/jap-8-187.PMC4919488.pdf
"919840749441: e-mail, drgopichander@gmail.comReceived September 12, 2015 / Last Revision February 1, 2016 /  Accepted March 24, 2016 © 2016  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b8/83/jap-8-187.PMC4919488.pdf
ORCID Gopi Naveen Chander  http://orcid.org/0000-0002-2040-4550 REfERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/b8/83/jap-8-187.PMC4919488.pdf
"[J Adv Prosthodont 2016;8:194-200] KEY WORDS: Dental bonding; Dental restoration failure; Dental marginal adaptation; Dental porcelain; Follow-up studies; Survival analysishttp://dx.doi.org/10.4047/jap.2016.8.3.194 http://jap.or.kr J Adv Prosthodont 2016;8:194-200 INTRODUCTION Lithium disilicate ceramic promises esthetic, minimally  invasive restorations.",Non-OADS,/arxiv_data1/oa_pdf/23/73/jap-8-194.PMC4919489.pdf
"49 7071 29 86183: e-mail, fabian.huettig@med.uni-tuebingen.de Received September 27, 2015 / Last Revision February 3, 2016 /  Accepted April 26, 2016 © 2016  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/23/73/jap-8-194.PMC4919489.pdf
ORCID Fabian Huettig  http://orcid.org/0000-0002-7253-5923 Ulf  Peter Gehrke http://orcid.org/0000-0002-9413-9788 REfERENCES 	1.,Non-OADS,/arxiv_data1/oa_pdf/23/73/jap-8-194.PMC4919489.pdf
"[J Adv Prosthodont 2016;8:201-6] KEY WORDS: Radiopacity; Resin cement; Luting cementhttp://dx.doi.org/10.4047/jap.2016.8.3.201 http://jap.or.kr J Adv Prosthodont 2016;8:201-6 INTRODUCTION A number of  factors - including preparation design, occlusal  forces, oral hygiene, and the restoration materials used - influ-ence the success of  fixed dental prostheses.",Non-OADS,/arxiv_data1/oa_pdf/45/e9/jap-8-201.PMC4919490.pdf
"34639256545: e-mail, raquelmontesfariza@gmail.comReceived October 24, 2015 / Last Revision December 22, 2015 /  Accepted January 12, 2016 © 2016  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/45/e9/jap-8-201.PMC4919490.pdf
ORCID Raquel Montes-Fariza  http://orcid.org/0000-0002-0495-4632 REfERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/45/e9/jap-8-201.PMC4919490.pdf
"[J Adv Prosthodont 2016;8:207-13] KEY WORDS: Accuracy; Guided surgery; Dental implants; Tolerance; Surgical drillshttp://dx.doi.org/10.4047/jap.2016.8.3.207 http://jap.or.kr J Adv Prosthodont 2016;8:207-13 INTRODUCTION Appropriate placement of  dental implants is essential for  esthetic and restorative aspects.1,2 The development of  computer-assisted guided surgery has helped realize resto-ration-driven implant placement.",Non-OADS,/arxiv_data1/oa_pdf/36/96/jap-8-207.PMC4919491.pdf
"82536007674: e-mail, kblee@knu.ac.kr Received November 17, 2015 / Last Revision January 26, 2016 /  Accepted April 26, 2016 © 2016  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/36/96/jap-8-207.PMC4919491.pdf
ORCID Du-Hyeong Lee  http://orcid.org/0000-0003-2803-7457Seo-Young An  http://orcid.org/0000-0001-6711-5986Min-Ho Hong  http://orcid.org/0000-0002-6456-2200Kyoung-Bae Jeon  http://orcid.org/0000-0002-5289-4179Kyu-Bok Lee  http://orcid.org/0000-0002-1838-7229 REfERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/36/96/jap-8-207.PMC4919491.pdf
"[J Adv Prosthodont 2016;8:214-8] KEY WORDS: Blue light scanner; Repeatability; Reproducibility; Color-difference-maphttp://dx.doi.org/10.4047/jap.2016.8.3.214 http://jap.or.kr J Adv Prosthodont 2016;8:214-8 INTRODUCTION Scanners are increasingly being utilized in the field of  den- tistry, and the evaluation of  their repeatability and repro - ducibility is necessary to validate their clinical use.1-3 Common prosthesis fabrication includes model fabrication by pouring dental stone into impressions of the patient’s teeth.",Non-OADS,/arxiv_data1/oa_pdf/c2/c4/jap-8-214.PMC4919492.pdf
"82232905665: e-mail, kuc2842@korea.ac.kr Received December 15, 2015 / Last Revision March 2, 2016 / Accepted  April 26, 2016 © 2016  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c2/c4/jap-8-214.PMC4919492.pdf
ORCID Jin-Hun Jeon  http://orcid.org/0000-0003-2833-8946Woong-Chul Kim  http://orcid.org/0000-0002-6730-4960 REfERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/c2/c4/jap-8-214.PMC4919492.pdf
"Available  from: http://www.iso.org/iso/store.html Accessed March 2, 2016.13.",Non-OADS,/arxiv_data1/oa_pdf/c2/c4/jap-8-214.PMC4919492.pdf
"[J Adv Prosthodont  2016;8:219-23] KEY WORDS: Digitized database; Obturators; Intraoral scanner; Modeling; 3D printing; Emergency http://dx.doi.org/10.4047/jap.2016.8.3.219 http://jap.or.kr J Adv Prosthodont 2016;8:219-23 INTRODUCTION During rehabilitation, maxillectomy patients are treated  with obturators, which are essential for oral functions such as speech, swallowing, mastication, and esthetics.",Non-OADS,/arxiv_data1/oa_pdf/1d/04/jap-8-219.PMC4919493.pdf
"81358035556: e-mail, sasamfp@tmd.ac.jp Received December 25, 2015 / Last Revision February 19, 2016 /  Accepted March 24, 2016 © 2016  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1d/04/jap-8-219.PMC4919493.pdf
ORCID Mahmoud Elbashti  http://orcid.org/0000-0002-0215-5335Mariko Hattori  http://orcid.org/0000-0003-2802-8016 fig.,Non-OADS,/arxiv_data1/oa_pdf/1d/04/jap-8-219.PMC4919493.pdf
"[J Adv Prosthodont 2016;8:224-8] KEY WORDS: Dentin; Resin-bonded bridge ; Bonding; Shear strength; Dental instrumentshttp://dx.doi.org/10.4047/jap.2016.8.3.224 http://jap.or.kr J Adv Prosthodont 2016;8:224-8 INTRODUCTION Since the introduction of resin bonded restorations by  Rochette, these prostheses have been notably enhanced and changed.",Non-OADS,/arxiv_data1/oa_pdf/4b/48/jap-8-224.PMC4919494.pdf
"98 41 33355965: e-mail, Hafezeqoran@gmail.com Received January 2, 2016 / Last Revision March 30, 2016 / Accepted  March 31, 2016 © 2016  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4b/48/jap-8-224.PMC4919494.pdf
ORCID Ali Hafezeqoran  http://orcid.org/0000-0002-7756-3616 REfERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/4b/48/jap-8-224.PMC4919494.pdf
"[J Adv Prosthodont 2016;8:229-34] KEY WORDS: Maxillofacial prosthesis; Head and neck neoplasms; Palatal obturators; Mandibular prosthesis; Velopharyngeal insufficiencyhttp://dx.doi.org/10.4047/jap.2016.8.3.229 http://jap.or.kr J Adv Prosthodont 2016;8:229-34 INTRODUCTION Cancer in the maxillofacial area is a disease with a long his- tory.1 The first evidence of it was found in an Egyptian  skull around 3000 B.C.2 People have struggled to fight against cancer since then, and treatments for oral and max - illofacial cancer, including maxillectomy and mandibulecto-my, have increased survival rates.",Non-OADS,/arxiv_data1/oa_pdf/00/09/jap-8-229.PMC4919495.pdf
"82220723816: e-mail, proskwon@snu.ac.kr Received January 18, 2016 / Last Revision May 10, 2016 / Accepted May  10, 2016 © 2016  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/00/09/jap-8-229.PMC4919495.pdf
ORCID Jee-Hwan Kim  http://orcid.org/0000-0002-0872-4906 Soo-Yeon Shin  http://orcid.org/0000-0001-6160-7277Janghyun Paek  http://orcid.org/0000-0002-1286-3140Ho-Beom Kwon  http://orcid.org/0000-0003-4973-7727 REfERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/00/09/jap-8-229.PMC4919495.pdf
"[J Adv Prosthodont 2016;8:235-40] KEY WORDS: MC3T3-E1; Modified SLA; ALP activity; Laser and acid-treated surface; Roughness http://dx.doi.org/10.4047/jap.2016.8.3.235 http://jap.or.kr J Adv Prosthodont 2016;8:235-40 INTRODUCTION The use of  titanium (Ti) implants is considered to be a suit -able treatment option for fully or partially edentulous  patients.1 In the context of titanium implants, surface  microstructure of  suspensions and pockets affect the cell spreading, morphology and its alignment.",Non-OADS,/arxiv_data1/oa_pdf/aa/22/jap-8-235.PMC4919496.pdf
"82536007672: e-mail, sacho@knu.ac.krReceived February 23, 2016 / Last Revision May 30, 2016 / Accepted  June 3, 2016 © 2016  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/aa/22/jap-8-235.PMC4919496.pdf
ORCID Sung-Am Cho  http://orcid.org/0000-0002-8315-7833 REfERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/aa/22/jap-8-235.PMC4919496.pdf
"[J Adv Prosthodont 2016;8:  241-50] KEY WORDS: Anterior guidance; Congenital tooth agenesis; Interarch tooth size discrepancy; Oligodontiahttp://dx.doi.org/10.4047/jap.2016.8.3.241 http://jap.or.kr J Adv Prosthodont 2016;8:241-50 INTRODUCTION Anomalies of tooth number, such as tooth agenesis or  supernumerary teeth, result from developmental distur - bances in the initiation and proliferation stages of tooth formation.",Non-OADS,/arxiv_data1/oa_pdf/7b/f0/jap-8-241.PMC4919497.pdf
"82336403153: e-mail, lila@gwnu.ac.kr Received September 22, 2015 / Last Revision December 28, 2015 /  Accepted January 12, 2016 © 2016  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/7b/f0/jap-8-241.PMC4919497.pdf
ORCID Hyeon-Goo Kang  http://orcid.org/0000-0001-6293-0121 Yoon-Hyuk Huh  http://orcid.org/0000-0003-4072-5199Chan-Jin Park  http://orcid.org/0000-0003-4734-214XLee-Ra Cho  http://orcid.org/0000-0003-3989-2870 REfERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/7b/f0/jap-8-241.PMC4919497.pdf
DOI of original article: http://dx.doi.org/10.1016/j.krcp.2015.08.008 .,OADS,/arxiv_data1/oa_pdf/10/ec/main.PMC4919498.pdf
Kidney Research and Clinical Practice journal homepage: http://www.krcp-ksn.com Contents lists available at ScienceDirect http://dx.doi.org/10.1016/j.krcp.2016.03.002 2211-9132/Copyright ©2016.,Non-OADS,/arxiv_data1/oa_pdf/10/ec/main.PMC4919498.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Kidney Res Clin Pract 35 (2016) 130,Non-OADS,/arxiv_data1/oa_pdf/10/ec/main.PMC4919498.pdf
DUX4 is located within a D4Z4 repeat array in the subtelomeric region of chromosome 4q and encodes the transcriptionalEBioMedicine 8 (2016) 8 –9 DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.04.038 .,OADS,/arxiv_data1/oa_pdf/2c/c7/main.PMC4919499.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.06.001 2352-3964/© 2016 The Author.,Non-OADS,/arxiv_data1/oa_pdf/2c/c7/main.PMC4919499.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2c/c7/main.PMC4919499.pdf
"Although these Abs could mediate direct protection through opsonization of infected/dying cells, another explanation might involveEBioMedicine 8 (2016) 18 –19 DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.04.029 .",Non-OADS,/arxiv_data1/oa_pdf/d3/5d/main.PMC4919500.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.05.042 2352-3964/© 2016 Published by Elsevier B.V.,Non-OADS,/arxiv_data1/oa_pdf/d3/5d/main.PMC4919500.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d3/5d/main.PMC4919500.pdf
"26 (7), 2479 –2489.EBioMedicine 8 (2016) 7 DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.05.003 .",OADS,/arxiv_data1/oa_pdf/61/86/main.PMC4919501.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.05.035 2352-3964/© 2016 The Author.,Non-OADS,/arxiv_data1/oa_pdf/61/86/main.PMC4919501.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/61/86/main.PMC4919501.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5f/7d/main.PMC4919502.pdf
Kidney Research and Clinical Practice journal homepage: http://www.krcp-ksn.com Contents lists available at ScienceDirect http://dx.doi.org/10.1016/j.krcp.2016.03.003 2211-9132/Copyright ©2016.,Non-OADS,/arxiv_data1/oa_pdf/5f/7d/main.PMC4919502.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Kidney Res Clin Pract 35 (2016) 114 e118,Non-OADS,/arxiv_data1/oa_pdf/5f/7d/main.PMC4919502.pdf
"In the context ofcomparing CCA-associated bile ducts to healthy tissues and the poten- tial mechanistic link that underlies O. viverrini infection, dysbiosis, and promotion of a carcinogenic microenvironment, the ﬁndings by ChngEBioMedicine 8 (2016) 12 –13 DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.04.034 .",Non-OADS,/arxiv_data1/oa_pdf/b8/03/main.PMC4919503.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.05.0382352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/b8/03/main.PMC4919503.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b8/03/main.PMC4919503.pdf
"22 (2) 178.e11 –22, (Available at: http://www.ncbi.nlm.nih.gov/pubmed/26493848 ).",Non-OADS,/arxiv_data1/oa_pdf/b8/03/main.PMC4919503.pdf
"Science (New York, N.Y.) 348 (6230), 80–86 (Available at: http://www.ncbi.nlm.nih.gov/pubmed/25838377 ).",Non-OADS,/arxiv_data1/oa_pdf/b8/03/main.PMC4919503.pdf
"12 (10), 661 –672 (Available at: http://www.ncbi.nlm.",Non-OADS,/arxiv_data1/oa_pdf/b8/03/main.PMC4919503.pdf
"27 (11), 4572 –4584 (Available at:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3804743&tool= pmcentrez&rendertype=abstract ).",OADS,/arxiv_data1/oa_pdf/b8/03/main.PMC4919503.pdf
"2015, 398585 (Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4363917&tool= pmcentrez&rendertype=abstract ).",OADS,/arxiv_data1/oa_pdf/b8/03/main.PMC4919503.pdf
"5 (10), e1000611 (Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?",Non-OADS,/arxiv_data1/oa_pdf/b8/03/main.PMC4919503.pdf
"11 (10),e1005209 (Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?",Non-OADS,/arxiv_data1/oa_pdf/b8/03/main.PMC4919503.pdf
"28 (10), 395 –407 (Available at: http://www.pubmedcentral.",Non-OADS,/arxiv_data1/oa_pdf/b8/03/main.PMC4919503.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: CDKN2Ap16 INK4a Genetic alterationsEpigenetic alterationsCancer Contents 1 .,Non-OADS,/arxiv_data1/oa_pdf/06/46/main.PMC4919535.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.04.017 2352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/06/46/main.PMC4919535.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/06/46/main.PMC4919535.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Bronchoalveolar lavage ﬂuid CD4/CD8 ratioSarcoidosisMeta-analysis 1.,Non-OADS,/arxiv_data1/oa_pdf/01/b3/main.PMC4919536.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.04.024 2352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/01/b3/main.PMC4919536.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/01/b3/main.PMC4919536.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Exosome miR-181cBurnInﬂammation 1.,Non-OADS,/arxiv_data1/oa_pdf/ad/8b/main.PMC4919539.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.04.0302352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/ad/8b/main.PMC4919539.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ad/8b/main.PMC4919539.pdf
"Array experiments were performed by Genechem Corp. (Shanghai, China) as described on the company's website ( http://www.genechem.",OADS,/arxiv_data1/oa_pdf/ad/8b/main.PMC4919539.pdf
"com.cn ) and in previous reports using an miRNA array (GeneChip miRNA Array; Affymetrix Inc., Santa Clara, CA, USA), which contains 6153 probe sets from the miRNAs registered in the Sanger miRBase miRNA database (release 21.0; http://www.mirbase.org/; accessed Jun 2014).",OADS,/arxiv_data1/oa_pdf/ad/8b/main.PMC4919539.pdf
S1 in the online version at http://dx.doi.org/10.1016/j.ebiom.2016.,OADS,/arxiv_data1/oa_pdf/ad/8b/main.PMC4919539.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Neurodegenerative disorder Parkinson's diseaseHematopoietic stem and progenitor cellsCell fusionAstrogliaWnt/β-catenin Intracerebral transplantation 1.,Non-OADS,/arxiv_data1/oa_pdf/af/36/main.PMC4919540.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.04.016 2352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/af/36/main.PMC4919540.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/af/36/main.PMC4919540.pdf
76. http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/af/36/main.PMC4919540.pdf
"Second, the needs of children inthese contexts are systematically underestimated; current protein and amino acid requirements do not account for conditions of energy de ﬁcit, and persistent or subclinical infections, which could be compounded bysu b-optimal digestive and absorptive intestinal function; emergingEBioMedicine 8 (2016) 28 –29 DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.02.030 .",Non-OADS,/arxiv_data1/oa_pdf/e4/0d/main.PMC4919554.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.05.026 2352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/e4/0d/main.PMC4919554.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e4/0d/main.PMC4919554.pdf
http://dx.doi.org/10.1016/S0140-6736(13)60996-4 .,OADS,/arxiv_data1/oa_pdf/e4/0d/main.PMC4919554.pdf
http://dx.doi.org/10.3390/nu7125508 .,Non-OADS,/arxiv_data1/oa_pdf/e4/0d/main.PMC4919554.pdf
"108, S77 –S87.http://dx.doi.org/10.1017/S0007114512002577 .",Non-OADS,/arxiv_data1/oa_pdf/e4/0d/main.PMC4919554.pdf
"1331, 76 –89.http://dx.doi.org/10.1111/nyas.12596 .",Non-OADS,/arxiv_data1/oa_pdf/e4/0d/main.PMC4919554.pdf
http://dx.doi.org/10.1016/j.foodpol.2009.11.003 .,Non-OADS,/arxiv_data1/oa_pdf/e4/0d/main.PMC4919554.pdf
http://dx.doi.org/10.3945/jn.115.227579.strongly .,Non-OADS,/arxiv_data1/oa_pdf/e4/0d/main.PMC4919554.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: TuberculosisAntibioticInhABactericidalDrug discoverySingle-cell imaging Catalase 1.,Non-OADS,/arxiv_data1/oa_pdf/8f/57/main.PMC4919555.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.05.006 2352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/8f/57/main.PMC4919555.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/8f/57/main.PMC4919555.pdf
Analysis of the time-lapse image stacks was carried out using ImageJ v 1.47a ( http://rsb.info.nih.gov/ij/ ).,OADS,/arxiv_data1/oa_pdf/8f/57/main.PMC4919555.pdf
"In this current issue alone, the journal features studiesEBioMedicine 8 (2016) 1 –2 http://dx.doi.org/10.1016/j.ebiom.2016.06.004 2352-3964/© 2016 The Author.",Non-OADS,/arxiv_data1/oa_pdf/7c/42/main.PMC4919556.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7c/42/main.PMC4919556.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/93/ab/main.PMC4919557.pdf
Kidney Research and Clinical Practice journal homepage: http://www.krcp-ksn.com Contents lists available at ScienceDirect http://dx.doi.org/10.1016/j.krcp.2016.02.002 2211-9132/Copyright ©2016.,Non-OADS,/arxiv_data1/oa_pdf/93/ab/main.PMC4919557.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Kidney Res Clin Pract 35 (2016) 107 e113,Non-OADS,/arxiv_data1/oa_pdf/93/ab/main.PMC4919557.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/37/06/main.PMC4919558.pdf
Kidney Research and Clinical Practice journal homepage: http://www.krcp-ksn.com Contents lists available at ScienceDirect http://dx.doi.org/10.1016/j.krcp.2016.02.003 2211-9132/Copyright ©2016.,Non-OADS,/arxiv_data1/oa_pdf/37/06/main.PMC4919558.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Kidney Res Clin Pract 35 (2016) 96 e101,Non-OADS,/arxiv_data1/oa_pdf/37/06/main.PMC4919558.pdf
"Sanger sequencing was carried out using the ABI 3137 auto-mated sequencer from Applied Biosystems (provided by thePishgam Biotech Company, Tehran, Iran, www.pishgambc.com ).Variant analysis The quality of sequencing was checked through assessing the obtained chromatogram by Sequence Scanner software, version 1.0 ( http://www.appliedbiosystems.com ).",OADS,/arxiv_data1/oa_pdf/37/06/main.PMC4919558.pdf
It is classi ﬁed as de ﬁnitely pathogenic according to the ADPKD Mutation Database ( http://pkdb.mayo.edu/cgi ).,Non-OADS,/arxiv_data1/oa_pdf/37/06/main.PMC4919558.pdf
"Selecting closely, STR markers can reduce the chance of recombination.Here, the physical distance of 2 adjacent markers was about 200 Kb, whereas according to the Marsh ﬁeld map, the genetic distance to telomeric end was 96.2 cM for both markers(http://research.marsh ﬁeldclinic.org ).",OADS,/arxiv_data1/oa_pdf/37/06/main.PMC4919558.pdf
In manyEBioMedicine 8 (2016) 26 –27 DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.03.048 .,OADS,/arxiv_data1/oa_pdf/41/43/main.PMC4919559.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.05.030 2352-3964/© 2016 The Author.,Non-OADS,/arxiv_data1/oa_pdf/41/43/main.PMC4919559.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/41/43/main.PMC4919559.pdf
EBioMedicine http://dx.doi.org/10.1016/j.ebiom.2016.03.048 .,OADS,/arxiv_data1/oa_pdf/41/43/main.PMC4919559.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/10/af/main.PMC4919560.pdf
Kidney Research and Clinical Practice journal homepage: http://www.krcp-ksn.com Contents lists available at ScienceDirect http://dx.doi.org/10.1016/j.krcp.2016.01.003 2211-9132/Copyright ©2016.,Non-OADS,/arxiv_data1/oa_pdf/10/af/main.PMC4919560.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Kidney Res Clin Pract 35 (2016) 102 e106,Non-OADS,/arxiv_data1/oa_pdf/10/af/main.PMC4919560.pdf
"Biocytin injection into single re- corded small HH neurons showed labeling of adjacent neurons, which was not observed in the presence of the neuronal gap-junction blocker, meﬂoquin e. Finally, microelectrode ﬁeld recordings from freshly resected HH slices demonstrated spontaneous ictal/interictal-like dis-charges which were signi ﬁcantly reduced by the application of gap- junction blockers without alterations of the action-potential ﬁring of small GABA neurons observed with patch-clamp whole-cell recordings.EBioMedicine 8 (2016) 5 –6 DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.04.026 .",OADS,/arxiv_data1/oa_pdf/1c/e0/main.PMC4919563.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.05.0242352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/1c/e0/main.PMC4919563.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/1c/e0/main.PMC4919563.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/71/3f/main.PMC4919564.pdf
Kidney Research and Clinical Practice journal homepage: http://www.krcp-ksn.com Contents lists available at ScienceDirect http://dx.doi.org/10.1016/j.krcp.2016.02.004 2211-9132/Copyright ©2016.,Non-OADS,/arxiv_data1/oa_pdf/71/3f/main.PMC4919564.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Kidney Res Clin Pract 35 (2016) 69 e77,Non-OADS,/arxiv_data1/oa_pdf/71/3f/main.PMC4919564.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b4/fa/main.PMC4919565.pdf
Kidney Research and Clinical Practice journal homepage: http://www.krcp-ksn.com Contents lists available at ScienceDirect http://dx.doi.org/10.1016/j.krcp.2015.09.001 2211-9132/Copyright ©2015.,Non-OADS,/arxiv_data1/oa_pdf/b4/fa/main.PMC4919565.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Kidney Res Clin Pract 35 (2016) 123 e126,Non-OADS,/arxiv_data1/oa_pdf/b4/fa/main.PMC4919565.pdf
Kidney Research and Clinical Practice journal homepage: http://www.krcp-ksn.com Contents lists available at ScienceDirect Kidney Res Clin Pract 35 (2016) 127 http://dx.doi.org/10.1016/j.krcp.2016.03.001 2211-9132/Copyright ©2016.,Non-OADS,/arxiv_data1/oa_pdf/dd/65/main.PMC4919566.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/dd/65/main.PMC4919566.pdf
"EBioMedicine 2/11 (2015) 1785 –1798 doi:10.1016/j.ebiom.2015.09.053.EBioMedicine 8 (2016) 349 DOIs of original article: http://dx.doi.org/10.1016/j.ebiom.2015.11.012 ,http://dx.doi.org/10.1016/j.ebiom.2015.09.053 .",OADS,/arxiv_data1/oa_pdf/ad/6e/main.PMC4919567.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.05.033 2352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/ad/6e/main.PMC4919567.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b2/8e/main.PMC4919570.pdf
Kidney Research and Clinical Practice journal homepage: http://www.krcp-ksn.com Contents lists available at ScienceDirect http://dx.doi.org/10.1016/j.krcp.2015.12.005 2211-9132/Copyright ©2016.,Non-OADS,/arxiv_data1/oa_pdf/b2/8e/main.PMC4919570.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Kidney Res Clin Pract 35 (2016) 84 e89,Non-OADS,/arxiv_data1/oa_pdf/b2/8e/main.PMC4919570.pdf
EBioMedicine http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/6d/e5/main.PMC4919571.pdf
http://dx.doi.org/10.1111/acer.13071 .,Non-OADS,/arxiv_data1/oa_pdf/6d/e5/main.PMC4919571.pdf
"DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.04.023 ,http:// dx.doi.org/10.1016/j.ebiom.2016.05.021 .",OADS,/arxiv_data1/oa_pdf/6d/e5/main.PMC4919571.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.05.0222352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/6d/e5/main.PMC4919571.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6d/e5/main.PMC4919571.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Docking proteinDOKRAS PPAR Colorectal cancer 1.,Non-OADS,/arxiv_data1/oa_pdf/95/33/main.PMC4919572.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.05.0032352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/95/33/main.PMC4919572.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/95/33/main.PMC4919572.pdf
"The Mdk-Ab (mouse anti-human MdkIgG1 monoclonal antibody, cross reactive to murine Mdk; ELISA EC50to human Mdk: 31.7 ng·mL/C01;a n d ELISA EC50to mouse Mdk: 37.8 ng·mL/C01, provided by Cellmid Ltd., Sydney, Australia) was administered s.c. at 25 mg·kg/C01twice weeklyTables of Links TARGETS Other protein targetsaCatalytic receptorsc α-Tubulin PTPRz (RTP type Z1) GPCRsbEnzymesd F4/80 (ADGRE1) GSK3 βLIGANDS β-Catenin Pleiotrophin Insulin TGF β1 These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacolog y.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (a,b,c,dAlexander et al., 2015a,b,c,d).",Non-OADS,/arxiv_data1/oa_pdf/65/11/BPH-173-2237.PMC4919577.pdf
"Supporting Information Additional Supporting Information may be found in the on- line version of this article at the publisher ’s web-site: http://dx.doi.org/10.1111/bph.13503 Figure S1 Mdk-Ab treatment accelerated fracture healing, whereas control IgG did not affect fracture healing.",Non-OADS,/arxiv_data1/oa_pdf/65/11/BPH-173-2237.PMC4919577.pdf
"NAMPT is involved in different immunometabolic disor- ders, including cancer (Bi and Che, 2010), and selective in-hibitors of this enzyme, such as FK866/APO866 andCHS828/GMX1777, have been entered into phase I/II clinicaltrials for solid and non-solid tumours (http://www.clinicaltrials.gov ) (Galli et al.",Non-OADS,/arxiv_data1/oa_pdf/c5/54/BPH-173-2182.PMC4919578.pdf
", 2013; Wang and Miao, 2015), and there- fore, this review will not cover reports on this enzyme inother disease states.Tables of Links TARGETS Other protein targetsaEnzymese CD28 Akt (PKB) CD38 COX-2 Notch receptors DDAH2, NG,NG-dimethylarginine dimethylaminohydrolase 2 GPCRsbERK CCR2 FAS, fatty acid synthase CCR5 HDACCXCR4 Indoleamine 2,3-dioxygenase 1CXCR7 iNOS Ligand-gated ion channels cMMP2 P2X7 channels MMP9Catalytic receptors dJAK2 Insulin receptor JNK TLR-4 p38 PKA PARPs SIRT1LIGANDS ATP Insulin CCL2 IL-7Chloroquine IL-10 CXCL8, IL-8 LPS CXCL12, SDF-1 SivelestatFK866, daporinad Trichostatin AG-CSF TNF- α IL-1ß VEGF IL-6 These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacolog y.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (a,b,c,d,eAlexander et al., 2015a,b,c,d,e).eNAMPT and cancer BJP British Journal of Pharmacology (2016) 173 2182 –2194 2183",Non-OADS,/arxiv_data1/oa_pdf/c5/54/BPH-173-2182.PMC4919578.pdf
"The use of enzyme inhibitors, such as those used in clinical trials (http://www.clinicaltrials.gov) (Zak et al.",Non-OADS,/arxiv_data1/oa_pdf/c5/54/BPH-173-2182.PMC4919578.pdf
"Abbreviations 7TM, seven transmembrane; PDB, Protein Data Bank Table of Links TARGETS 5-HT 1Breceptor CCR5 NTS 1receptor β1-adrenoceptor D 3receptor OX 2receptor β2-adrenoceptor FFA1 receptor PAR1 δreceptor H 3receptor P2Y 1receptor μreceptor LPA 1receptor S1P 1receptor A2Areceptor M 2receptor AT1receptor mGlu 1receptor This table lists key protein targets in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the co m- mon portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015).",Non-OADS,/arxiv_data1/oa_pdf/c1/81/BPH-173-2195.PMC4919580.pdf
The complete sourcecode is freely available at https://bitbucket.org/gpcr/protwis.,Non-OADS,/arxiv_data1/oa_pdf/c1/81/BPH-173-2195.PMC4919580.pdf
"Moreover, this work and espe-cially the in vivo experiments rely on previously described experiments on bladder pressure evaluation by telemetry inTables of Links TARGETS GPCRsaEnzymesb PAR1 COX1 PAR2 Neutrophil elastase PAR3 Neuronal NOS PAR4LIGANDS Acrolein Lidocaine Cyclophosphamide TFLLR-NH 2 Furosemide Thrombin GTPγS These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacolog y.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (a,bAlexander et al., 2015a,b).F16357 for the management of interstitial cystitis BJP British Journal of Pharmacology (2016) 173 2224 –2236 2225",Non-OADS,/arxiv_data1/oa_pdf/fa/b3/BPH-173-2224.PMC4919585.pdf
The authors conclude that LEDGINs may help reduce the portion of the HIV reservoir that is susceptible toEBioMedicine 8 (2016) 14 –15 DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.04.039 .,OADS,/arxiv_data1/oa_pdf/84/43/main.PMC4919589.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.05.007 2352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/84/43/main.PMC4919589.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/84/43/main.PMC4919589.pdf
"Magnes Trace Elem 9:1e14, 1990 Kidney Research and Clinical Practice journal homepage: http://www.krcp-ksn.com Contents lists available at ScienceDirect Kidney Res Clin Pract 35 (2016) 128 e129 http://dx.doi.org/10.1016/j.krcp.2016.04.002 2211-9132/Copyright ©2016.",Non-OADS,/arxiv_data1/oa_pdf/33/86/main.PMC4919590.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/33/86/main.PMC4919590.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/ licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/9f/f2/main.PMC4919591.pdf
Kidney Research and Clinical Practice journal homepage: http://www.krcp-ksn.com Contents lists available at ScienceDirect http://dx.doi.org/10.1016/j.krcp.2015.08.006 2211-9132/Copyright ©2015.,Non-OADS,/arxiv_data1/oa_pdf/9f/f2/main.PMC4919591.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Kidney Res Clin Pract 35 (2016) 119 e122,Non-OADS,/arxiv_data1/oa_pdf/9f/f2/main.PMC4919591.pdf
"To date, more than 1,272 PKD1 and 202 PKD2 different pathologic mutations have been reported ( http://pkdb.mayo.",Non-OADS,/arxiv_data1/oa_pdf/5c/58/main.PMC4919592.pdf
"Hum Mutat 35:1393 e1406, 2014 [3]Hateboer N, v Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, Torra R, Breuning M, Ravine D: Comparison of Kidney Research and Clinical Practice journal homepage: http://www.krcp-ksn.com Contents lists available at ScienceDirect Kidney Res Clin Pract 35 (2016) 67 e68 http://dx.doi.org/10.1016/j.krcp.2016.04.004 2211-9132/Copyright ©2016.",Non-OADS,/arxiv_data1/oa_pdf/5c/58/main.PMC4919592.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5c/58/main.PMC4919592.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: HIV EnvelopeNeutralizationCo-receptorEvolutionResistanceTropism 1.,Non-OADS,/arxiv_data1/oa_pdf/33/c1/main.PMC4919596.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.04.040 2352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/33/c1/main.PMC4919596.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/33/c1/main.PMC4919596.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Energy metabolism Brush cellsCatecholamineInsulin 1.,Non-OADS,/arxiv_data1/oa_pdf/93/4a/main.PMC4919597.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.04.031 2352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/93/4a/main.PMC4919597.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/93/4a/main.PMC4919597.pdf
"All microarray data are MIAME compliant and have been deposited in a MIAME-compliant database, the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus ( http://www.ncbi.nlm.nih.gov/geo/ , GEO Se- ries accession number GSE76936), as described in more detail on the MGED Society web site ( http://www.mged.org/Workgroups/MIAME/ miame.html ).61 S. Ushiama et al.",OADS,/arxiv_data1/oa_pdf/93/4a/main.PMC4919597.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: MxBHIV-1Capsid variantsPositive selection 1.,Non-OADS,/arxiv_data1/oa_pdf/58/38/main.PMC4919602.pdf
Approximately 35.0 million people were infected with HIV at the end of 2013 globally ( http://www.who.int/ mediacentre/factsheets/fs360/en/ ).,Non-OADS,/arxiv_data1/oa_pdf/58/38/main.PMC4919602.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.04.020 2352-3964/© 2016 Published by Elsevier B.V.,Non-OADS,/arxiv_data1/oa_pdf/58/38/main.PMC4919602.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/58/38/main.PMC4919602.pdf
"This is of interest given that the drinking of moder- ate amounts of red wine regularly is probably associated with a relative health bene ﬁt thanks to antioxidants such as polyphenols, particularly resveratrol.EBioMedicine 8 (2016) 23 –24 DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.04.023 .",Non-OADS,/arxiv_data1/oa_pdf/57/a9/main.PMC4919607.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.05.021 2352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/57/a9/main.PMC4919607.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/57/a9/main.PMC4919607.pdf
http://dx.doi.org/10.1111/hepr.,Non-OADS,/arxiv_data1/oa_pdf/57/a9/main.PMC4919607.pdf
EBioMedicine http://dx.doi.org/10.1016/j.ebiom.2016.04.023 .,OADS,/arxiv_data1/oa_pdf/57/a9/main.PMC4919607.pdf
"Because inﬂammation can result in DNA damage and vice versa, the use of such inhibitors in preclinical models might also permit investigators intheﬁeld to sort out the order of events in Fanconi anemia pathogenesis.EBioMedicine 8 (2016) 10 –11 DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.05.055 .",Non-OADS,/arxiv_data1/oa_pdf/a5/e9/main.PMC4919608.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.06.005 2352-3964/© 2016 The Author.,Non-OADS,/arxiv_data1/oa_pdf/a5/e9/main.PMC4919608.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a5/e9/main.PMC4919608.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Human epilepsy Hypothalamic hamartoma Gelastic seizuresPatch-clampGap junction 1.,Non-OADS,/arxiv_data1/oa_pdf/bc/00/main.PMC4919609.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.04.026 2352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/bc/00/main.PMC4919609.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/bc/00/main.PMC4919609.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: HyperinsulinemiaCell activationInﬂammation Coagulation Endothelium 1.,Non-OADS,/arxiv_data1/oa_pdf/de/00/main.PMC4919610.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.05.008 2352-3964/© 2016 Published by Elsevier B.V.,Non-OADS,/arxiv_data1/oa_pdf/de/00/main.PMC4919610.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/de/00/main.PMC4919610.pdf
http://dx.doi.org/10.1189/jlb.4A1215-534R .,Non-OADS,/arxiv_data1/oa_pdf/de/00/main.PMC4919610.pdf
http://dx.doi.org/10.1189/jlb.5AB0915-406R .,OADS,/arxiv_data1/oa_pdf/de/00/main.PMC4919610.pdf
http://dx.doi.org/10.1111/hiv.12310 .,Non-OADS,/arxiv_data1/oa_pdf/de/00/main.PMC4919610.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: CBFβ RUNX PPI Transcription factor inhibitorLeukemiaTriple negative breast cancer 1.,Non-OADS,/arxiv_data1/oa_pdf/23/27/main.PMC4919611.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.04.032 2352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/23/27/main.PMC4919611.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/23/27/main.PMC4919611.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Non-speci ﬁce f f e c t s Vaccination StuntingTime-dependencyPolicy 1.,Non-OADS,/arxiv_data1/oa_pdf/51/41/main.PMC4919612.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.05.010 2352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/51/41/main.PMC4919612.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/51/41/main.PMC4919612.pdf
"Meeting of the strategic advisory group of experts on immunization.Available from: http://www.who.int/immunization/sage/meetings/2014/april/3_ NSE_Epidemiology_review_Report_to_SAGE_14_Mar_FINAL.pdf (Website accessed March 5, 2015).",Non-OADS,/arxiv_data1/oa_pdf/51/41/main.PMC4919612.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: β-catenin Melanoma BRAF Stat3ResistanceVemurafenib 1.,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.04.037 2352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1172/JCI65780 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1172/JCI70156 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1126/science.aaa4559 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1126/scisignal.2002274 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1038/nature13572 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1158/1535-7163.MCT-13-0011 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
Book http://dx.doi.org/10.1200/EdBook_AM.2013.33.e80 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1056/NEJMoa1103782 .,OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1371/journal.pone.0094748 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.4161/cc.21645 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1038/nature00766 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1038/sj.onc.1204064 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1074/jbc.M700075200 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
Pigment Cell MelanomaRes.http://dx.doi.org/10.1111/j.1755-148X.2011.00871.x .,OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1056/NEJMoa1002011 .,OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1158/2159-8290.CD-12-0386 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1126/scisignal.2003398 .147 T. Sinnberg et al.,OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1016/S0140-6736(12)60868-X .,OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1158/0008-5472.CAN-07-2491 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1038/nrc3760 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1111/pcmr.12347 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1016/j.molcel.2009.09.034 .,OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1200/JCO.2014.57.3535 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1093/carcin/bgr222 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1016/j.celrep.2015.04.049 .,OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
"1276, 1–10.http://dx.doi.org/10.1016/j.brainres.2009.04.031 .",OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1038/jid.2013.32 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1200/JCO.2010.32.4327 .,OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
371. http://dx.doi.org/10.1056/NEJMoa1406037 (140929070023009).,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1126/scisignal.2002372 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1016/S1470-2045(14)70072-5 .,OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1371/journal.pbio.0040115 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
"5, 5712. http://dx.doi.org/10.1038/ncomms6712 .",Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
"http://dx.doi.org/10.1038/nature09626 .O'Connell, M.P., Marchbank, K., Webster, M.R., Valiga, A.A., Kaur, A., Vultur, A., Li, L., Herlyn, M., Villanueva, J., Liu, Q., Yin, X., Widura, S., Nelson, J., Ruiz, N., Camilli, T.C., Indig, F.E., Flaherty, K.T., Wargo, J.A., Frederick, D.T., Cooper, Z.A., Nair, S., Amaravadi, R.K., Schuchter, L.M., Karakousis, G.C., Xu, W., Xu, X., Weeraratna, A.T., 2013.",Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1158/2159-8290.CD-13-0005 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
"30, 96. http://dx.doi.org/10.1186/1756-9966-30-96 .",Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1016/j.cellsig.2013.11.021 .,OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1158/1078-0432.CCR-13-3122 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
372. http://dx.doi.org/10.1056/NEJMoa1412690 (141116004513004).,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
"Cancer 9, 310. http://dx.doi.org/10.1186/1476-4598-9-310 .",Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1038/jid.2012.45 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1093/nar/gkt1060 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1158/2159-8290.CD-13-0642 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1158/0008-5472.CAN-10-0645 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
"PLoS One 6, e23429.http://dx.doi.org/10.1371/journal.pone.0023429 .",Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1016/j.ccell.2016.02.003 .,OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1016/j.celrep.2014.07.010 .,OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1038/nature11183 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1038/nature13121 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1038/oncsis.2014.23 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1074/mcp.M114.044016 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1093/emboj/19.18.4944 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
"369, 101 – 114. http://dx.doi.org/10.1016/j.ydbio.2012.06.020 .",OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1038/sj.embor.embor865 .,OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1016/j.ccr.2010.11.023 .,OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1038/onc.2013.131 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1200/JCO.2010.33.2312 .,OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1158/1078-0432.CCR-06-1387 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
"http://dx.doi.org/10.1371/journal.pone.0143142 .Watanabe, K., Dai, X., 2011.",OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1126/scisignal.2002436 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1083/jcb.200202049 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1038/nature11249 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1186/1749-8104-8-7 .,Non-OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
http://dx.doi.org/10.1002/jcb.23079 .149 T. Sinnberg et al.,OADS,/arxiv_data1/oa_pdf/d4/35/main.PMC4919613.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution- NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commercial use, distributio n, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/8a/5c/zano-7-11821429.PMC4919641.pdf
"Citation: Nano Reviews 2016, 7:31996 - http://dx.doi.org/10.3402/nano.v7.319961 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/8a/5c/zano-7-11821429.PMC4919641.pdf
"2 (page number not for citation purpose)Citation: Nano Reviews 2016, 7: 31996 - http://dx.doi.org/10.3402/nano.v7.31996",Non-OADS,/arxiv_data1/oa_pdf/8a/5c/zano-7-11821429.PMC4919641.pdf
"Before adding the poly(vinyl alcohol) (PV A), large interfacial tension is formed at curved surfaces (causing formation of unstable emulsion); after theaddition of the PV A, the interfacial tension decreases by making the interfacial surface ﬂat.MTX PLA-PEG-PLA nanoparticles for breast cancer treatment Citation: Nano Reviews 2016, 7: 31996 - http://dx.doi.org/10.3402/nano.v7.31996 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/8a/5c/zano-7-11821429.PMC4919641.pdf
"4 (page number not for citation purpose)Citation: Nano Reviews 2016, 7: 31996 - http://dx.doi.org/10.3402/nano.v7.31996",Non-OADS,/arxiv_data1/oa_pdf/8a/5c/zano-7-11821429.PMC4919641.pdf
"Particle size of BSA-coated, MTX-loaded nano- particles at different PV A concentrations Formulation PVA%Particle size (nm) PDI BSA/C1MTX-loaded NPs 3 168.75 91.10 0.254 90.012 BSA/C1MTX-loaded NPs 2 196.35 91.63 0.324 90.006 BSA/C1MTX-loaded NPs 1 218.67 92.70 0.332 90.10 BSA/C1MTX-loaded NPs 0.5 274.36 94.86 0.306 90.012MTX PLA-PEG-PLA nanoparticles for breast cancer treatment Citation: Nano Reviews 2016, 7: 31996 - http://dx.doi.org/10.3402/nano.v7.31996 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/8a/5c/zano-7-11821429.PMC4919641.pdf
"6 (page number not for citation purpose)Citation: Nano Reviews 2016, 7: 31996 - http://dx.doi.org/10.3402/nano.v7.31996",Non-OADS,/arxiv_data1/oa_pdf/8a/5c/zano-7-11821429.PMC4919641.pdf
"Drug release of MTX-loaded PLA-PEG-PLA NPs and BSA-coated, MTX-loaded PLA-PEG-PLA NPs.MTX PLA-PEG-PLA nanoparticles for breast cancer treatment Citation: Nano Reviews 2016, 7: 31996 - http://dx.doi.org/10.3402/nano.v7.31996 7 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/8a/5c/zano-7-11821429.PMC4919641.pdf
"8 (page number not for citation purpose)Citation: Nano Reviews 2016, 7: 31996 - http://dx.doi.org/10.3402/nano.v7.31996",Non-OADS,/arxiv_data1/oa_pdf/8a/5c/zano-7-11821429.PMC4919641.pdf
"Ge H, Hu Y , Yang S, Jiang X, Yang C. Preparation, characterization, and drug release behaviors of drug-loadedMTX PLA-PEG-PLA nanoparticles for breast cancer treatment Citation: Nano Reviews 2016, 7: 31996 - http://dx.doi.org/10.3402/nano.v7.31996 9 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/8a/5c/zano-7-11821429.PMC4919641.pdf
"10 (page number not for citation purpose)Citation: Nano Reviews 2016, 7: 31996 - http://dx.doi.org/10.3402/nano.v7.31996",OADS,/arxiv_data1/oa_pdf/8a/5c/zano-7-11821429.PMC4919641.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/27/30/main.PMC4919657.pdf
Kidney Research and Clinical Practice journal homepage: http://www.krcp-ksn.com Contents lists available at ScienceDirect http://dx.doi.org/10.1016/j.krcp.2016.02.001 2211-9132/Copyright ©2016.,Non-OADS,/arxiv_data1/oa_pdf/27/30/main.PMC4919657.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Kidney Res Clin Pract 35 (2016) 78 e83,Non-OADS,/arxiv_data1/oa_pdf/27/30/main.PMC4919657.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Antiretroviral therapyGut microbiotaHIVImmune recoveryMetabolome Metaproteome 1.,Non-OADS,/arxiv_data1/oa_pdf/a3/4c/main.PMC4919658.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.04.033 2352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a3/4c/main.PMC4919658.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/4c/main.PMC4919658.pdf
"Table 1 summarizes the characteristics of the individuals, which are detailed in Table S1 in the online version at http://dx.doi.",OADS,/arxiv_data1/oa_pdf/a3/4c/main.PMC4919658.pdf
The resulting list of accurate masses that sig- niﬁcantly differed between groups was searched using the CEU Mass Mediator search tool ( http://biolab.uspceu.com/mediator; error ± 5 Da) to obtain tentative identi ﬁcations.,OADS,/arxiv_data1/oa_pdf/a3/4c/main.PMC4919658.pdf
Their identities were con ﬁrmed by comparing the fragments that were obtained with the structure of the proposed compound in the MS/MS spectra in a public database (METLIN: https://metlin.scripps.edu/metabolites_list.php ) or against commercially available standards.,OADS,/arxiv_data1/oa_pdf/a3/4c/main.PMC4919658.pdf
After treatment of the data (Table S3 in the online ver- sion at http://dx.doi.org/10.1016/j.ebiom.2016.04.033 .,OADS,/arxiv_data1/oa_pdf/a3/4c/main.PMC4919658.pdf
"Statistically signi ﬁcant differences for the innate immune activation markers CD4+ T-cells, nadir CD4+ T-cells, CD4/CD8 ratio and %CD8+ HLA-DR + CD38+ T cells (Table S1 in the online version at http://dx.doi.org/10.1016/j.ebiom.2016.04.033 .)",OADS,/arxiv_data1/oa_pdf/a3/4c/main.PMC4919658.pdf
S3; Table S3 in the online version at http://dx.doi.org/ 10.1016/j.ebiom.2016.04.033 .,OADS,/arxiv_data1/oa_pdf/a3/4c/main.PMC4919658.pdf
The plasma metabolomes (Table S5 in the online version at http://dx.doi.org/10.1016/j.ebiom.,OADS,/arxiv_data1/oa_pdf/a3/4c/main.PMC4919658.pdf
were less complex than those in the gut microbiota (Table S3 in the online version at http://dx.doi.org/10.1016/j.ebiom.,OADS,/arxiv_data1/oa_pdf/a3/4c/main.PMC4919658.pdf
(2013) as distinguishing HIV-infected and uninfected in- dividuals such as lipids and lipopolysaccharides (Table S5 in the online version at http://dx.doi.org/10.1016/j.ebiom.2016.04.033 .,OADS,/arxiv_data1/oa_pdf/a3/4c/main.PMC4919658.pdf
We captured the protein expression pro ﬁles and the differences in the composition and abundance of proteins being expressed and the active community members expressing them (Table S6 in the online ver- sion at http://dx.doi.org/10.1016/j.ebiom.2016.04.033 .),OADS,/arxiv_data1/oa_pdf/a3/4c/main.PMC4919658.pdf
Samples were selected to cover the widest spectrum of sampling factors (Table S1 in the online version at http://dx.doi.org/10.1016/j.ebiom.2016.04.033 .,OADS,/arxiv_data1/oa_pdf/a3/4c/main.PMC4919658.pdf
The taxonomic distribution of the identi ﬁed expressed proteins at the family level (Table S5 in the online version at http://dx.doi.org/ 10.1016/j.ebiom.2016.04.033 .),OADS,/arxiv_data1/oa_pdf/a3/4c/main.PMC4919658.pdf
By examining the taxonomic assign- ments of the proteins that are expressed (Table S6 in the online version athttp://dx.doi.org/10.1016/j.ebiom.2016.04.033 .,OADS,/arxiv_data1/oa_pdf/a3/4c/main.PMC4919658.pdf
"This hypothesis is supported by the fact that a solute-binding domain of the SLC5/6 protein trans- porter (gi|671,503,691) binned to Succinivibrionaceae was exclusivelyexpressed in this group of patients (Table S6 in the online version at http://dx.doi.org/10.1016/j.ebiom.2016.04.033 .",Non-OADS,/arxiv_data1/oa_pdf/a3/4c/main.PMC4919658.pdf
"Correlations between Markers of Innate and Adaptive Immunity and Active Gut Microbiota Finally, we used the Generalized Linear Model (GLM) to explore the interactions between the abundance level of active taxonomic groups ex- pressing proteins (Table S6 in the online version at http://dx.doi.org/10.",OADS,/arxiv_data1/oa_pdf/a3/4c/main.PMC4919658.pdf
http://dx.doi.org/10.1164/rccm.201202-0320ST .,Non-OADS,/arxiv_data1/oa_pdf/da/e9/main.PMC4919717.pdf
http://dx.doi.org/10.1164/ajrccm.160.2.ats4 –99.,Non-OADS,/arxiv_data1/oa_pdf/da/e9/main.PMC4919717.pdf
http://dx.doi.org/10.1378/chest.13 –2339 .,Non-OADS,/arxiv_data1/oa_pdf/da/e9/main.PMC4919717.pdf
http://dx.doi.org/10.1111/resp.12449 .,Non-OADS,/arxiv_data1/oa_pdf/da/e9/main.PMC4919717.pdf
http://dx.doi.org/10.2478/v10039 –008-0014-z .EBioMedicine 8 (2016) 20 DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.04.024 .,OADS,/arxiv_data1/oa_pdf/da/e9/main.PMC4919717.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.05.002 2352-3964/© 2016 The Author.,Non-OADS,/arxiv_data1/oa_pdf/da/e9/main.PMC4919717.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/da/e9/main.PMC4919717.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/73/32/main.PMC4919718.pdf
Kidney Research and Clinical Practice journal homepage: http://www.krcp-ksn.com Contents lists available at ScienceDirect http://dx.doi.org/10.1016/j.krcp.2016.04.001 2211-9132/Copyright ©2016.,Non-OADS,/arxiv_data1/oa_pdf/73/32/main.PMC4919718.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Kidney Res Clin Pract 35 (2016) 90 e95,Non-OADS,/arxiv_data1/oa_pdf/73/32/main.PMC4919718.pdf
This  is  an  open access article under the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/dc/cc/main.PMC4919719.pdf
http://dx.doi.org/10.1016/j.ijscr.2016.06.007 2210-2612/© 2016  The  Author(s).,Non-OADS,/arxiv_data1/oa_pdf/dc/cc/main.PMC4919719.pdf
Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) http://dx.doi.org/10.1016/j.nmni.2016.05.014,Non-OADS,/arxiv_data1/oa_pdf/8e/43/main.PMC4919720.pdf
massiliodielmoens ’is available at http://www.mediterranee-infection.com/article.php?,Non-OADS,/arxiv_data1/oa_pdf/8e/43/main.PMC4919720.pdf
"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI ,13,2 7 –28 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/8e/43/main.PMC4919720.pdf
"The use of standard clinical measurements may provide insights into risk for comorbidities in ART-treated HIV+ individuals, however, measurement of traditional lipid panels (LDL, HDL, and tri- glycerides) ( Munger et al., 2015 ) and risk calculators such as theEBioMedicine 8 (2016) 16 –17 DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.05.008 .",Non-OADS,/arxiv_data1/oa_pdf/13/d5/main.PMC4919721.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.05.012 2352-3964/© 2016 The Author.,Non-OADS,/arxiv_data1/oa_pdf/13/d5/main.PMC4919721.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/13/d5/main.PMC4919721.pdf
"Biophysical Journal 110, 2581–2584, June 21, 2016 2581http://dx.doi.org/10.1016/j.bpj.2016.05.028 /C2112016 Biophysical Society.",OADS,/arxiv_data1/oa_pdf/e6/66/main.PMC4919722.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Non-alcoholic fatty liverAlcoholic fatty liverAlcohol drinkingBinge drinkingPrevalenceIncidence Systematic review Meta-analysis 1.,Non-OADS,/arxiv_data1/oa_pdf/2f/1b/main.PMC4919723.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.04.023 2352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/2f/1b/main.PMC4919723.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2f/1b/main.PMC4919723.pdf
"Evidence from a systematic review and meta-analysis, Journal of Gastro-enterology and Hepatology http://dx.doi.org/10.1111/jgh.13264 (Epub ahead of print).",Non-OADS,/arxiv_data1/oa_pdf/2f/1b/main.PMC4919723.pdf
Hepatology http://dx.doi.org/10.1002/hep.28431 (Epub ahead of print).,Non-OADS,/arxiv_data1/oa_pdf/2f/1b/main.PMC4919723.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2d/71/main.PMC4919724.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.elsevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2016.06.004 2213-0071/ ©2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/2d/71/main.PMC4919724.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Respiratory Medicine Case Reports 19 (2016) 15 e17,Non-OADS,/arxiv_data1/oa_pdf/2d/71/main.PMC4919724.pdf
"Biophysical Journal 110, 2779–2789, June 21, 2016 2779http://dx.doi.org/10.1016/j.bpj.2016.03.023 /C2112016 Biophysical Society This is an open access article under the CC BY-NC-ND license ( http:// creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/7e/fd/main.PMC4919725.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Non-valvular atrial ﬁbrillation Chronic kidney disease StrokeMajor bleedingClinical outcomes 1.,Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.04.013 2352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.1001/jama.293.6.690 .,OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.1093/eurheartj/ eht328 .,Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.1016/j.jacc.2013.02.035 .,OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.1378/chest.13-2103 .,Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.1016/j.jacc.2014.09.051 .,OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.1093/ eurheartj/ehs253 .,Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.1161/CIRCULATIONAHA.107.750000 .,Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.1160/TH13-06-0443 .,Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
"JAMA 291, 844. http://dx.doi.org/10.1001/jama.291.7.844 .",Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
297– 306. http://dx.doi.org/10.1093/eurheartj/ehu139 .,Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.1016/S0002-8703(03)00325-9 .,OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.2215/CJN.02400311 .,Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.1371/ journal.pone.0094420 .,Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.1001/jama.2015.0602 .,Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.1053/j.ajkd.2014.11.004 .,OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
"1), 25 –30.http://dx.doi.org/10.1159/ 000083081 .",Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
"http://dx.doi.org/10.1378/chest.09-1584 .Lip, G.Y.H., Skjøth, F., Rasmussen, L.H., Larsen, T.B., 2015.",OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.1016/j.ahj.2015.03.017 .,OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.1093/ europace/euv416 .,Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.1016/j.amjcard.,OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
"Circulation 116, 85 –97.http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.1111/j.1538-7836.2005.01204.x .,Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
"278, 1–18.http://dx.doi.org/10.1111/joim.12360 .",Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
http://dx.doi.org/10.1001/archinte.167.3.239 .316 M. Proietti et al.,Non-OADS,/arxiv_data1/oa_pdf/56/ba/main.PMC4919727.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Adult B-ALLPediatric B-ALLNext-generation sequencingMEF2D fusions ZNF384 fusions 1.,Non-OADS,/arxiv_data1/oa_pdf/e3/a1/main.PMC4919728.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.04.0382352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/e3/a1/main.PMC4919728.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e3/a1/main.PMC4919728.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: HIV latencyHIV remissionIntegrationLEDGINLEDGF/p75 1.,Non-OADS,/arxiv_data1/oa_pdf/a5/a8/main.PMC4919729.pdf
http://dx.doi.org/10.1016/j.ebiom.2016.04.039 2352-3964/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a5/a8/main.PMC4919729.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a5/a8/main.PMC4919729.pdf
This  is  an  open access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d2/6e/main.PMC4919793.pdf
"She  had  an  uncomplicated course  after  her  hysterectomy,  she  was  not  receiving  hormonal http://dx.doi.org/10.1016/j.ijscr.2016.06.004 2210-2612/© 2016  The  Author(s).",Non-OADS,/arxiv_data1/oa_pdf/d2/6e/main.PMC4919793.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/16/35/main.PMC4919797.pdf
Contents lists available at ScienceDirect Annals of Medicine and Surgery journal homepage: www.annalsjournal.com http://dx.doi.org/10.1016/j.amsu.2016.05.018 2049-0801/ ©2016 The Author(s).,Non-OADS,/arxiv_data1/oa_pdf/16/35/main.PMC4919797.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/dibData in Brief http://dx.doi.org/10.1016/j.dib.2016.05.079 2352-3409/ &2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/b8/fc/main.PMC4919798.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).DOI of original article: http://dx.doi.org/10.1016/j.jep.2016.05.009 nCorresponding author.,Non-OADS,/arxiv_data1/oa_pdf/b8/fc/main.PMC4919798.pdf
Supplementary material Transparency data associated with this article can be found in the online version at http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b8/fc/main.PMC4919798.pdf
Supplementary material Supplementary document associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.dib.2016.05.079 .,Non-OADS,/arxiv_data1/oa_pdf/b8/fc/main.PMC4919798.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c1/5d/main.PMC4919802.pdf
Contents lists available at ScienceDirect International Journal for Parasitology: Parasites and Wildlife journal homepage: www.elsevier.com /locate/ijppaw http://dx.doi.org/10.1016/j.ijppaw.2016.06.002 2213-2244/ ©2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c1/5d/main.PMC4919802.pdf
This assay is designed for qualitative in vitro detection ofhuman immunoglobulin G (IgG) antibody to individual proteins of B. burgdorferi (B31) in human serum ( http://www.trinitybiotech.,Non-OADS,/arxiv_data1/oa_pdf/c1/5d/main.PMC4919802.pdf
http://www.cdc.gov/ lyme/ (accessed 16.12.15.).,OADS,/arxiv_data1/oa_pdf/c1/5d/main.PMC4919802.pdf
http://dx.doi.org/10.1016/j.ttbdis.2016.02.012 .,OADS,/arxiv_data1/oa_pdf/c1/5d/main.PMC4919802.pdf
"2012, 959101.http://dx.doi.org/10.1155/2012/959101 .",Non-OADS,/arxiv_data1/oa_pdf/c1/5d/main.PMC4919802.pdf
https://tpwd.texas.,Non-OADS,/arxiv_data1/oa_pdf/c1/5d/main.PMC4919802.pdf
Available from: http://www.mciindia.org/Rules-and-Regulation/TEQ- REGULA TIONS-16.05.15.pdf.,Non-OADS,/arxiv_data1/oa_pdf/0a/6f/IJCM-41-169.PMC4919927.pdf
[Online] Available from: https://scholarlyoa.com/2015/01/02/bealls-list-of-predatory-publishers-2015/ [Last accessed on 2016 May 24] 5.,Non-OADS,/arxiv_data1/oa_pdf/0a/6f/IJCM-41-169.PMC4919927.pdf
[Online] Available from: http://www.earlham.edu/~peters/fos/ overview.htm [Last accessed on 2016 Jun 3] 6.,Non-OADS,/arxiv_data1/oa_pdf/0a/6f/IJCM-41-169.PMC4919927.pdf
[Online] Available from: http://oad.simmons.edu/oadwiki/ OA_journal_ business_models.,Non-OADS,/arxiv_data1/oa_pdf/0a/6f/IJCM-41-169.PMC4919927.pdf
Available from: https://en.wikipedia.org/wiki/Open_access#cite_note- Suber2012-14.,Non-OADS,/arxiv_data1/oa_pdf/0a/6f/IJCM-41-169.PMC4919927.pdf
Available from: http://www.mciindia.org/circulars/Circular-03.09.2015-TEQ-PromotionPublication.pdf.,Non-OADS,/arxiv_data1/oa_pdf/0a/6f/IJCM-41-169.PMC4919927.pdf
Available from: http://indmed.nic.in/.,OADS,/arxiv_data1/oa_pdf/0a/6f/IJCM-41-169.PMC4919927.pdf
Available from: http://thinkchecksubmit.org/.,Non-OADS,/arxiv_data1/oa_pdf/0a/6f/IJCM-41-169.PMC4919927.pdf
Available from: http://www.thehindu.com/news/national/other-states/ima-protests-bsc-course-in-community-health/article7815885.ece.,Non-OADS,/arxiv_data1/oa_pdf/ef/d6/IJCM-41-172.PMC4919928.pdf
Available from: http://www.slate.com/authors.brian_palmer.html.,Non-OADS,/arxiv_data1/oa_pdf/74/a9/IJCM-41-177.PMC4919929.pdf
Available from: http://www.nchpeg.org/bssr/index.php [Last accessed on 2014 Jun 3].,OADS,/arxiv_data1/oa_pdf/74/a9/IJCM-41-177.PMC4919929.pdf
"Available from: http://www.fhi.no/eway/default.aspx?pid=240& trg=MainContent_6898&Main_6664=6898:0:25,7697:1:0:0:::0:0&MainContent_6898=6706:0:25,8379:1:0:0:::0:0.",OADS,/arxiv_data1/oa_pdf/74/a9/IJCM-41-177.PMC4919929.pdf
Available from: http://www.sdu.dk/en/omsdu/instituttercentre/ist_sundhedstjenesteforsk/centre/dtr.,OADS,/arxiv_data1/oa_pdf/74/a9/IJCM-41-177.PMC4919929.pdf
Available from: http://ki.se/en/research/the-swedish-twin-registry-1.,OADS,/arxiv_data1/oa_pdf/74/a9/IJCM-41-177.PMC4919929.pdf
Available  from: http://www.ird.lk /T win%20Registry.php.,OADS,/arxiv_data1/oa_pdf/74/a9/IJCM-41-177.PMC4919929.pdf
Available from: http://www.searo.who.int/india/tobacco/en/.,Non-OADS,/arxiv_data1/oa_pdf/1f/6f/IJCM-41-190.PMC4919931.pdf
Available from: http://www.rcplondon.ac.uk/pubs/books/nicotine.,Non-OADS,/arxiv_data1/oa_pdf/1f/6f/IJCM-41-190.PMC4919931.pdf
Available from: http://mohfw.nic.in/ WriteReadData/l892s/1455618937GATS%20India.pdf.,Non-OADS,/arxiv_data1/oa_pdf/1f/6f/IJCM-41-190.PMC4919931.pdf
Available from: http://apps.nccd.cdc.gov/gtssdata/Ancillary/DataReports.aspx?CAID=2.,OADS,/arxiv_data1/oa_pdf/1f/6f/IJCM-41-190.PMC4919931.pdf
Available from: http://mohfw.nic.in/ NRHM/FP/ECP_Book_Final.pdf.,Non-OADS,/arxiv_data1/oa_pdf/db/d4/IJCM-41-198.PMC4919932.pdf
Available from: http://www.who.int/pmnch/countries/ tanzaniamapstrategic.pdf [Last accessed on 2015 Nov 22].,Non-OADS,/arxiv_data1/oa_pdf/c0/3e/IJCM-41-213.PMC4919935.pdf
India’s Aging Population - TodaysResearchAging25.pdf; Available  from: http://www.prb.org/pdf12/TodaysResearchAging25.pdf.,Non-OADS,/arxiv_data1/oa_pdf/d9/74/IJCM-41-219.PMC4919936.pdf
Available from: http://www.ncbi.nlm.nih.gov/books/NBK109220/?report=reader.,Non-OADS,/arxiv_data1/oa_pdf/d9/74/IJCM-41-219.PMC4919936.pdf
Available from: http://www.who.int/countryfocus/cooperation_strategy/ccsbrief_ind_en.pdf.,Non-OADS,/arxiv_data1/oa_pdf/d9/74/IJCM-41-219.PMC4919936.pdf
Available from: http://oii.igidr.ac.in:8080/jspui/ handle/2275/140.,OADS,/arxiv_data1/oa_pdf/d9/74/IJCM-41-219.PMC4919936.pdf
Available from: https://nrhm-mis.nic.,Non-OADS,/arxiv_data1/oa_pdf/87/77/IJCM-41-228.PMC4919938.pdf
Availablefrom: http://www.ahrq.gov/professionals/quality-patient-safety/ patientsafetyculture/hospital/index.html.,Non-OADS,/arxiv_data1/oa_pdf/58/6f/IJCM-41-235.PMC4919939.pdf
Available from: http://www.unaids.org.cn/pics/20110525091 555.pdf.,Non-OADS,/arxiv_data1/oa_pdf/b6/de/IJCM-41-241.PMC4919940.pdf
Available from: http://www.naco.gov.,Non-OADS,/arxiv_data1/oa_pdf/b6/de/IJCM-41-241.PMC4919940.pdf
Available from: http://www.idi-makerere.com/128/show/publication.,Non-OADS,/arxiv_data1/oa_pdf/b6/de/IJCM-41-241.PMC4919940.pdf
Available from: http://www.who.int/hiv/pub/guidelines/ arv2013/art/arv2013_chapter07_low.pdf.,Non-OADS,/arxiv_data1/oa_pdf/b6/de/IJCM-41-241.PMC4919940.pdf
"1981 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/65/60/btw052.PMC4920109.pdf
"Motivated by strong multivari- ate signals in the lipid genes tested, we envision that multivariate association testing using metaCCA has a great potential to provide novel insights from already published summary statistics from high-throughput phenotyping technologies.Availability and implementation : Code is available at https://github.com/aalto-ics-kepaco Contacts: anna.cichonska@helsinki.ﬁ or matti.pirinen@helsinki.ﬁ Supplementary information: Supplementary data are available at Bioinformatics online.",OADS,/arxiv_data1/oa_pdf/65/60/btw052.PMC4920109.pdf
"1974 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a2/11/btw065.PMC4920110.pdf
"Both the UK10K cohort and the 1000GP have, in turn, very recently been incorporated into a new, much larger panel by the (HRC) Haplotype Reference Consortium (http://www.haplo type-reference-consortium.org).",Non-OADS,/arxiv_data1/oa_pdf/a2/11/btw065.PMC4920110.pdf
The 100000 Genomes Project http://www.genomicsengland.co.uk will construct an even larger panel using high coverage sequencing.,Non-OADS,/arxiv_data1/oa_pdf/a2/11/btw065.PMC4920110.pdf
2.7 A phasing server We have created a phasing server that allows clinical samples sequenced at high coverage to be phased against the HRC referencepanel or the UK10K reference panels https://phasingserver.stats.ox.,Non-OADS,/arxiv_data1/oa_pdf/a2/11/btw065.PMC4920110.pdf
To address theserestrictions we have developed a phasing server that allows clinicalsamples sequenced at high coverage to be phased against the HRC ref-erence panel or the UK10K reference panels https://phasingserver.stats.ox.ac.uk/.,Non-OADS,/arxiv_data1/oa_pdf/a2/11/btw065.PMC4920110.pdf
Availability and implementation: Free access at http://www.rgenome.net/cas-database/.,OADS,/arxiv_data1/oa_pdf/49/35/btw103.PMC4920116.pdf
"2017 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/49/35/btw103.PMC4920116.pdf
"Because this step is very time-consuming, we ran Cas-OFFinder on anOpenCL-enabled cluster computer such as Chundoong (http://chundoong.snu.ac.kr/) for all sites in parallel.",OADS,/arxiv_data1/oa_pdf/49/35/btw103.PMC4920116.pdf
"We chosePostgreSQL (http://www.postgresql.org/) as the database server,which showed the best performance in our case.",OADS,/arxiv_data1/oa_pdf/49/35/btw103.PMC4920116.pdf
2.4 Web interface We built a web interface for Cas-Database using the Python webframework Django (https://www.djangoproject.com/).,OADS,/arxiv_data1/oa_pdf/49/35/btw103.PMC4920116.pdf
"For creating the HTML part of the interface, we used theweb development framework Bootstrap (http://getbootstrap.com/)and the JavaScript framework JQuery (https://jquery.com/).",OADS,/arxiv_data1/oa_pdf/49/35/btw103.PMC4920116.pdf
"2081 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/be/3d/btw104.PMC4920117.pdf
http://mafft.cbrc.jp/alignment/software/ Contact: katoh@ifrec.osaka-u.ac.jp Supplementary information: Supplementary data are available at Bioinformatics online.,OADS,/arxiv_data1/oa_pdf/4e/85/btw108.PMC4920119.pdf
"1933 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4e/85/btw108.PMC4920119.pdf
"1943 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/31/92/btw112.PMC4920122.pdf
"1990 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c8/9c/btw128.PMC4920127.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/78/9b/dddt-10-2021.PMC4920224.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 2021–2028Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  2021Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S10728 3 a novel ph–enzyme-dependent mesalamine  colon-specific delivery system lei Jin Yi-cun Ding Yu Zhang Xiao-qing Xu Qin cao Department of gastroenterology,   Putuo hospital, shanghai University  of Traditional chinese Medicine,   shanghai, People’s republic of chinaAbstract:  The aim of the present study was to design a new pH–enzyme double-dependent  mesalamine colon-specific delivery system.",Non-OADS,/arxiv_data1/oa_pdf/78/9b/dddt-10-2021.PMC4920224.pdf
"Most of the previous articles about colonic targeting have focused on the development  of a colonic delivery system based on time and pH as well as systems that utilize  bacteria, which colonizes the colon or enzymes produced by these bacteria that affect  the drug release.5–8 However, these colon-specific delivery systems have poor specificity due to large  variations in gastric emptying time and in pH of the gastrointestinal tract.9–11 The pH–enzyme double-dependent colon-specific delivery system combines the  advantages of the previously explained methods; this system produces sustained  target release after oral administration, with low toxicity potential for other organs.12,13 correspondence: Qin cao Department of gastroenterology,  Putuo hospital, shanghai University of  Traditional chinese Medicine, 164 lanxi  road, Putuo District, shanghai 200062,  People’s republic of china Tel +86 21 2223 3222 Fax +86 21 2223 3222 email drqincao@163.co m Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Jin et al Running head recto: A novel mesalamine colon-specific delivery system DOI: http://dx.doi.org/10.2147/DDDT.S107283",Non-OADS,/arxiv_data1/oa_pdf/78/9b/dddt-10-2021.PMC4920224.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/78/9b/dddt-10-2021.PMC4920224.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/78/9b/dddt-10-2021.PMC4920224.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/ec/45/copd-11-1353.PMC4920225.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 1353–1357International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1353OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S10740 8 Immediate effect of manual therapy on  respiratory functions and inspiratory muscle  strength in patients with COPD gul Deniz Yilmaz Yelvar1 Yasemin Çirak2 Yasemin Parlak Demir3 Murat Dalkilinç1 Bülent Bozkurt4 1Department of Musculoskeletal  Physiotherapy, 2Department of  Cardiopulmonary Physiotherapy,   3Department of neurological  rehabilitation, school of  Physiotherapy and rehabilitation,   4Department of respiratory Medicine,   Faculty of Medicine, Turgut Özal  University, ankara, T urkeyObjective:  The objective of this study was to investigate the immediate effect of manual therapy  (MT) on respiratory functions and inspiratory muscle strength in patients with COPD.",Non-OADS,/arxiv_data1/oa_pdf/ec/45/copd-11-1353.PMC4920225.pdf
"Hyperinflation and respiratory muscle fatigue produce Correspondence: gul Deniz Yilmaz Yelvar school of Physiotherapy and  rehabilitation, Turgut Özal University,  Yunus emre Mahallesi, Takdir Caddesi,  no 5 Yenimahalle, ankara, Turkey Tel +90 312 327 8250 ext 7203 email guldenizy@yahoo.co m Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Yilmaz Y elvar et al Running head recto: Immediate effect of manual therapy in COPD DOI: http://dx.doi.org/10.2147/COPD.S107408",Non-OADS,/arxiv_data1/oa_pdf/ec/45/copd-11-1353.PMC4920225.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/ec/45/copd-11-1353.PMC4920225.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/ec/45/copd-11-1353.PMC4920225.pdf
Available from: http://goldcopd.org/global-strategy-diagnosis- management-prevention-copd-201 6.,Non-OADS,/arxiv_data1/oa_pdf/ec/45/copd-11-1353.PMC4920225.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/f1/d9/cia-11-819.PMC4920226.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2016:11 819–827Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  819OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S10739 4 Inappropriate prescribing of antithrombotic therapy  in ethiopian elderly population using updated 2015  sTOPP/sTAr T criteria: a cross-sectional study henok getachew Akshaya srikanth  Bhagavathula Tamrat Befekadu Abebe sewunet Admasu Belachew Department of Clinical Pharmacy,   school of Pharmacy, College of  Medicine and health sciences,   University of gondar, gondar,   ethiopiaBackground:  Inappropriate use of antiplatelets and anticoagulants among elderly patients  increases the risk of adverse outcomes.",Non-OADS,/arxiv_data1/oa_pdf/f1/d9/cia-11-819.PMC4920226.pdf
"Keywords:  prevalence, inappropriate prescribing, antithrombotic, STOPP/START criteria,  elderly, Ethiopia Introduction Antithrombotics, including antiaggregants and anticoagulants, are complex drugs  mainly used in primary and secondary cardiovascular disease prevention, and for  treating thrombosis in patients with atrial fibrillation (AF) or prosthetic heart valves.1,2  Different studies showed that the risk of bleeding and drug-related hospitalizations with  antithrombotics contributes to the complexity of the treatment.3–5 For these reasons, Correspondence: henok getachew Department of Clinical Pharmacy, school  of Pharmacy, College of Medicine and  health sciences, University of gondar,  PO Box 196, gondar, ethiopia Tel +251 91 143 8077 Fax +251 58 114 1240 email heniget@gmail.co mJournal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Getachew et al Running head recto: Antithrombotic therapy in Ethiopian elderly population DOI: http://dx.doi.org/10.2147/CIA.S107394 Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/f1/d9/cia-11-819.PMC4920226.pdf
Or use: http://youtu.be/nRUCzwVMht EVideo abstract,Non-OADS,/arxiv_data1/oa_pdf/f1/d9/cia-11-819.PMC4920226.pdf
"[Internet]  Zuidlaren, NL: Pharmaceutical Care Network Europe Foundation ;  2010 [cited 2015, 2015-12-02]; Available from: http://www.pcne.org/ upload/files/11_PCNE_classification_V6-2.pd f  8.",Non-OADS,/arxiv_data1/oa_pdf/f1/d9/cia-11-819.PMC4920226.pdf
Available from:  http://www.who.int/classifications/icd/en/ 31.,Non-OADS,/arxiv_data1/oa_pdf/f1/d9/cia-11-819.PMC4920226.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/f1/d9/cia-11-819.PMC4920226.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/f1/d9/cia-11-819.PMC4920226.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/0f/e5/ott-9-3633.PMC4920227.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3633–3642OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3633Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10131 0 The effects of mir-1207-5p expression in peripheral  blood on cisplatin-based chemosensitivity of primary  gallbladder carcinoma er-Dong shen1 Bo liu2 Xin-shuang Yu3 Zhen-Fei Xiang4 hui-Yun huang5 1Department of Oncology, The First  People’s hospital of Yueyang, Yueyang,   2Department of general surgery,   The second Xiangya hospital of  central south University, changsha,   3Department of radiotherapy, Qianfou  Mount hospital of shandong Province,   Jinan, 4Department of radiotherapy,   ningbo Medical Treatment center  lihuili hospital, ningbo, 5Department  of Dermatology, The First People’s  hospital of Yueyang, Yueyang, People’s  republic of chinaObjective:  The aim of this study was to investigate the association between miR-1207-5p  expression in peripheral blood and the chemosensitivity of primary gallbladder carcinoma  (PGBC).",Non-OADS,/arxiv_data1/oa_pdf/0f/e5/ott-9-3633.PMC4920227.pdf
"Keywords:  primary gallbladder carcinoma, miR-1207-5p, peripheral blood, chemosensitizer,  diagnosis, cisplatin Introduction Primary gallbladder carcinoma (PGBC) is a malignant gastrointestinal cancer with  high mortality, and the mortality of PGBC ranks sixth among gastrointestinal can - cers worldwide.1 Despite a relatively low incidence (2.5 per 100,000 individuals), correspondence: er-Dong shen Ward Three, Department of Oncology,  The First People’s hospital of Yueyang,  no 39 Dongmaoling road,  Yueyang 414000, People’s  republic of china Tel/fax +86 730 824 6724 email erdong_shen@sina.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Shen et al Running head recto: miR-1207-5p expression and PGBC DOI: http://dx.doi.org/10.2147/OTT.S101310",Non-OADS,/arxiv_data1/oa_pdf/0f/e5/ott-9-3633.PMC4920227.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/0f/e5/ott-9-3633.PMC4920227.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/0f/e5/ott-9-3633.PMC4920227.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/1a/7c/cia-11-835.PMC4920228.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2016:11 835–841Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  835OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S10394 3 glucosamine-containing supplement improves  locomotor functions in subjects with knee  pain – a pilot study of gait analysis noriyuki Kanzaki1 Yuta Otsuka1 Takayuki Izumo1 hiroshi shibata1 hideyuki nagao2 Keita Ogawara3 hiroshi Yamada3 seiji Miyazaki3 Yutaka nakamura3 1Institute for health Care science,   suntory Wellness ltd, seika-cho,   soraku-gun, Kyoto, Japan; 2research  Institute of sports Medical science,   T okai University, hiratsuka, Kanagawa,   Japan; 3school of Physical education,   T okai University, hiratsuka,   Kanagawa,  JapanBackground:  Previously, we demonstrated that glucosamine-containing supplementation  was effective for improving locomotor functions, especially walking speed.",Non-OADS,/arxiv_data1/oa_pdf/1a/7c/cia-11-835.PMC4920228.pdf
"In 2007, the Japanese  Orthopaedic Association proposed the concept of “locomotive syndrome” (LS), which  refers to the conditions under which people require or may soon require nursing-care  services because of problems with the locomotor system.1 The Japanese Ministry of  Health, Labour and Welfare has devoted effort to increasing the percentage of individuals  who know about LS in “The second term of National Health Promotion Movement in  the 21st Century (Health Japan 21 [second term])” to solve the problem of LS.2 Screening  tools for risk of LS in the elderly, the 25-question Geriatric Locomotive Function Correspondence: noriyuki Kanzaki Institute for health Care science, suntory  Wellness ltd, 8-1-1 seikadai, seika-cho,  soraku-gun, Kyoto 619-0284, Japan Tel +81 50 3182 0666 Fax +81 774 98 6262 email noriyuki_Kanzaki@suntory.co.j p Journal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Kanzaki et al Running head recto: Mechanism of improved walking speed with glucosamine supplement DOI: http://dx.doi.org/10.2147/CIA.S103943",Non-OADS,/arxiv_data1/oa_pdf/1a/7c/cia-11-835.PMC4920228.pdf
Available from: http://www.mhlw.,Non-OADS,/arxiv_data1/oa_pdf/1a/7c/cia-11-835.PMC4920228.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/1a/7c/cia-11-835.PMC4920228.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/1a/7c/cia-11-835.PMC4920228.pdf
"Available from: https://www.jstage.jst.go.jp/article/hppt/1/2/1_131/_pd f.   Accessed August 27th, 2015.",OADS,/arxiv_data1/oa_pdf/1a/7c/cia-11-835.PMC4920228.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/7a/f8/ott-9-3653.PMC4920229.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3653–3659OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3653Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10140 8Potential role of S-adenosylmethionine in  osteosarcoma development hui shi1,2,* Wei-dong Mu1,* Bing Zhang3 Tao Meng2 shou-tao Zhang2 Dong-sheng Zhou1 1Department of Traumatic  Orthopaedics, shandong Provincial  hospital affiliated to shandong  University, Jinan, 2Department of  Bone and Joint surgery, 3Department  of Urology surgery, Binzhou Medical  University hospital, Binzhou,   shandong, People’s republic of china *These authors contributed equally  to this workAbstract:  The metastatic form of osteosarcoma is a life threatening one since it metastasizes  to the lungs.",Non-OADS,/arxiv_data1/oa_pdf/7a/f8/ott-9-3653.PMC4920229.pdf
"The polyamine helps to condense and correspondence: Dong-sheng Zhou Department of Traumatic Orthopaedics,  Shandong Provincial Hospital Affiliated  to shandong University, number 324,  Wuweiqi road, Jinan, shandong 250021,  People’s republic of china Tel +86 531 6877 6382 Fax +86 531 8793 3120 email zhouddsss@gmail.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Shi et al Running head recto: Role of S-adenosylmethionine in osteosarcoma development DOI: http://dx.doi.org/10.2147/OTT.S101408",Non-OADS,/arxiv_data1/oa_pdf/7a/f8/ott-9-3653.PMC4920229.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/7a/f8/ott-9-3653.PMC4920229.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/7a/f8/ott-9-3653.PMC4920229.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/49/d3/jbm-7-121.PMC4920230.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/49/d3/jbm-7-121.PMC4920230.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Blood Medicine 2016:7 121–128Journal of Blood Medicine Dovepress submit your manuscript | www.dovepress.com Dovepress  121 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JBM.S82457Potential role of a new PEGylated recombinant  factor VIII for hemophilia A T ung Thanh Wynn1 Burak Gumuscu2,3 1Department of Pediatrics, Division  of Pediatric Hematology/Oncology,   University of Florida, Gainesville, FL,   2Pediatric Hematology-Oncology, Bon  Secours Health System, St. Mary’s Hospital, Richmond, VA,  3Department  of Pediatrics, Division of Pediatric Hematology/Oncology, University of Virginia, Charlottesville, VA, USAAbstract:  Hemophilia A, a deficiency in the activity of coagulation factor (F) VIII, is an X-linked  bleeding disorder with an approximate incidence of one in 5,000 male infants.",Non-OADS,/arxiv_data1/oa_pdf/49/d3/jbm-7-121.PMC4920230.pdf
"While one-half of all hemophilia  Correspondence: Tung Thanh Wynn Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Florida, PO Box 100298, 1600 SW Archer Rd, Gainesville, FL 32610, USATel +1 352 273 9120Fax +1 352 294 8091Email twynn@ufl.eduJournal name: Journal of Blood Medicine Article Designation: REVIEWY ear: 2016V olume: 7Running head verso: Wynn and GumuscuRunning head recto: Role of PEGylated factor VIIIDOI: http://dx.doi.org/10.2147/JBM.S82457",Non-OADS,/arxiv_data1/oa_pdf/49/d3/jbm-7-121.PMC4920230.pdf
"Journal of Blood Medicine 2016:7submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Blood Medicine Publish your work in this journal Submit your manuscript here: http://www.dovepress.com/journal-of-blood-medicine-journalThe Journal of Blood Medicine is an international, peer-reviewed, open  access, online journal publishing laboratory, experimental and clinical aspects   of all aspect pertaining to blood based medicine including but not limited to:   Transfusion Medicine; Blood collection, Donor issues, Transmittable diseases,   and Blood banking logistics; Immunohematology; Artificial and alternative blood based therapeutics; Hematology; Biotechnology/nanotechnology of blood related medicine; Legal aspects of blood medicine; Historical perspec-tives.",Non-OADS,/arxiv_data1/oa_pdf/49/d3/jbm-7-121.PMC4920230.pdf
Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.Dovepress 128 Wynn and Gumuscu,Non-OADS,/arxiv_data1/oa_pdf/49/d3/jbm-7-121.PMC4920230.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/e0/96/ott-9-3613.PMC4920231.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3613–3619OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3613Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S9936 3roles of microrna-99 family in human glioma Mingyu Zhang1 Y ong guo1 Jun Wu1 Fenghua chen1 Zhijie Dai2 shuangshi Fan1 Pengcheng li1 Tao song1 1Department of n eurosurgery,   Xiangya hospital of central south  University, changsha, 2institute of  endocrinology and Metabolism,   second Xiangya hospital, central  south University, changsha, hunan,   People’s republic of chinaObjective:  Deregulation of microRNA (miR)-99 family members (miR-99a, miR-99b, and  miR-100) has been reported to play a crucial role in many cancer types.",Non-OADS,/arxiv_data1/oa_pdf/e0/96/ott-9-3613.PMC4920231.pdf
"The annual incidence of malignant glioma is more than five per 100,000 population.5 correspondence: Tao song Department of neurosurgery, Xiangya  hospital of central south University, 87  Xiangya road, changsha, hunan 410008,  People’s republic of china Tel/fax +86 731 89753039 email songtao97119@163.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Zhang et al Running head recto: miR-99 family in glioma DOI: http://dx.doi.org/10.2147/OTT.S99363",Non-OADS,/arxiv_data1/oa_pdf/e0/96/ott-9-3613.PMC4920231.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/e0/96/ott-9-3613.PMC4920231.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/e0/96/ott-9-3613.PMC4920231.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/fc/bb/cia-11-829.PMC4920232.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2016:11 829–834Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  829OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S9941 9Prediction of critical illness in elderly outpatients  using elder risk assessment: a population-based  study Michelle Biehl1 Paul Y Takahashi2 stephen s Cha3 rajeev Chaudhry2 Ognjen gajic1 Bjorg Thorsteinsdottir2 1Division of Pulmonary and Critical  Care Medicine, Department of  Medicine, 2Division of Primary Care  Internal Medicine, 3health sciences  research, Mayo Clinic, rochester,   Mn, UsARationale:  Identifying patients at high risk of critical illness is necessary for the development  and testing of strategies to prevent critical illness.",Non-OADS,/arxiv_data1/oa_pdf/fc/bb/cia-11-829.PMC4920232.pdf
"Keywords:  aged, prognostication, critical care, mortality, elder risk assessment Introduction Frequent hospitalizations and burdensome care transitions are common in the last  3 months of a frail elderly patient’s life.1,2 In a large study of Medicare beneficiaries,  intensive care unit (ICU) use in the last month of life was 26.3%, a significant increase  between 2000 and 2009.2 There are increasing calls for advanced care planning to  help patients and families facing advanced life-limiting illness.3–5 The American  Geriatrics Society has called for a dramatic change in the approach to medical care  for the frail elderly patients with multimorbidity, emphasizing that a discussion of Correspondence: Bjorg Thorsteinsdottir Division of Primary Care Internal  Medicine, Mayo Clinic, 200 First street  sW, rochester, Mn 55905, UsA Tel +1 507 284 1978 Fax +1 507 266 0038 email thorsteinsdottir.bjorg@mayo.ed uJournal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Biehl et al Running head recto: Predicting critical illness in elderly outpatients DOI: http://dx.doi.org/10.2147/CIA.S99419",Non-OADS,/arxiv_data1/oa_pdf/fc/bb/cia-11-829.PMC4920232.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/fc/bb/cia-11-829.PMC4920232.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/fc/bb/cia-11-829.PMC4920232.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p  and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/d4/db/hmer-8-069.PMC4920234.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Transarterial chemoembolization with drug- eluting beads versus conventional transarterial  chemoembolization in locally advanced  hepatocellular carcinoma Johannes Baur1 Christian O Ritter2 Christoph-Thomas  Germer1 Ingo Klein1 Ralph Kickuth2 Ulrich Steger1 1Department of General, Visceral,   Vascular, and Pediatric Surgery,   2Institute of Radiology, University  Hospital Würzburg, Würzburg,   Germany Correspondence: Johannes Baur   Department of General, Visceral, Vascular  and Pediatric Surgery, University Hospital  Würzburg, Oberdürrbacherstraße, 97080  Würzburg, Germany   T el +49 931 2013 8812   Email baur_j@ukw.d ePurpose:  In hepatocellular carcinoma patients with large or multinodal tumors, where curative  treatment options are not feasible, transarterial therapies play a major role.",Non-OADS,/arxiv_data1/oa_pdf/d4/db/hmer-8-069.PMC4920234.pdf
"Hepatic Medicine: Evidence and Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/hepatic-medicine-evidence-and-research-journa lHepatic Medicine: Evidence and Research is an international, peer- reviewed, open access journal covering all aspects of adult and pedi - atric hepatology in the clinic and laboratory including the following  topics: Pathology, pathophysiology of hepatic disease; Investigation  and treatment of hepatic disease; Pharmacology of drugs used for the treatment of hepatic disease.",Non-OADS,/arxiv_data1/oa_pdf/d4/db/hmer-8-069.PMC4920234.pdf
Visit http://www.dovepress.com/   testimonials.php to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d4/db/hmer-8-069.PMC4920234.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/44/fd/clep-8-231.PMC4920235.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/44/fd/clep-8-231.PMC4920235.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Clinical Epidemiology 2016:8 231–239Clinical Epidemiology Dovepress submit your manuscript | www.dovepress.com Dovepress 231 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CLEP .S105888 Rate of bleeding-related episodes in adult  patients with primary immune thrombocytopenia:  a retrospective cohort study using a large  administrative medical claims database in the US Ivy Altomare1  Karynsa Cetin2  Sally Wetten3  Jeffrey S Wasser4 1Department of Medicine, Duke  University School of Medicine,   Durham, NC, 2Center for  Observational Research, Amgen Inc., Cambridge, MA, USA;  3Centre  for Observational Research, Amgen Ltd., Uxbridge, UK;  4Carole and Ray  Neag Comprehensive Cancer Center,  University of Connecticut School of Medicine, Farmington, CT, USABackground: Immune thrombocytopenia (ITP) is a rare disorder characterized by low platelet  counts and an increased tendency to bleed.",Non-OADS,/arxiv_data1/oa_pdf/44/fd/clep-8-231.PMC4920235.pdf
"Low platelet counts, increasing patient age, use of concurrent medications, and  male sex are all associated with an increased risk of bleeding in patients with ITP .2  Symptoms range in severity from no bleeding to relatively mild petechiae or pur -Correspondence: Ivy Altomare   Duke University Medical Center, 3100  Tower Boulevard, Suite 600, Durham, NC 27707, USA Tel +1 919 419 5002   Fax +1 919 493 3234   Email Ivy.altomare@duke.eduJournal name: Clinical Epidemiology Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 8Running head verso: Altomare et alRunning head recto: Bleeding-related episodes in ITP patientsDOI: http://dx.doi.org/10.2147/CLEP .S105888",Non-OADS,/arxiv_data1/oa_pdf/44/fd/clep-8-231.PMC4920235.pdf
"Clinical Epidemiology 2016:8submit your manuscript | www.dovepress.com Dovepress Dovepress Clinical Epidemiology Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/clinical-epidemiology-journalClinical Epidemiology is an international, peer-reviewed, open access,  online journal focusing on disease and drug epidemiology, identifica-tion of risk factors and screening procedures to develop optimal pre-ventative initiatives and programs.",Non-OADS,/arxiv_data1/oa_pdf/44/fd/clep-8-231.PMC4920235.pdf
"The abstract of this paper was presented at the American Society of Hematology annual meeting, December 6–9, 2014, San Francisco, CA, USA, as an oral presentation: http://www.bloodjournal.org/content/124/21/202.",Non-OADS,/arxiv_data1/oa_pdf/44/fd/clep-8-231.PMC4920235.pdf
Available from: http://kff.org/other/state-indicator/total-population/.,OADS,/arxiv_data1/oa_pdf/44/fd/clep-8-231.PMC4920235.pdf
Available from: http://kff.org/medicare/issue-brief/an-overview-of-medicare/.,Non-OADS,/arxiv_data1/oa_pdf/44/fd/clep-8-231.PMC4920235.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/fc/b0/ott-9-3621.PMC4920236.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3621–3631OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3621Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S9683 0 a systematic review and meta-analysis of the risk  of diarrhea associated with vandetanib treatment  in carcinoma patients Zijun huo* shuang Yu* shubin hong Xiaopei cao lingling Xiu Zhihong liao Yanbing li haipeng Xiao Department of endocrinology,   The First affiliated hospital of sun  Yat-sen University, guangzhou,   guangdong, People’s republic  of china *These authors contributed equally  to this workBackground and purpose:  Vandetanib is a promising anticancer targeted agent for treating  advanced carcinomas, such as non-small-cell lung cancer, small-cell lung cancer, breast cancer,  malignant glioma, hepatocellular cancer, and unresectable, locally advanced, or metastatic  medullary thyroid cancer.",Non-OADS,/arxiv_data1/oa_pdf/fc/b0/ott-9-3621.PMC4920236.pdf
"Nowadays, a large number of clinical studies have demonstrated that a  newly developing therapy, molecular-targeted therapy, exerts a positive influence on  advanced tumors, which shows considerable promise.correspondence: haipeng Xiao Department of endocrinology, The First  Affiliated Hospital of Sun Yat-sen  University, no 58 Zhongshan 2nd road,  guangzhou 510080, guangdong,  People’s republic of china Tel +86 20 8775 5766 ext 8803 Fax +86 20 8733 0736 email xiaohp@mail.sysu.edu.c n Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Huo et al Running head recto: Risk of diarrhea of vandetanib treatment DOI: http://dx.doi.org/10.2147/OTT.S96830",Non-OADS,/arxiv_data1/oa_pdf/fc/b0/ott-9-3621.PMC4920236.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/fc/b0/ott-9-3621.PMC4920236.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/fc/b0/ott-9-3621.PMC4920236.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/1e/06/ijn-11-2901.PMC4920237.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 2901–2920International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  2901OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S9465 8Development of transmucosal patch loaded with  anesthetic and analgesic for dental procedures  and in vivo evaluation Malviya Nidhi1 M Nagaraju Patro1 somisetty Kusumvalli2 Vemula Kusumdevi1 1Department of Pharmaceutics,   al-ameen college of Pharmacy,   2Department of endodontics and  conservative Dentistry, sri rajiv  gandhi college of Dental sciences,   Bengaluru, Karnataka, IndiaAbstract:  Most of the dental surgeries require preoperative anesthetic and postoperative  analgesic for painless procedures.",Non-OADS,/arxiv_data1/oa_pdf/1e/06/ijn-11-2901.PMC4920237.pdf
"Keywords:  solid lipid nanoparticle,  Box–Behnken design, transmucosal patch, pharmacokinet - ics and pharmacodynamics, Caco-2 permeability, histopathology Introduction Most of the dental procedures, namely deep tooth scaling, root canal treatment,  tooth extraction, and apicoectomy employed for the prevention and treatment of  dental problems and diseases, require preoperative anesthetic and postoperative  analgesic.1 Patients are most often concerned about the dental pain; thus, its preven - tion is more important rather than the treatment.2 In the current study, we aimed to  design a patient-friendly and easy-to-administer transmucosal drug delivery system:  a bilayer transmucosal patch (TP) containing lignocaine (Lig) and diclofenac (Dic) correspondence: Vemula Kusumdevi Department of Pharmaceutics, al-ameen  college of Pharmacy, hosur road,  Bengaluru 560027, Karnataka, India Tel +91 9342859850 email kusumal62@yahoo.co m Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Nidhi et al Running head recto: Transmucosal patch with anesthetic and analgesic DOI: http://dx.doi.org/10.2147/IJN.S94658",Non-OADS,/arxiv_data1/oa_pdf/1e/06/ijn-11-2901.PMC4920237.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/1e/06/ijn-11-2901.PMC4920237.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/1e/06/ijn-11-2901.PMC4920237.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/8b/6d/ppa-10-1101.PMC4920238.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Patient Preference and Adherence 2016:10 1101–1113Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1101OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S10631 1 Patients’ and rheumatologists’ preferences for  the attributes of biological agents used in the  treatment of rheumatic diseases in spain Joan M nolla1 Manuel rodríguez2 emilio Martin-Mola3 enrique raya4 isabel ibero5 gonzalo nocea6 Belén Aragon6 luis lizán7 Miriam Prades7 1Department of rheumatology,   hospital Universitari de Bellvitge,   Barcelona, spain; 2Department of  rheumatology, complejo hospitalario  de Ourense, Ourense, spain;   3Department of rheumatology,   hospital Universitario la Paz, Madrid,   spain; 4Department of rheumatology,   hospital Universitario san cecilio,   granada, spain; 5hospital general  de elda, Alicante, spain; 6Outcomes  research, M sD, Madrid, spain;   7Outcomes’10, castellón, spainPurpose:  To define importance values assigned to attributes of biological agents (BAs) by  Spanish patients with rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, and  psoriatic arthritis) and rheumatologists.",Non-OADS,/arxiv_data1/oa_pdf/8b/6d/ppa-10-1101.PMC4920238.pdf
"Keywords:  preferences, conjoint analysis, attributes, biological agents, rheumatic diseases Introduction Rheumatic diseases (RDs) represent a multitude of chronic degenerative, inflamma - tory, and autoimmune conditions affecting millions of people worldwide.1 In Spain,  the prevalence of RD can reach 23%.2 Three of the most prevalent RDs are rheumatoid  arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA).3–6 All three  pathologies are characterized by their potential to cause disability,7 their negative influ - ence on patients’ quality of life (QoL)8 and functional capacity, and by the immense  consumption of health care resources and loss of productivity they entail.9 Traditional treatment of inflammatory RDs includes the use of symptom-modifying  therapies (nonsteroidal anti-inflammatory drugs and corticosteroids), combined with  nonbiologic disease-modifying antirheumatic drugs (DMARDs).10,11 The develop - ment of new biological therapies, particularly TNF inhibitors, has led to significant  improvement in clinical outcomes, including symptoms, health-related QoL (HRQoL), correspondence: Joan Miquel nolla Department of rheumatology, hospital  Universitari de Bellvitge, Feixa llarga,  l’hospitalet de llobregat, Barcelona  08907, spain Tel +34 932 607 615 email jmnolla@ub.ed uJournal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Nolla et al Running head recto: Preferences for biologic RD treatments in Spain DOI: http://dx.doi.org/10.2147/PPA.S106311",Non-OADS,/arxiv_data1/oa_pdf/8b/6d/ppa-10-1101.PMC4920238.pdf
"The poster  abstracts were published in V alue in Health , volume 17,  issue 7 ( http://www.valueinhealthjournal.com/article/S1098- 3015(14)03648-1/pd f).",Non-OADS,/arxiv_data1/oa_pdf/8b/6d/ppa-10-1101.PMC4920238.pdf
Available from: http://www.msssi.gob.,Non-OADS,/arxiv_data1/oa_pdf/8b/6d/ppa-10-1101.PMC4920238.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/8b/6d/ppa-10-1101.PMC4920238.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/da/bc/opth-10-1139.PMC4920242.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 1139–1144Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1139Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S10936 0 a comparison of patient pain and visual outcome  using topical anesthesia versus regional anesthesia  during cataract surgery Y oshikatsu hosoda shoji Kuriyama Y oko Jingami hidetsugu hattori hisako hayashi Miho Matsumoto Department of Ophthalmology, Otsu  red-Cross hospital, Otsu, JapanPurpose:  The purpose of this study was to compare the level of patient pain during the pha - coemulsification and implantation of foldable intraocular lenses while under topical, intracameral,  or sub-Tenon lidocaine.",Non-OADS,/arxiv_data1/oa_pdf/da/bc/opth-10-1139.PMC4920242.pdf
"Recent studies regarding local anesthesia Correspondence: Yoshikatsu hosoda Department of Ophthalmology, Otsu  red-Cross hospital, 1-1-35 nagara,  Otsu, shiga 520-0046, Japan Tel +81 77 522 4131 email kubrick@kuhp.kyoto-u.ac.j p Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Hosoda et al Running head recto: A comparison of anesthesia in cataract surgery DOI: http://dx.doi.org/10.2147/OPTH.S109360",Non-OADS,/arxiv_data1/oa_pdf/da/bc/opth-10-1139.PMC4920242.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/da/bc/opth-10-1139.PMC4920242.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/da/bc/opth-10-1139.PMC4920242.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/fa/ee/ott-9-3643.PMC4920243.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3643–3651OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3643Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10368 2 Microrna-190 regulates FOXP2  genes in human  gastric cancer Wen-Zhuo Jia1 Tao Yu1 Qi an1 hua Yang1 Zhu Zhang2 Xiao liu2 gang Xiao1 1Department of general surgery,   2Department of gastroenterology,   Beijing hospital, Beijing, People’s  republic of chinaObjective:  To investigate how microRNA-190 (miR-190) regulates  FOXP2  genes in gastric  cancer (GC) cell line SGC7901.",Non-OADS,/arxiv_data1/oa_pdf/fa/ee/ott-9-3643.PMC4920243.pdf
"FOX family members are involved in many  important biological processes, including metabolism, development, differentiation,  proliferation, apoptosis, migration, and invasion.2 Function loss or functional change of correspondence: gang Xiao Department of general surgery,  Beijing hospital, Dongcheng District,  no 1 Dahua road, Beijing 100730,  People’s republic of china Tel +86 10 8513 6162 email xiaogang0819@yeah.ne t Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Jia et al Running head recto: Regulation of miR-190 to FOXP2  in GC DOI: http://dx.doi.org/10.2147/OTT.S103682",Non-OADS,/arxiv_data1/oa_pdf/fa/ee/ott-9-3643.PMC4920243.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/fa/ee/ott-9-3643.PMC4920243.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/fa/ee/ott-9-3643.PMC4920243.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/d1/32/ppa-10-1115.PMC4920255.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Patient Preference and Adherence 2016:10 1115–1119Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1115Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S10947 7 Drugs under preclinical and clinical study for  treatment of acute and chronic lymphoblastic  leukemia Joe Antony Jacob Jumah Masoud Mohammad  Salmani Baoan Chen Department of Hematology and  Oncology, Zhongda Hospital, School  of Medicine, Southeast University,   Nanjing, People’s Republic of ChinaAbstract:  Targeted therapy has modernized the treatment of both chronic and acute  lymphoblastic leukemia.",Non-OADS,/arxiv_data1/oa_pdf/d1/32/ppa-10-1115.PMC4920255.pdf
"In vitro analysis in T-lineage cell lines with PTEN mutation and in Correspondence: Baoan Chen Department of Hematology and  Oncology, Zhongda Hospital, School  of Medicine, Southeast University,  Dingjiaqiao 87, Gulou District, Nanjing  210009, Jiangsu Province, People’s  Republic of China Tel +86 25 8327 2006 Fax +86 25 8327 2011 email cba8888@hotmail.co m Journal name: Patient Preference and Adherence Article Designation: Review Y ear: 2016 Volume: 10 Running head verso: Jacob et al Running head recto: Acute and chronic lymphoblastic leukemia treatment DOI: http://dx.doi.org/10.2147/PPA.S109477",Non-OADS,/arxiv_data1/oa_pdf/d1/32/ppa-10-1115.PMC4920255.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/d1/32/ppa-10-1115.PMC4920255.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/62/b7/cia-11-807.PMC4920256.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2016:11 807–817Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  807OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S10618 0 The home Independence Program with non- health professionals as care managers: an  evaluation gill lewin1 Karyn Concanen2 David Y ouens3 1school of nursing, Midwifery and  Paramedicine, Curtin University,   Perth, WA, Australia; 2silver Chain  group, Osborne Park, WA, Australia;   3Faculty of health science, Curtin  University, Perth, WA, AustraliaAbstract:  The Home Independence Program (HIP), an Australian restorative home  care/reablement service for older adults, has been shown to be effective in reducing functional  dependency and increasing functional mobility, confidence in everyday activities, and quality  of life.",Non-OADS,/arxiv_data1/oa_pdf/62/b7/cia-11-807.PMC4920256.pdf
"These types of services have been found to significantly increase the likelihood that  an older person referred for home care will not need ongoing home care assistance;1–4  significantly reduce the likelihood of admission to residential care,5,6 hospital,7,8 or  presentation to an emergency department;7,9 and affect the rate and type of home care  support needed for up to 5 years afterwards.10Correspondence: gill lewin school of nursing, Midwifery and  Paramedicine, Curtin University, gPO  Box U1987, Perth WA 6845, Australia email g.lewin@curtin.edu.a u Journal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Lewin et al Running head recto: HIP coordinator evaluation DOI: http://dx.doi.org/10.2147/CIA.S106180",Non-OADS,/arxiv_data1/oa_pdf/62/b7/cia-11-807.PMC4920256.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/62/b7/cia-11-807.PMC4920256.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/62/b7/cia-11-807.PMC4920256.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/27/63/copd-11-1343.PMC4920257.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 1343–1351International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1343OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S10676 5 The impact of coping on the somatic and mental  status of patients with COPD: a cross-sectional  study Ion Papava1 Cristian Oancea2 Virgil radu enatescu1 ana Cristina Bredicean1 liana Dehelean1 radu stefan romosan1 Bogdan Timar3 1Department of neurosciences –  Discipline of Psychiatry, 2Department  of Infectious Diseases, 3Department  of Functional sciences, “Victor Babes”  University of Medicine and Pharmacy,   Timişoara, RomaniaBackground and objectives:  Chronic obstructive pulmonary disease (COPD) is one of the  most debilitating somatic diseases, having anxiety and depression frequently as comorbidities.",Non-OADS,/arxiv_data1/oa_pdf/27/63/copd-11-1343.PMC4920257.pdf
"It is a progressive airway disease  associated with psychological distress.1 Therefore, two of the most frequent comor - bidities of COPD are depression and anxiety; some studies mention the presence of  depressive and anxious symptoms in over 70% of cases.2–8 Failure in identifying and Correspondence: Cristian Oancea Department of Infectious Diseases,  “Victor Babes” University of Medicine  and Pharmacy, 2 eftimieMurgu, 30041  Timişoara, Romania Tel +40 769 221 057 email oancea@umft.r o Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Papava et al Running head recto: The impact of coping on the somatic and mental status of patients with COPD DOI: http://dx.doi.org/10.2147/COPD.S106765",Non-OADS,/arxiv_data1/oa_pdf/27/63/copd-11-1343.PMC4920257.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/27/63/copd-11-1343.PMC4920257.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/27/63/copd-11-1343.PMC4920257.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/a3/03/mder-9-143.PMC4920258.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/a3/03/mder-9-143.PMC4920258.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Medical Devices: Evidence and Research 2016:9 143–150Medical Devices: Evidence and Research Dovepress submit your manuscript | www.dovepress.com Dovepress 143 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/MDER.S99091 Three-dimensional needle-tip localization by  electric field potential and camera hybridization for  needle electromyography exam robotic simulator Siyu He1 Jose Gomez-Tames1 Wenwei Yu1,2 1Medical System Engineering  Department, Graduate School of  Engineering, 2Center for Frontier  Medical Engineering, Chiba University,  Chiba, JapanAbstract: As one of neurological tests, needle electromygraphy exam (NEE) plays an important  role to evaluate the conditions of nerves and muscles.",Non-OADS,/arxiv_data1/oa_pdf/a3/03/mder-9-143.PMC4920258.pdf
"There are three important technology components that need to be realized: physical modeling of upper limb morphological features, position-dependent EMG generation, Correspondence: Siyu He Medical System Engineering Department, Graduate School of Engineering, Yayoi Chou, Inage Ku, 1-33, Chiba 263-8522, JapanTel +81 80 4912 1656Fax +81 43 290 3231Email hesiyu9013@chiba-u.jpJournal name: Medical Devices: Evidence and Research Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: He et alRunning head recto: Needle localization for robotic simulatorDOI: http://dx.doi.org/10.2147/MDER.S99091",Non-OADS,/arxiv_data1/oa_pdf/a3/03/mder-9-143.PMC4920258.pdf
"Medical Devices: Evidence and Research 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Medical Devices: Evidence and Research Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/medical-devices-evidence-and-research-journalMedical Devices: Evidence and Research is an international, peer- reviewed, open access journal that focuses on the evidence, technology, research, and expert opinion supporting the use and application of   medical devices in the diagnosis, monitoring, treatment and management of clinical conditions and physiological processes.",Non-OADS,/arxiv_data1/oa_pdf/a3/03/mder-9-143.PMC4920258.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/a2/9e/ott-9-3661.PMC4920259.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3661–3669OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3661Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S9642 7Dose-enhanced combined priming regimens for  refractory acute myeloid leukemia and middle- and-high-risk myelodysplastic syndrome: a single- center, retrospective cohort study Xiaorong Ma Jin Wang Yan Xu Wanggang Zhang Jie liu Xingmei cao aili he Fangxia Wang liufang gu Bo lei Jianli Wang Department of hematology, The  second affiliated hospital of Xi’an  Jiaotong University, Xi’an, People’s  republic of chinaObjective:  To assess chemotherapeutic regimens for refractory acute myeloid leukemia (AML)  and middle-and-high-risk myelodysplastic syndrome (MDS).",Non-OADS,/arxiv_data1/oa_pdf/a2/9e/ott-9-3661.PMC4920259.pdf
"While chemotherapeutic regimen has demonstrated success in inducing  remission, AML often progresses subsequently into refractory leukemia, and both  AML and MDS are associated with diverse complications, short survival time, and  poor long-term survival.1–7correspondence: Xiaorong Ma Department of hematology, The second  Affiliated Hospital of Xi’an Jiaotong  University, no 157, Xiwu road, Xi’an  710004, shaanxi Province, People’s  republic of china email xrma225@sina.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Ma et al Running head recto: Priming regimens for leukemia DOI: http://dx.doi.org/10.2147/OTT.S96427",Non-OADS,/arxiv_data1/oa_pdf/a2/9e/ott-9-3661.PMC4920259.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/a2/9e/ott-9-3661.PMC4920259.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/a2/9e/ott-9-3661.PMC4920259.pdf
Availableat: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.,OADS,/arxiv_data1/oa_pdf/86/6b/igj-26-1154.PMC4920274.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Bone CalciumCationic mineralsStrontiumMale miceOsteoporosis 1.,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1016/j.bonr.2016.05.0022352-1872/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
"2, 14001. http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1007/ s00223-010-9340-9 .,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
"Integr Cancer Res 9, 93 –99.http://dx.doi.org/10.1177/ 1534735409360360 .",Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1007/s12011-011- 9316-2 .,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1007/s12011- 013-9820-7 .,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/ 10.3945/jn.111.149914 .,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1177/0022034510377791 .148 M.N.,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1002/jbmr.141 .,OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1159/ 000059441 .,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1016/S0140-6736(98)09075-8 .,OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1359/jbmr.1998.13.10.1587 .,OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1016/j.beem.,OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1359/jbmr.070507 .,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1016/j.jbspin.2009.10.001 .,OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1016/j.bone.,OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1080/07315724.2005.,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/ 10.1007/s00198-006-0172-4 .,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1016/j.bone.2009.07.078 .,OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/ 10.1056/NEJMoa022436 .,OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
"Carcinogenesis 30, 88 –92.http://dx.doi.org/10.1093/carcin/bgn229 .",Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
"http://dx.doi.org/10.1359/jbmr.2001.16.1.182 .Peacock, M., Liu, G., Carey, M., McClintock, R., Ambrosius, W., Hui, S., Johnston, C.C., 2000.",Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1210/jcem.85.9.6836 .,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1016/j.ajpath.2012.05.034 .,OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1111/j.,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
"5, 52 –55.http://dx.doi.org/10.1038/nmat1545 .",Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1017/S0007114507764760 .,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1079/PHN2003590 .,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
391 –405 http://dx.doi.org/10.1016/B978-012088562-6/50024-8 .,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1016/8756-3282(93)90087-Q .,OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1016/j.bone.2007.12.009 .,OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1196/annals.1346.039 .,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
Washington DC http://health.gov/dietaryguidelines/2015/guidelines/ .,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1007/ s00198-007-0385-1 .,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1079/BJN2003952 .,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
http://dx.doi.org/10.1002/(SICI)1520-670X(1998)11:2/33.3.,Non-OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
"Bone 16, 25 –31.http://dx.doi.org/10.1016/8756- 3282(95)80007-D .149 M.N.",OADS,/arxiv_data1/oa_pdf/98/53/main.PMC4920365.pdf
2015. https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS/MeasuresCodes.html.,Non-OADS,/arxiv_data1/oa_pdf/90/0e/acm-91-925.PMC4920441.pdf
2012. http://www.ices.on.ca/Publications/ Atlases-and-Reports/2012/Ontario-Stroke- Evaluation-Report-2012.,Non-OADS,/arxiv_data1/oa_pdf/90/0e/acm-91-925.PMC4920441.pdf
1946. http://www.who.int/governance/eb/who_ constitution_en.pdf.,Non-OADS,/arxiv_data1/oa_pdf/90/0e/acm-91-925.PMC4920441.pdf
2015. https://decisionaid.ohri.ca/docs/ develop/ODSF.pdf.,Non-OADS,/arxiv_data1/oa_pdf/90/0e/acm-91-925.PMC4920441.pdf
2015. http://www.nap.edu/catalog.php?record_id=19402.,Non-OADS,/arxiv_data1/oa_pdf/90/0e/acm-91-925.PMC4920441.pdf
http://www.c2e2.ca/sites/default/files/2013_04_23%20 PROMS%20Report%20Final%201.pdf.,OADS,/arxiv_data1/oa_pdf/90/0e/acm-91-925.PMC4920441.pdf
2015. http://acocahps.cms.gov/Content/Default.aspx.,OADS,/arxiv_data1/oa_pdf/90/0e/acm-91-925.PMC4920441.pdf
2015. http://journals.lww.com/academicmedicine/ toc/9000/00000?roi=echo4-21016927950- 18562511-992f531f2a21bd8428bf467b4284c778&.,Non-OADS,/arxiv_data1/oa_pdf/90/0e/acm-91-925.PMC4920441.pdf
"All  of the participants were provided participants with information on healthy weight loss based  on the Small Steps, Big Rewards  program (available at http://ndep.nih.gov/partners-commu- nityorganization/campaigns/SmallStepsBigRewards.aspx ).",Non-OADS,/arxiv_data1/oa_pdf/64/c9/nihms-794709.PMC4920480.pdf
http://www2.niddk.nih.gov/ .,Non-OADS,/arxiv_data1/oa_pdf/64/c9/nihms-794709.PMC4920480.pdf
"[ 6,7], who developed a stochastic “front end” Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> Received 14 March 2016 | Accepted 15 June 2016 | Published 17 June 2016© 2016 Molecular Vision 674Quantitative modeling of the molecular steps underlying shut-off  of rhodopsin activity in rod phototransduction Trevor D. Lamb,1 Timothy W. Kraft2 1Eccles Institute of Neuroscience, John Curtin School of Medical Research,   The Australian National University, Canberra, ACT, Australia; 2Department of Optometry and Vision Science, University of  Alabama at Birmingham, Birmingham, AL Purpose:  To examine the predictions of alternative models for the stochastic shut-off of activated rhodopsin (R*) and  their implications for the interpretation of experimentally recorded single-photon responses (SPRs) in mammalian rods.",Non-OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  675description of R* shut-off that fed into a deterministic  downstream description of the remainder of the cascade.,Non-OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  676states bind arrestin with a fixed rate constant.,Non-OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
"Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  677Amazingly, the assumption embodied in Equation (0.1)  leads to a major simplification.",Non-OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
"Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  678a function of the minimum number of sites, M, required for  arrestin binding.",Non-OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
"Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  679permitted in [ 9], whereas in [ 6] and [ 11] it was assumed that  ωG = ωP.",Non-OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
"Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  680  Rt Pt Pt *( )( )( )( ).tril ow Fl ow FL    (3.4) =− + 1ρρ  In the general case, with arbitrary rate constants, it is  necessary to evaluate the terms PF(t) and PFL(t) in Equation  (3.4) by numerical integration.",Non-OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
"Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  681  Jt jx tj xt x L() {( ,) (,)} =+∫ cG ex d   (4.9)   The membrane currents above are expressed as current  density  per unit length of outer segment, jcG(x,t) and jex(x,t).",OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  682infinitesimally narrow.,Non-OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  683Numerical integration of equations for downstream photo - transduction cascade:  The differential equations for the  deterministic reactions of the downstream phototransduction  cascade were integrated numerically using a Matlab o.d.e.,OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
"Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  684had the longest times to exit from state R*·P(2), and these are  plotted in blue.",Non-OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
"Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  685to every other state, there are some factors that combine to  generate “unusual” events for the doubly phosphorylated  state.",Non-OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
"Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  686checking the accuracy of our stochastic simulations, but it  also allows us to predict the distribution of SPR amplitudes.",Non-OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
"Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  687cyclase rate to the value used by Koch and Dell’Orco [ 22], αmax  = 120  µM s−1.",OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
"Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  688the simplifying cases of ratios of rate constants, as set out in  the Theory section.",Non-OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  689equal to the other rate constants at κ = ν = μ = 60 s−1.,OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  690present at around the time of the peak; the first eight such  peaks are visually apparent with this bin width.,Non-OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
"Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  691decay of E* leads on the one hand to SPR responses (Figure  5C) that more nearly resemble the shape of observed dim  flash responses but on the other hand leads to only minor  changes in the form of the ensemble mean, SD, and amplitude  distribution.",Non-OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
"Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  692νRE βsub or equivalently by the “amplification constant” A  = νRE βsub ncG [1], where ncG is the cooperativity of channel  opening by cGMP, which is widely accepted to be ncG = 3.",Non-OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  693nearly resembled the shape of observed dim flash responses.,Non-OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
"Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  694This, in fact, is approximately what the binary and three-state  models achieve.",Non-OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  695subsequent transition to the low-activity state is delayed for  the order of seconds.,Non-OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
Molecular Vision  2016; 22:674-696 <http://www.molvis.org/molvis/v 22/674> © 2016 Molecular Vision  69619.,Non-OADS,/arxiv_data1/oa_pdf/09/7b/mv-v22-674.PMC4920504.pdf
1Jonathan Irish and Jamie Mills contributed equally to this work.available at www.sciencedirect.com ScienceDirect www.elsevier.com /locate/molonc http://dx.doi.org/10.1016/j.molonc.2016.02.003 1574-7891/ ª2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d9/d6/MOL2-10-850.PMC4920706.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).MOLECULAR ONCOLOGY 10 (2016) 850 e865,Non-OADS,/arxiv_data1/oa_pdf/d9/d6/MOL2-10-850.PMC4920706.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d9/d6/MOL2-10-850.PMC4920706.pdf
Supplementary data Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.molonc.2016.02.003 .,OADS,/arxiv_data1/oa_pdf/d9/d6/MOL2-10-850.PMC4920706.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the originalauthor(s) and the source, provide a link to the Creative Commonslicense, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/ff/1e/40265_2016_Article_594.PMC4920836.pdf
http://www.ijph.it/pdf/99/014.pdf .,Non-OADS,/arxiv_data1/oa_pdf/ff/1e/40265_2016_Article_594.PMC4920836.pdf
The authors would like to thank Editage ( http://www.editage.com ) for English-language editing.,Non-OADS,/arxiv_data1/oa_pdf/51/93/12325_2016_Article_338.PMC4920838.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, providea link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/51/93/12325_2016_Article_338.PMC4920838.pdf
"Conclusion : The review ﬁndings emphasize the importance of early diagnosis, early initiation ofEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ A1D4F0601A5546F4 .",Non-OADS,/arxiv_data1/oa_pdf/1a/04/12325_2016_Article_343.PMC4920839.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any non- commercial use, distribution, and reproductionin any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/1a/04/12325_2016_Article_343.PMC4920839.pdf
"Consequently, IBS results in a substantial ﬁnancial and economic burden including costsEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/13C4 F0607800E00A .",Non-OADS,/arxiv_data1/oa_pdf/8d/57/12325_2016_Article_336.PMC4920845.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate creditto the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.Adv Ther (2016) 33:877–893 889",Non-OADS,/arxiv_data1/oa_pdf/8d/57/12325_2016_Article_336.PMC4920845.pdf
"Finally, patients’ and physicians’ opinions on OPTIMA were assessed using the PRAgmatic Content and face validity TestEnhanced content To view enhance content for this article go to http://www.medengine.com/Redeem/F5C4 F0600A47A71C .",Non-OADS,/arxiv_data1/oa_pdf/84/a3/12325_2016_Article_341.PMC4920846.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, andindicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/84/a3/12325_2016_Article_341.PMC4920846.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/f6/98/40263_2016_Article_342.PMC4920848.pdf
This can beEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/72C4 F0601857FBF0 .,Non-OADS,/arxiv_data1/oa_pdf/88/29/12325_2016_Article_333.PMC4920851.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, andindicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/88/29/12325_2016_Article_333.PMC4920851.pdf
http://www.who.int/mental_health/ media/68.pdf .,Non-OADS,/arxiv_data1/oa_pdf/88/29/12325_2016_Article_333.PMC4920851.pdf
This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/Adv Ther (2016) 33:1012–1024 1023,Non-OADS,/arxiv_data1/oa_pdf/6c/4f/12325_2016_Article_335.PMC4920852.pdf
"Creating new value with patients, carers and communities 2015. http://www.kpmg.com/Global/ en/IssuesAndInsights/ArticlesPublications .A c c e s s e d Dec 7, 2015.1024 Adv Ther (2016) 33:1012–1024",Non-OADS,/arxiv_data1/oa_pdf/6c/4f/12325_2016_Article_335.PMC4920852.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the originalauthor(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/de/9b/40272_2016_Article_176.PMC4920853.pdf
"Seer Cancer Statistics Review, 1975–2012 National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/ csr/1975_2012/ , based on November 2014 SEER data submis- sion, posted to the SEER web site, April 2015.",Non-OADS,/arxiv_data1/oa_pdf/de/9b/40272_2016_Article_176.PMC4920853.pdf
2000. http://clinicaltrials.gov/show/NCT02475863 .,Non-OADS,/arxiv_data1/oa_pdf/de/9b/40272_2016_Article_176.PMC4920853.pdf
http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/ 009218s115lbl.pdf .,Non-OADS,/arxiv_data1/oa_pdf/de/9b/40272_2016_Article_176.PMC4920853.pdf
Updated 2015. http://www.ginasthma.,Non-OADS,/arxiv_data1/oa_pdf/de/9b/40272_2016_Article_176.PMC4920853.pdf
2014. https://www.gipdatabank.nl/databank.asp?tabel=03-lftgesl &geg=gebr&item=B01AA .,OADS,/arxiv_data1/oa_pdf/de/9b/40272_2016_Article_176.PMC4920853.pdf
2015. http://www.ema.,Non-OADS,/arxiv_data1/oa_pdf/de/9b/40272_2016_Article_176.PMC4920853.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the originalauthor(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/94/30/40263_2016_Article_339.PMC4920856.pdf
2008. http://www.encyclopedia.com/doc/1G2-2830900619.,Non-OADS,/arxiv_data1/oa_pdf/94/30/40263_2016_Article_339.PMC4920856.pdf
"Paris, 1845. http://www.biusante.",Non-OADS,/arxiv_data1/oa_pdf/94/30/40263_2016_Article_339.PMC4920856.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commer cial use, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Microbial Ecology in Health & Disease 2016, 27: 30418 - http://dx.doi.org/10.3402/mehd.v27.30418 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/a7/4a/MEHD-27-30418.PMC4920936.pdf
"2 (page number not for citation purpose)Citation: Microbial Ecology in Health & Disease 2016, 27: 30418 - http://dx.doi.org/10.3402/mehd.v27.30418",Non-OADS,/arxiv_data1/oa_pdf/a7/4a/MEHD-27-30418.PMC4920936.pdf
"Skin lesions disappearance as a result of treatment with Lactoﬁltrum (Group 1) compared to the control (Group 2) on 21 day of treatment.Lactulose and lignin hydrolysed combination in therapy of AD Citation: Microbial Ecology in Health & Disease 2016, 27: 30418 - http://dx.doi.org/10.3402/mehd.v27.30418 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/a7/4a/MEHD-27-30418.PMC4920936.pdf
"4 (page number not for citation purpose)Citation: Microbial Ecology in Health & Disease 2016, 27: 30418 - http://dx.doi.org/10.3402/mehd.v27.30418",Non-OADS,/arxiv_data1/oa_pdf/a7/4a/MEHD-27-30418.PMC4920936.pdf
"Efﬁcacy of AD treatment with Lactoﬁltrum (Group 1) compared to the control (Group 2), in %.Lactulose and lignin hydrolysed combination in therapy of AD Citation: Microbial Ecology in Health & Disease 2016, 27: 30418 - http://dx.doi.org/10.3402/mehd.v27.30418 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/a7/4a/MEHD-27-30418.PMC4920936.pdf
"6 (page number not for citation purpose)Citation: Microbial Ecology in Health & Disease 2016, 27: 30418 - http://dx.doi.org/10.3402/mehd.v27.30418",Non-OADS,/arxiv_data1/oa_pdf/a7/4a/MEHD-27-30418.PMC4920936.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commer cial use, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Pathobiology of Aging & Age-related Diseases 2016, 6: 31793 - http://dx.doi.org/10.3402/pba.v6.31793 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/1b/f3/PBA-6-31793.PMC4920937.pdf
"2 (page number not for citation purpose)Citation: Pathobiology of Aging & Age-related Diseases 2016, 6: 31793 - http://dx.doi.org/10.3402/pba.v6.31793",Non-OADS,/arxiv_data1/oa_pdf/1b/f3/PBA-6-31793.PMC4920937.pdf
"Data from liver and adipose were presented previously in (23,24).Pharmaceutical inhibition of mTOR in the common marmoset Citation: Pathobiology of Aging & Age-related Diseases 2016, 6: 31793 - http://dx.doi.org/10.3402/pba.v6.31793 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/1b/f3/PBA-6-31793.PMC4920937.pdf
"4 (page number not for citation purpose)Citation: Pathobiology of Aging & Age-related Diseases 2016, 6: 31793 - http://dx.doi.org/10.3402/pba.v6.31793",Non-OADS,/arxiv_data1/oa_pdf/1b/f3/PBA-6-31793.PMC4920937.pdf
"(c) Representative immunoblot for skeletal muscle data presented in (a).Pharmaceutical inhibition of mTOR in the common marmoset Citation: Pathobiology of Aging & Age-related Diseases 2016, 6: 31793 - http://dx.doi.org/10.3402/pba.v6.31793 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/1b/f3/PBA-6-31793.PMC4920937.pdf
"6 (page number not for citation purpose)Citation: Pathobiology of Aging & Age-related Diseases 2016, 6: 31793 - http://dx.doi.org/10.3402/pba.v6.31793",Non-OADS,/arxiv_data1/oa_pdf/1b/f3/PBA-6-31793.PMC4920937.pdf
"Rapamycin, but not resveratrol or simvastatin,Pharmaceutical inhibition of mTOR in the common marmoset Citation: Pathobiology of Aging & Age-related Diseases 2016, 6: 31793 - http://dx.doi.org/10.3402/pba.v6.31793 7 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/1b/f3/PBA-6-31793.PMC4920937.pdf
"8 (page number not for citation purpose)Citation: Pathobiology of Aging & Age-related Diseases 2016, 6: 31793 - http://dx.doi.org/10.3402/pba.v6.31793",Non-OADS,/arxiv_data1/oa_pdf/1b/f3/PBA-6-31793.PMC4920937.pdf
"2012; 8(3): 310 /C125.Pharmaceutical inhibition of mTOR in the common marmoset Citation: Pathobiology of Aging & Age-related Diseases 2016, 6: 31793 - http://dx.doi.org/10.3402/pba.v6.31793 9 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/1b/f3/PBA-6-31793.PMC4920937.pdf
"[http://dx.doi.org/10.1016/S0266-7681(98)80004-1 ] [PMID: 9821596 ] [3] Lefevre-Colau MM, Poiraudeau S, Oberlin C, et al.",OADS,/arxiv_data1/oa_pdf/a0/35/TOORTHJ-10-190.PMC4920970.pdf
[http://dx.doi.org/10.1016/S0003-9993(03)00128-X ] [PMID: 12881830 ] [4] Horger MM.,OADS,/arxiv_data1/oa_pdf/a0/35/TOORTHJ-10-190.PMC4920970.pdf
[http://dx.doi.org/10.5014/ajot.44.4.342 ] [PMID: 2330964 ],Non-OADS,/arxiv_data1/oa_pdf/a0/35/TOORTHJ-10-190.PMC4920970.pdf
"[http://dx.doi.org/10.1191/0269215502cr513oa ] [PMID: 12194627 ] [7] Jonsson P, Johnson PW.",OADS,/arxiv_data1/oa_pdf/a0/35/TOORTHJ-10-190.PMC4920970.pdf
"[http://dx.doi.org/10.1016/S0003-6870(01)00036-9 ] [PMID: 11703046 ] [8] Armstrong AD, MacDermid JC, Chinchalkar S, Stevens RS, King GJ.",OADS,/arxiv_data1/oa_pdf/a0/35/TOORTHJ-10-190.PMC4920970.pdf
"[http://dx.doi.org/10.1016/S1058-2746(98)90003-9 ] [PMID: 9883416 ] [9] Jonsson P, Johnson PW, Hagberg M. Accuracy and feasibility of using an electrogoniometer for measuring simple thumb movements.",OADS,/arxiv_data1/oa_pdf/a0/35/TOORTHJ-10-190.PMC4920970.pdf
"[http://dx.doi.org/10.1080/00140130601164490 ] [PMID: 17454085 ] [10] Breger-Lee D, Voelker ET, Giurintano D, Novick A, Browder L. Reliability of torque range of motion: a preliminary study.",OADS,/arxiv_data1/oa_pdf/a0/35/TOORTHJ-10-190.PMC4920970.pdf
"[http://dx.doi.org/10.1016/S0894-1130(12)80178-5 ] [PMID: 8343872 ] [11] Roberson L, Giurintano DJ.",OADS,/arxiv_data1/oa_pdf/a0/35/TOORTHJ-10-190.PMC4920970.pdf
"[http://dx.doi.org/10.1016/S0894-1130(12)80315-2 ] [PMID: 7550628 ] [12] Reese NB, Bandy WD.",OADS,/arxiv_data1/oa_pdf/a0/35/TOORTHJ-10-190.PMC4920970.pdf
"[http://dx.doi.org/10.1037/0033-2909.86.2.420 ] [PMID: 18839484 ] [16] Streiner DL, Norman GR.",Non-OADS,/arxiv_data1/oa_pdf/a0/35/TOORTHJ-10-190.PMC4920970.pdf
"[http://dx.doi.org/10.1016/S0140-6736(86)90837-8 ] [PMID: 2868172 ] [22] Atkinson G, Nevill AM.",OADS,/arxiv_data1/oa_pdf/a0/35/TOORTHJ-10-190.PMC4920970.pdf
"[http://dx.doi.org/10.2165/00007256-199826040-00002 ] [PMID: 9820922 ] [23] Mason RO, Lind DA, Marchal WG.",OADS,/arxiv_data1/oa_pdf/a0/35/TOORTHJ-10-190.PMC4920970.pdf
"[http://dx.doi.org/10.1111/j.1440-1681.2009.05288.x ] [PMID: 19719745 ] [25] Bland JM, Altman DG.",OADS,/arxiv_data1/oa_pdf/a0/35/TOORTHJ-10-190.PMC4920970.pdf
"[http://dx.doi.org/10.1093/ije/24.Supplement_1.S7 ] [PMID: 7558556 ] [26] Adams BD, Grosland NM, Murphy DM, McCullough M. Impact of impaired wrist motion on hand and upper-extremity performance(1).",OADS,/arxiv_data1/oa_pdf/a0/35/TOORTHJ-10-190.PMC4920970.pdf
"[http://dx.doi.org/10.1016/S0363-5023(03)00424-6 ] [PMID: 14642503 ] [27] Kasapinova K, Kamiloski V. Outcome evaluation in patients with distal radius fracture.",OADS,/arxiv_data1/oa_pdf/a0/35/TOORTHJ-10-190.PMC4920970.pdf
[http://dx.doi.org/10.1053/jhsu.2000.jhsu25a0330 ] [PMID: 10722826 ],OADS,/arxiv_data1/oa_pdf/a0/35/TOORTHJ-10-190.PMC4920970.pdf
"[http://dx.doi.org/10.1097/00005131-199811000-00009 ] [PMID: 9840793 ] [30] Karnezis IA, Fragkiadakis EG.",Non-OADS,/arxiv_data1/oa_pdf/a0/35/TOORTHJ-10-190.PMC4920970.pdf
"[http://dx.doi.org/10.1302/0301-620X.84B7.12673 ] [PMID: 12358387 ] [31] Harris JE, MacDermid JC, Roth J.",Non-OADS,/arxiv_data1/oa_pdf/a0/35/TOORTHJ-10-190.PMC4920970.pdf
"[http://dx.doi.org/10.1186/1477-7525-3-73 ] [PMID: 16288664 ] [32] MacDermid JC, Donner A, Richards RS, Roth JH.",OADS,/arxiv_data1/oa_pdf/a0/35/TOORTHJ-10-190.PMC4920970.pdf
[http://dx.doi.org/10.1016/S0895-4356(02)00445-6 ] [PMID: 12393071 ] © Bashardoust Tajali et al.,Non-OADS,/arxiv_data1/oa_pdf/a0/35/TOORTHJ-10-190.PMC4920970.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/legalcode ), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a0/35/TOORTHJ-10-190.PMC4920970.pdf
"[http://dx.doi.org/10.2106/JBJS.F.00222] [PMID: 17403800] [3] Jones CA, Voaklander DC, Johnston DW, Suarez-Almazor ME.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.3109/09638288.2010.543749] [PMID: 21184628] [5] Liang MH, Cullen KE, Larson MG, et al.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1002/art.1780290801] [PMID: 3091041] [6] Singh JA, O’Byrne M, Harmsen S, Lewallen D. Predictors of moderate-severe functional limitation after primary Total Knee Arthroplasty (TKA): 4701 TKAs at 2-years and 2935 TKAs at 5-years.",Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1016/j.joca.2009.12.001] [PMID: 20060950] [7] Wylde V, Hewlett S, Learmonth ID, Dieppe P. Persistent pain after joint replacement: prevalence, sensory qualities, and postoperative determinants.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1016/j.pain.2010.11.023] [PMID: 21239114] [8] Santaguida PL, Hawker GA, Hudak PL, et al.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1002/art.10631] [PMID: 12483739] [10] Jones CA, Voaklander DC, Suarez-Alma ME.",Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1007/s00167-012-2294-x] [PMID: 23160846] [12] Vissers MM, Bussmann JB, Verhaar JA, Busschbach JJ, Bierma-Zeinstra SM, Reijman M. Psychological factors affecting the outcome of total hip and knee arthroplasty: a systematic review.",Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1016/j.semarthrit.2011.07.003] [PMID: 22035624] [13] von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1016/j.ypmed.2007.08.012] [PMID: 17950122] [14] Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.7326/0003-4819-144-6-200603210-00010] [PMID: 16549855] [15] Fortin PR, Clarke AE, Joseph L, et al.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1002/1529-0131(199908)42:8<1722::AID-ANR22>3.0.CO;2-R] [PMID: 10446873] [16] Baker PN, Deehan DJ, Lees D, et al.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1302/0301-620X.94B8.28786] [PMID: 22844046] [17] Desmeules F, Dionne CE, Belzile EL, Bourbonnais R, Champagne F, Frémont P. Determinants of pain, functional limitations and health- related quality of life six months after total knee arthroplasty: results from a prospective cohort study.",Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1186/2052-1847-5-2] [PMID: 23566925] [18] Lopez-Olivo MA, Landon GC, Siff SJ, et al.",Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1136/ard.2010.146423] [PMID: 21791452] [19] Perruccio AV, Power JD, Evans HM, et al.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1002/acr.21629] [PMID: 22570306] [20] Rajgopal V, Bourne RB, Chesworth BM, MacDonald SJ, McCalden RW, Rorabeck CH.",Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1016/j.arth.2007.08.005] [PMID: 18534516] [21] Gandhi R, Santone D, Takahashi M, Dessouki O, Mahomed NN.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1016/j.knee.2012.10.015] [PMID: 23157967] [22] Riddle DL, Wade JB, Jiranek WA, Kong X. Preoperative pain catastrophizing predicts pain outcome after knee arthroplasty.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1007/s11999-009-0963-y] [PMID: 19585177] [23] Neuburger  J,  Hutchings  A,  Black  N,  van  der  Meulen  JH.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1093/pubmed/fds048] [PMID: 22729275] [24] Escobar A, Quintana JM, Bilbao A, et al.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1093/rheumatology/kel184] [PMID: 16735451] [25] Judge A, Arden NK, Cooper C, et al.",Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1093/rheumatology/kes075] [PMID: 22532699] [26] Lingard EA, Katz JN, Wright EA, Sledge CB, Kinemax Outcomes G. Predicting the outcome of total knee arthroplasty.",Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1302/0301-620X.96B2.31136] [PMID: 24493186] [28] Papakostidou I, Dailiana ZH, Papapolychroniou T, et al.",Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1186/1471-2474-13-116] [PMID: 22748117] [29] Ramaesh R, Jenkins P, Lane JV, Knight S, Macdonald D, Howie C. Personality, function and satisfaction in patients undergoing total hip or knee replacement.",Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1007/s00776-013-0509-8] [PMID: 24362559] [30] Sullivan M, Tanzer M, Stanish W, et al.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1016/j.pain.2009.02.011] [PMID: 19304392] [31] Wylde V, Dixon S, Blom AW.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
[http://dx.doi.org/10.1002/msc.1008] [PMID: 22368121],Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1302/0301-620X.95B12.31684] [PMID: 24293592] [33] Alzahrani  K,  Gandhi  R,  Debeer  J,  Petruccelli  D,  Mahomed  N.  Prevalence  of  clinically  significant  improvement  following  total  knee replacement.",Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.3899/jrheum.100233] [PMID: 21239743] [34] Davis ET, Lingard EA, Schemitsch EH, Waddell JP.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1093/intqhc/mzm059] [PMID: 18174221] [35] Clement ND, MacDonald D, Burnett R, Breusch SJ.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1016/j.knee.2013.07.009] [PMID: 23993274] [36] Yakobov E, Scott W, Stanish W, Dunbar M, Richardson G, Sullivan M. The role of perceived injustice in the prediction of pain and function after total knee arthroplasty.",Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1016/j.pain.2014.07.007] [PMID: 25064836] [37] Caracciolo B, Giaquinto S. Determinants of the subjective functional outcome of total joint arthroplasty.",Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1016/j.archger.2005.01.005] [PMID: 16085068] [38] Lingard EA, Riddle DL.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.2106/JBJS.F.00914] [PMID: 17545417] [39] Gandhi R, Razak F, Davey JR, Mahomed NN.",Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.3899/jrheum.091242] [PMID: 20634242] [40] Clement ND, Jenkins PJ, MacDonald D, et al.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1302/0301-620X.95B1.29749] [PMID: 23307673] [41] Jones CA, Voaklander DC, Johnston DW, Suarez-Almazor ME.",Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1001/archinte.161.3.454] [PMID: 11176772] [42] Ayers DC, Franklin PD, Ploutz-Snyder R, Boisvert CB.",Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1097/01.blo.0000185447.43622.93] [PMID: 16239800] [43] Carr JL, Moffett JA.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1016/S1521-6942(03)00063-9] [PMID: 12915154] [45] Katz NP, Paillard FC, Ekman E. Determining the clinical importance of treatment benefits for interventions for painful orthopedic conditions.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1186/s13018-014-0144-x] [PMID: 25645576] [46] Chesworth BM, Mahomed NN, Bourne RB, Davis AM.",Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1016/j.jclinepi.2007.10.014] [PMID: 18687289] [47] Clement ND, MacDonald D, Simpson AH.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
[http://dx.doi.org/10.1007/s00167-013-2776-5] [PMID: 24253376] [48] Dougados M. It’s good to feel better but it’s better to feel good.,Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1016/j.joca.2011.11.007] [PMID: 22155074] [50] Escobar A, Quintana JM, Bilbao A, Aróstegui I, Lafuente I, Vidaurreta I. Responsiveness and clinically important differences for the WOMAC and SF-36 after total knee replacement.",Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1016/j.joca.2006.09.001] [PMID: 17052924] [51] Engel C, Hamilton NA, Potter PT, Zautra AJ.",OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
[http://dx.doi.org/10.3200/BMED.30.3.113-123] [PMID: 15816314],Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
[http://dx.doi.org/10.1207/s15327558ijbm1104_2] [PMID: 15657019] © Lungu et al.,OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/legalcode ), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/35/bb/TOORTHJ-10-213.PMC4920971.pdf
"[http://dx.doi.org/10.1016/j.arth.2007.07.014 ] [PMID: 18722294 ] [3] Woo RY, Morrey BF.",OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1016/j.otsr.2009.08.003 ] [PMID: 19945930 ] [5] Dorr LD, Wolf AW, Chandler R, Conaty JP.",OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1016/j.clinbiomech.2011.12.014 ] [PMID: 22261012 ] [7] Amstutz HC, Lodwig RM, Schurman DJ, Hodgson AG.",OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1097/00003086-197509000-00016 ] [PMID: 1157408 ] [8] Matsushita A, Nakashima Y, Jingushi S, Yamamoto T, Kuraoka A, Iwamoto Y.",OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1016/j.arth.2008.02.008 ] [PMID: 18534445 ] [9] Matsushita A, Nakashima Y, Fujii M, Sato T, Iwamoto Y. Modular necks improve the range of hip motion in cases with excessively anteverted or retroverted femurs in THA.",Non-OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1007/s11999-010-1385-6 ] [PMID: 20473596 ] [10] Daly PJ, Morrey BF.",Non-OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1302/0301-620X.79B3.7149 ] [PMID: 9180312 ] [12] Digioia AM III, Jaramaz B, Plakseychuk AY, et al.",OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1054/arth.2002.30411 ] [PMID: 11938515 ] [13] Eddine TA, Migaud H, Chantelot C, Cotten A, Fontaine C, Duquennoy A.",OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1007/s00276-001-0105-z ] [PMID: 11462858 ] [14] Parratte S, Argenson JN.",OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
[http://dx.doi.org/10.2106/JBJS.F.00529 ] [PMID: 17332097 ],OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1007/s11999-008-0521-z ] [PMID: 18830796 ] [16] DiGioia AM, Hafez MA, Jaramaz B, Levison TJ, Moody JE.",OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1097/01.blo.0000238862.92356.45 ] [PMID: 17006364 ] [17] Schwab F, Lafage V, Patel A, Farcy JP.",OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1097/BRS.0b013e3181a13c08 ] [PMID: 19644334 ] [18] Bhan S, Eachempati KK, Malhotra R. Primary cementless total hip arthroplasty for bony ankylosis in patients with ankylosing spondylitis.",Non-OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1016/j.arth.2007.07.014 ] [PMID: 18722294 ] [19] Tang WM, Chiu KY. Primary total hip arthroplasty in patients with ankylosing spondylitis.",OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1016/S0883-5403(00)91155-0 ] [PMID: 10654462 ] [20] Sato T, Nakashima Y, Matsushita A, Fujii M, Iwamoto Y.",OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1016/j.clinbiomech.2012.12.011 ] [PMID: 23312621 ] [21] Lewinnek GE, Lewis JL, Tarr R, Compere CL, Zimmerman JR. Dislocations after total hip-replacement arthroplasties.",OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1097/01.blo.0000069891.31220.fd ] [PMID: 12782869 ] [23] Tang WM, Chiu KY, Kwan MF, Ng TP.",OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1002/jor.20225 ] [PMID: 17343279 ] [24] Tannast M, Murphy SB, Langlotz F, Anderson SE, Siebenrock KA.",OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1007/s00256-005-0050-8 ] [PMID: 16365745 ] [25] Tamura S, Takao M, Sakai T, Nishii T, Sugano N. Spinal Factors Influencing Change in Pelvic Sagittal Inclination From Supine Position to Standing Position in Patients Before Total Hip Arthroplasty.",Non-OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1016/j.ijscr.2014.07.015 ] [PMID: 25128730 ] [27] Meek RM, Allan DB, McPhillips G, Kerr L, Howie CR.",OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.3121/cmr.2008.770 ] [PMID: 18591373 ] [28] von Knoch M, Berry DJ, Harmsen WS, Morrey BF.",OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1016/j.arth.2014.07.009 ] [PMID: 25249516 ] [30] Itokawa T, Nakashima Y, Yamamoto T, et al.",OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1007/s00264-013-1921-6 ] [PMID: 23677511 ] [31] Hernigou P, Filippini P, Flouzat-Lachaniette CH, Batista SU, Poignard A.",Non-OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1007/s11999-010-1340-6 ] [PMID: 20376709 ] [32] Combes A, Migaud H, Girard J, Duhamel A, Fessy MH.",OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
[http://dx.doi.org/10.1007/s11999-013-2929-3 ] [PMID: 23516032 ] © Kobayashi et al.,OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/legalcode ), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ed/3a/TOORTHJ-10-206.PMC4920972.pdf
"[http://dx.doi.org/10.1053/joms.2001.25827 ] [PMID: 11526568 ] [2] Szalma J, Lempel E, Jeges S, Szabó G, Olasz L. The prognostic value of panoramic radiography of inferior alveolar nerve damage after",Non-OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
"[http://dx.doi.org/10.1016/j.tripleo.2009.09.023 ] [PMID: 19846324 ] [3] Jerjes W, Swinson B, Moles DR, et al.",OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
"[http://dx.doi.org/10.1016/j.tripleo.2006.01.016 ] [PMID: 16997083 ] [4] Gomes AC, Vasconcelos BC, Silva ED, Caldas AdeF Jr, Pita NIC.",OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
"[http://dx.doi.org/10.1016/j.joms.2007.08.020 ] [PMID: 18201605 ] [5] Hasegawa T, Ri S, Shigeta T, et al.",OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
"[http://dx.doi.org/10.1016/j.ijom.2013.01.023 ] [PMID: 23499150 ] [6] Neves FS, Souza TC, Almeida SM, Haiter-Neto F, Freitas DQ, Bóscolo FN.",OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
"[http://dx.doi.org/10.1259/dmfr/22263461 ] [PMID: 22282507 ] [7] Palma-Carrió C, García-Mira B, Larrazabal-Morón C, Peñarrocha-Diago M. Radiographic signs associated with inferior alveolar nerve damage following lower third molar extraction.",Non-OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
"[http://dx.doi.org/10.4317/medoral.15.e886 ] [PMID: 20526245 ] [8] Park W, Choi JW, Kim JY, Kim BC, Kim HJ, Lee SH.",OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
"[http://dx.doi.org/10.14219/jada.archive.2010.0160 ] [PMID: 20194382 ] [9] Tantanapornkul W, Okochi K, Bhakdinaronk A, Ohbayashi N, Kurabayashi T. Correlation of darkening of impacted mandibular third molar root on digital panoramic images with cone beam computed tomography findings.",OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
[http://dx.doi.org/10.1259/dmfr/83819416 ] [PMID: 19114418 ] [10] Rood JP.,Non-OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
"[http://dx.doi.org/10.1016/0007-117X(83)90054-9 ] [PMID: 6575812 ] [11] Sedaghatfar M, August MA, Dodson TB.",OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
"[http://dx.doi.org/10.1016/j.joms.2004.05.217 ] [PMID: 15635549 ] [12] Tantanapornkul W, Okouchi K, Fujiwara Y, et al.",OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
"[http://dx.doi.org/10.1016/j.tripleo.2006.06.060 ] [PMID: 17234544 ] [13] Monaco  G,  Montevecchi  M,  Bonetti  GA,  Gatto  MR,  Checchi  L.  Reliability  of  panoramic  radiography  in  evaluating  the  topographic relationship between the mandibular canal and impacted third molars.",Non-OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
"[http://dx.doi.org/10.14219/jada.archive.2004.0179 ] [PMID: 15058618 ] [14] Nakamori K, Fujiwara K, Miyazaki A, et al.",OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
"[http://dx.doi.org/10.1016/j.joms.2008.06.042 ] [PMID: 18940497 ] [15] Ghaeminia H, Meijer GJ, Soehardi A, Borstlap WA, Mulder J, Bergé SJ.",OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
"[http://dx.doi.org/10.1016/j.ijom.2009.06.007 ] [PMID: 19640685 ] [16] Streiner DL, Norman GR.",OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
"[http://dx.doi.org/10.1016/0007-117X(83)90054-9 ] [PMID: 6575812 ] [18] Shahidi S, Zamiri B, Bronoosh P. Comparison of panoramic radiography with cone beam CT in predicting the relationship of the mandibular third molar roots to the alveolar canal.",OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
"[http://dx.doi.org/10.5624/isd.2013.43.2.105 ] [PMID: 23807934 ] [19] Nakayama K, Nonoyama M, Takaki Y, et al.",OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
"[http://dx.doi.org/10.1016/j.joms.2009.07.017 ] [PMID: 19925976 ] [20] Jhamb  A,  Dolas  RS,  Pandilwar  PK,  Mohanty  S.  Comparative  efficacy  of  spiral  computed  tomography  and  orthopantomography  in preoperative detection of relation of inferior alveolar neurovascular bundle to the impacted mandibular third molar.",Non-OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
"Panoramic Radiograph in Assessment The Open Dentistry Journal, 2016, Volume 10    329 [http://dx.doi.org/10.1016/j.joms.2008.06.014 ] [PMID: 19070749 ] [21] Szalma J, Lempel E, Jeges S, Olasz L. Darkening of third molar roots: panoramic radiographic associations with inferior alveolar nerve exposure.",Non-OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
"[http://dx.doi.org/10.1016/j.joms.2010.09.009 ] [PMID: 21292368 ] [22] Mahasantipiya PM, Savage NW, Monsour PA, Wilson RJ.",OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
"[http://dx.doi.org/10.1259/dmfr/31872903 ] [PMID: 15897286 ] [23] Ferretti F, Malventi M, Malasoma R. Dental magnetic resonance imaging: study of impacted mandibular third molars.",Non-OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
[http://dx.doi.org/10.1259/dmfr/29929241 ] [PMID: 19700532 ] © Tantanapornkul et al.,Non-OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/legalcode ), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f2/cd/TODENTJ-10-322.PMC4920973.pdf
"[http://dx.doi.org/10.1016/S0140-6736(03)12990-X ] [PMID: 12699969 ] [3] Lee S-H, Yoon H-J.",OADS,/arxiv_data1/oa_pdf/bd/17/TODENTJ-10-330.PMC4920974.pdf
"[http://dx.doi.org/10.1016/j.oooo.2011.11.035 ] [PMID: 22771407 ] [4] Eckardt A, Schultze A. Maxillofacial manifestations of Langerhans cell histiocytosis: a clinical and therapeutic analysis of 10 patients.",OADS,/arxiv_data1/oa_pdf/bd/17/TODENTJ-10-330.PMC4920974.pdf
"[http://dx.doi.org/10.1016/S1368-8375(03)00080-0 ] [PMID: 12907208 ] [5] Hicks J, Flaitz CM.",OADS,/arxiv_data1/oa_pdf/bd/17/TODENTJ-10-330.PMC4920974.pdf
"[http://dx.doi.org/10.1016/j.tripleo.2005.06.016 ] [PMID: 16037792 ] [6] Bottomley  WK,  Gabriel  SA,  Corio  RL,  Jacobson  RJ,  Rothchild  N.  Histiocytosis  X:  report  of  an  oral  soft  tissue  lesion  without  bony involvement.",OADS,/arxiv_data1/oa_pdf/bd/17/TODENTJ-10-330.PMC4920974.pdf
"[http://dx.doi.org/10.1016/0030-4220(87)90318-5 ] [PMID: 3493462 ] [7] Finney DS, Rees TD, Wright JM, Blanton PL.",OADS,/arxiv_data1/oa_pdf/bd/17/TODENTJ-10-330.PMC4920974.pdf
"[http://dx.doi.org/10.1902/jop.1988.59.7.457 ] [PMID: 3166058 ] [8] Cleveland DB, Goldberg KM, Greenspan JS, Seitz TE, Miller AS.",OADS,/arxiv_data1/oa_pdf/bd/17/TODENTJ-10-330.PMC4920974.pdf
"[http://dx.doi.org/10.1016/S1079-2104(96)80201-0 ] [PMID: 8936519 ] [9] Milián MA, Bagán JV, Jiménez Y, Pérez A, Scully C, Antoniades D. Langerhans’ cell histiocytosis restricted to the oral mucosa.",Non-OADS,/arxiv_data1/oa_pdf/bd/17/TODENTJ-10-330.PMC4920974.pdf
"[http://dx.doi.org/10.1067/moe.2001.110031 ] [PMID: 11174575 ] [10] Takahashi  K,  Harada  M,  Kimoto  M,  Kondo  F.  Diagnostic  confirmation  of  Langerhans  cell  histiocytosis  of  the  jaws  with  CD1a immunostaining:  a  case  report.",OADS,/arxiv_data1/oa_pdf/bd/17/TODENTJ-10-330.PMC4920974.pdf
"[http://dx.doi.org/10.1053/joms.2003.50019 ] [PMID: 12524618 ] [11] Esen A, Dolanmaz D, Kalaycı A, Günhan O, Avunduk MC.",Non-OADS,/arxiv_data1/oa_pdf/bd/17/TODENTJ-10-330.PMC4920974.pdf
"[http://dx.doi.org/10.1016/j.tripleo.2009.10.015 ] [PMID: 20123398 ] [12] Plona GA, Wiltz M, Kelsch R. Spontaneous resolution of an eosinophilic granuloma of the mandible following open biopsy.",OADS,/arxiv_data1/oa_pdf/bd/17/TODENTJ-10-330.PMC4920974.pdf
[http://dx.doi.org/10.1016/j.oooo.2015.11.008 ] [PMID: 27033671 ] © Gambirazi et al; Licensee Bentham Open.,OADS,/arxiv_data1/oa_pdf/bd/17/TODENTJ-10-330.PMC4920974.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/legalcode ), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/bd/17/TODENTJ-10-330.PMC4920974.pdf
[http://dx.doi.org/10.1111/j.1600-9657.2009.00791.x ] [PMID: 19496800 ] [5] Al-Hayali A. Traumatized anterior teeth among 4–11 years old in the central region of Iraq.,Non-OADS,/arxiv_data1/oa_pdf/6a/ea/TODENTJ-10-315.PMC4920975.pdf
"[http://dx.doi.org/10.1111/j.1600-9657.2008.00704.x ] [PMID: 19302204 ] [7] Naidoo S, Sheiham A, Tsakos G. Traumatic dental injuries of permanent incisors in 11- to 13-year-old South African schoolchildren.",Non-OADS,/arxiv_data1/oa_pdf/6a/ea/TODENTJ-10-315.PMC4920975.pdf
"[http://dx.doi.org/10.1111/j.1600-9657.2008.00749.x ] [PMID: 19290905 ] [8] Cavalcanti AL, Bezerra PK, de Alencar CR, Moura C. Traumatic anterior dental injuries in 7- to 12-year-old Brazilian children.",Non-OADS,/arxiv_data1/oa_pdf/6a/ea/TODENTJ-10-315.PMC4920975.pdf
[http://dx.doi.org/10.1111/j.1600-9657.2008.00746.x ] [PMID: 19290900 ],Non-OADS,/arxiv_data1/oa_pdf/6a/ea/TODENTJ-10-315.PMC4920975.pdf
"[http://dx.doi.org/10.1111/j.1600-9657.2009.00826.x ] [PMID: 19788423 ] [13] Tham RC, Cassell E, Calache H. Traumatic orodental injuries and the development of an orodental injury surveillance system: a pilot study in Victoria, Australia.",Non-OADS,/arxiv_data1/oa_pdf/6a/ea/TODENTJ-10-315.PMC4920975.pdf
"[http://dx.doi.org/10.1111/j.1600-9657.2008.00720.x ] [PMID: 19208021 ] [14] Malikaew P, Watt RG, Sheiham A.",OADS,/arxiv_data1/oa_pdf/6a/ea/TODENTJ-10-315.PMC4920975.pdf
[http://dx.doi.org/10.1111/j.1600-9657.2006.00457.x ] [PMID: 17803486 ] [16] Locker D. Prevalence of traumatic dental injury in grade 8 children in six Ontario communities.,Non-OADS,/arxiv_data1/oa_pdf/6a/ea/TODENTJ-10-315.PMC4920975.pdf
[http://dx.doi.org/10.1001/jama.282.24.2328 ] [PMID: 10612320 ] [18] Ellis RG.,OADS,/arxiv_data1/oa_pdf/6a/ea/TODENTJ-10-315.PMC4920975.pdf
[http://dx.doi.org/10.1111/j.1600-9657.2006.00342.x ] [PMID: 16499629 ] © Alkhadra et al.,OADS,/arxiv_data1/oa_pdf/6a/ea/TODENTJ-10-315.PMC4920975.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/legalcode ), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6a/ea/TODENTJ-10-315.PMC4920975.pdf
URL: http://clinicaltrials.gov/ct2/show/NCT01130519Concurrent renal-cell carcinoma and cutaneous leiomyomas: A case of HLRCC RCR  Radiology Case Reports | radiology.casereports.net!,Non-OADS,/arxiv_data1/oa_pdf/b0/da/main.PMC4921156.pdf
"Online Mendelian Inheritance in Man, 247100;  http://www.ncbi.",Non-OADS,/arxiv_data1/oa_pdf/02/27/main.PMC4921162.pdf
"http://emedicine.medscape.com/article/462885-treat ment#a1128 Updated: Feb 27, 2014  7.",Non-OADS,/arxiv_data1/oa_pdf/3a/cc/main.PMC4921167.pdf
DOI: http://dx.doi.org/10.1148/radiol.2342042574Extraosseus Ewing sarcoma: An uncommon periclavicular location RCR  Radiology Case Reports | radiology.casereports.net !,Non-OADS,/arxiv_data1/oa_pdf/65/e1/main.PMC4921171.pdf
DOI:http://dx.doi.org/10.1016/j.radi.2013.10.006Lingular pneumonia obscured by implanted cardioverter-deﬁbrillator: Lateral thinking RCR  Radiology Case Reports | radiology.casereports.net !,Non-OADS,/arxiv_data1/oa_pdf/e4/99/main.PMC4921173.pdf
Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cf maude/detail.cfm?mdrfoi__id=1397902Combined rheolytic thrombectomy & stent placement in SVC & brachiocephalic vein thrombosis RCR  Radiology Case Reports | radiology.casereports.net!,Non-OADS,/arxiv_data1/oa_pdf/26/ae/main.PMC4921187.pdf
[http://dx.doi.org/10.1148/radiol.2393050823][PubMed ] 2.,Non-OADS,/arxiv_data1/oa_pdf/35/f4/main.PMC4921191.pdf
[http://dx.doi.org/10.1016/j.clineuro.2011.11.006][PubMed ] 4.,OADS,/arxiv_data1/oa_pdf/35/f4/main.PMC4921191.pdf
[http://dx.doi.org/10.10161/j.jocn.2006.10.028][PubMed ]Traumatic rupture of an intracranial dermoid cyst RCR  Radiology Case Reports | radiology.casereports.net!,Non-OADS,/arxiv_data1/oa_pdf/35/f4/main.PMC4921191.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Stroke outcomeSickle cell traitStroke mortality 1.,Non-OADS,/arxiv_data1/oa_pdf/b0/56/main.PMC4921203.pdf
http://dx.doi.org/10.1016/j.ensci.2016.02.009 2405-6502/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/b0/56/main.PMC4921203.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b0/56/main.PMC4921203.pdf
Contents lists available at ScienceDirect eNeurologicalSci journal homepage: http://ees.elsevier.com/ensci/,Non-OADS,/arxiv_data1/oa_pdf/b0/56/main.PMC4921203.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/09/ce/ircmj-18-04-35006.PMC4921213.pdf
Available from: http://www.cblynch.com/HTML/ technique.html .,Non-OADS,/arxiv_data1/oa_pdf/09/ce/ircmj-18-04-35006.PMC4921213.pdf
[cited 2015 August 3rd]; Available from:  http://www.who.int/hiv/data/en/ 2.,OADS,/arxiv_data1/oa_pdf/a0/e4/nihms760396.PMC4921313.pdf
[cited 2015 August 13th];  Available from: https://clinicaltrials.gov/ct2/show/NCT02344290 125.,Non-OADS,/arxiv_data1/oa_pdf/a0/e4/nihms760396.PMC4921313.pdf
[cited 2015 August 4th];  Available from: https://clinicaltrials.gov/ct2/show/NCT01949116 134.,Non-OADS,/arxiv_data1/oa_pdf/a0/e4/nihms760396.PMC4921313.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6f/a4/pnv047.PMC4921346.pdf
"2009. http://www.mdanderson.org/education-and-research/departments-programs-and-labs/depart-ments-and-divisions/symptom-research/symptom-assessment-tools/BPI_UserGuide.pdf (accessedSeptember 21, 2015).Daily Morphine Decreases Right Amygdala Volume 1503",Non-OADS,/arxiv_data1/oa_pdf/6f/a4/pnv047.PMC4921346.pdf
"http://www.fda.gov/Drugs/NewsEvents/ucm456973.htm (accessed September 25, 2015).Lin et al.",OADS,/arxiv_data1/oa_pdf/6f/a4/pnv047.PMC4921346.pdf
"The remote monitoring system consisted of a belt strap with a sensor (Ucare  RG10, http://www.microsen- stech.com), a smartphone with an application, servers and a  web portal.",Non-OADS,/arxiv_data1/oa_pdf/c2/66/jgc-13-04-326.PMC4921545.pdf
http://www.nielsen.com/content/  dam/corporate/uk/en/documents/Mobile-Consumer-Report-2013.,Non-OADS,/arxiv_data1/oa_pdf/c2/66/jgc-13-04-326.PMC4921545.pdf
"Original Article J Vet Sci 2016, 17(2), 127-136 ㆍhttp://dx.doi.org/10.4142/jvs.2016.17.2.127 JVS Received 27 Mar.",Non-OADS,/arxiv_data1/oa_pdf/c9/1e/jvs-17-127.PMC4921660.pdf
"Original Article J Vet Sci 2016, 17(2), 137-144 ㆍhttp://dx.doi.org/10.4142/jvs.2016.17.2.137 JVS Received 3 Jun.",Non-OADS,/arxiv_data1/oa_pdf/01/a5/jvs-17-137.PMC4921661.pdf
"Original Article J Vet Sci 2016, 17(2), 145-152 ㆍhttp://dx.doi.org/10.4142/jvs.2016.17.2.145 JVS Received 31 Mar.",Non-OADS,/arxiv_data1/oa_pdf/9c/4e/jvs-17-145.PMC4921662.pdf
"Original Article J Vet Sci 2016, 17(2), 153-158 ㆍhttp://dx.doi.org/10.4142/jvs.2016.17.2.153 JVS Received 2 Mar.",Non-OADS,/arxiv_data1/oa_pdf/b9/db/jvs-17-153.PMC4921663.pdf
"Original Article J Vet Sci 2016, 17(2), 159-170 ㆍhttp://dx.doi.org/10.4142/jvs.2016.17.2.159 JVS Received 20 May.",Non-OADS,/arxiv_data1/oa_pdf/ce/53/jvs-17-159.PMC4921664.pdf
"Original Article J Vet Sci 2016, 17(2), 171-178 ㆍhttp://dx.doi.org/10.4142/jvs.2016.17.2.171 JVS Received 3 Feb. 2015, Revised 30 Apr.",Non-OADS,/arxiv_data1/oa_pdf/11/d5/jvs-17-171.PMC4921665.pdf
"Original Article J Vet Sci 2016, 17(2), 179-188 ㆍhttp://dx.doi.org/10.4142/jvs.2016.17.2.179 JVS Received 5 Mar.",Non-OADS,/arxiv_data1/oa_pdf/51/7a/jvs-17-179.PMC4921666.pdf
"Original Article J Vet Sci 2016, 17(2), 189-197 ㆍhttp://dx.doi.org/10.4142/jvs.2016.17.2.189 JVS Received 17 Jul.",Non-OADS,/arxiv_data1/oa_pdf/39/35/jvs-17-189.PMC4921667.pdf
"Original Article J Vet Sci 2016, 17(2), 199-206 ㆍhttp://dx.doi.org/10.4142/jvs.2016.17.2.199 JVS Received 2 Jul.",Non-OADS,/arxiv_data1/oa_pdf/63/65/jvs-17-199.PMC4921668.pdf
"Original Article J Vet Sci 2016, 17(2), 207-216 ㆍhttp://dx.doi.org/10.4142/jvs.2016.17.2.207 JVS Received 15 Jun.",Non-OADS,/arxiv_data1/oa_pdf/76/5b/jvs-17-207.PMC4921669.pdf
"Original Article J Vet Sci 2016, 17(2), 217-224 ㆍhttp://dx.doi.org/10.4142/jvs.2016.17.2.217 JVS Received 8 May.",Non-OADS,/arxiv_data1/oa_pdf/28/9f/jvs-17-217.PMC4921670.pdf
"Original Article J Vet Sci 2016, 17(2), 225-234 ㆍhttp://dx.doi.org/10.4142/jvs.2016.17.2.225 JVS Received 27 Feb. 2015, Revised 15 Sep. 2015, Accepted 7 Oct. 2015 *Corresponding author: Tel: +90-312-317-0315; Fax: +90-312-316-4472; E-mail: besalti@hotmail.com Journal of Veterinary Science ㆍⓒ 2016 The Korean Society of Veterinary Science.",Non-OADS,/arxiv_data1/oa_pdf/0e/60/jvs-17-225.PMC4921671.pdf
"Original Article J Vet Sci 2016, 17(2), 235-242 ㆍhttp://dx.doi.org/10.4142/jvs.2016.17.2.235 JVS Received 21 Jan. 2015, Revised 26 Aug. 2015, Accepted 7 Oct. 2015 *Corresponding author: Tel: +86-451-55190150; Fax: +86-451-55190150; E-mail: abliuyun@yeah.net Journal of Veterinary Science ㆍⓒ 2016 The Korean Society of Veterinary Science.",Non-OADS,/arxiv_data1/oa_pdf/80/d9/jvs-17-235.PMC4921672.pdf
"Original Article J Vet Sci 2016, 17(2), 243-251 ㆍhttp://dx.doi.org/10.4142/jvs.2016.17.2.243 JVS Received 19 Mar.",Non-OADS,/arxiv_data1/oa_pdf/3a/be/jvs-17-243.PMC4921673.pdf
" Short Communication J Vet Sci 2016, 17(2), 253-256 ㆍhttp://dx.doi.org/10.4142/jvs.2016.17.2.253 JVS Received 9 Jun.",Non-OADS,/arxiv_data1/oa_pdf/9f/af/jvs-17-253.PMC4921674.pdf
"Case Report J Vet Sci 2016, 17(2), 257-260 ㆍhttp://dx.doi.org/10.4142/jvs.2016.17.2.257 JVS Received 26 Feb. 2015, Revised 11 Aug. 2015, Accepted 7 Oct. 2015 *Corresponding author: Tel: +82-62-530-2821; Fax: +82-62-530-2897; E-mail: imsono@chonnam.ac.kr †The first two authors contributed equally to this work.",Non-OADS,/arxiv_data1/oa_pdf/a3/0a/jvs-17-257.PMC4921675.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org   389Exposure and sensitization to allergens can promote develop - ment and exacerbation of allergic disease.",Non-OADS,/arxiv_data1/oa_pdf/67/13/aair-8-389.PMC4921691.pdf
"Young Yoo1,2* 1Department of Pediatrics, Korea University Anam Hospital 2Allergy Immunology Center, Korea University, Seoul, Korea This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/67/13/aair-8-389.PMC4921691.pdf
2016 September;8(5):389-390. http://dx.doi.org/10.4168/aair.2016.8.5.389 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/67/13/aair-8-389.PMC4921691.pdf
"2016 September;8(5):389-390. http://dx.doi.org/10.4168/aair.2016.8.5.389Volume 8, Number 5, September 2016 390  http://e-aair.orgMeanwhile, recent studies11,12 have demonstrated the clinical  implications of a high concentration of small fungal fragments  in asthma severity.",Non-OADS,/arxiv_data1/oa_pdf/67/13/aair-8-389.PMC4921691.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org   391INTRODUCTION In the last century, the massive increase in emissions of air  pollutants due to the economic and industrial growth has made  air quality a major problem in many industrialized countries,  and an emerging problem for the rest of the world.",Non-OADS,/arxiv_data1/oa_pdf/24/0a/aair-8-391.PMC4921692.pdf
"Monaldi” and University “Federico II” Medical School, Naples, Italy 6Department of Medicine and Surgery, University of Salerno, Salerno, Italy This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/24/0a/aair-8-391.PMC4921692.pdf
2016 September;8(5):391-395. http://dx.doi.org/10.4168/aair.2016.8.5.391 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/24/0a/aair-8-391.PMC4921692.pdf
"2016 September;8(5):391-395. http://dx.doi.org/10.4168/aair.2016.8.5.391Volume 8, Number 5, September 2016 392  http://e-aair.orgcentury is very likely due to the observed increase in anthropo - genic greenhouse gas concentrations.",Non-OADS,/arxiv_data1/oa_pdf/24/0a/aair-8-391.PMC4921692.pdf
"2016 September;8(5):391-395. http://dx.doi.org/10.4168/aair.2016.8.5.391AAIR http://e-aair.org   393ry hospital admissions and deaths in Europe and the USA.16 It is  estimated that there will be an annual ozone level of >1,500  ppm associated deaths by the year 2020 in the UK alone.16 Pol- lution models for climate change scenarios predict an increase  in ozone concentrations over large areas, while the effect on  particle concentrations is less clear.24 The short-term effects of  ozone on daily mortality and respiratory disease are extensively  studied, while there is only limited documentation of long-term  effects on mortality.24,25  Positive associations have been observed between urban air  pollution and respiratory symptoms in children, and the litera - ture contains many reports of relations between motor vehicle  exhausts and acute or chronic respiratory symptoms in chil - dren living near traffic.24-26 Air pollution can negatively influence lung development in  children and adolescents.25,27,28 Most studies have suggested ad - verse effects of air pollution on children’s lung function and re - spiratory symptoms.",Non-OADS,/arxiv_data1/oa_pdf/24/0a/aair-8-391.PMC4921692.pdf
"2016 September;8(5):391-395. http://dx.doi.org/10.4168/aair.2016.8.5.391Volume 8, Number 5, September 2016 394  http://e-aair.orgfirst phase of a thunderstorm, that is, the first 20-30 minutes,  there is evidence of high respirable allergen loadings in the air.",Non-OADS,/arxiv_data1/oa_pdf/24/0a/aair-8-391.PMC4921692.pdf
Available  from: http://www.ipcc.ch/pdf/assessment-report/ar4/wg1/ar4_ wg1_full_report.pdf.,OADS,/arxiv_data1/oa_pdf/24/0a/aair-8-391.PMC4921692.pdf
2016 September;8(5):391-395. http://dx.doi.org/10.4168/aair.2016.8.5.391AAIR http://e-aair.org   3952008;62:209-15.,Non-OADS,/arxiv_data1/oa_pdf/24/0a/aair-8-391.PMC4921692.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease 396  http://e-aair.orgINTRODUCTION Urticaria is a heterogeneous skin disorder that may be acute  or chronic, intermittent or persistent, and may occur alone or  in association with other related conditions such as angioede - ma.",Non-OADS,/arxiv_data1/oa_pdf/7b/a5/aair-8-396.PMC4921693.pdf
"Isolated urticaria without angioedema occurs in Guideline of Chronic Urticaria Beyond Lauren M. Fine,1 Jonathan A. Bernstein2* 1 Department of Medicine, University of Miami Miller School of Medicine, Department of Internal Medicine, Division of Pulmonary, Allergy, Critical Care and  Sleep Medicine, Miami, FL, USA 2 Department of Medicine, University of Cincinnati College of Medicine, Department of Internal Medicine, Division of Immunology/Allergy Section, Cincinnati,  Ohio, USA This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/7b/a5/aair-8-396.PMC4921693.pdf
2016 September;8(5):396-403. http://dx.doi.org/10.4168/aair.2016.8.5.396 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/7b/a5/aair-8-396.PMC4921693.pdf
"2016 September;8(5):396-403. http://dx.doi.org/10.4168/aair.2016.8.5.396AAIR http://e-aair.org   397approximately 40% of cases, whereas angioedema occurs con - currently with urticaria in up to 40% of cases.",Non-OADS,/arxiv_data1/oa_pdf/7b/a5/aair-8-396.PMC4921693.pdf
"2016 September;8(5):396-403. http://dx.doi.org/10.4168/aair.2016.8.5.396Volume 8, Number 5, September 2016 398  http://e-aair.orgevance of autoantibodies associated with autoimmune diseas - es remains unclear it has been hypothesized that the inflam - matory processes associated with these autoimmune condi - tions may lead directly to urticaria or increase the individual’s  susceptibility to CU.23  Approximately 40%-50% of adults and children with CU have  evidence of an autoantibody directed against the FcER1 alpha  subunit of the high-affinity IgE receptor.24,25 In vitro  studies have  demonstrated that these IgG antibodies can cross-link the high- affinity IgE FcER1 of mast cells and basophils or by binding to  IgE antibodies already occupying these receptors.26,27 The pres - ence of circulating antibodies can be assessed by various in vi - tro tests, including Western blot analysis for anti-Fc ϵRI autoan - tibodies, histamine release assays, flow cytometry or in vivo  au- tologous serum or plasma skin tests.27,28 Although these autoan - tibodies are of significant academic interest, their clinical rele - vance remains unclear as most therapies used to treat hives ( i.e.,  omalizumab or cyclosporine) have been demonstrated to be  effective in the presence or absence of these antibodies.",Non-OADS,/arxiv_data1/oa_pdf/7b/a5/aair-8-396.PMC4921693.pdf
2016 September;8(5):396-403. http://dx.doi.org/10.4168/aair.2016.8.5.396AAIR http://e-aair.org   399antihistamines.,OADS,/arxiv_data1/oa_pdf/7b/a5/aair-8-396.PMC4921693.pdf
"2016 September;8(5):396-403. http://dx.doi.org/10.4168/aair.2016.8.5.396Volume 8, Number 5, September 2016 400  http://e-aair.orgdine, has also been shown to be better than placebo for control  of urticaria.42,43 Although all 3 have been proven to be effective  in control of CU, none are consistently superior and response  varies among patients.44-46 Third-generation antihistamines include desloratadine and  levocetirizine, isomeric forms of loratadine and cetirizine, re - spectively.",Non-OADS,/arxiv_data1/oa_pdf/7b/a5/aair-8-396.PMC4921693.pdf
"2016 September;8(5):396-403. http://dx.doi.org/10.4168/aair.2016.8.5.396AAIR http://e-aair.org   401ab, a humanized recombinant IgG1 kappa monoclonal anti-IgE  antibody previously approved for treatment of moderate to se - vere persistent asthma since 2003, was recently approved for  the treatment of CU unresponsive to H1 antihistamines in  2014.64 Whereas dosing of omalizumab for asthma treatment is  based on pre-treatment IgE level and patient weight, these pre- specifications are not necessary for CU.",Non-OADS,/arxiv_data1/oa_pdf/7b/a5/aair-8-396.PMC4921693.pdf
"2016 September;8(5):396-403. http://dx.doi.org/10.4168/aair.2016.8.5.396Volume 8, Number 5, September 2016 402  http://e-aair.orgMaurer M. How to assess disease activity in patients with chronic  urticaria?",Non-OADS,/arxiv_data1/oa_pdf/7b/a5/aair-8-396.PMC4921693.pdf
2016 September;8(5):396-403. http://dx.doi.org/10.4168/aair.2016.8.5.396AAIR http://e-aair.org   403Int J Dermatol 2001;40:72-6.,Non-OADS,/arxiv_data1/oa_pdf/7b/a5/aair-8-396.PMC4921693.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease404  http://e-aair.orgINTRODUCTION Fungi are ubiquitous in the environment, and their spores are  found widely in the air.",Non-OADS,/arxiv_data1/oa_pdf/c4/3d/aair-8-404.PMC4921694.pdf
": The Role of  Allergenic Fungal Species Wan-Rou Lin,1 Yi-Hsing Chen,2,3* Mey-Fann Lee,4 Ling-Yi Hsu,5 Chih-Jen Tien,1 Feng-Ming Shih,1 Shih-Ching Hsiao,1   Pi-Han Wang1*  1Department of Life Science, Tunghai University, Taichung, Taiwan 2Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan 3Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan 4Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan 5The Environmental Analysis Laboratory, Taoyuan, Taiwan This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c4/3d/aair-8-404.PMC4921694.pdf
2016 September;8(5):404-411. http://dx.doi.org/10.4168/aair.2016.8.5.404 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/c4/3d/aair-8-404.PMC4921694.pdf
2016 September;8(5):404-411. http://dx.doi.org/10.4168/aair.2016.8.5.404 AAIR http://e-aair.org   405Increasing evidence has shown positive associations of in - door dampness or the presence of fungi with the development  and exacerbation of asthma as well as eczema and allergy.,Non-OADS,/arxiv_data1/oa_pdf/c4/3d/aair-8-404.PMC4921694.pdf
"2016 September;8(5):404-411. http://dx.doi.org/10.4168/aair.2016.8.5.404 Volume 8, Number 5, September 2016 406  http://e-aair.orgternaria alternata  (A. alternata ).",Non-OADS,/arxiv_data1/oa_pdf/c4/3d/aair-8-404.PMC4921694.pdf
"2016 September;8(5):404-411. http://dx.doi.org/10.4168/aair.2016.8.5.404 AAIR http://e-aair.org   407tients ranged from 0.9 to 157.3 CFU/m3 in the active stage, and  from non-detectable to 26.2 CFU/m3 in the inactive stage (Sup - plemental Table, Fig.",OADS,/arxiv_data1/oa_pdf/c4/3d/aair-8-404.PMC4921694.pdf
"2016 September;8(5):404-411. http://dx.doi.org/10.4168/aair.2016.8.5.404 Volume 8, Number 5, September 2016 408  http://e-aair.orgFig.",Non-OADS,/arxiv_data1/oa_pdf/c4/3d/aair-8-404.PMC4921694.pdf
"2016 September;8(5):404-411. http://dx.doi.org/10.4168/aair.2016.8.5.404 AAIR http://e-aair.org   409tration of total fungi and exacerbations of allergic symp - toms.10,26-30 We examined indoor total and specific allergenic  fungal concentrations precisely in this study and found the im - portance of specific allergenic fungi in inducing exacerbation  rather than total fungal concentration in triggering or exacer - bating allergic symptoms among sensitized individuals.",OADS,/arxiv_data1/oa_pdf/c4/3d/aair-8-404.PMC4921694.pdf
"2016 September;8(5):404-411. http://dx.doi.org/10.4168/aair.2016.8.5.404 Volume 8, Number 5, September 2016 410  http://e-aair.orgstudy showed that only 6% of 579 Taiwanese asthmatic patients  had specific IgE to C. herbarum .37 We did not find the spores of  C. herbarum  in the households of any of our patients, and only  C. oxysporum  and C. cladosporioides  were found with C. oxys - porum  being predominant.",Non-OADS,/arxiv_data1/oa_pdf/c4/3d/aair-8-404.PMC4921694.pdf
2016 September;8(5):404-411. http://dx.doi.org/10.4168/aair.2016.8.5.404 AAIR http://e-aair.org   41124.,Non-OADS,/arxiv_data1/oa_pdf/c4/3d/aair-8-404.PMC4921694.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease 412  http://e-aair.orgINTRODUCTION Allergy to hymenoptera venom is a potentially life-threaten - ing disease, but long-term control is possible through venom  immunotherapy (VIT).",Non-OADS,/arxiv_data1/oa_pdf/6f/43/aair-8-412.PMC4921695.pdf
"The basophil activation test (BAT) has  been used for the diagnosis of hypersensitivity to inhalants, la  Short-, Intermediate-, and Long-Term Changes in Basophil  Reactivity Induced by Venom Immunotherapy Ana Rodríguez Trabado,1* Carmen Cámara Hijón,2 Alfonso Ramos Cantariño,3 Silvia Romero-Chala,2   José Antonio García-Trujillo,2 Luis Miguel Fernández Pereira2 1Ciudad de Coria Hospital, Allergy Department, Cáceres, Spain 2San Pedro de Alcántara Hospital, Immunology Department, Cáceres Spain 3Department of Mathematics, University of Extremadura, Cáceres, Spain This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6f/43/aair-8-412.PMC4921695.pdf
2016 September;8(5):412-420. http://dx.doi.org/10.4168/aair.2016.8.5.412 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/6f/43/aair-8-412.PMC4921695.pdf
"2016 September;8(5):412-420. http://dx.doi.org/10.4168/aair.2016.8.5.412AAIR http://e-aair.org   413tex, food, and drugs.15-17 It is a very sensitive and specific meth - od to diagnose venom allergy.18-22 Its high specificity is due to  the fact that it studies cellular response following antigen stim - ulation in real time.",Non-OADS,/arxiv_data1/oa_pdf/6f/43/aair-8-412.PMC4921695.pdf
"2016 September;8(5):412-420. http://dx.doi.org/10.4168/aair.2016.8.5.412Volume 8, Number 5, September 2016 414  http://e-aair.orgreceived immunotherapy for almost 5 years (n =12) (Table 2).",Non-OADS,/arxiv_data1/oa_pdf/6f/43/aair-8-412.PMC4921695.pdf
2016 September;8(5):412-420. http://dx.doi.org/10.4168/aair.2016.8.5.412AAIR http://e-aair.org   415the negative control.,Non-OADS,/arxiv_data1/oa_pdf/6f/43/aair-8-412.PMC4921695.pdf
"2016 September;8(5):412-420. http://dx.doi.org/10.4168/aair.2016.8.5.412Volume 8, Number 5, September 2016 416  http://e-aair.orgtrast to 23.33% in 1m, 28% in 3m, 30% in 6m, 38.8% in 12m,  15.78% in 18m, and 21.05% in 24m.",OADS,/arxiv_data1/oa_pdf/6f/43/aair-8-412.PMC4921695.pdf
"2016 September;8(5):412-420. http://dx.doi.org/10.4168/aair.2016.8.5.412AAIR http://e-aair.org   417DISCUSSION Although similar studies concerning VIT monitoring by using  BAT have been published, in this work the longitudinal controls  throughout a complete 5 years period of treatment were per - formed more frequently than those previously reported, and a  wider range of concentrations was tested.",Non-OADS,/arxiv_data1/oa_pdf/6f/43/aair-8-412.PMC4921695.pdf
"2016 September;8(5):412-420. http://dx.doi.org/10.4168/aair.2016.8.5.412Volume 8, Number 5, September 2016 418  http://e-aair.orgtions tested each time were analyzed in blocks by repeated  measures ANOVA which allows the evaluation of the global  evolution of basophil response during the VIT and helps over - come this problem.",OADS,/arxiv_data1/oa_pdf/6f/43/aair-8-412.PMC4921695.pdf
2016 September;8(5):412-420. http://dx.doi.org/10.4168/aair.2016.8.5.412AAIR http://e-aair.org   419writing assistance.,Non-OADS,/arxiv_data1/oa_pdf/6f/43/aair-8-412.PMC4921695.pdf
"2016 September;8(5):412-420. http://dx.doi.org/10.4168/aair.2016.8.5.412Volume 8, Number 5, September 2016 420  http://e-aair.orgguez Martín E, Fletes Peral C, Pereira Navarro G, et al.",OADS,/arxiv_data1/oa_pdf/6f/43/aair-8-412.PMC4921695.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org   421INTRODUCTION Subcutaneous allergen immunotherapy (SCIT) is confirmed  with significant benefit in properly selected patients with aller - gic rhinitis and/or asthma.1 However, SCIT is associated with  risk of systemic reaction (SR), which may be severe, even life- threatening.",Non-OADS,/arxiv_data1/oa_pdf/a5/f0/aair-8-421.PMC4921696.pdf
"The study  was approved by the Independent Ethical Committee of Tongji Systemic Reactions to Dust Mite Subcutaneous Immunotherapy:  A 3-Year Follow-up Study Xiang Dong, Nan Huang, Wenjing Li, Lintao Hu, Xiaolong Wang, Yin Wang, Ning Xiang, Guanghui Liu, Rongfei Zhu* Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a5/f0/aair-8-421.PMC4921696.pdf
2016 September;8(5):421-427. http://dx.doi.org/10.4168/aair.2016.8.5.421 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/a5/f0/aair-8-421.PMC4921696.pdf
"2016 September;8(5):421-427. http://dx.doi.org/10.4168/aair.2016.8.5.421Volume 8, Number 5, September 2016 422  http://e-aair.orgHospital, and each participator or his/her statutory guardian  signed the informed consent of the immunotherapy.",Non-OADS,/arxiv_data1/oa_pdf/a5/f0/aair-8-421.PMC4921696.pdf
"2016 September;8(5):421-427. http://dx.doi.org/10.4168/aair.2016.8.5.421AAIR http://e-aair.org   423and 12.5 respectively, ranging from 4 to 65 years, and there were  121 children ( <18 years) and 87 adults ( ≥18 years).",Non-OADS,/arxiv_data1/oa_pdf/a5/f0/aair-8-421.PMC4921696.pdf
"2016 September;8(5):421-427. http://dx.doi.org/10.4168/aair.2016.8.5.421Volume 8, Number 5, September 2016 424  http://e-aair.organd maintenance phases (1.71% vs 1.78%, P=0.9), which was  the same in children subgroups (2.87% vs 2.93%, P=0.9).",OADS,/arxiv_data1/oa_pdf/a5/f0/aair-8-421.PMC4921696.pdf
2016 September;8(5):421-427. http://dx.doi.org/10.4168/aair.2016.8.5.421AAIR http://e-aair.org   425who received SCIT.,OADS,/arxiv_data1/oa_pdf/a5/f0/aair-8-421.PMC4921696.pdf
"2016 September;8(5):421-427. http://dx.doi.org/10.4168/aair.2016.8.5.421Volume 8, Number 5, September 2016 426  http://e-aair.orgWe found that SR was more common among children than  among adults, and the maintenance dose did not reach the  maximum more commonly in children than in adults.",OADS,/arxiv_data1/oa_pdf/a5/f0/aair-8-421.PMC4921696.pdf
2016 September;8(5):421-427. http://dx.doi.org/10.4168/aair.2016.8.5.421AAIR http://e-aair.org   42722.,Non-OADS,/arxiv_data1/oa_pdf/a5/f0/aair-8-421.PMC4921696.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease 428  http://e-aair.orgINTRODUCTION Hypersensitivity to fungi is associated with rhinoconjunctivi - tis and asthma.1,2 This association was described in 1,726 by  Floyer in asthmatic patients visiting a winery.3 Other allergic  diseases are allergic fungal sinusitis, allergic bronchopulmona - ry aspergillosis, and extrinsic allergic alveolitis.",Non-OADS,/arxiv_data1/oa_pdf/f5/2b/aair-8-428.PMC4921697.pdf
"The aims of this study  was to determine hypersensitivity to fungi in dwellings in pa -Orthologous Allergens and Diagnostic Utility of Major Allergen  Alt a 1 Antonio Moreno,1 Fernando Pineda,2* Javier Alcover,2 David Rodríguez,2 Ricardo Palacios,2 Eduardo Martínez-Naves3 1Allergy Service, Hospital of Cuenca, Cuenca, Spain  2DIATER laboratories, Madrid, Spain 3Department of Microbiology, School of Medicine, University Complutense of Madrid, Madrid, Spain This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f5/2b/aair-8-428.PMC4921697.pdf
2016 September;8(5):428-437. http://dx.doi.org/10.4168/aair.2016.8.5.428 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/f5/2b/aair-8-428.PMC4921697.pdf
"2016 September;8(5):428-437. http://dx.doi.org/10.4168/aair.2016.8.5.428AAIR http://e-aair.org   429tients from Cuenca, Spain, and to study polysensitization and  cross-reactivity due to the known sensitization to various spe - cies, and the recognition of allergens belonging or not to a same  group species from the same taxonomic family.11  MATERIALS AND METHODS Patients Patients were selected randomly and prospectively.",Non-OADS,/arxiv_data1/oa_pdf/f5/2b/aair-8-428.PMC4921697.pdf
"2016 September;8(5):428-437. http://dx.doi.org/10.4168/aair.2016.8.5.428Volume 8, Number 5, September 2016 430  http://e-aair.orgtracts of C. albicans , U. botrytis , Mucor mucedo , Fusarium  sp,  Trichophyton rubrum , Aspergillus niger , A. alternata  , S. charta - rum , S. botryosum , P .",Non-OADS,/arxiv_data1/oa_pdf/f5/2b/aair-8-428.PMC4921697.pdf
"2016 September;8(5):428-437. http://dx.doi.org/10.4168/aair.2016.8.5.428AAIR http://e-aair.org   431the extracts tested was measured by ELISA inhibition assays,  according to the method of Ceska and Lundqvist19 with modifi - cations.",OADS,/arxiv_data1/oa_pdf/f5/2b/aair-8-428.PMC4921697.pdf
"2016 September;8(5):428-437. http://dx.doi.org/10.4168/aair.2016.8.5.428Volume 8, Number 5, September 2016 432  http://e-aair.org Fig.",Non-OADS,/arxiv_data1/oa_pdf/f5/2b/aair-8-428.PMC4921697.pdf
"2016 September;8(5):428-437. http://dx.doi.org/10.4168/aair.2016.8.5.428AAIR http://e-aair.org   433Taking into account the fact that the allergen Alt a 1 is the  most important allergen described in A. alternata  and is possi - bly what most patients react to, we decided to study its capacity  to inhibit binding of IgE to extracts of various fungi.",Non-OADS,/arxiv_data1/oa_pdf/f5/2b/aair-8-428.PMC4921697.pdf
"2016 September;8(5):428-437. http://dx.doi.org/10.4168/aair.2016.8.5.428Volume 8, Number 5, September 2016 434  http://e-aair.org Fig.",Non-OADS,/arxiv_data1/oa_pdf/f5/2b/aair-8-428.PMC4921697.pdf
"2016 September;8(5):428-437. http://dx.doi.org/10.4168/aair.2016.8.5.428AAIR http://e-aair.org   4351 MQFTTIASLF AAAGLAAAAP LESRQDNASC PVTTK  GDYVW KISEFYGRKP 51 EGTYYNSLGF NIK  ATNGGTL DFTCSAQADK LEDHK - WYSCG ENSFMDFSFD 101 SDRSGLLLKQ  KVSDE Histamine release  To evaluate the ex vivo  behavior of the allergenic extract used  in the skin tests, histamine release tests were made using sam - ples from the 26 patients selected in the skin tests.",OADS,/arxiv_data1/oa_pdf/f5/2b/aair-8-428.PMC4921697.pdf
"2016 September;8(5):428-437. http://dx.doi.org/10.4168/aair.2016.8.5.428Volume 8, Number 5, September 2016 436  http://e-aair.orgfect the respiratory tract (asthma and rhinitis), skin (dermatitis,  urticaria, and eczema), and different expressions of sensitivity  to food and medicine that are considered impaired T h2-(Th2)  immune responses.23   The diagnosis of these disorders is essentially based on a com - bination of (1) etiological identification tests that show the pres - ence of the source of sensitization in the patient’s environment  and the possible cause and effect, (2) the patient’s medical re - cords, and (3) in vivo  and in vitro  diagnostic tests.24 Diagnostic  tests require allergenic extracts, and the results obtained will  depend on their quality.25 Allergenic extracts are therefore in - dispensable tools for the diagnosis and treatment of allergic  diseases and research on processes involved in this inflamma - tory phenomenon.26  In the specific case of allergy to fungi, the problem is com - pounded due to the wide variety and polymorphisms of spe - cies, and the high variability of these organisms which is mani - fested in different compositions and potency of allergenic ex - tracts obtained, even from those of the same strain.",Non-OADS,/arxiv_data1/oa_pdf/f5/2b/aair-8-428.PMC4921697.pdf
2016 September;8(5):428-437. http://dx.doi.org/10.4168/aair.2016.8.5.428AAIR http://e-aair.org   437proposal.,Non-OADS,/arxiv_data1/oa_pdf/f5/2b/aair-8-428.PMC4921697.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease 438  http://e-aair.orgINTRODUCTION Airborne fungi which are ubiquitous in our environment have  been identified as important causative agents of human respi - ratory atopic disorders.1,2 Characterization of major allergens of  environmental fungi is beneficial in the diagnosis and treat - ment of clinical fungal allergy.2-4   We have identified previously serine proteases as major aller - gens of prevalent airborne Penicillium  (Pen ch 13, Pen ch 18),5-7  Aspergillus  (Asp f 13, Asp f 18),5,8,9 and Cladosporium  (Cla c 9)10  species.",Non-OADS,/arxiv_data1/oa_pdf/60/f3/aair-8-438.PMC4921698.pdf
"It is crucial to characterize IgE cross-reactivity among allergens Vacuolar Serine Protease Is a Major Allergen of Fusarium  proliferatum  and an IgE-Cross Reactive Pan-Fungal Allergen Chang-Ching Yeh,1 Hsiao-Yun Tai,2 Hong Chou,2 Keh-Gong Wu,3 Horng-Der Shen2* 1 Department of Obstetrics and Gynecology, Taipei Veterans General Hospital and Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan,  R.O.C  2Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C 3Department of Pediatrics, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan, R.O.C This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/60/f3/aair-8-438.PMC4921698.pdf
2016 September;8(5):438-444. http://dx.doi.org/10.4168/aair.2016.8.5.438 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/60/f3/aair-8-438.PMC4921698.pdf
2016 September;8(5):438-444. http://dx.doi.org/10.4168/aair.2016.8.5.438AAIR http://e-aair.org   439from different fungal species.,OADS,/arxiv_data1/oa_pdf/60/f3/aair-8-438.PMC4921698.pdf
"2016 September;8(5):438-444. http://dx.doi.org/10.4168/aair.2016.8.5.438Volume 8, Number 5, September 2016 440  http://e-aair.orgnucleotidyl transferase (Promega) before using as a template in  the 5´-RACE reaction.",Non-OADS,/arxiv_data1/oa_pdf/60/f3/aair-8-438.PMC4921698.pdf
2016 September;8(5):438-444. http://dx.doi.org/10.4168/aair.2016.8.5.438AAIR http://e-aair.org   4415´- and 3´-end RACE reactions.,OADS,/arxiv_data1/oa_pdf/60/f3/aair-8-438.PMC4921698.pdf
"2016 September;8(5):438-444. http://dx.doi.org/10.4168/aair.2016.8.5.438Volume 8, Number 5, September 2016 442  http://e-aair.orgine proteases contain 3 cysteine residues.",Non-OADS,/arxiv_data1/oa_pdf/60/f3/aair-8-438.PMC4921698.pdf
2016 September;8(5):438-444. http://dx.doi.org/10.4168/aair.2016.8.5.438AAIR http://e-aair.org   443for serum nos.,Non-OADS,/arxiv_data1/oa_pdf/60/f3/aair-8-438.PMC4921698.pdf
"2016 September;8(5):438-444. http://dx.doi.org/10.4168/aair.2016.8.5.438Volume 8, Number 5, September 2016 444  http://e-aair.orgclinical diagnosis of fungal allergy, studies of these serine prote - ase major allergens may elucidate diverse allergic disease  mechanisms and facilitate development of better therapeutic  strategies.",Non-OADS,/arxiv_data1/oa_pdf/60/f3/aair-8-438.PMC4921698.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org   445INTRODUCTION “One airway, one disease” is a well-established concept that  links the upper and lower airways.",Non-OADS,/arxiv_data1/oa_pdf/b5/86/aair-8-445.PMC4921699.pdf
"A previous study showed  the incidence of atopy was 24% in the study population com - prising patients who had otitis media with effusion (OME) per - sisting for more than 3 months and unresponsiveness to antibi -Synergistic Effect of Dermatophagoides farinae  and  Lipopolysaccharides in Human Middle ear Epithelial Cells Ji-Eun Lee,1,2 Yeon Hoo Kim,1 Chae-Seo Rhee,3,4,5,6 Dong-Young Kim7* 1Department of Otorhinolaryngology-Head and Neck Surgery, Chosun University College of Medicine, Gwangju, Korea 2Department of Otorhinolaryngology-Head and Neck Surgery, Graduate school of Medicine, Seoul National University, Seoul, Korea 3Sensory Organ Research Center, Seoul National University Biomedical Research Institute, Seoul, Korea 4Institute of Allergy and Clinical Immunology, Seoul National University Biomedical Research Institute, Seoul, Korea 5Graduate School of Immunology, Seoul National University, Seoul, Korea 6 Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine,  Seongnam, Korea 7Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University College of Medicine, Seoul, Korea This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b5/86/aair-8-445.PMC4921699.pdf
2016 September;8(5):445-456. http://dx.doi.org/10.4168/aair.2016.8.5.445 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/b5/86/aair-8-445.PMC4921699.pdf
"2016 September;8(5):445-456. http://dx.doi.org/10.4168/aair.2016.8.5.445Volume 8, Number 5, September 2016 446  http://e-aair.orgotics.4 Another study suggested that 35% of patients with recur - rent OME have allergic rhinitis.5 Significantly higher numbers  of eosinophils and T lymphocytes, as well as significantly high - er levels of IL-4 and IL-5 mRNA+ cells, have been reported in  patients with atopic OME than in non-atopic controls.6 Further - more, other studies have shown increased expression of IL-5  and major basic proteins in the middle ear mucosa of patients  with OME than that in normal controls, as well as higher levels  of eosinophilic cationic proteins in the supernatant of middle  ear effusion of atopic patients with OME than in that of non- atopic controls.7,8 These findings support the concept that the  middle ear may be part of the united airway and may behave  similarly to the nose or lung under allergic inflammatory con - ditions.",Non-OADS,/arxiv_data1/oa_pdf/b5/86/aair-8-445.PMC4921699.pdf
2016 September;8(5):445-456. http://dx.doi.org/10.4168/aair.2016.8.5.445AAIR http://e-aair.org   447LPS24h); 4) LPS 1.0 μg/mL for 48 hours and add Der f 2.0 μg/ mL for 24 hours (LPS48h/Df24h); or 5) Der f 2.0 μg/mL and LPS  1.0 μg/mL both simultaneously for 48 hours (Df48h/LPS48h)  (Fig.,Non-OADS,/arxiv_data1/oa_pdf/b5/86/aair-8-445.PMC4921699.pdf
"2016 September;8(5):445-456. http://dx.doi.org/10.4168/aair.2016.8.5.445Volume 8, Number 5, September 2016 448  http://e-aair.orgis, MO, USA), TLR-4, p-p38, p38, p-CREB (Santa Cruz Biotech - nology, Dallas, TX, USA) and GAPDH (Santa Cruz Biotechnolo - gy) followed by peroxidase-conjugated anti-mouse IgG or anti- rabbit IgG (Jackson Immuno Research, West Grove, PA, USA).",OADS,/arxiv_data1/oa_pdf/b5/86/aair-8-445.PMC4921699.pdf
2016 September;8(5):445-456. http://dx.doi.org/10.4168/aair.2016.8.5.445AAIR http://e-aair.org   449Fig.,Non-OADS,/arxiv_data1/oa_pdf/b5/86/aair-8-445.PMC4921699.pdf
"2016 September;8(5):445-456. http://dx.doi.org/10.4168/aair.2016.8.5.445Volume 8, Number 5, September 2016 450  http://e-aair.orgPD98059 (a specific inhibitor of MAPK/MEK-1), Bay (a NF- κB  inhibitor), LY294002 (PI3K inhibitor), and a JNK inhibitor (data  not shown).",Non-OADS,/arxiv_data1/oa_pdf/b5/86/aair-8-445.PMC4921699.pdf
"2016 September;8(5):445-456. http://dx.doi.org/10.4168/aair.2016.8.5.445AAIR http://e-aair.org   451cause it is one of the major molecules that the airway epitheli - um produces in large amounts in response to several stimuli,  such as TNF- α, IL-1β, LPS, oxidative stress, and neutrophil elas - tase, and because it has been implicated in numerous airway  diseases.24 Mucins are broadly classified as either cell mem - brane-bound or secreted; notably, MUC2, MUC5AC, MUC5B,  MUC6, MUC7, MUC8, MUC9, and MUC19 are categorized as  secreted mucins.25,26 MUC5AC and MUC5B are predominant in the sinus and nasal cavity, respectively, and considered primar - ily responsible for the gel-like characteristics of mucoid middle  ear fluids.27-30 The MUC  8 gene is over-expressed in chronic rhi - nosinusitis and nasal polyp epithelium, and its expression lev - els are also increased by inflammatory mediators in nasal epi - thelial cells.31,32 Airway mucus obstruction is a shared feature  among lower airway diseases, such as cystic fibrosis, asthma,  and chronic obstructive lung disease.33 Hence, investigating the MD2 mRNA/GAPDH MUC4 mRNA/GAPDH CD14 mRNA/GAPDH MUC 5b mRNA/GAPDH TLR4 mRNA/GAPDH MUC 8 mRNA/GAPDH18 16 14 12 10 8 6 4 2 0 12 10 8 6 4 2 03.5 3.0 2.5 2.0 1.5 1.0 0.5 0 3.0 2.5 2.0 1.5 1.0 0.5 08 7 6 5 4 3 2 1 0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0* ** *** ** *MD2 MUC 4CD14 MUC 5BTLR4 MUC 8 A - + + +  - + + +  - + + + Df 48h Df 48h Df 48h  - + + +  - + + +  - + + + LPS 24h LPS 24h LPS 24h  - - + -  - - + -  - - + - Si-TLR4 Si-TLR4 Si-TLR4  - - - +  - - - +  - - - + Si-MD2 Si-MD2 Si-MD2 Fig.",Non-OADS,/arxiv_data1/oa_pdf/b5/86/aair-8-445.PMC4921699.pdf
"2016 September;8(5):445-456. http://dx.doi.org/10.4168/aair.2016.8.5.445Volume 8, Number 5, September 2016 452  http://e-aair.orgFig.",Non-OADS,/arxiv_data1/oa_pdf/b5/86/aair-8-445.PMC4921699.pdf
2016 September;8(5):445-456. http://dx.doi.org/10.4168/aair.2016.8.5.445AAIR http://e-aair.org   453mucin gene expression in HMEECs is considered an appropri - ate approach to evaluating the “extended one airway concept.,Non-OADS,/arxiv_data1/oa_pdf/b5/86/aair-8-445.PMC4921699.pdf
"2016 September;8(5):445-456. http://dx.doi.org/10.4168/aair.2016.8.5.445Volume 8, Number 5, September 2016 454  http://e-aair.orgCD14, and have a role in endotoxin recognition in cases of defi - ciency of the MD-2 protein.",OADS,/arxiv_data1/oa_pdf/b5/86/aair-8-445.PMC4921699.pdf
2016 September;8(5):445-456. http://dx.doi.org/10.4168/aair.2016.8.5.445AAIR http://e-aair.org   455duction.,Non-OADS,/arxiv_data1/oa_pdf/b5/86/aair-8-445.PMC4921699.pdf
"2016 September;8(5):445-456. http://dx.doi.org/10.4168/aair.2016.8.5.445Volume 8, Number 5, September 2016 456  http://e-aair.org48.",Non-OADS,/arxiv_data1/oa_pdf/b5/86/aair-8-445.PMC4921699.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org   457INTRODUCTION Chronic spontaneous urticaria (CSU) is defined as urticaria  that persists for at least 6 weeks.1,2 Apart from mast cells which  are the major effector cell type in urticaria, other cells of the  skin tissue are infiltrated in CSU patients, including CD4+ T  lymphocytes (especially the Th2 subclass), eosinophils, and  neutrophils.3,4 A few studies demonstrated that Th2 cytokines,  such as interleukin (IL)-4 and IL-13, are increased in the sera of  CSU patients or their production is increased in peripheral  mononuclear cells from CSU patients.5,6 Periostin, an extracellular matrix protein, plays an important  role in the pathogenesis of chronic allergic inflammatory dis - eases, such as bronchial asthma and atopic dermatitis.7-12 IL-4  and IL-13, key cytokines of the Th2-type immune response,  have considerable influences on the synthesis and amplifica - tion of periostin by stimulating fibroblasts, the major source of  periostin.7 It has been demonstrated that serum periostin levels  are the most significant single predictor of eosinophilic airway  inflammation in asthmatics, rather than fraction of exhaled ni - tric oxide (F ENO), blood eosinophil count, or serum IgE levels,  suggesting that periostin is a useful biomarker of eosinophilic  airway inflammation in asthmatics and Th2-targeted asthma therapy.8 Furthermore, Periostin levels has been shown to be  well correlated with disease severity and chronicity in atopic  dermatitis.12 In this regard, periostin might be involved in the  pathogenesis of CSU, for which a Th2 immune response has  been implicated, and periostin levels could be a biomarker of  disease severity or treatment response in CSU.",Non-OADS,/arxiv_data1/oa_pdf/e5/0f/aair-8-457.PMC4921700.pdf
"MATERIALS AND METHODS Study subjects Eighty-four patients with CSU and 43 normal healthy controls Periostin and Interleukin-13 Are Independently Related to Chronic  Spontaneous Urticaria Youin Bae,1 Kenji Izuhara,2 Soichiro Ohta,3 Junya Ono,4 Gwan Ui Hong,5 Jai Youl Ro,5 Gyeong Hun Park,1 Jeong-Hee Choi6 1Department of Dermatology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea  2Division of Medical Biochemistry, Department of Biomolecular Sciences, 3Department of Laboratory Medicine, Saga Medical School, Saga, Japan 4The Shino-Test Corporation, Sagamihara, Japan 5Department of Pharmacology and SBRI, Sungkyunkwan University School of Medicine, Suwon, Korea 6Department of Pulmonology and Allergy, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e5/0f/aair-8-457.PMC4921700.pdf
2016 September;8(5):457-460. http://dx.doi.org/10.4168/aair.2016.8.5.457 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/e5/0f/aair-8-457.PMC4921700.pdf
"2016 September;8(5):457-460. http://dx.doi.org/10.4168/aair.2016.8.5.457Volume 8, Number 5, September 2016 458  http://e-aair.org(NCs) were included in this study.",Non-OADS,/arxiv_data1/oa_pdf/e5/0f/aair-8-457.PMC4921700.pdf
2016 September;8(5):457-460. http://dx.doi.org/10.4168/aair.2016.8.5.457AAIR http://e-aair.org   459the positivity of ASST.,Non-OADS,/arxiv_data1/oa_pdf/e5/0f/aair-8-457.PMC4921700.pdf
"2016 September;8(5):457-460. http://dx.doi.org/10.4168/aair.2016.8.5.457Volume 8, Number 5, September 2016 460  http://e-aair.orgostin has not yet been investigated in chronic urticaria.",Non-OADS,/arxiv_data1/oa_pdf/e5/0f/aair-8-457.PMC4921700.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org   461INTRODUCTION Asthma affects over than 300 million individuals worldwide,  making it one of the most prevalent diseases.",Non-OADS,/arxiv_data1/oa_pdf/f3/32/aair-8-461.PMC4921701.pdf
"The type 1 transmembrane glycoproteine CD93(C1qRP) is en - coded by the CD93 gene found on chromosome 20.5 It is ex - pressed early on the surface of myeloid cells during B-cell differ - entiation in the bone marrow and on the surface of hematopoi - etic stem cells, natural killer cells, endothelial cells, platelets, and  microglia.6-8 The predicted molecular weight of CD93 is 120 kD  and consist of a c-type carbohydrate-recognition domain, a fine Soluble CD93 as a Novel Biomarker in Asthma Exacerbation  Naseh Sigari,1* Ali Jalili,2 Laili Mahdawi,3  Ebrahim Ghaderi,4 Mohammadi Shilan5 1Internal Medicine Department, Medical Faculty, Kurdistan University of Medical Sciences, Sanandaj, Iran 2Kurdistan Cellular & Molecular Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran 3Internal Medicine Department, Kurdistan University of Medical Sciences, Sanandaj, Iran 4Department of Epidemiology and Biostatistics, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran 5Pediatrics Department, Medical Faculty,Kurdistan University of Medical Sciences, Sanandaj, Iran This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f3/32/aair-8-461.PMC4921701.pdf
2016 September;8(5):461-465. http://dx.doi.org/10.4168/aair.2016.8.5.461 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/f3/32/aair-8-461.PMC4921701.pdf
"2016 September;8(5):461-465. http://dx.doi.org/10.4168/aair.2016.8.5.461Volume 8, Number 5, September 2016 462  http://e-aair.orgepidermal growth factor-like domain, a single transmembrane  domain, a main domain, and an intracellular domain.5,9,10 CD93 has been implicated in regulating adhesive processes  and expressions on the endothelial and circulating cells consis - tent with the role of CD93 in cellular homing to the sites of in - flammation.11 It was hypothesized that CD93 could be involved  in endothelial cell migration, angiogenesis, and leukocytes ex - travasation,12 and it was reported that CD93 plays a role in the  C1q/MBL/SP-A-mediated removal of immune complexes and  pathogens via phagocytosis.13 Other studies have demonstrated  a role of CD93 in apoptosis, innate immunity, and inflamma - tion.14,15  Soluble CD93 was detected in normal human plasma, sug - gesting that the cleavage event is physiologically relevant.16 In  addition, production of sCD93 was induced by the inflammato - ry mediators TNF- α and LPS, indicating physiologic pathways  that trigger this event.17  Based on previous studies that identified a soluble form of  CD93 in human plasma in response to activation with inflam - matory stimuli, we hypothesized that sCD93 would be elevated  during the acute phase of asthma.",OADS,/arxiv_data1/oa_pdf/f3/32/aair-8-461.PMC4921701.pdf
2016 September;8(5):461-465. http://dx.doi.org/10.4168/aair.2016.8.5.461AAIR http://e-aair.org   463(P=0.004) (Fig.,Non-OADS,/arxiv_data1/oa_pdf/f3/32/aair-8-461.PMC4921701.pdf
"2016 September;8(5):461-465. http://dx.doi.org/10.4168/aair.2016.8.5.461Volume 8, Number 5, September 2016 464  http://e-aair.orgThirteen (22.6%) out of 57asthmatics were current smokers.",Non-OADS,/arxiv_data1/oa_pdf/f3/32/aair-8-461.PMC4921701.pdf
2016 September;8(5):461-465. http://dx.doi.org/10.4168/aair.2016.8.5.461AAIR http://e-aair.org   465ORCID Naseh Sigari  http://orcid.org/0000-0002-5098-1877 REFERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/f3/32/aair-8-461.PMC4921701.pdf
Available from:  http://www.ginasthma.org/documents/4.,OADS,/arxiv_data1/oa_pdf/f3/32/aair-8-461.PMC4921701.pdf
Available from: http://www.nhlbi.nih.gov/health-pro/ guidelines/current/asthma-guidelines.,Non-OADS,/arxiv_data1/oa_pdf/f3/32/aair-8-461.PMC4921701.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease 466  http://e-aair.orgINTRODUCTION Over 300 genes related to the asthma phenotype have been  identified in genetic association studies.1 However, some genes  and loci have been associated, replicated numerous times, and  are recognized as the “gold standard” .",Non-OADS,/arxiv_data1/oa_pdf/ad/a5/aair-8-466.PMC4921702.pdf
"Genes Involved in Interleukin-1 Receptor Type II Activities Are  Associated With Asthmatic Phenotypes Anne-Marie Madore,1 Vanessa T. Vaillancourt,1 Emmanuelle Bouzigon,2,3 Chloé Sarnowski,2,3 Florent Monier,2,3   Marie-Hélène Dizier,2,3 Florence Demenais,2,3 Catherine Laprise1* 1Département des sciences fondamentales, Université du Québec à Chicoutimi, Chicoutimi, Canada 2INSERM, U946, Genetic Variation and Human Diseases Unit, Paris, France  3Université Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d’Hématologie, Paris, France This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ad/a5/aair-8-466.PMC4921702.pdf
2016 September;8(5):466-470. http://dx.doi.org/10.4168/aair.2016.8.5.466 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/ad/a5/aair-8-466.PMC4921702.pdf
2016 September;8(5):466-470. http://dx.doi.org/10.4168/aair.2016.8.5.466AAIR http://e-aair.org   467MATERIALS AND METHODS The French-Canadian Saguenay‒Lac-St-Jean (SLSJ) asthma  familial collection and the French Epidemiological Study on  the Genetics and Environment of Asthma (EGEA) are both  large collections that bring power to this study.,Non-OADS,/arxiv_data1/oa_pdf/ad/a5/aair-8-466.PMC4921702.pdf
"The power to detect single SNP associations and SNP ×SNP interactions in the discovery collection was determined using  the Quanto program (http://biostats.usc.edu/Quanto.html).13,14  The power was estimated under an additive genetic model with  minor allele frequencies (maf) between 0.05 and 0.50 and main  effect size (odds ratio) or interaction effect size (odds ratio in in - teraction analyses) ranging from 1.1 to 2.5.",OADS,/arxiv_data1/oa_pdf/ad/a5/aair-8-466.PMC4921702.pdf
"2016 September;8(5):466-470. http://dx.doi.org/10.4168/aair.2016.8.5.466Volume 8, Number 5, September 2016 468  http://e-aair.orgGenotypes were extracted from the genome-wide data ob - tained in the context of the European GABRIEL asthma consor - tium using the 610K Quad Array from Illumina (Illumina, San  Diego, CA, USA).",OADS,/arxiv_data1/oa_pdf/ad/a5/aair-8-466.PMC4921702.pdf
A single SNP analysis was performed using  the Family-Based Association Test (FBAT; http://www.hsph.,OADS,/arxiv_data1/oa_pdf/ad/a5/aair-8-466.PMC4921702.pdf
"2016 September;8(5):466-470. http://dx.doi.org/10.4168/aair.2016.8.5.466AAIR http://e-aair.org   469replicated in the EGEA study and reached statistical signifi - cance in the combined analysis (p SLSJ=0.05, p EGEA=0.04, and  pcombined = 0.004).",OADS,/arxiv_data1/oa_pdf/ad/a5/aair-8-466.PMC4921702.pdf
"2016 September;8(5):466-470. http://dx.doi.org/10.4168/aair.2016.8.5.466Volume 8, Number 5, September 2016 470  http://e-aair.orgACKNOWLEDGMENTS The authors thank all of the families for their valuable partici - pation in this study.",Non-OADS,/arxiv_data1/oa_pdf/ad/a5/aair-8-466.PMC4921702.pdf
Available from: http://hydra.usc.,Non-OADS,/arxiv_data1/oa_pdf/ad/a5/aair-8-466.PMC4921702.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org   471INTRODUCTION The prevalence of immune-mediated chronic diseases, such  as allergic diseases, has increased over the last 50 years.1  Changes in life-style and environmental factors may have con - tributed to an imbalance in gut microbiota,2-4 which can affect  the host immune responses, nutritional status and metabolic  status, resulting in systemic chronic inflammation.5 This chron - ic low-grade inflammation can cause various noncommunica - ble diseases, including allergic diseases.2 The composition of gut microbiota is influenced by various  factors, such as age, ethnicity, and environmental factors.6,7 Giv- en that gut microbiota profiles tend to fluctuate until 3 years of age,8,9 and that allergic diseases occur earlier in life compared  with other non-communicable diseases, it is essential to char - acterize early gut microbiota profiles for identification of the  mechanisms underlying their relationship to immune-mediat - ed diseases.Dynamics of Gut Microbiota According to the Delivery Mode in  Healthy Korean Infants Eun Lee,1 Byoung-Ju Kim,1,2 Mi-Jin Kang,3 Kil Yong Choi,4 Hyun-Ju Cho,5 Yeongho Kim,5 Song I Yang,6 Young-Ho Jung,7   Hyung Young Kim,8 Ju-Hee Seo,9 Ji-Won Kwon,10 Hyo-Bin Kim,11 So-Yeon Lee,6 Soo-Jong Hong5* 1Department of Pediatrics, Inje University Haeundae Paik Hospital, Busan, Korea 2Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA 3Asan Institute for Life Sciences, University of Ulsan College of Medicine, Seoul, Korea 4Department of Environmental Health Research, Seoul Medical Center, Seoul, Korea 5 Department of Pediatrics, Childhood Asthma and Atopy Center, Environmental Health Center, Asan Medical Center, University of Ulsan College of Medicine,  Seoul, Korea 6Department of Pediatrics, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea 7Department of Pediatrics, CHA University School of Medicine, Seongnam, Korea 8Department of Pediatrics, Pusan National University Yangsan Hospital, Pusan National University College of Medicine, Yangsan, Korea 9Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea  10Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Korea 11Department of Pediatrics, Inje University Sanggye Paik Hospital, Seoul, Korea This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/19/2e/aair-8-471.PMC4921703.pdf
2016 September;8(5):471-477. http://dx.doi.org/10.4168/aair.2016.8.5.471 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/19/2e/aair-8-471.PMC4921703.pdf
"2016 September;8(5):471-477. http://dx.doi.org/10.4168/aair.2016.8.5.471Volume 8, Number 5, September 2016 472  http://e-aair.orgEnvironmental factors, such as perinatal antibiotic adminis - tration, mode of delivery, type of infant feeding, gestational age,  and probiotic administration affect the composition of the gut  microbiota.10-12 Among the modifying factors, mode of delivery  has been reported to strongly affect the development of allergic  diseases.13-16 In particular, the risk of allergic diseases, including  asthma and allergic rhinitis, is increased in infants born by ce - sarean section.13-16 This association may be attributable to the  lack of contact with maternal gut microbiota during cesarean  section.10 However, studies on the effects of delivery mode on  the gut microbiota have been limited by confounding factors  such as antibiotic usage and a single specimen collection.10,17 The aim of our current study was to identify the effects of de - livery mode on the composition of gut microbiota in infants af - ter controlling for confounding factors such as perinatal antibi - otics, perinatal probiotics, and feeding type.",Non-OADS,/arxiv_data1/oa_pdf/19/2e/aair-8-471.PMC4921703.pdf
"2016 September;8(5):471-477. http://dx.doi.org/10.4168/aair.2016.8.5.471AAIR http://e-aair.org   473 400 300 200 100 0 Chao1 index 4 3 2 1 0Shannon index CS 1 CS 2 CS 3 VD 1 VD 2 VD 3 CS 1 CS 2 CS 3 VD 1 VD 2 VD 3 in infants born by vaginal delivery, although they subsequently  increased (Table 2).",Non-OADS,/arxiv_data1/oa_pdf/19/2e/aair-8-471.PMC4921703.pdf
"2016 September;8(5):471-477. http://dx.doi.org/10.4168/aair.2016.8.5.471Volume 8, Number 5, September 2016 474  http://e-aair.orgtinuously increased with age.",Non-OADS,/arxiv_data1/oa_pdf/19/2e/aair-8-471.PMC4921703.pdf
"2016 September;8(5):471-477. http://dx.doi.org/10.4168/aair.2016.8.5.471AAIR http://e-aair.org   475cesarean section.19 In our present study, the relative propor - tions of the Bacteroides  genus and the Bacteroidetes phylum at  1-3 days after birth were higher in infants born vaginally.",Non-OADS,/arxiv_data1/oa_pdf/19/2e/aair-8-471.PMC4921703.pdf
"2016 September;8(5):471-477. http://dx.doi.org/10.4168/aair.2016.8.5.471Volume 8, Number 5, September 2016 476  http://e-aair.orging mixed feeding of breastmilk and formula during the first six  months of life.",Non-OADS,/arxiv_data1/oa_pdf/19/2e/aair-8-471.PMC4921703.pdf
"2016 September;8(5):471-477. http://dx.doi.org/10.4168/aair.2016.8.5.471AAIR http://e-aair.org   477(NRF), funded by the Ministry of Education, Science and Tech - nology (NRF-2012R1A1A1015308).",Non-OADS,/arxiv_data1/oa_pdf/19/2e/aair-8-471.PMC4921703.pdf
"Production and hosting by ElsevierJournal of Advanced Research (2016) 7, 559 –563 Cairo University Journal of Advanced Research http://dx.doi.org/10.1016/j.jare.2016.01.004 2090-1232 /C2112016 Production and hosting by Elsevier B.V. on behalf of Cairo University.",Non-OADS,/arxiv_data1/oa_pdf/71/d1/main.PMC4921772.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/71/d1/main.PMC4921772.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).,Non-OADS,/arxiv_data1/oa_pdf/71/d1/main.PMC4921772.pdf
"Production and hosting by ElsevierJournal of Advanced Research (2016) 7, 589 –596 Cairo University Journal of Advanced Research http://dx.doi.org/10.1016/j.jare.2016.02.001 2090-1232 /C2112016 Production and hosting by Elsevier B.V. on behalf of Cairo University.",Non-OADS,/arxiv_data1/oa_pdf/00/ea/main.PMC4921778.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/00/ea/main.PMC4921778.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).,Non-OADS,/arxiv_data1/oa_pdf/00/ea/main.PMC4921778.pdf
"Production and hosting by ElsevierJournal of Advanced Research (2016) 7, 565 –570 Cairo University Journal of Advanced Research http://dx.doi.org/10.1016/j.jare.2016.02.007 2090-1232 /C2112016 Production and hosting by Elsevier B.V. on behalf of Cairo University.",Non-OADS,/arxiv_data1/oa_pdf/88/06/main.PMC4921779.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/88/06/main.PMC4921779.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).,Non-OADS,/arxiv_data1/oa_pdf/88/06/main.PMC4921779.pdf
J Cancer Epidemiol 2013:2013.Article ID 965212. http://dx.doi.org/10.1155/2013/965212 .,Non-OADS,/arxiv_data1/oa_pdf/88/06/main.PMC4921779.pdf
Article ID 875125. http://dx.doi.org/10.4061/2011/875125 .,Non-OADS,/arxiv_data1/oa_pdf/88/06/main.PMC4921779.pdf
Article ID 691719. http://dx.doi.org/10.4061/2011/691719 .Thyroid cancer and pregnancy 569,Non-OADS,/arxiv_data1/oa_pdf/88/06/main.PMC4921779.pdf
Article ID 549609. http://dx.doi.org/10.4061/2011/549609 .,Non-OADS,/arxiv_data1/oa_pdf/88/06/main.PMC4921779.pdf
http://dx.doi.org/10.1093/annonc/mds230 .,Non-OADS,/arxiv_data1/oa_pdf/88/06/main.PMC4921779.pdf
"Production and hosting by ElsevierJournal of Advanced Research (2016) 7, 575 –580 Cairo University Journal of Advanced Research http://dx.doi.org/10.1016/j.jare.2016.03.007 2090-1232 /C2112016 Production and hosting by Elsevier B.V. on behalf of Cairo University.",Non-OADS,/arxiv_data1/oa_pdf/cc/0f/main.PMC4921780.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/cc/0f/main.PMC4921780.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).,Non-OADS,/arxiv_data1/oa_pdf/cc/0f/main.PMC4921780.pdf
Diagnost Pathol 2009;4:15. http://dx.doi.org/10.1186/1746-1596-4-15 .,Non-OADS,/arxiv_data1/oa_pdf/cc/0f/main.PMC4921780.pdf
BMC Cancer2015;15(1):1013. http://dx.doi.org/10.1186/s12885-015-2031-1 .,Non-OADS,/arxiv_data1/oa_pdf/cc/0f/main.PMC4921780.pdf
"[35] Drug Use During Pregnancy – Women’s Health Issues – MSD Manual Consumer Version, http://www.msdmanuals.com/ home/womens-health-issues/drug-use-during-pregnancy/drug- use-during-pregnancy > [accessed February 22, 2016].",Non-OADS,/arxiv_data1/oa_pdf/cc/0f/main.PMC4921780.pdf
"[43] Avastin – FDA Prescribing Information, Side Effects and Uses, ” <http://www.drugs.com/pro/avastin.html >, [accessed February 26, 2016].",Non-OADS,/arxiv_data1/oa_pdf/cc/0f/main.PMC4921780.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/06/28/main.PMC4921781.pdf
We recently described a novel negative feedback loop where theparacrine peptide Urocortin 3 (Ucn3) is co-released with insulin frombeta cells and promotes glucose-stimulated somatostatin release via the type 2 corticotropin-releasing hormone (Crhr2) receptor expressed The transcriptome data reported in this paper can be accessed at http://huisinglab.com/islet_txomes_2016/ and have been deposited in the Gene Expression Omnibus (GEO) repository under accession number GSE80673.,OADS,/arxiv_data1/oa_pdf/06/28/main.PMC4921781.pdf
"Abbreviations: Crhr2, Corticotropin-releasing hormone receptor type 2; FISH, Fluorescent in situ hybridization; Ghsr, Growth hormone secretagogue receptor; GS SS, Glucose- stimulated somatostatin secretion; Iapp, Islet amyloid polypeptide; RPKM, Reads per kilobase gene model per million reads sequenced; Trpm2, Trans ient receptor potential melastatin 2; Ucn3, Urocortin 3; YFP, Yellow ﬂuorescent protein Received March 10, 2016 /C15Revision received April 14, 2016 /C15Accepted April 21, 2016 /C15Available online 3 May 2016 http://dx.doi.org/10.1016/j.molmet.2016.04.007 Original article MOLECULAR METABOLISM 5 (2016) 449 e458/C2112016 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/06/28/main.PMC4921781.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/06/28/main.PMC4921781.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/06/28/main.PMC4921781.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/06/28/main.PMC4921781.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/06/28/main.PMC4921781.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/06/28/main.PMC4921781.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/06/28/main.PMC4921781.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/06/28/main.PMC4921781.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/06/28/main.PMC4921781.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/06/28/main.PMC4921781.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/06/28/main.PMC4921781.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/06/28/main.PMC4921781.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2c/04/main.PMC4921782.pdf
"Received March 14, 2016 /C15Revision received April 12, 2016 /C15Accepted April 13, 2016 /C15Available online 22 April 2016 http://dx.doi.org/10.1016/j.molmet.2016.04.004 Original article MOLECULAR METABOLISM 5 (2016) 527 e537/C2112016 The Authors.",OADS,/arxiv_data1/oa_pdf/2c/04/main.PMC4921782.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2c/04/main.PMC4921782.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2c/04/main.PMC4921782.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2c/04/main.PMC4921782.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2c/04/main.PMC4921782.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2c/04/main.PMC4921782.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2c/04/main.PMC4921782.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2c/04/main.PMC4921782.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2c/04/main.PMC4921782.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2c/04/main.PMC4921782.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2c/04/main.PMC4921782.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2c/04/main.PMC4921782.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2c/04/main.PMC4921782.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commer cial use, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Extracellular Vesicles 2016, 5: 29254 - http://dx.doi.org/10.3402/jev.v5.29254 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b5/90/JEV-5-29254.PMC4921784.pdf
"2 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 29254 - http://dx.doi.org/10.3402/jev.v5.29254",OADS,/arxiv_data1/oa_pdf/b5/90/JEV-5-29254.PMC4921784.pdf
"Percentages of gated populations are shown.Characterization of exosomal EGFR by FAVS Citation: Journal of Extracellular Vesicles 2016, 5: 29254 - http://dx.doi.org/10.3402/jev.v5.29254 3 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/b5/90/JEV-5-29254.PMC4921784.pdf
"4 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 29254 - http://dx.doi.org/10.3402/jev.v5.29254",OADS,/arxiv_data1/oa_pdf/b5/90/JEV-5-29254.PMC4921784.pdf
"Percentages of gated populations are shown.Characterization of exosomal EGFR by FAVS Citation: Journal of Extracellular Vesicles 2016, 5: 29254 - http://dx.doi.org/10.3402/jev.v5.29254 5 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/b5/90/JEV-5-29254.PMC4921784.pdf
"6 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 29254 - http://dx.doi.org/10.3402/jev.v5.29254",OADS,/arxiv_data1/oa_pdf/b5/90/JEV-5-29254.PMC4921784.pdf
"Blots were probed for EGFR, AREG and exosomal markers, CD81 and syntenin-1.Characterization of exosomal EGFR by FAVS Citation: Journal of Extracellular Vesicles 2016, 5: 29254 - http://dx.doi.org/10.3402/jev.v5.29254 7 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/b5/90/JEV-5-29254.PMC4921784.pdf
"8 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 29254 - http://dx.doi.org/10.3402/jev.v5.29254",OADS,/arxiv_data1/oa_pdf/b5/90/JEV-5-29254.PMC4921784.pdf
"The relationship between the number of human exosomesadded to mouse plasma-derived exosomes and the number of positive events detected with FA VS was linearCharacterization of exosomal EGFR by FAVS Citation: Journal of Extracellular Vesicles 2016, 5: 29254 - http://dx.doi.org/10.3402/jev.v5.29254 9 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/b5/90/JEV-5-29254.PMC4921784.pdf
"10 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 29254 - http://dx.doi.org/10.3402/jev.v5.29254",OADS,/arxiv_data1/oa_pdf/b5/90/JEV-5-29254.PMC4921784.pdf
"This cytometer was uniquely configured to measure light scattered at multiple anglesconcurrently and resulted in greatly enhanced resolutionCharacterization of exosomal EGFR by FAVS Citation: Journal of Extracellular Vesicles 2016, 5: 29254 - http://dx.doi.org/10.3402/jev.v5.29254 11 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/b5/90/JEV-5-29254.PMC4921784.pdf
"12 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 29254 - http://dx.doi.org/10.3402/jev.v5.29254",OADS,/arxiv_data1/oa_pdf/b5/90/JEV-5-29254.PMC4921784.pdf
"2015;4:27575, doi: http://dx.doi.org/10.3402/jev.v4.27575 12.",Non-OADS,/arxiv_data1/oa_pdf/b5/90/JEV-5-29254.PMC4921784.pdf
"2013;22:4988 /C15000.Characterization of exosomal EGFR by FAVS Citation: Journal of Extracellular Vesicles 2016, 5: 29254 - http://dx.doi.org/10.3402/jev.v5.29254 13 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b5/90/JEV-5-29254.PMC4921784.pdf
"J Extracell Vesicles.2013;2:21045, doi: http://dx.doi.org/10.3402/jev.v2i0.21045 17. van der Pol E, Coumans FA, Grootemaat AE, Gardiner C, Sargent IL, Harrison P, et al.",OADS,/arxiv_data1/oa_pdf/b5/90/JEV-5-29254.PMC4921784.pdf
"2013;2:21494, doi: http://dx.doi.org/10.3402/jev.v2i0.21494 19.",Non-OADS,/arxiv_data1/oa_pdf/b5/90/JEV-5-29254.PMC4921784.pdf
"2015;4:25530, doi: http://dx.doi.org/10.3402/jev.v4.25530 39.",Non-OADS,/arxiv_data1/oa_pdf/b5/90/JEV-5-29254.PMC4921784.pdf
"14 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 29254 - http://dx.doi.org/10.3402/jev.v5.29254",OADS,/arxiv_data1/oa_pdf/b5/90/JEV-5-29254.PMC4921784.pdf
"2014;3:25011, doi: http://dx.doi.org/ 10.3402/jev.v3.25011Characterization of exosomal EGFR by FAVS Citation: Journal of Extracellular Vesicles 2016, 5: 29254 - http://dx.doi.org/10.3402/jev.v5.29254 15 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/b5/90/JEV-5-29254.PMC4921784.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commer cial use, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Extracellular Vesicles 2016, 5: 30281 - http://dx.doi.org/10.3402/jev.v5.30281 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
"2 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 30281 - http://dx.doi.org/10.3402/jev.v5.30281",OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
"1) Protocol to obtain HFDa; 2) protocol to obtain HFDa 0.22 mm; 3) protocol to obtain HFDa tablet; 4) protocol of microbiological analysis with HFDa fractions; and 5) differential centrifugations protocol for microbiological analysis.Urinary extracellular vesicles for RNA extraction Citation: Journal of Extracellular Vesicles 2016, 5: 30281 - http://dx.doi.org/10.3402/jev.v5.30281 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
"4 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 30281 - http://dx.doi.org/10.3402/jev.v5.30281",OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
"For this reason, we investigated different methods to limit the bacterial presence in the HFDa samples prior toUrinary extracellular vesicles for RNA extraction Citation: Journal of Extracellular Vesicles 2016, 5: 30281 - http://dx.doi.org/10.3402/jev.v5.30281 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
"6 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 30281 - http://dx.doi.org/10.3402/jev.v5.30281",OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
"(a) Microbiological testing of fractions HFDa 0.22 mmexperiment performed in triplicate; (b) SDS-PAGE stained with colloidal Coomassie; (c) western blots with anti- ALIX, anti-TSGl0l; and (d) anti-DPPlV , anti-CD63; (e) PicoChip, (f) Small Chip electropherograms from HFDa 0.22 mmRNA extracted with Norgen Kit; ST-molecular weight marker, 1,2,3 /C1HFDa 0.22 mmfractions (triplicate), 4,5,6 /C1SDS elution from Steritop ﬁlters (triplicate), kDa /C1kilodalton.Urinary extracellular vesicles for RNA extraction Citation: Journal of Extracellular Vesicles 2016, 5: 30281 - http://dx.doi.org/10.3402/jev.v5.30281 7 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
"8 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 30281 - http://dx.doi.org/10.3402/jev.v5.30281",OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
"Red colo ur/C1measure under the threshold.Urinary extracellular vesicles for RNA extraction Citation: Journal of Extracellular Vesicles 2016, 5: 30281 - http://dx.doi.org/10.3402/jev.v5.30281 9 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
"10 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 30281 - http://dx.doi.org/10.3402/jev.v5.30281",OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
"Pico 6000 RNA Chip electropherograms run in Agilent 2100 Bioanalyzer for RNA samples coming from UEVs extracted with different methods: (a) FastRNA; (b) Qiagen; (c) TRIzol; (d) Norgen; (e) Nucleo-Spin; (f) Quick RNA; (g) mirVana; nt /C1nucleotide size, grey arrow /C1marker peak, FU /C1ﬂuorescence units.Urinary extracellular vesicles for RNA extraction Citation: Journal of Extracellular Vesicles 2016, 5: 30281 - http://dx.doi.org/10.3402/jev.v5.30281 11 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
"12 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 30281 - http://dx.doi.org/10.3402/jev.v5.30281",OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
Front Immunol.2015;6. doi: http://dx.doi.org/10.3389/ﬁmmu.2015.00006 2.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
"J Extracell Vesicles.2013;2:20389, doi: http://dx.doi.org/10.3402/jev.v2i0.20389 3.",OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi: http://dx.doi.org/10.1016/j.jprot.2013.10.037 4.,OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
"2015;2015:289734, doi: http://dx.doi.org/10.1155/2015/289734 5.",Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi: http://dx.doi.org/ 10.1002/pmic.201200285 7.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi: http://dx.doi.org/10.1038/ki.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi: http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi: http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi: http://dx.doi.org/10.1371/journal.pone.0073798 13.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi: http://dx.doi.org/10.1371/journal.pone.0096094 14.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi: http://dx.doi.org/10.7150/ijbs.6100 15.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
Sci Rep. 2014;4:7532. doi: http://dx.doi.org/10.1038/srep07532 16.,OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
"Eldh M, Lo ¨tvall J, Malmha ¨ll C, Ekstro ¨m K. Import- ance of RNA isolation methods for analysis of exosomalUrinary extracellular vesicles for RNA extraction Citation: Journal of Extracellular Vesicles 2016, 5: 30281 - http://dx.doi.org/10.3402/jev.v5.30281 13 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi: http://dx.doi.org/10.1016/j.molimm.2012.02.001 17.,OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi: http://dx.doi.org/10.1515/ cclm-2013-0562 18.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi: http://dx.doi.org/10.1038/ki.2012.256 19.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi: http://dx.doi.org/10.1038/ki.2013.502 20.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
2014;369:20130502. doi: http://dx.doi.org/10.1098/rstb.2013.0502 21.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi: http://dx.doi.org/10.1373/ clinchem.2008.112797 22.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
2013;23:2. doi: http://dx.doi.org/10.3402/jev.v2i0.22859 23.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi: http://dx.doi.org/10.1007/978-1-62703-4531_12 24.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi: http://dx.doi.org/10.3109/02656736.2013.775355 25.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
2012;3:162. doi: http://dx.doi.org/10.3389/fphys.2012.00162 26.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
2009;7:4. doi: http://dx.doi.org/10.1186/1479-5876-7-4 29.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
"2014;3:23111, doi: http://dx.doi.org/10.3402/jev.v3.23111 30.",Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
Available from: https://www.genome.duke.edu/sites/default/ﬁles/AgilentmRNA.pdf 34.,OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi: http://dx.doi.org/ 10.1016/j.carres.2014.01.007 35.,OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
Available from: http://www.nanodrop.com/Library/T009-NanoDrop 1000-&-NanoDrop 8000-Nucleic-Acid-Purity-Ratios.pdf 36.,OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi:http://dx.doi.org/10.1371/journal.pone.0147249 37.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi: http://dx.doi.org/ 10.1586/14737159.1043272 38.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
2015;45:394404. doi: http://dx.doi.org/10.1111/eci.12420 39.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi: http://dx.doi.org/10.2144/ 000114002 40.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi: http://dx.doi.org/10.5662/wjm.v3.i1.11 42.,OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
2013;12:2. doi: http://dx.doi.org/10.3402/jev.v2i0.20677 43.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
Front Cell Infect Microbiol.2013;3:41. doi: http://dx.doi.org/10.3389/fcimb.2013.00041 44.,OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
J Transl Med.2012;10:174. doi: http://dx.doi.org/10.1186/1479-5876-10-174 45.,Non-OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi: http://dx.doi.org/1 0.1016/j.jemermed.2015.,OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
doi: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
"14 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2016, 5: 30281 - http://dx.doi.org/10.3402/jev.v5.30281",OADS,/arxiv_data1/oa_pdf/a3/71/JEV-5-30281.PMC4921785.pdf
"”,http://dx.doi.org/10.1016/j.molmet.",OADS,/arxiv_data1/oa_pdf/fa/e4/main.PMC4921788.pdf
"Received May 4, 2016 /C15Accepted May 4, 2016 /C15Available online 24 May 2016 http://dx.doi.org/10.1016/j.molmet.2016.05.009Commentary MOLECULAR METABOLISM 5 (2016) 435 e436/C2112016 The Author(s).",OADS,/arxiv_data1/oa_pdf/fa/e4/main.PMC4921788.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/fa/e4/main.PMC4921788.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/fa/e4/main.PMC4921788.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f3/4e/main.PMC4921790.pdf
"Abbreviations: AgRP, Agouti-related protein; AMPK, AMP-activated protein kinase; FOXO1, Forkhead protein 1; PGC-1 a, Peroxisome proliferator-activated receptor g coactivator 1 a; POMC, Pro-opiomelanocortin; SIRT1, NADþ-dependent protein deacetylase sirtuin-1; TBP, TATA-binding protein Received May 3, 2016 /C15Revision received May 10, 2016 /C15Accepted May 12, 2016 /C15Available online 18 May 2016 http://dx.doi.org/10.1016/j.molmet.2016.05.008 Original article 580MOLECULAR METABOLISM 5 (2016) 580 e588/C2112016 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/f3/4e/main.PMC4921790.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f3/4e/main.PMC4921790.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f3/4e/main.PMC4921790.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f3/4e/main.PMC4921790.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f3/4e/main.PMC4921790.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f3/4e/main.PMC4921790.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f3/4e/main.PMC4921790.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f3/4e/main.PMC4921790.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f3/4e/main.PMC4921790.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f3/4e/main.PMC4921790.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f3/4e/main.PMC4921790.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
"Received April 6, 2016 /C15Revision received April 15, 2016 /C15Accepted April 19, 2016 /C15Available online 22 April 2016 http://dx.doi.org/10.1016/j.molmet.2016.04.006 Original article 538MOLECULAR METABOLISM 5 (2016) 538 e551/C2112016 The Author(s).",OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.1056/NEJM196910092811503 .,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.1016/j.cmet.2009.02.002 .,OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.2337/dc08-2075 .,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.1007/s00125-009-1637-8 .,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.1038/nm.2307 .,OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.1161/ CIRCGENETICS.109.852814 .,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
"http://dx.doi.org/10.1126/sci- translmed.3002043 , 80re2.",Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.1007/s00125-011-2356-5 .,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.1016/j.cmet.2012.01.024 .,OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
"Science (New York, N.Y.) 341(6150):1241214. http://dx.doi.org/ 10.1126/science.1241214 .",Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/ 10.2337/db14-0312 .,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.1016/j.cmet.2014.09.003 .,OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.1074/jbc.M109.075184 .,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.1152/ ajpendo.00219.2010 .,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
Nature Reviews Endocrinology 10(12):723 e 736. http://dx.doi.org/10.1038/nrendo.2014.171 .,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/ 10.1007/s00125-003-1129-1 .,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.3945/jn.108.100081 .,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.1371/journal.pone.0021187 .,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
Nutrition & Metabolism 7:57. http://dx.doi.org/10.1186/ 1743-7075-7-57 .,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.1371/journal.pone.0059443 .Original article 550MOLECULAR METABOLISM 5 (2016) 538 e551/C2112016 The Author(s).,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.1074/jbc.M511908200 .,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.1016/j.ab.2013.05.002 .,OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.1007/s00125-015-3705-6 .,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.2337/db13-0396 .,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.1016/j.cmet.2007.10.013 .,OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.1016/j.cmet.2012.04.005 .,OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.1038/ nm.4057 .,OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.1016/ j.celrep.2015.12.030 .,OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/ 10.1007/s00726-012-1330-y .,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.1021/ac1003213 .,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
http://dx.doi.org/10.1126/science.1124147 .,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
Nature Chemical Biology 12(1):15 e 21.http://dx.doi.org/10.1038/nchembio.1961 .,OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ef/69/main.PMC4921791.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
"Received March 19, 2016 /C15Revision received April 26, 2016 /C15Accepted May 4, 2016 /C15Available online 11 May 2016 http://dx.doi.org/10.1016/j.molmet.2016.05.003 Original article MOLECULAR METABOLISM 5 (2016) 459 e471/C2112016 The Author(s).",OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1016/S0140- 6736(11)60679-X .,OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.2337/dc14-S081 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.2337/dc13-1879 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1016/S0168-8227(11) 70010-9 .,OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1007/s00125-012-2650-x .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1172/JCI8339 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1038/ng872 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1016/j.cmet.2010.11.005 .,OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1074/jbc.M110.200295 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1371/ journal.pone.0047381 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/ 10.1074/jbc.M114.577510 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1006/bbrc.2000.2514 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1074/jbc.M208984200 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
Biochimica Et Bio-physica Acta 1792(2):83 e92.http://dx.doi.org/10.1016/j.bbadis.2008.10.019 .,OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1210/me.2014-1330 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1042/BJ20070003 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1038/ nm1232 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
The Biochemical Journal 438(1):53 e62.http://dx.doi.org/10.1042/BJ20110502 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1210/en.2007-0968 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1242/jcs.107201 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1172/JCI82498 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1016/ j.bbrc.2006.07.136 .,OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1016/j.metabol.2007.07.020 .,OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1210/edrv.19.4.0339 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
The Journal of General Physiology 124(6):653 e662 http://dx.doi.org/ 10.1085/jgp.200409082 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/ 10.1074/jbc.M109.095992 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1016/ j.bcp.2008.07.025 .,OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1006/bbrc.1995.2858 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1111/j.1463-1326.2012.01632.x .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1371/journal.pone.0014191 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/ 10.1016/j.celrep.2015.10.052 .,OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1007/s00125- 013-2903-3 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
Physiological Reviews 85(4):1303 e 1342. http://dx.doi.org/10.1152/physrev.00001.2005 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/ 10.1073/pnas.1513004112 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1111/j.1463-1326.2009.01108.x .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1111/j.1365- 2826.2012.02386.x .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1038/nn885 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
Cell Reports 13(1):15 e22.http://dx.doi.org/ 10.1016/j.celrep.2015.08.058 .,OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1016/j.bbrc.2004.09.149 .,OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
http://dx.doi.org/10.1007/ s00125-007-0671-7 .,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c0/61/main.PMC4921792.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ad/e5/main.PMC4921793.pdf
"Received April 4, 2016 /C15Revision received April 28, 2016 /C15Accepted May 3, 2016 /C15Available online 10 May 2016 http://dx.doi.org/10.1016/j.molmet.2016.05.001 Original article MOLECULAR METABOLISM 5 (2016) 437 e448/C2112016 The Author(s).",OADS,/arxiv_data1/oa_pdf/ad/e5/main.PMC4921793.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ad/e5/main.PMC4921793.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ad/e5/main.PMC4921793.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ad/e5/main.PMC4921793.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ad/e5/main.PMC4921793.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ad/e5/main.PMC4921793.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ad/e5/main.PMC4921793.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ad/e5/main.PMC4921793.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ad/e5/main.PMC4921793.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ad/e5/main.PMC4921793.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ad/e5/main.PMC4921793.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found online at http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/ad/e5/main.PMC4921793.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ad/e5/main.PMC4921793.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ad/e5/main.PMC4921793.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/21/39/main.PMC4921803.pdf
"Received March 24, 2016 /C15Revision received April 26, 2016 /C15Accepted May 6, 2016 /C15Available online 14 May 2016 http://dx.doi.org/10.1016/j.molmet.2016.05.005 Original article 480MOLECULAR METABOLISM 5 (2016) 480 e490/C2112016 The Author(s).",OADS,/arxiv_data1/oa_pdf/21/39/main.PMC4921803.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/21/39/main.PMC4921803.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/21/39/main.PMC4921803.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/21/39/main.PMC4921803.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/21/39/main.PMC4921803.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/21/39/main.PMC4921803.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/21/39/main.PMC4921803.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/21/39/main.PMC4921803.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/21/39/main.PMC4921803.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/21/39/main.PMC4921803.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/21/39/main.PMC4921803.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/21/39/main.PMC4921803.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/21/39/main.PMC4921803.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5d/4d/main.PMC4921804.pdf
"Received February 13, 2016 /C15Revision received April 29, 2016 /C15Accepted May 6, 2016 /C15Available online 13 May 2016 http://dx.doi.org/10.1016/j.molmet.2016.05.004 Original article MOLECULAR METABOLISM 5 (2016) 491 e505/C2112016 The Authors.",OADS,/arxiv_data1/oa_pdf/5d/4d/main.PMC4921804.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5d/4d/main.PMC4921804.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5d/4d/main.PMC4921804.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5d/4d/main.PMC4921804.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5d/4d/main.PMC4921804.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5d/4d/main.PMC4921804.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5d/4d/main.PMC4921804.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5d/4d/main.PMC4921804.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5d/4d/main.PMC4921804.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5d/4d/main.PMC4921804.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5d/4d/main.PMC4921804.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5d/4d/main.PMC4921804.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5d/4d/main.PMC4921804.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5d/4d/main.PMC4921804.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found online at http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/5d/4d/main.PMC4921804.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5d/4d/main.PMC4921804.pdf
Journal of Biological Chemistry 289:4762 e 4777. http://dx.doi.org/10.1074/jbc.M113.530998 [Epub 2014 Jan 14].,Non-OADS,/arxiv_data1/oa_pdf/5d/4d/main.PMC4921804.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5d/4d/main.PMC4921804.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.ANTIOXIDANTS & REDOX SIGNALING Volume 24, Number 17, 2016 Mary Ann Liebert, Inc.DOI: 10.1089/ars.2015.6437 974",Non-OADS,/arxiv_data1/oa_pdf/08/92/ars.2015.6437.PMC4921902.pdf
"On the other hand, it is available as an antisense oligonucleotide designedto inhibit sod1 expression (ISIS 333611) and delivered in- trathecally in SOD1 familial amyotrophic lateral sclerosis patients (https://clinicaltrials.gov).",Non-OADS,/arxiv_data1/oa_pdf/08/92/ars.2015.6437.PMC4921902.pdf
The mRNA expression of CRH in the PVN was quantiﬁed as graydensity minus background in digitized images using the NIH ImageJ 1.6 program (http://rsb.info.nih.gov/ij).,OADS,/arxiv_data1/oa_pdf/08/92/ars.2015.6437.PMC4921902.pdf
"Production and hosting by ElsevierJournal of Advanced Research (2016) 7, 557 Cairo University Journal of Advanced Research http://dx.doi.org/10.1016/j.jare.2016.03.001 2090-1232 /C2112016 Production and hosting by Elsevier B.V. on behalf of Cairo University.",Non-OADS,/arxiv_data1/oa_pdf/c1/f5/main.PMC4921933.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/c1/f5/main.PMC4921933.pdf
"Production and hosting by ElsevierJournal of Advanced Research (2016) 7, 581 –587 Cairo University Journal of Advanced Research http://dx.doi.org/10.1016/j.jare.2016.01.003 2090-1232 /C2112016 Production and hosting by Elsevier B.V. on behalf of Cairo University.",Non-OADS,/arxiv_data1/oa_pdf/99/df/main.PMC4921935.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/99/df/main.PMC4921935.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).,Non-OADS,/arxiv_data1/oa_pdf/99/df/main.PMC4921935.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/2c/main.PMC4921936.pdf
"Received April 1, 2016 /C15Revision received April 28, 2016 /C15Accepted May 4, 2016 /C15Available online 12 May 2016 http://dx.doi.org/10.1016/j.molmet.2016.05.002 Original article 566MOLECULAR METABOLISM 5 (2016) 566 e579/C2112016 The Author(s).",OADS,/arxiv_data1/oa_pdf/a7/2c/main.PMC4921936.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/2c/main.PMC4921936.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/2c/main.PMC4921936.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/2c/main.PMC4921936.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/2c/main.PMC4921936.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/2c/main.PMC4921936.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/2c/main.PMC4921936.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/2c/main.PMC4921936.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/2c/main.PMC4921936.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/2c/main.PMC4921936.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/2c/main.PMC4921936.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/2c/main.PMC4921936.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/2c/main.PMC4921936.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/2c/main.PMC4921936.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/2c/main.PMC4921936.pdf
"”,http://dx.doi.org/10.1016/j.molmet.2016.04.007 .",OADS,/arxiv_data1/oa_pdf/74/e8/main.PMC4921939.pdf
"Received May 11, 2016 /C15Accepted May 11, 2016 /C15Available online 20 May 2016 http://dx.doi.org/10.1016/j.molmet.2016.05.007Commentary MOLECULAR METABOLISM 5 (2016) 433 e434/C2112016 The Author(s).",OADS,/arxiv_data1/oa_pdf/74/e8/main.PMC4921939.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/74/e8/main.PMC4921939.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/74/e8/main.PMC4921939.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/eb/e8/main.PMC4921941.pdf
"Received April 19, 2016 /C15Revision received May 4, 2016 /C15Accepted May 6, 2016 /C15Available online 13 May 2016 http://dx.doi.org/10.1016/j.molmet.2016.05.006 Original article 472MOLECULAR METABOLISM 5 (2016) 472 e479/C2112016 The Author(s).",OADS,/arxiv_data1/oa_pdf/eb/e8/main.PMC4921941.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/eb/e8/main.PMC4921941.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/eb/e8/main.PMC4921941.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/eb/e8/main.PMC4921941.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/eb/e8/main.PMC4921941.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/eb/e8/main.PMC4921941.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/eb/e8/main.PMC4921941.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/eb/e8/main.PMC4921941.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/eb/e8/main.PMC4921941.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/69/main.PMC4921942.pdf
"Received March 30, 2016 /C15Revision received April 14, 2016 /C15Accepted April 27, 2016 /C15Available online 4 May 2016 http://dx.doi.org/10.1016/j.molmet.2016.04.008 Original article 552MOLECULAR METABOLISM 5 (2016) 552 e565/C2112016 The Author(s).",OADS,/arxiv_data1/oa_pdf/a3/69/main.PMC4921942.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/69/main.PMC4921942.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/69/main.PMC4921942.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/69/main.PMC4921942.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/69/main.PMC4921942.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/69/main.PMC4921942.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/69/main.PMC4921942.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/69/main.PMC4921942.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/69/main.PMC4921942.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/69/main.PMC4921942.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/69/main.PMC4921942.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/69/main.PMC4921942.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a3/69/main.PMC4921942.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/69/main.PMC4921942.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/69/main.PMC4921942.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/69/main.PMC4921942.pdf
"Received March 20, 2016 /C15Revision received April 8, 2016 /C15Accepted April 18, 2016 /C15Available online 23 April 2016 http://dx.doi.org/10.1016/j.molmet.2016.04.005 Original article 506MOLECULAR METABOLISM 5 (2016) 506 e526/C2112016 The Authors.",OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1152/phys- rev.00017.2012 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.4049/jimmunol.1402655 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1002/ eji.200737638 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
Mediators ofInﬂammation 2010:513948. http://dx.doi.org/10.1155/2010/513948 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/ 10.1172/JCI29069 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1161/CIRCRESAHA.109.215715 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1016/j.cmet.2014.08.010 .,OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1016/Original article 522MOLECULAR METABOLISM 5 (2016) 506 e526/C2112016 The Authors.,OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1038/ni.,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
The Journal of Experimental Medicine 213(1):15 e 23. http://dx.doi.org/10.1084/jem.20151570 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1038/ni.,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1016/ j.immuni.2015.02.005 .,OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1074/jbc.M113.522037 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1016/j.cmet.2012.04.023 .,OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1371/journal.- pone.0111394 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1152/ ajpendo.00187.2014 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1038/ni.,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1182/blood-2012-03-419747 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1074/ jbc.M306575200 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1371/journal.- pone.0098109 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1128/ MCB.26.9.3455 e3467.2006 [pii] 26/9/3455.,OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1172/JCI18917 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
FASEB Journal 24(11):4229 e 4239. http://dx.doi.org/10.1096/fj.10-159723 [pii] fj.10-159723.,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1371/journal.pone.0045087 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
[35] https://www.immgen.org/ .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1007/s10549-013-2741-5 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1074/jbc.M604427200 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1073/ pnas.1205995109 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/ 10.1096/fj.11-188300 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1172/ JCI57559 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/ 10.1038/oby.2011.18 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1016/j.jaut.2012.05.013 .,OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.4049/jimmu- nol.1202429 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1096/fj.14-258566 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1038/ng.,OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.2337/db12-1363 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1038/nprot.2011.457 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/ 10.1186/gb-2009-10-11-r130 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1016/j.tips.2015.09.003 .,OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.2337/db11-1595 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
Epigenomics 7(7):1155 e 1164. http://dx.doi.org/10.2217/epi.15.71 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
Science 345(6204): 1251086. http://dx.doi.org/10.1126/science.1251086 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1001/ jama.2014.6228 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1111/ j.1365-2125.2012.04297.x .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1097/HJH.0b013e328354663c .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1210/jc.2010- 1170 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1001/jama.2011.878 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1002/acr.20657 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1016/j.redox.2013.12.026 .,OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
Nature Immunology 13(4):352 e357 http://dx.doi.org/10.1038/ni.,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/ 10.1074/jbc.M111.304998 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
Biochemical and Biophysical Research Communications.http://dx.doi.org/10.1016/j.bbrc.2016.03.113 .,OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1172/ JCI64801 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/ 10.1039/c1mb05114h .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1139/y04-067 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1021/ pr200815c .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1016/j.bba- gen.2006.01.006 .,OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1002/ eji.201343940 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1017/ S0007114512005351 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1146/ annurev-immunol-032713-120236 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1016/j.bbamem.2009.06.002 .,OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1182/blood-2010- 04-278887 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1016/j.bcp.2007.04.005 .,OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
http://dx.doi.org/10.1006/ taap.1997.8197 .,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7a/3b/main.PMC4921943.pdf
"Production and hosting by ElsevierJournal of Advanced Research (2016) 7, 571 –574 Cairo University Journal of Advanced Research http://dx.doi.org/10.1016/j.jare.2015.12.004 2090-1232 /C2112016 Production and hosting by Elsevier B.V. on behalf of Cairo University.",Non-OADS,/arxiv_data1/oa_pdf/25/3a/main.PMC4921954.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/25/3a/main.PMC4921954.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).,Non-OADS,/arxiv_data1/oa_pdf/25/3a/main.PMC4921954.pdf
"Email: a.harris@maastrichtuniversity.nl Extra material: http://theoryculturesociety.org/2016, Vol.",Non-OADS,/arxiv_data1/oa_pdf/0a/1e/10.1177_1357034X15604031.PMC4922000.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercialuse, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.TISSUE ENGINEERING: Part C Volume 22, Number 6, 2016 Mary Ann Liebert, Inc.DOI: 10.1089/ten.tec.2016.0071 517",Non-OADS,/arxiv_data1/oa_pdf/98/53/ten.tec.2016.0071.PMC4922008.pdf
"ReviewThis is an Open Access article distributed under the terms of the Creative Commons   Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which   permits non-commercial re-use, distribution, and reproduction in any medium, provided the original   work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/02/07/dxw015.PMC4922024.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/ed/50/ijcp-09-01-3467.PMC4922200.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a7/72/ijcp-09-01-3505.PMC4922201.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/f5/c3/ijcp-09-01-3752.PMC4922202.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/aa/b2/ijcp-09-01-3900.PMC4922203.pdf
Available at : http://icmr.nic.in/annu - al/hqds2004/reproductive.pdf.,Non-OADS,/arxiv_data1/oa_pdf/aa/b2/ijcp-09-01-3900.PMC4922203.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/20/81/ijcp-09-01-3919.PMC4922204.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/ba/7d/ijcp-09-01-3961.PMC4922205.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom - mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us - ages, provided the original work is properly cited.1.",Non-OADS,/arxiv_data1/oa_pdf/fb/98/ijcp-09-01-4022.PMC4922206.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/40/8d/ijcp-09-01-5266.PMC4922207.pdf
"This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a8/5b/ijcp-09-01-5443.PMC4922208.pdf
Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/a3/a8/NJMS-6-136.PMC4922222.pdf
Available from: http://www.fda.gov/ downloads/Drugs/DrugSafety/UCM176360.pdf.,Non-OADS,/arxiv_data1/oa_pdf/e1/d6/NJMS-6-152.PMC4922224.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b3/ee/mdw155.PMC4922317.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f3/0b/mdw162.PMC4922318.pdf
IR parameters were calculated from fasting glu- cose and insulin concentrations by using the HOMAcalculator software (http://www.dtu.ox.ac.uk/homa - calculator/download.php).,OADS,/arxiv_data1/oa_pdf/0c/4d/jomb-2014-0033.PMC4922324.pdf
Methods Search strategyThis study was designed according to the guide- lines of the preferred reporting items for systematicreviews and meta-analyses (PRISMA) statement (27).A systematic literature search for English-languagearticles was performed in the following databasesfrom inception through December 2012: PubMed-Medline (http://www.ncbi.nlm.nih.gov/pubmed ) and SCOPUS (http://www.scopus.com ) and the Cochrane Database of Systematic Review published (http ://www.,OADS,/arxiv_data1/oa_pdf/46/df/jomb-2014-0030.PMC4922328.pdf
http://www.genet.sickkids.on.ca/cftr (accessed April2014).,Non-OADS,/arxiv_data1/oa_pdf/1a/a5/jomb-2014-0055.PMC4922332.pdf
"Clin Chim Acta (2013), http://dx.doi.org/10.1016/j.cca.2013.03.030 54.",OADS,/arxiv_data1/oa_pdf/4f/24/jomb-2014-0059.PMC4922334.pdf
"Quality control We are participating in the ERNDIM (European Research Network for Evaluation and Improvement ofScreening, Diagnosis and T reatment of InheritedDisorders of Metabolism) schemes for qualitativeorganic acids, quantitative amino acids, qualitativeblood spot acylcarnitine, congenital disorders of gly-cosylation (http://cms.erndimqa.nl/) and the IN - STAND (Institute for Standardization and Documen - tation in the Medical Laboratory) scheme forNeonatal Screening – Inborn Errors of Metabolism(http://www.instandev.de/).",Non-OADS,/arxiv_data1/oa_pdf/8c/0a/jomb-2014-0056.PMC4922335.pdf
http://www.screening.nhs.uk/criteria (accessed 14 thMarch 2014) 5.,Non-OADS,/arxiv_data1/oa_pdf/16/85/jomb-2014-0040.PMC4922336.pdf
http://www.nichd.nih.gov/news/releases/Pages/090413-newborn-sequencing.aspx(accessed 14 thMarch 2014) 15.,Non-OADS,/arxiv_data1/oa_pdf/16/85/jomb-2014-0040.PMC4922336.pdf
http://newbornbloodspot.screen-ing.nhs.uk/cms.php?folder=2701 (accessed 20 th March 2014) 18.,Non-OADS,/arxiv_data1/oa_pdf/16/85/jomb-2014-0040.PMC4922336.pdf
"Lyon,France: International Agency for Research on Cancer(online), <http://www.globocan.iarc.fr/factsheets/can-cers/breast.asp>; 2010 (accessed on 24.09.2012).",Non-OADS,/arxiv_data1/oa_pdf/a0/04/jomb-2014-0067.PMC4922358.pdf
"Reports and Statistics: Aswan, Damietta & El-Minia (online), http://www.cancerregistry.gov.eg/reports.aspx> (accessed 5.09.2012).",Non-OADS,/arxiv_data1/oa_pdf/a0/04/jomb-2014-0067.PMC4922358.pdf
Available at: http://apps.who.int/iris/bitstream/10665/75584/1/WHO_NMH_NHD_EPG_12.1_eng.,OADS,/arxiv_data1/oa_pdf/09/e1/jomb-2014-0046.PMC4922360.pdf
Available at:http://www.goldcopd.org.,Non-OADS,/arxiv_data1/oa_pdf/09/e1/jomb-2014-0046.PMC4922360.pdf
2016;19(2):58–65.The June Issue of the CGJ DOI:http://dx.doi.org/10.5770/cgj.19.241EDITORIAL © 2016 Author(s).,Non-OADS,/arxiv_data1/oa_pdf/28/fb/cgj-19-33.PMC4922365.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial   No-Derivative license (http://creativecommons.org/licenses/by-nc-nd/2.5/ca/), which permits unrestricted non-commercial use and distribution, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/28/fb/cgj-19-33.PMC4922365.pdf
"Frailty, distinct from co-morbidity and age, is a state of vulnerability predisposing certain individuals to increased risk of falls, delirium, disability, and mortality Clinical Frailty Scale in an Acute Medicine Unit:   a Simple Tool That Predicts Length of Stay Salina Juma, MD1, Mary-Margaret Taabazuing, MD, FRCPC2,   Manuel Montero-Odasso, MD, PhD FRCPC, AGSF1,2,3 1Department of Medicine, Internal Medicine, London Health Sciences Centre, The University of Western Ontario,   London, ON;  2Department of Medicine, Division of Geriatric Medicine, The University of Western Ontario, London, ON;  3Gait and Brain Lab, Lawson Health Research Institute, Parkwood Hospital, London, ON; 4Department of Epidemiology   & Biostatistics, The University of Western Ontario, London, ON, Canada DOI:http://dx.doi.org/10.5770/cgj.19.196ORIGINAL RESEARCH © 2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/78/e7/cgj-19-34.PMC4922366.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial   No-Derivative license (http://creativecommons.org/licenses/by-nc-nd/2.5/ca/), which permits unrestricted non-commercial use and distribution, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/78/e7/cgj-19-34.PMC4922366.pdf
"This study compared the effectiveness and safety (days within INR range 2.0–3.0) of pharmacist-managed warfarin dosing Advantages of a Warfarin Protocol for   Long-term Care Pharmacists: a Retrospective   Cohort Study  Randall Sargent, MSc, MD1,2,3, Cynthia Brocklebank, ACPR, PharmD4, Helen Tam-Tham, MSc5,   Tyler Williamson, PhD5, Patrick Quail, MB, BCh2,3, Diana Turner, MSc, MD2,6, Neil Drummond, PhD7 1Family Medicine and Primary Care Research Office, Cumming School of Medicine, University of Calgary, Calgary;   2Integrated Supportive and Facility Living, Alberta Health Services, Calgary; 3Southern Alberta Primary Care Research  Network, University of Calgary, Calgary; 4Pharmacy Services, Alberta Health Services, Edmonton; 5Department of   Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary; 6Carewest, Calgary;   7Department of Family Medicine and Dentistry, University of Alberta, Edmonton, Alberta DOI:http://dx.doi.org/10.5770/cgj.19.205ORIGINAL RESEARCH © 2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/5d/77/cgj-19-40.PMC4922367.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial   No-Derivative license (http://creativecommons.org/licenses/by-nc-nd/2.5/ca/), which permits unrestricted non-commercial use and distribution, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5d/77/cgj-19-40.PMC4922367.pdf
Available from:  https://d10k7k7mywg42z.cloudfront.net/assets/562fabf3d4   c9610610181c2c/HQCA_LTC_Provincial_Report_2015.pdf  8.,OADS,/arxiv_data1/oa_pdf/5d/77/cgj-19-40.PMC4922367.pdf
Available from: http://www12.statcan.gc.ca/census-recensement   /2011/ dp-pd/prof/details/Page.cfm?Lang=E&Geo1=   PR&Code1=48&Geo2=PR&Code2=01&Data=Count&Search   Text=Alberta&SearchType=Begins&SearchPR=01&B1=All&   GeoLevel=PR&GeoCode=48  9.,OADS,/arxiv_data1/oa_pdf/5d/77/cgj-19-40.PMC4922367.pdf
Available from: http://humansystems.arc.nasa.gov/groups/tlx/downloads/ NASA-TLXChapter.pdf  16.,OADS,/arxiv_data1/oa_pdf/5d/77/cgj-19-40.PMC4922367.pdf
Available from: http://bmcgeriatr.biomedcentral.,OADS,/arxiv_data1/oa_pdf/5d/77/cgj-19-40.PMC4922367.pdf
"We hypothesized that the Effectiveness of a Core-Competency–based   Program on Residents' Learning and Experience Lesley Charles, MBChB, CCFP, Dip COE , Jean Triscott, MD, CCFP, Dip COE , Bonnie Dobbs, PhD,   Jasneet Parmar, MBBS , Peter George Tian, MD, MPH, FPSO-HNS, FPCS , Oksana Babenko, PhD Division of Care of the Elderly, Department of Family Medicine, University of Alberta, Edmonton, AB  DOI: http://dx.doi.org/10.5770/cgj.19.213ORIGINAL RESEARCH © 2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/cf/d4/cgj-19-50.PMC4922368.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial   No-Derivative license (http://creativecommons.org/licenses/by-nc-nd/2.5/ca/), which permits unrestricted non-commercial use and distribution, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/cf/d4/cgj-19-50.PMC4922368.pdf
"(Ont)2, Shannon Stanners, MCISc, SLP2,  Maureen Montemuro, MHSc, RN5, Aidan Giangregorio1, Alexandra Papaioannou, MD1,2,3  1Geriatric Education and Research in Aging Sciences (GERAS) Centre, St Peter’s Hospital, Hamilton, ON; Department of  Medicine, McMaster University, Hamilton, ON; 2Hamilton Health Sciences-St Peter’s Hospital, Hamilton, ON; 3Department  of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON; 4Art Gallery of Hamilton, Hamilton, ON;  5School of Nursing, McMaster University, Hamilton, ON, Canada DOI:http://dx.doi.org/10.5770/cgj.19.220ORIGINAL RESEARCH © 2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/c1/d8/cgj-19-58.PMC4922369.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial   No-Derivative license (http://creativecommons.org/licenses/by-nc-nd/2.5/ca/), which permits unrestricted non-commercial use and distribution, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c1/d8/cgj-19-58.PMC4922369.pdf
"(9) To do so, the core clinical criterion  of impaired episodic memory should be accompanied by at The New Criteria for Alzheimer’s Disease -   Implications for Geriatricians* Pierre Molin, MD, FRCPC1,2, Kenneth Rockwood, MD, FRCPC, FRCP1 1Department of Medicine, Divisions of Geriatric Medicine and of Neurology, Dalhousie University, Halifax, NS;   2Département de médecine, Division de gériatrie, Université Laval, Québec, QC, Canada DOI:http://dx.doi.org/10.5770/cgj.19.207COMMENTARIES © 2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/4a/01/cgj-19-66.PMC4922370.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial   No-Derivative license (http://creativecommons.org/licenses/by-nc-nd/2.5/ca/), which permits unrestricted non-commercial use and distribution, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4a/01/cgj-19-66.PMC4922370.pdf
"Ces nouveaux critères sont-ils susceptibles Les nouveaux critères de la Maladie d’Alzheimer  – Perspective gériatrique* Pierre Molin, MD, FRCPC1,2, Kenneth Rockwood, MD, FRCPC, FRCP1 1Department of Medicine, Divisions of Geriatric Medicine and of Neurology, Dalhousie University, Halifax, NS;   2Département de médecine, Division de gériatrie, Université Laval, Québec, QC DOI:http://dx.doi.org/10.5770/cgj.19.242COMMENTARIES © 2016 Author(s).",Non-OADS,/arxiv_data1/oa_pdf/74/6d/cgj-19-74.PMC4922371.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial   No-Derivative license (http://creativecommons.org/licenses/by-nc-nd/2.5/ca/), which permits unrestricted non-commercial use and distribution, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/74/6d/cgj-19-74.PMC4922371.pdf
"6, 963 –975 http://dx.doi.org/10.1080/15548627.2016.1164359",Non-OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
"28After background subtraction, CYCS cell-associated signals were quanti ﬁed by manually outlining individual cells and measuring cell-associated ﬂuorescence intensity with the ImageJ software (http://rsb.info.nih.gov/ij/).",OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
"2010; 191:155-68; PMID:20921139; http://dx.doi.org/10.1083/jcb.201002100 [3] He C, Levine B.",Non-OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
"2010; 2:140-9; http://dx.doi.org/10.1016/j.ceb.2010.01.001 [4] Nazio F, Strappazzon F, Antonioli M, Bielli P, Cianfanelli V, Bordi M, Gretzmeier C, Dengjel J, Piacentini M, Fimia GM, et al.",OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
2013; 4:406-16; http://dx.doi.org/10.1038/ncb2708974 F. STRAPPAZZON ET AL.,Non-OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
"2015; 17:20-30; PMID:25438055; http://dx.doi.org/10.1038/ncb3072 [6] Antonioli M, Albiero F, Nazio F, Vescovo T, Perdomo AB, Corazzari M, Marsella C, Piselli P, Greztmeier P, Denjiel J, et al.",OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
"2014; 6:734-46; http://dx.doi.org/10.1016/j.devcel.2014.11.013 [7] Strappazzon F, Vietri-Rudan M, Campello S, Nazio F, Floren- zano F, Fimia GM, Piacentini M, Levine B, Cecconi F. Mito- chondrial BCL-2 inhibits AMBRA1-induced autophagy.",OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
"Embo j.2011; 30:1195-208; PMID:21358617; http://dx.doi.org/10.1038/emboj.2011.49 [8] Strappazzon F, Nazio F, Corrado M, Cianfanelli V, Romagnoli A, Fimia GM, Campello S, Nardacci R, Piacentini M, Campanella M.et al.",Non-OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
"2015; 3:419- 32; http://dx.doi.org/10.1038/cdd.2014.139 [9] Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD, Levine B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy.",OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
"Cell 2005; 122:927-39; PMID:16179260; http://dx.doi.org/10.1016/j.cell.2005.07.002 [10] Chang NC, Nguyen M, Germain M, Shore GC.",OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
"Cell Death Differ 2010; 17:268-277; PMID:19713971; http://dx.doi.org/10.1038/cdd.2009.121 [13] Zhu Y, Zhao L, Liu L, Gao P, Tian W, Wang X, Jin H, Xu H, Chen Q. Beclin 1 cleavage by caspase-3 inactivates autophagy and promotes apoptosis.",Non-OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
"Protein Cell 2010; 1:468-477; PMID:21203962; http://dx.doi.org/10.1007/s13238-010-0048-4 [14] Djavaheri-Mergny M, Maiuri MC, Kroemer G. Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1.",OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
"Oncogene 2010; 12:1717-9; http://dx.doi.org/10.1038/onc.2009.519 [15] Maiuri MC, Criollo A, Kroemer G. Crosstalk between apoptosis and autophagy within the Beclin 1 interactome.",OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
"Embo J 2010; 29:515-6; PMID:20125189; http://dx.doi.org/10.1038/emboj.2009.377 [16] Pyo JO, Jang MH, Kwon YK, Lee HJ, Jun JI, Woo HN, Cho DH, Choi B, Lee H, Kim JH, et al.",OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
"2005; 280:20722-9; PMID:15778222; http://dx.doi.org/10.1074/jbc.M413934200 [17] Youse ﬁS, Perozzo R, Schmid I, Ziemiecki A, Schaffner T, Scapozza L, Brunner T, Simon HU.",OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
"2006; 8:1124-32; PMID:16998475; http://dx.doi.org/10.1038/ncb1482 [18] Zalckvar E, Yosef N, Reef S, Ber Y, Rubinstein AD, Mor I, Sharan R, Ruppin E, Kimchi A.",Non-OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
"2010; 17:1244-53; PMID:20150916;http://dx.doi.org/10.1038/cdd.2010.7 [19] Maskey D, Youse ﬁS, Schmid I, Zlobec I, Perren A, Friis R, Simon HU.",OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
"2013;4:2130; PMID:23945651; http://dx.doi.org/10.1038/ncomms3130 [20] Pagliarini V, Wirawan E, Romagnoli A, Ciccosanti F, Lisi G, Lippens S, Cecconi F, Fimia GM, Vandenabeele P, Corazzari M, et al.",OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
"2012; 9:1495- 504; http://dx.doi.org/10.1038/cdd.2012.27 [21] Rubinstein AD, Eisenstein M, Ber Y, Bialik S, Kimchi A.",Non-OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
"2011; 5:698-709; http://dx.doi.org/10.1016/j.molcel.2011.10.014 [22] Lee JY, Nagano Y, Taylor JP, Lim KL, Yao TP.",OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
"Cell Science at a glance 2015; 11:2003-8; http://dx.doi.org/10.1242/jcs.168153 [24] Malik SA, Shen S, Mari ~no G, BenYoun /C18es A, Maiuri MC, Kroemer G. BH3 mimetics reveal the network properties of autophagy-regulatory signaling cascades.",OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
2011; 8:914-6; http://dx.doi.org/ 10.4161/auto.7.8.15785 [25] Huang Z. Bcl-2 family proteins as targets for anticancer drug design.,Non-OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
Oncogene 19:6627-31; PMID:11426648; http://dx.doi.org/10.1038/sj.,OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
"Curr Drug Targets 2010; 11:699-707;PMID:20298153; http://dx.doi.org/10.2174/138945010791170888 [27] Cianfanelli V, D ’Orazio M, Cecconi F. AMBRA1 and BECLIN 1 interplay in the crosstalk between autophagy and cell proliferation.Cell cycle 2015; 14:959-63; PMID:25803737; http://dx.doi.org/ 10.1080/15384101.2015.1021526 [28] Oddi S, Latini L, Viscomi MT, Bisicchia E, Molinari M, Maccarrone M. Distinct regulation of nNOS and iNOS by CB2 receptor in remotedelayed neurodegeneration.",Non-OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
J Mol Med (Berl) 2012; 90:371-87; PMID:22198001; http://dx.doi.org/10.1007/s00109-011-0846-zAUTOPHAGY 975,Non-OADS,/arxiv_data1/oa_pdf/92/71/kaup-12-06-1164359.PMC4922440.pdf
"6, 999 –1014 http://dx.doi.org/10.1080/15548627.2016.1166318",Non-OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
Nat Rev Mol Cell Biol 2010; 11:872-84; PMID:21102612;http://dx.doi.org/10.1038/nrm3013 [2] Chan DC.,OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
Cell 2006; 125:1241-52; PMID:16814712; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"FASEB J 2012; 26:2175-86; PMID:22321727; http://dx.doi.org/10.1096/fj.11-196543 [4] Jin B, Fu G, Pan H, Cheng X, Zhou L, Lv J, Chen G, Zheng S. Anti- tumour ef ﬁcacy of mitofusin-2 in urinary bladder carcinoma.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Medi- cal oncology 2011; 28 Suppl 1:S373-80; PMID:20803103; http://dx.doi.org/10.1007/s12032-010-9662-5 [5] Zhao J, Zhang J, Yu M, Xie Y, Huang Y, Wolff DW, Abel PW, Tu Y. Mitochondrial dynamics regulates migration and invasion of breast cancer cells.",Non-OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Oncogene 2013; 32:4814-24; PMID:23128392; http://dx.doi.org/10.1038/onc.2012.494 [ 6 ] C h i a n gY Y ,C h e nS L ,H s i a oY T ,H u a n gC H ,L i nT Y ,C h i a n gI P ,H s u WH, Chow KC.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Mod P athol 2009; 22:1139-50; PMID:19525928; http://dx.doi.org/10.1038/modpathol.2009.83 [7] Inoue-Yamauchi A, Oda H. Depletion of mitochondrial ﬁssion factor DRP1 causes increased apoptosis in human colon cancer cells.",Non-OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Bio-chem Biophys Res Commun 2012; 421:81-5; PMID:22487795; http://dx.doi.org/10.1016/j.bbrc.2012.03.118 [8] Singh SB, Ornatowski W, Vergne I, Naylor J, Delgado M, Roberts E, Ponpuak M, Master S, Pilli M, White E, et al.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Nat Cell Biol 2010; 12:1154-65; PMID:21102437; http://dx.doi.org/10.1038/ncb2119 [9] Chang Y, Yan W, He X, Zhang L, Li C, Huang H, Nace G, Geller DA, Lin J, Tsung A. miR-375 inhibits autophagy and reduces viability ofhepatocellular carcinoma cells under hypoxic conditions.",Non-OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Gastroen- terology 2012; 143:177-87e8; PMID:22504094; http://dx.doi.org/ 10.1053/j.gastro.2012.04.009 [10] Hu F, Han J, Zhai B, Ming X, Zhuang L, Liu Y, Pan S, Liu T. Blocking autophagy enhances the apoptosis effect of bufalin on human hepa- tocellular carcinoma cells through endoplasmic reticulum stress andJNK activation.",Non-OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Apoptosis 2014; 19:210-23; PMID:24114361; http://dx.doi.org/10.1007/s10495-013-0914-7 [11] Ikeda Y, Shirakabe A, Maejima Y, Zhai P, Sciarretta S, Toli J, Nomura M, Mihara K, Egashira K, Ohishi M, et al.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Circ Res 2015; 116:264-78; PMID:25332205; http://dx.doi.org/10.1161/CIRCRESAHA.116.303356 [12] Twig G, Elorza A, Molina AJ, Mohamed H, Wikstrom JD, Walzer G, Stiles L, Haigh SE, Katz S, Las G, et al.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"EMBO J 2008; 27:433-46; PMID:18200046; http://dx.doi.org/10.1038/sj.emboj.7601963 [13] Guido C, Whitaker-Menezes D, Lin Z, Pestell RG, Howell A, Zimmers TA, Casimiro MC, Aquila S, Ando ’S, Martinez-Out- schoorn UE, et al.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Oncotarget 2012; 3:798-810; PMID:22878233; http://dx.doi.org/10.18632/oncotarget.574 [14] Clerkin JS, Naughton R, Quiney C, Cotter TG.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
Cancer Lett 2008; 266:30-6; PMID:18372105; http://dx.doi.org/10.1016/j.canlet.,OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
Autophagy 2013; 9:1292-307; PMID:23800749; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Cancer research 2013; 73:6700-10; PMID:24080278; http://dx.doi.org/10.1158/0008-5472.CAN-13-1411 [17] Mazure NM, Pouyssegur J. Hypoxia-induced autophagy: cell death or cell survival?",Non-OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Curr Opin Cell Biol 2010; 22:177-80; PMID: 20022734; http://dx.doi.org/10.1016/j.ceb.2009.11.015 [18] Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
Mol Cell 2010; 40:280-93; PMID:20965422; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Oncogene 2010; 29:2795-806; PMID:20190799; http://dx.doi.org/ 10.1038/onc.2010.46 [20] Webster GA, Perkins ND.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Mol Cell Biol 1999; 19:3485-95; PMID:10207072; http://dx.doi.org/10.1128/MCB.19.5.3485 [21] Dolado I, Nebreda AR.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
Cancer Cell 2008; 14:427-9; PMID:19061832; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
J Hepatol 2014; 61:859-66; PMID:24801417; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Int J Cancer 2009; 125:2863-70; PMID:19609947; http://dx.doi.org/10.1002/ijc.24748 [24] Liesa M, Palacin M, Zorzano A. Mitochondrial dynamics in mamma- lian health and disease.",Non-OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Physiol Rev 2009; 89:799-845; PMID:19584314; http://dx.doi.org/10.1152/physrev.00030.2008 [25] Szabadkai G, Simoni AM, Chami M, Wieckowski MR, Youle RJ, Riz- zuto R. Drp-1-dependent division of the mitochondrial network blocks intraorganellar Ca 2Cwaves and protects against Ca2C-medi- ated apoptosis.",Non-OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Mol Cell 2004; 16:59-68; PMID:15469822; http://dx.doi.org/10.1016/j.molcel.2004.09.026 [26] Qian W, Choi S, Gibson GA, Watkins SC, Bakkenist CJ, Van Houten B. Mitochondrial hyperfu sion induced by loss of the ﬁssion protein Drp1 causes ATM-dependent G2/M arrest and aneuploidy throughDNA replication stress.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"J Cell Sci 2012; 125:5745-57; PMID:23015593; http://dx.doi.org/10.1242/jcs.109769 [27] Shen T, Zheng M, Cao C, Chen C, Tang J, Zhang W, Cheng H, Chen KH, Xiao RP.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"J Biol Chem 2007; 282:23354-61; PMID:17562700; http://dx.doi.org/10.1074/ jbc.M702657200 [28] Legros F, Lombes A, Frachon P, Rojo M. Mitochondrial fusion in human cells is ef ﬁcient, requires the inner membrane potential, and is mediated by mitofusins.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Mol Biol Cell 2002; 13:4343-54; PMID:12475957; http://dx.doi.org/10.1091/mbc.E02-06-0330 [29] Landes T, Martinou JC.",Non-OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Biochim Biophys Acta 2011; 1813:540-5; PMID:21277336; http://dx.doi.org/10.1016/j.bbamcr.2011.01.021 [30] Mao K, Klionsky DJ.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Autophagy 2013; 9:1900-1; PMID:24025250; http://dx.doi.org/10.4161/auto.25804 [31] Dagda RK, Cherra SJ, 3rd, Kulich SM, Tandon A, Park D, Chu CT. Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial ﬁssion.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
J Biol Chem 2009; 284:13843-55; PMID:19279012; http://dx.doi.org/10.1074/jbc.M808515200AUTOPHAGY 1013,OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Antioxid Redox Signal 2011; 14:1939-51;PMID:21128700; http://dx.doi.org/10.1089/ars.2010.3779 [33] Wei Y, Pattingre S, Sinha S, Bassik M, Levine B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy.",Non-OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Mol Cell 2008; 30:678-88; PMID:18570871; http://dx.doi.org/10.1016/j.molcel.2008.06.001 [34] Bodur C, Kutuk O, Tezil T, Basaga H. Inactivation of Bcl-2 through IkappaB kinase (IKK)-dependent phosphorylation medi-ates apoptosis upon exposure to 4-hydroxynonenal (HNE).",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
J CellPhysiol 2012; 227:3556-65; PMID:22262057; http://dx.doi.org/ 10.1002/jcp.24057 [35] Blagosklonny MV.,OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Leukemia 2001; 15:869-74; PMID:11417471; http://dx.doi.org/10.1038/sj.leu.2402134 [36] Ruvolo PP, Deng X, Carr BK, May WS.",Non-OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"J Biol Chem 1998; 273:25436-42;PMID:9738012; http://dx.doi.org/10.1074/jbc.273.39.25436 [37] Tamura Y, Simizu S, Osada H. The phosphorylation status and anti- apoptotic activity of Bcl-2 are regulated by ERK and protein phos-phatase 2A on the mitochondria.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"FEBS Lett 2004; 569:249-55; PMID:15225643; http://dx.doi.org/10.1016/j.febslet.2004.06.003 [38] Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P. Redox regulation of cell survival.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Antioxid Redox Signal 2008; 10:1343-74;PMID:18522489; http://dx.doi.org/10.1089/ars.2007.1957 [39] Scherz-Shouval R, Elazar Z.",Non-OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Trends Biochem Sci 2011; 36:30-8;PMID:20728362; http://dx.doi.org/10.1016/j.tibs.2010.07.007 [40] Yu T, Sheu SS, Robotham JL, Yoon Y. Mitochondrial ﬁssion mediates high glucose-induced cell death through elevated production of reac- tive oxygen species.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
Cardiovasc Res 2008; 79:341-51;PMID:18440987; http://dx.doi.org/10.1093/cvr/cvn104 [41] Perkins ND.,Non-OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Nat Rev Mol Cell Biol 2007; 8:49-62;PMID:17183360; http://dx.doi.org/10.1038/nrm2083 [42] An J, Wang X, Guo P, Zhong Y, Zhang X, Yu Z. Hexabromocyclodo- decane and polychlorinated biphenyls increase resistance of hepato- cellular carcinoma cells to cisplatin through the phosphatidylinositol3-kinase/protein kinase B pathway.",Non-OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Toxicol Lett 2014; 229:265-72;PMID:24960055; http://dx.doi.org/10.1016/j.toxlet.2014.06.025 [43] Factor V, Oliver AL, Panta GR, Thorgeirsson SS, Sonenshein GE, Arsura M. Roles of Akt/PKB and IKK complex in constitutive induc-tion of NF-kappaB in hepatocellular carcinomas of transforminggrowth factor a/c-myc transgenic mice.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Hepatology 2001; 34:32-41; PMID:11431731; http://dx.doi.org/10.1053/jhep.2001.25270 [44] Weisz L, Damalas A, Liontos M, Karakaidos P, Fontemaggi G, Maor- Aloni R, Kalis M, Levrero M, Strano S, Gorgoulis VG, et al.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Cancer Res 2007; 67:2396-401; PMID:17363555; http://dx.doi.org/10.1158/0008-5472.CAN-06-2425 [45] Liu J, Ma Q, Zhang M, Wang X, Zhang D, Li W, Wang F, Wu E. Alterations of TP53 are associated with a poor outcome for patientswith hepatocellular carcinoma: evidence from a systematic reviewand meta-analysis.",Non-OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Eur J Cancer 2012; 48:2328-38; PMID:22459764; http://dx.doi.org/10.1016/j.ejca.2012.03.001 [46] Frebourg T, Barbier N, Kassel J, Ng YS, Romero P, Friend SH.",Non-OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Mol Cell 2008; 29:409-10; PMID:18313377; http://dx.doi.org/10.1016/j.molcel.2008.02.005 [48] Cassidy-Stone A, Chipuk JE, Ingerman E, Song C, Yoo C, Kuwana T, Kurth MJ, Shaw JT, Hinshaw JE, Green DR, et al.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Dev Cell 2008; 14:193-204; PMID:18267088; http://dx.doi.org/10.1016/j.devcel.2007.11.019 [49] Ferrari LF, Chum A, Bogen O, Reichling DB, Levine JD.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"J Neurosci 2011; 31:11404-10; PMID:21813700; http://dx.doi.org/10.1523/JNEUROSCI.2223-11.2011 [50] Brooks C, Wei Q, Cho SG, Dong Z.",Non-OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"J Clin Invest 2009; 119:1275-85; PMID:19349686; http://dx.doi.org/10.1172/JCI37829 [51] Wang J, Hansen K, Edwards R, Van Houten B, Qian W. Mitochon- drial division inhibitor 1 (mdivi-1) enhances death receptor-medi-ated apoptosis in human ovarian cancer cells.",Non-OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
"Biochem Biophys ResCommun 2015; 456:7-12; PMID:25446129; http://dx.doi.org/ 10.1016/j.bbrc.2014.11.010 [52] Qian W, Wang J, Roginskaya V, McDermott LA, Edwards RP, Stolz DB, Llambi F, Green DR, Van Houten B.",OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
Oncotarget 2014; 5:4180-94; PMID:24952704; http://dx.doi.org/10.18632/oncotarget.19441014 Q. HUANG ET AL.,OADS,/arxiv_data1/oa_pdf/f3/61/kaup-12-06-1166318.PMC4922447.pdf
Available at:http://www.ebtox.com/nov2014_wksp/.,Non-OADS,/arxiv_data1/oa_pdf/b4/59/kfw059.PMC4922539.pdf
Available at: http://www.ebtox.com/.,Non-OADS,/arxiv_data1/oa_pdf/b4/59/kfw059.PMC4922539.pdf
Available at: http://www.metaxis.com/EFSAInventory/.,Non-OADS,/arxiv_data1/oa_pdf/b4/59/kfw059.PMC4922539.pdf
Available at:http://ntp.niehs.nih.gov/go/38673.,Non-OADS,/arxiv_data1/oa_pdf/b4/59/kfw059.PMC4922539.pdf
Supporting Publications 2012: EN-367 http://www.efsa.europa.eu/en/sup porting/pub/367e.htm.,Non-OADS,/arxiv_data1/oa_pdf/b4/59/kfw059.PMC4922539.pdf
http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b4/59/kfw059.PMC4922539.pdf
Available at: http://www2.epa.gov/sites/production/ﬁles/2014-06/documents/iris_stoppingrules.pdf.,OADS,/arxiv_data1/oa_pdf/b4/59/kfw059.PMC4922539.pdf
"Background for Advancing Systematic Review Workshop (December 2015).Available at: http://www2.epa.gov/iris/advancing-systematic-review-workshop-december-2015#background.Accessed December 2, 2015.",OADS,/arxiv_data1/oa_pdf/b4/59/kfw059.PMC4922539.pdf
Available at: http://www.epa.gov/iris/systematic-review-workshop-materials.,OADS,/arxiv_data1/oa_pdf/b4/59/kfw059.PMC4922539.pdf
"The measured heightand weight were converted to height-for-age (HAZ), weight-for- age (WAZ), and BMI-for-age z-scores (BAZ; SD scores), using the WHO growth reference for school-aged children and adoles-cents (http://www.who.int/growthref/tools/en/).",OADS,/arxiv_data1/oa_pdf/e9/4b/kfw060.PMC4922540.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/28/82/kfw080.PMC4922544.pdf
"Available at:http://www.inchem.org/documents/ehc/ehc/ehc134.htm Published 1992, Accessed January 24, 2016.",OADS,/arxiv_data1/oa_pdf/28/82/kfw080.PMC4922544.pdf
"Available at: http://apps.who.int/food-additives-contaminants-jecfa-database/chemical.aspx?chemID ¼1376 Published 2010, Accessed January 24, 2016.",OADS,/arxiv_data1/oa_pdf/28/82/kfw080.PMC4922544.pdf
"ZENBU browser website.Available at: http://fantom.gsc.riken.jp/zenbu/gLyphs/ Released February 2016, Accessed March 30, 2016.",Non-OADS,/arxiv_data1/oa_pdf/28/82/kfw080.PMC4922544.pdf
"Available at: http://browser.1000genomes.org/Homo_sapiens/Variation/Population?db ¼core;r ¼16:566419 91-56642991;v ¼rs28366003;vdb ¼variation;vf ¼8729869 Released November 2015, Accessed January 24, 2016.",Non-OADS,/arxiv_data1/oa_pdf/28/82/kfw080.PMC4922544.pdf
"Available at: http://browser.1000genomes.org/Homo_sapiens/Variation/HighLD?db ¼core;r ¼16:56641991- 56642991;v ¼rs28366003;vdb ¼variation;vf ¼8729869#373429_ tablePanel Released November 2015, Accessed January 24, 2016.",Non-OADS,/arxiv_data1/oa_pdf/28/82/kfw080.PMC4922544.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Language mapping High-density grid IntraoperativeElectrocorticographyElectrical cortical stimulationfMRI 1.,Non-OADS,/arxiv_data1/oa_pdf/ea/6c/main.PMC4922734.pdf
http://dx.doi.org/10.1016/j.ebcr.2016.03.003 2213-3232/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/ea/6c/main.PMC4922734.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ea/6c/main.PMC4922734.pdf
We created a three-dimensional patient-speci ﬁc cortical surface brain model by submitting the preoperative high resolution MRI scans to Freesurfer ( http://surfer.nmr.mgh.harvard.edu ).,OADS,/arxiv_data1/oa_pdf/ea/6c/main.PMC4922734.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/54/c4/ceg-9-143.PMC4922744.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/54/c4/ceg-9-143.PMC4922744.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Clinical and Experimental Gastroenterology 2016:9 143–149Clinical and Experimental Gastroenterology Dovepress submit your manuscript | www.dovepress.com Dovepress  143 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CEG.S103485Gastroesophageal reflux disease symptoms in the  Greek general population: prevalence and risk  factors Nikolaos Spantideas1 Eirini Drosou1 Anastasia Bougea2 Dimitrios Assimakopoulos3 1Athens Speech Language and  Swallowing Institute, Glyfada, Athens,   Greece; 2Athens Speech Language and  Swallowing Institute, Agios Dimitrios,  Athens, Greece;  3Department of  Otorhinolaryngology, Medical School of Ioannina University, University Hospital of Ioannina, Ioannina, GreeceBackground and aims:  Population-based data regarding the prevalence of gastroesophageal  reflux disease (GERD) in Greece are very poor.",Non-OADS,/arxiv_data1/oa_pdf/54/c4/ceg-9-143.PMC4922744.pdf
"9Correspondence: Nikolaos Spantideas Athens Speech Language and Swallowing Institute, 10 Lontou Street, Glyfada, Athens 16675, GreeceTel +30 694 452 6007Fax +30 21 0961 4420Email spandideas@gmail.com Journal name: Clinical and Experimental Gastroenterology Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Spantideas et alRunning head recto: Prevalence of GERD symptoms and risk factors in Greek general populationDOI: http://dx.doi.org/10.2147/CEG.S103485",Non-OADS,/arxiv_data1/oa_pdf/54/c4/ceg-9-143.PMC4922744.pdf
"Clinical and Experimental Gastroenterology 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Clinical and Experimental Gastroenterology Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/clinical-and-experimental-gastroenterology-journalClinical and Experimental Gastroenterology is an international, peer- reviewed, open access, online journal publishing original research, reports, editorials, reviews and commentaries on all aspects of   gastroenterology in the clinic and laboratory.",Non-OADS,/arxiv_data1/oa_pdf/54/c4/ceg-9-143.PMC4922744.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 149 Prevalence of GERD symptoms and risk factors in Greek general population 20.,Non-OADS,/arxiv_data1/oa_pdf/54/c4/ceg-9-143.PMC4922744.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/11/89/ccid-9-143.PMC4922745.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/11/89/ccid-9-143.PMC4922745.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Clinical, Cosmetic and Investigational Dermatology 2016:9 143–150Clinical, Cosmetic and Investigational Dermatology Dovepress submit your manuscript | www.dovepress.com Dovepress 143 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CCID.S98633Results from in vitro and ex vivo skin aging models  assessing the antiglycation and anti-elastase   MMP-12 potential of glycylglycine oleamide Patrick Bogdanowicz   Marie-José Haure   Isabelle Ceruti   Sandrine Bessou-T ouya   Nathalie Castex-Rizzi Department of Pharmacology,  Pierre  Fabre Dermo-Cosmétique,   T oulouse,  FranceBackground: Glycation is an aging reaction of naturally occurring sugars with dermal proteins.",Non-OADS,/arxiv_data1/oa_pdf/11/89/ccid-9-143.PMC4922745.pdf
"4,8 In the skin, cell–ECM interactions  influence normal homeostasis, aging, wound healing, and diseases.9Correspondence: Patrick Bogdanowicz   Department of Pharmacology, Pierre  Fabre Dermo-Cosmétique, Avenue Hubert Curien – BP 13562, 31035 Toulouse Cedex 1, France   Tel +33 5 34 50 64 37   Fax +33 5 34 50 34 33   Email patrick.bogdanowicz@pierre-fabre.comJournal name: Clinical, Cosmetic and Investigational Dermatology Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Bogdanowicz et alRunning head recto: Glycylglycine oleamide inhibits glycation and elastase MMP-12DOI: http://dx.doi.org/10.2147/CCID.S98633",Non-OADS,/arxiv_data1/oa_pdf/11/89/ccid-9-143.PMC4922745.pdf
"Clinical, Cosmetic and Investigational Dermatology 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Clinical, Cosmetic and Investigational Dermatology Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal Clinical, Cosmetic and Investigational Dermatology is an interna- tional, peer-reviewed, open access, online journal that focuses on   the latest clinical and experimental research in all aspects of skin   disease and cosmetic interventions.",Non-OADS,/arxiv_data1/oa_pdf/11/89/ccid-9-143.PMC4922745.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authorsDovepress 150 Bogdanowicz et al 23.,Non-OADS,/arxiv_data1/oa_pdf/11/89/ccid-9-143.PMC4922745.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/c0/26/ott-9-3695.PMC4922760.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3695–3704OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3695Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10373 5 risk of venous and arterial thromboembolic events  associated with anti-VegF agents in advanced  non-small-cell lung cancer: a meta-analysis and  systematic review Dianbao Zhang1,* Xianfen Zhang2,* chunling Zhao1 1Department of Medical Oncology,   2Department of cardiac surgery, The  First affiliated hospital of henan  University of science and T echnology,   luoyang, henan Province, People’s  republic of china *These authors contributed equally  to this workAims:  To assess the incidence and risk of arterial and venous thromboembolic events (ATEs  and VTEs) associated with antivascular endothelial growth factor (VEGF) agents, including  VEGF receptor-tyrosine kinase inhibitors and VEGF monoclonal antibodies, in advanced non- small-cell lung cancer (NSCLC) patients.",Non-OADS,/arxiv_data1/oa_pdf/c0/26/ott-9-3695.PMC4922760.pdf
"Until  now, three anti-VEGF agents, including bevacizumab, ramucirumab, and nintedanib,  have been approved by the US Food and Drug Administration (FDA) for the treatment correspondence: Xianfen Zhang Department of cardiac surgery, The First  Affiliated Hospital of Henan University  of science and Technology, number 24,  Jinghua road, luoyang, henan Province  471003, People’s republic of china Tel +86 379 6982 3326 Fax +86 379 6483 0604 email xianfenzhang2015@21cn.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Zhang et al Running head recto: Risk of VTEs and ATEs with anti-VEGF agent in advanced NSCLC DOI: http://dx.doi.org/10.2147/OTT.S103735",Non-OADS,/arxiv_data1/oa_pdf/c0/26/ott-9-3695.PMC4922760.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/c0/26/ott-9-3695.PMC4922760.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/c0/26/ott-9-3695.PMC4922760.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/30/d3/ott-9-3783.PMC4922761.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3783–3789OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3783Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10519 2 Percutaneous microwave ablation combined  with synchronous transcatheter arterial  chemoembolization for the treatment of colorectal  liver metastases: results from a follow-up cohort Zeng-Bao Wu1,* Zeng-Mei si1,* sheng Qian1 ling-Xiao liu1 Xu-Dong Qu1 Bo Zhou1 Wei Zhang1 guang-Zhi Wang2 rong liu1 Jian-hua Wang1 1Department of interventional  radiology, Zhongshan hospital, Fudan  University, shanghai, People’s republic  of china; 2Department of intervention  radiology, Fudan University shanghai  cancer center, shanghai, People’s  republic of china *These authors contributed equally  to this workBackground:  The purpose of this study was to retrospectively evaluate the therapeutic efficacy  and safety of ultrasound-guided percutaneous microwave ablation (MWA) combined with  synchronous transcatheter arterial chemoembolization (TACE) in patients with colorectal liver  metastases (CRLM).",Non-OADS,/arxiv_data1/oa_pdf/30/d3/ott-9-3783.PMC4922761.pdf
"The reported 5-year survival rate after resection is ~40%.3  Unfortunately, only 10%–15% of patients with colorectal liver metastases (CRLM)  are suitable for curative resection at initial diagnosis.4,5 The management of patients correspondence: rong liu;   Jian-hua Wang Department of interventional radiology,  Zhongshan hospital, Fudan University,  180 Fenglin road, Xuhui District,  shanghai 200032, People’s republic  of china Tel/fax +86 21 6404 1990 ext 3088 email shfdzslr@sina.co m;   shfdzswjh@sina.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Wu et al Running head recto: MWA combined with synchronous TACE for CRLM DOI: http://dx.doi.org/10.2147/OTT.S105192",Non-OADS,/arxiv_data1/oa_pdf/30/d3/ott-9-3783.PMC4922761.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/30/d3/ott-9-3783.PMC4922761.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/30/d3/ott-9-3783.PMC4922761.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/1e/aa/ijn-11-2953.PMC4922762.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 2953–2965International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  2953OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S10351 3 robust aptamer–polydopamine-functionalized  M-Plga–TPgs nanoparticles for targeted delivery  of docetaxel and enhanced cervical cancer therapy guojun Xu1–3,* Xinghua Yu2,* Jinxie Zhang1,2,* Yingchao sheng4 gan liu2 Wei Tao1,2 lin Mei1,2 1school of life sciences, Tsinghua  University, Beijing, 2graduate school  at shenzhen, Tsinghua University,   shenzhen, 3school of Materials  science and engineering, Tsinghua  University, Beijing, 4Department  of Orthopedic surgery, changshu  hospital of T cM, changshu, People’s  republic of china *These authors contributed equally  to this workAbstract:  One limitation of current biodegradable polymeric nanoparticles (NPs) is the  contradiction between functional modification and maintaining formerly excellent bioproper - ties with simple procedures.",Non-OADS,/arxiv_data1/oa_pdf/1e/aa/ijn-11-2953.PMC4922762.pdf
"Aptamers can also be combined with ribozymes correspondence: Wei Tao school of life sciences, Tsinghua  University, 30 shuangqing road, Beijing  100084, People’s republic of china Tel/fax +86 010 6277 3411 email taowei@tsinghua.edu.c n Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Xu et al Running head recto: Robust NPs for targeted delivery of docetaxel DOI: http://dx.doi.org/10.2147/IJN.S103513",Non-OADS,/arxiv_data1/oa_pdf/1e/aa/ijn-11-2953.PMC4922762.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/1e/aa/ijn-11-2953.PMC4922762.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/1e/aa/ijn-11-2953.PMC4922762.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/5e/0c/ijn-11-2873.PMC4922763.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 2873–2881International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  2873OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S10386 7controlled release of curcumin from curcumin-loaded  nanomicelles to prevent peritendinous adhesion  during achilles tendon healing in rats Weizhong Zhang1 Xuanyi li2 Mauro comes Franchini3 Ke Xu1 erica locatelli3 robert c Martin2 Ilaria Monaco3 Yan li2 shusen cui1 1Department of hand surgery, china- Japan Union hospital, Jilin University,   changchun, People’s republic of  china; 2Division of surgical Oncology,   Department of surgery, University  of louisville school of Medicine,   louisville, KY, Usa; 3Department  of Industrial chemistry “Toso  Montanari”, University of Bologna,   Bologna, ItalyAbstract:  We introduced curcumin-loaded nanomicelles into a tendon-healing model to evaluate  their effects on tendon healing and adhesion.",Non-OADS,/arxiv_data1/oa_pdf/5e/0c/ijn-11-2873.PMC4922763.pdf
"Anti-fibrotic, anti-inflammatory, and anti-oxidation strategies have been correspondence: shusen cui Department of hand surgery, china- Japan Union hospital, Jilin University,  126 Xiantai st, erdao, changchun, Jilin  130033, People’s republic of china Tel +86 431 8987 6962 email sscui916@126.co m  Yan li Division of surgical Oncology,  Department of surgery, University of  louisville school of Medicine, 511 south  Floyd street, MDr Building room 324,  louisville, KY 40202, Usa Tel +1 502 852 7107 email y an.li@louisville.ed u Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Zhang et al Running head recto: Curcumin-loaded nanomicelles prevent peritendinous adhesion DOI: http://dx.doi.org/10.2147/IJN.S103867",Non-OADS,/arxiv_data1/oa_pdf/5e/0c/ijn-11-2873.PMC4922763.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/5e/0c/ijn-11-2873.PMC4922763.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/5e/0c/ijn-11-2873.PMC4922763.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/c2/4e/copd-11-1403.PMC4922764.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 1403–1411International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1403OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S10798 5 effect of outpatient therapy with inhaled  corticosteroids on decreasing in-hospital  mortality from pneumonia in patients with COPD Yasuhiro Yamauchi1 hideo Yasunaga2 Wakae hasegawa1 Yukiyo sakamoto1 hideyuki Takeshima1 Taisuke Jo1,3 hiroki Matsui2 Kiyohide Fushimi4 Takahide nagase1 1Department of respiratory Medicine,   graduate school of Medicine,   2Department of Clinical epidemiology  and health economics, school of  Public health, 3Division for health  service Promotion, The University of  T okyo, 4Department of health Policy  and Informatics, Tokyo Medical and  Dental University graduate school  of Medicine, T okyo, JapanBackground and objectives:  Inhaled corticosteroids (ICS) and long-acting inhaled  bronchodilators (IBD) are beneficial for the management of COPD.",Non-OADS,/arxiv_data1/oa_pdf/c2/4e/copd-11-1403.PMC4922764.pdf
"Keywords:  inhaled corticosteroids, bronchodilators, in-hospital mortality, pneumonia, COPD Introduction COPD is the third leading cause of death in the world.1 COPD is characterized by  persistent airflow restriction, which is associated with chronic airway inflammation.2  Mainstream treatments for COPD, as recommended by international guidelines,3  are mainly inhaled bronchodilators (IBD), including long-acting β stimulants and  long-acting muscarinic antagonists, to improve respiratory function and reduce  respiratory symptoms,4–6 and inhaled corticosteroids (ICS) to reduce the frequency  of exacerbations and improve the quality of life in patients with severe COPD.5,7,8  However, regular treatment with ICS does not modify the long-term decline of  respiratory functions and mortality in COPD.9,10 Combination therapy with ICS  and IBD is recommended for patients with severe COPD symptoms and frequent  exacerbations.3Correspondence: Yasuhiro Yamauchi Department of respiratory  Medicine, graduate school of  Medicine, The University of Tokyo,  7-3-1, hongo, Bunkyo-ku, Tokyo  113-8655, Japan Tel +81 3 3815 5411 Fax +81 3 3815 5954 email yamauchiy-int@h.u-tokyo.ac,j pJournal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Y amauchi et al Running head recto: Effect of inhaled corticosteroids on mortality from pneumonia in COPD DOI: http://dx.doi.org/10.2147/COPD.S107985",Non-OADS,/arxiv_data1/oa_pdf/c2/4e/copd-11-1403.PMC4922764.pdf
Available from: http://www.who.int/mediacentre/factsheets/fs310/en /.,Non-OADS,/arxiv_data1/oa_pdf/c2/4e/copd-11-1403.PMC4922764.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/c2/4e/copd-11-1403.PMC4922764.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/c2/4e/copd-11-1403.PMC4922764.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/1a/a2/ott-9-3711.PMC4922765.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3711–3726OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3711Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OTT .S10639 9 intrinsic resistance to eGFR tyrosine kinase  inhibitors in advanced non-small-cell lung cancer  with activating eGFR mutations Jun wang Baocheng wang Huili Chu Yunfeng Yao Department of Oncology, General  Hospital, Jinan Command of the  People’s Liberation Army, Jinan,   People’s Republic of ChinaAbstract:  Identifying activating EGFR mutations is a useful predictive strategy that helps select  a population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with EGFR  tyrosine kinase inhibitors (TKIs).",Non-OADS,/arxiv_data1/oa_pdf/1a/a2/ott-9-3711.PMC4922765.pdf
"Several large Phase III clinical trials have demonstrated that  patients with a sensitizing exon 19 deletion or an exon 21 substitution mutation are  highly responsive to first-generation EGFR TKIs, such as gefitinib and erlotinib,  compared to traditional platinum-based doublet chemotherapy, with a prolonged time Correspondence: Jun wang Department of Oncology, General  Hospital, Jinan Command of the People’s  Liberation Army, Shifan Street 25,   Tianqiao District, Jinan 250031,  People’s Republic of China Tel +86 531 5166 5337 Fax +86 531 5166 6649 email ggjun2005@126.co m Journal name: OncoTargets and Therapy Article Designation: Review Y ear: 2016 Volume: 9 Running head verso: Wang et al Running head recto: EGFR TKI intrinsic resistance in NSCLC DOI: http://dx.doi.org/10.2147/OTT.S106399",Non-OADS,/arxiv_data1/oa_pdf/1a/a2/ott-9-3711.PMC4922765.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/1a/a2/ott-9-3711.PMC4922765.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/1a/a2/ott-9-3711.PMC4922765.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/3a/1e/ijn-11-2967.PMC4922766.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 2967–2978International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  2967OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S10646 7 Chemically cross-linked silk fibroin hydrogel  with enhanced elastic properties, biodegradability,  and biocompatibility Min hee Kim Won ho Park Department of Advanced Organic  Materials and T extile Engineering  System, Chungnam National  University, Daejeon, KoreaAbstract:  In this study, the synthesis of silk fibroin (SF) hydrogel via chemical cross-linking  reactions of SF due to gamma-ray ( γ-ray) irradiation was investigated, as were the resultant  hydrogel’s properties.",Non-OADS,/arxiv_data1/oa_pdf/3a/1e/ijn-11-2967.PMC4922766.pdf
"The formation of thermodynamically correspondence: Won ho Park Department of Advanced Organic  Materials and Textile Engineering  System, Chungnam National University,  Daejeon 305-764, Korea Tel +82 42 821 6613 Fax +82 42 823 3736 email parkwh@cnu.ac.k r Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Kim and Park Running head recto: Chemically cross-linked silk fibroin hydrogel DOI: http://dx.doi.org/10.2147/IJN.S106467",Non-OADS,/arxiv_data1/oa_pdf/3a/1e/ijn-11-2967.PMC4922766.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/3a/1e/ijn-11-2967.PMC4922766.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/3a/1e/ijn-11-2967.PMC4922766.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/df/eb/copd-11-1367.PMC4922767.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 1367–1379International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1367RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/COPD.S10539 4 Association between TNF- α -308 G/A  polymorphism and COPD susceptibility:   a meta-analysis update Lu Zhang1 Hao Gu2 Yihang Gu2 Xiaoning Zeng2 1Clinical Research Centre,   2Department of Respiratory &  Critical Care Medicine, The First  Affiliated Hospital of Nanjing  Medical  University, Nanjing, People’s  Republic of ChinaBackground and objective:  The association between TNF- α -308 G/A polymorphism and  COPD remains controversial due to insufficiently strict study designs and small group sizes  among different studies.",Non-OADS,/arxiv_data1/oa_pdf/df/eb/copd-11-1367.PMC4922767.pdf
"However, only 25%–40% of cigarette  smokers develop COPD,4 indicating that other components may be involved in COPD  development.5–7Correspondence: Xiaoning Zeng Department of Respiratory & Critical  Care Medicine, The First Affiliated  Hospital of Nanjing Medical University,  300 Guangzhou Road, Nanjing 210029,  Jiangsu, People’s Republic of China Tel +86 25 6813 6804 Fax +86 25 8367 3567 email zeng_xiao_ning@hotmail.co m Journal name: International Journal of COPD Article Designation: Review Y ear: 2016 Volume: 11 Running head verso: Zhang et al Running head recto: TNF- α -308 G/A polymorphism and COPD susceptibility DOI: http://dx.doi.org/10.2147/COPD.S105394",Non-OADS,/arxiv_data1/oa_pdf/df/eb/copd-11-1367.PMC4922767.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/df/eb/copd-11-1367.PMC4922767.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/df/eb/copd-11-1367.PMC4922767.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/27/08/ott-9-3763.PMC4922768.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3763–3770OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3763Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10290 9 In vitro-activated tumor-specific T lymphocytes  prolong the survival of patients with advanced  gastric cancer: a retrospective cohort study Jun Kuai1 Fang Yang1 guang-Jun li2 Xiang-Jie Fang3 Bao-Qin gao2 1Department of gastroenterology,   2First Department of general surgery,   3second Department of general  surgery, First affiliated hospital of  Xin-Xiang Medical University, henan,   People’s republic of chinaBackground:  Conventional tumor managements have limited survival benefits and cause  severely impaired immune function in patients with advanced gastric cancer (GC) whereas  immunotherapies could restore antitumor immunity.",Non-OADS,/arxiv_data1/oa_pdf/27/08/ott-9-3763.PMC4922768.pdf
"Various immunocytes are used for immunotherapy in cancer, such as dendritic cell  (DC)-based vaccine, natural killer cells, and cytokine-induced killer cells.6–11 Many  studies have tested the efficacy of adoptive transfer of these immune cells in animal  models and in the clinic; however, efficacy is limited for solid cancer owing to tumor  specific lacking of immune cells.12 Therefore, development of a more tumor-specific correspondence: Fang Yang Department of gastroenterology, First  Affiliated Hospital of Xin-Xiang Medical  University, 88 Jiankang road, Weihui,  henan 463000, People’s republic  of china Tel/fax +86 373 440 2120 email yangf880@sina.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Kuai et al Running head recto: T lymphocytes benefit survival of advanced gastric cancer DOI: http://dx.doi.org/10.2147/OTT.S102909",Non-OADS,/arxiv_data1/oa_pdf/27/08/ott-9-3763.PMC4922768.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/27/08/ott-9-3763.PMC4922768.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/27/08/ott-9-3763.PMC4922768.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/2f/e9/ndt-12-1507.PMC4922769.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 1507–1515Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1507OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S11097 8 effect of adjuvant sleep hygiene psychoeducation  and lorazepam on depression and sleep quality in  patients with major depressive disorders: results  from a randomized three-arm intervention alireza rahimi1 Mohammad ahmadpanah1 Farshid shamsaei1 Fatemeh cheraghi2 Dena sadeghi Bahmani3 edith holsboer-Trachsler3 serge Brand3,4 1Behavioral Disorders and substances  abuses research center, hamadan  University of Medial sciences,   hamadan, 2research center for  chronic Disease care at home,   hamadan University of Medial  sciences, hamadan, iran; 3Psychiatric  clinics of the University of Basel,   center for affective, stress and sleep  Disorders (Zass), 4Department of  sport, exercise, and health, Division  of sport and Psychosocial health,   University of Basel, Basel, switzerlandBackground:  Sleep disturbances are a common co-occurring disturbance in patients with major  depressive disorders (MDDs) and accordingly deserve particular attention.",Non-OADS,/arxiv_data1/oa_pdf/2f/e9/ndt-12-1507.PMC4922769.pdf
"Indeed, research investigating  associations between sleep and affective illness has largely focused on depression  and major depressive disorder (MDD).7–10 In this regard, epidemiological data indicate that people with psychiatric disorders  account for 30%–40% of those in the community reporting symptoms of insomnia.11 correspondence: serge Brand center for affective, stress and  sleep Disorders, Psychiatric clinics  of the University of Basel, Wilhelm  Klein-strasse 27, 4012 Basel, switzerland Tel +41 61 32 55 114 Fax +41 61 32 55 513 email serge.brand@upkbs.c h Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Rahimi et al Running head recto: Effect of adjuvant sleep hygiene psychoeducation and lorazepam DOI: http://dx.doi.org/10.2147/NDT.S110978",Non-OADS,/arxiv_data1/oa_pdf/2f/e9/ndt-12-1507.PMC4922769.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/2f/e9/ndt-12-1507.PMC4922769.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/2f/e9/ndt-12-1507.PMC4922769.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/70/ab/ndt-12-1499.PMC4922770.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2016:12 1499–1506Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1499OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S8632 9a door-to-door survey to estimate the prevalence  of Parkinsonism in Pakistan suliman Khan1 ghulam Nabi2 Muhammad Naeem3 liaqat ali4 Peter a silburn1,5 george D Mellick1 1clinical Neuroscience group, eskitis  institute for Drug Discovery, griffith  University, Nathan, QlD, australia;   2Department of animal sciences,   3Department of Biotechnology,   Quaid-i-azam University, islamabad,   4saidu Medical college, saidu sharif  swat Khyber Pakhtunkhwa, Pakistan;   5The University of Queensland centre  for clinical research, Brisbane, QlD,   australiaIntroduction:  Parkinson’s disease (PD) occurs in all races and cultures, and population-related  differences in frequency may provide etiological clues.",Non-OADS,/arxiv_data1/oa_pdf/70/ab/ndt-12-1499.PMC4922770.pdf
"Highly consanguineous populations, such as the Pakistani  population, may exhibit nearly twice the risk of inherited disorders (autosomal recessive) correspondence: george D Mellick clinical Neuroscience group, eskitis  Institute for Drug Discovery, Griffith  University, 46 Don Young road, Nathan,  QlD 4111, australia Tel +61 7 3735 5019 Fax +61 7 3735 4255 email g.mellick@griffith.edu.a u Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Khan et al Running head recto: Prevalence of Parkinsonism in Pakistan DOI: http://dx.doi.org/10.2147/NDT.S86329",Non-OADS,/arxiv_data1/oa_pdf/70/ab/ndt-12-1499.PMC4922770.pdf
Available from: http://kpbos.gov.pk / 8.,Non-OADS,/arxiv_data1/oa_pdf/70/ab/ndt-12-1499.PMC4922770.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/70/ab/ndt-12-1499.PMC4922770.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/70/ab/ndt-12-1499.PMC4922770.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/df/66/mder-9-151.PMC4922771.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/df/66/mder-9-151.PMC4922771.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Medical Devices: Evidence and Research 2016:9 151–160Medical Devices: Evidence and Research Dovepress submit your manuscript | www.dovepress.com Dovepress 151 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/MDER.S91201 Fractional exhaled nitric oxide-measuring devices:  technology update Mauro Maniscalco1  Carolina Vitale2  Alessandro Vatrella2  Antonio Molino3  Andrea Bianco4  Gennaro Mazzarella4 1Unit of Respiratory Diseases,   Hospital “S Maria della Pietà” of  Casoria, Naples, 2Unit of Respiratory  Medicine, Department of Medicine and Surgery, University of Salerno,  Salerno,  3Department of Respiratory  Medicine, University Federico II,   4Department of Cardiothoracic  and Respiratory Sciences, Second,  University of Naples, Naples, ItalyAbstract: The measurement of exhaled nitric oxide (NO) has been employed in the diagnosis of  specific types of airway inflammation, guiding treatment monitoring by predicting and assessing  response to anti-inflammatory therapy and monitoring for compliance and detecting relapse.",Non-OADS,/arxiv_data1/oa_pdf/df/66/mder-9-151.PMC4922771.pdf
"To date,  several techniques have been developed, such as chemiluminescence, electrochemical sensors, and laser-based technology (Figure 1), all of which present advantages and disadvantages in a clinical setting (Table 1).Correspondence: Mauro Maniscalco   Unit of Respiratory Diseases, Hospital “S  Maria della Pietà” of Casoria, Largo delle Mimose 1, 80131 Naples, Italy   Tel +39 338 177 9679   Fax +39 81 741 1457   Email mauromaniscalco@hotmail.comJournal name: Medical Devices: Evidence and Research Article Designation: REVIEWY ear: 2016V olume: 9Running head verso: Maniscalco et alRunning head recto: Nitric oxide devices and technology updateDOI: http://dx.doi.org/10.2147/MDER.S91201",Non-OADS,/arxiv_data1/oa_pdf/df/66/mder-9-151.PMC4922771.pdf
"Medical Devices: Evidence and Research 2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Medical Devices: Evidence and Research Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/medical-devices-evidence-and-research-journalMedical Devices: Evidence and Research is an international, peer- reviewed, open access journal that focuses on the evidence, technology, research, and expert opinion supporting the use and application of   medical devices in the diagnosis, monitoring, treatment and management of clinical conditions and physiological processes.",Non-OADS,/arxiv_data1/oa_pdf/df/66/mder-9-151.PMC4922771.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/cc/d9/ijn-11-2921.PMC4922772.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 2921–2933International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  2921OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S10756 9 cyclosporine a micellar delivery system for dry  eyes han Kang1,2 Kwang-ho cha1 Wonkyung cho1 Junsung Park1 hee Jun Park1 Bo Kyung sun1,2 sang-Min hyun1,2 sung-Joo hwang1,2 1Yonsei Institute of Pharmaceutical  sciences, 2college of Pharmacy, Y onsei  University, Incheon, south KoreaBackground:  The objectives of this study were to develop stable cyclosporine A (CsA)  ophthalmic micelle solutions for dry-eye syndrome and evaluate their physicochemical properties  and therapeutic efficacy.",Non-OADS,/arxiv_data1/oa_pdf/cc/d9/ijn-11-2921.PMC4922772.pdf
kr Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Kang et al Running head recto: Novel micellar cyclosporine A for dry-eye syndrome DOI: http://dx.doi.org/10.2147/IJN.S107569,Non-OADS,/arxiv_data1/oa_pdf/cc/d9/ijn-11-2921.PMC4922772.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/cc/d9/ijn-11-2921.PMC4922772.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/cc/d9/ijn-11-2921.PMC4922772.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/4f/b2/ndt-12-1525.PMC4922773.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 1525–1538Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1525Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/NDT .S8458 5 Aggression in autism spectrum disorder:  presentation and treatment options Sarah e Fitzpatrick Laura Srivorakiat Logan K wink ernest v Pedapati Craig A erickson Cincinnati Children’s Hospital Medical  Center, University of Cincinnati  College of Medicine, Cincinnati,   OH, USAAbstract:  Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by  persistent difficulties in social communication and social interaction, coupled with restricted,  repetitive patterns of behavior or interest.",Non-OADS,/arxiv_data1/oa_pdf/4f/b2/ndt-12-1525.PMC4922773.pdf
"In response, researchers Correspondence: Craig A erickson Cincinnati Children’s Hospital Medical  Center, University of Cincinnati College  of Medicine, 3333 Burnet Avenue,  Cincinnati, OH 45229-3026, USA Tel +1 513 636 6265 Fax +1 513 636 3800 email craig.erickson@cchmc.or g Journal name: Neuropsychiatric Disease and Treatment Article Designation: Review Y ear: 2016 Volume: 12 Running head verso: Fitzpatrick et al Running head recto: Treatment of aggression in ASD DOI: http://dx.doi.org/10.2147/NDT.S84585",Non-OADS,/arxiv_data1/oa_pdf/4f/b2/ndt-12-1525.PMC4922773.pdf
Available from:  http://www.centerwatch.com/drug-information/fda-approved-drugs/ year/200 9.,Non-OADS,/arxiv_data1/oa_pdf/4f/b2/ndt-12-1525.PMC4922773.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/4f/b2/ndt-12-1525.PMC4922773.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/4f/b2/ndt-12-1525.PMC4922773.pdf
"Available from: http://www.cdc.gov/ncbddd/ autism/data.htm l. Accessed April 26, 2016.",OADS,/arxiv_data1/oa_pdf/4f/b2/ndt-12-1525.PMC4922773.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/fb/27/ott-9-3727.PMC4922774.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3727–3737OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3727Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10315 9 association of polymorphisms in interleukin-8  gene with cancer risk: a meta-analysis of   22 case–control studies Meng Zhang1–3,* Tingting Fang1–3,* Kai Wang1–3,* hongbing Mei3 Zhaojie lv3 Feng Wang3 Zhiming cai3 chaozhao liang1,2 1Department of Urology, The First  affiliated hospital of anhui Medical  University, 2institute of Urology,   anhui Medical University, hefei, anhui,   3Department of Urology, shenzhen  second People’s hospital, The First  affiliated hospital of shenzhen  University, shenzhen, guangdong,   People’s republic of china *These authors contributed equally  to this workAbstract:  Interleukin-8 (IL-8) is a kind of chemokine that plays an important role in the  development and progression of many human malignancies.",Non-OADS,/arxiv_data1/oa_pdf/fb/27/ott-9-3727.PMC4922774.pdf
"The interleukin production is regulated by the polymorphisms of cytokine genes  in promoter regions.13 Thus, IL-8 is located on chromosome 4q13-21 and contains  three introns, four exons, and a proximal promoter region.14 Five polymorphisms in  IL-8, +781C/T (rs2227306), +678T/C, 276A/T (rs1126647), +1633C/T, and +396G/T  (rs2227307), have been extensively studied.15 The +781C/T polymorphism is situ - ated in an intron and acts as an important factor in the process of gene transcription  and regulation.16 The +678T/C polymorphism is associated with Behcet’s disease correspondence: chaozhao liang Department of Urology, The First  Affiliated Hospital of Anhui Medical  University, Meishan road 81, shushan  District, hefei, anhui Province 230032,  People’s republic of china  Tel +86 551 6292 3861 email liang_chaozhao@163.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Zhang et al Running head recto: Association of polymorphisms in IL-8 gene with cancer risk DOI: http://dx.doi.org/10.2147/OTT.S103159",Non-OADS,/arxiv_data1/oa_pdf/fb/27/ott-9-3727.PMC4922774.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/fb/27/ott-9-3727.PMC4922774.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/fb/27/ott-9-3727.PMC4922774.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).The treatment of type 2 diabetes in the presence  of renal impairment: what we should know about  newer therapies Melanie Davies1,2 Sudesna Chatterjee1,2 Kamlesh Khunti1,2 1Diabetes Research Centre, University  of Leicester, 2Leicester Diabetes  Centre, University Hospitals of  Leicester NHS Trust, Leicester, UK Correspondence: Melanie Davies   Leicester Diabetes Centre, University  Hospitals of Leicester NHS Trust,  Gwendolen Road, Leicester LE5 4PW, UK   T el +44 116 258 6481   Email melanie.davies@uhl-tr.nhs.u kAbstract:  Worldwide, an estimated 200 million people have chronic kidney disease (CKD), the  most common causes of which include hypertension, arteriosclerosis, and diabetes.",Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Or use: http://youtu.be/oLoPH5WOp6 w,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.org.uk/emc/medicine/423 6.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.org.uk/ emc/medicine/104 3.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.org.uk/emc/medicine/   9851.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.org.uk/ emc/medicine/3041 1.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.org.uk/emc/medicine/   2776 2.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.org.uk/emc/ medicine/2581 3.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.org.uk/ emc/medicine/1898 0.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.org.uk/emc/ medicine/2550 6.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.org.uk/ emc/medicine/1458 4.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.org.uk/ emc/medicine/2736 0.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.org.uk/emc/  medicine/2647 6.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.org.uk/ emc/medicine/859 1.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.org.uk/emc/medicine/2782 9.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: http://guidance.nice.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: http://www.accessdata.fda.gov/drugsatfda_docs/ label/2015/021332s025lbl.pd f. Accessed February 2016.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: http://www.accessdata.fda.gov/drugsatfda_docs/ label/2016/020866s009lbl.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.org.uk/emc/medicine/   30586.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
2015; Available from: https://www.medicines.org.uk/ emc/medicine/22315.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.org.uk/emc/ medicine/28513.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.org.uk/ emc/medicine/19257.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.org.uk/ emc/medicine/24665.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.org.uk/emc/ medicine/27405.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.org.uk/ emc/medicine/21986.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Forxiga (dapagliflozin) Summary of Product  Characteristics; 2014 Available from: https://www.medicines.org.uk/ emc/medicine/27188.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.org.uk/ emc/medicine/28400.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://www.medicines.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://clinicaltrials.gov/ct2/show/ NCT02150707?term =NCT02150707&rank =1.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://clinicaltrials.gov/ct2/ show/NCT01897532?term =NCT01897532&rank =1.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://clinicaltrials.gov/ ct2/show/record/NCT0179251 8.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://clinicaltrials.gov/ct2/show/NCT01903070?,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Avail - able from: https://clinicaltrials.gov/ct2/show/NCT01377935?term =  Comparison +of+Risk +of+Hospitalization +for+Acute +Kidney +  Injury +Between +Patients +With +Type +2+Diabetes +Initiating +  Saxagliptin&rank =1.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available  from: https://clinicaltrials.gov/ct2/show/NCT0225143 1.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://clinicaltrials.gov/ct2/show/ NCT0227619 6.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://clinicaltrials.gov/ct2/show/NCT01847313?,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://clinicaltrials.gov/ct2/ show/NCT02413398?term =Study +to+Evaluate +the+Effect +of+  Dapagliflozin +on+Blood +Glucose +Level +and+Renal +Safety + in+Patients +With +Type +2+Diabetes&rank =1.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from:  https://clinicaltrials.gov/ct2/show/record/NCT0198975 4.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Available from: https://clinicaltrials.gov/ct2/show/ NCT01867307?term =Effect +of+Empagliflozin +Kinetics +on+Renal +  Glucose +Reabsorption +in+Patients +With +Type +II+Diabetes +and+  Healthy +Controls&rank =1.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
"Clinical Pharmacology: Advances and Applications Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-pharmacology-advances-and-applications-journa lClinical Pharmacology: Advances and Applications is an international,  peer-reviewed, open access journal publishing original research, reports,  reviews and commentaries on all areas of drug experience in humans.",Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/8a/42/cpaa-8-061.PMC4922775.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/da/03/ndt-12-1435.PMC4922776.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 1435–1444Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1435OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S10551 3 Deep brain stimulation of pallidal versus  subthalamic for patients with Parkinson’s disease:  a meta-analysis of controlled clinical trials Fan Xu1 Wenbin Ma2 Y ongmin huang1 Zhihai Qiu1 lei sun1 1interdisciplinary Division of  Biomedical engineering, The hong  Kong Polytechnic University, hung  hom, hong Kong sar, People’s  republic of china; 2Department  of Neurology, Binzhou Medical  University hospital, Binzhou,   shandong, People’s republic of chinaBackground:  Parkinson’s disease (PD) is a common neurodegenerative disorder that affects  many people every year.",Non-OADS,/arxiv_data1/oa_pdf/da/03/ndt-12-1435.PMC4922776.pdf
"As for treatment correspondence: lei sun interdisciplinary Division of Biomedical  engineering, The hong Kong Polytechnic  University, hung hom 999077, hong  Kong sar, People’s republic of china Tel +852 2766 7663 email htsunlei@polyu.edu.h k Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Xu et al Running head recto: Deep brain stimulation for patients with PD DOI: http://dx.doi.org/10.2147/NDT.S105513",Non-OADS,/arxiv_data1/oa_pdf/da/03/ndt-12-1435.PMC4922776.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/da/03/ndt-12-1435.PMC4922776.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/da/03/ndt-12-1435.PMC4922776.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/3c/95/opth-10-1153.PMC4922777.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 1153–1159Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1153Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S10730 5 Toric intraocular lenses for correction of   astigmatism in keratoconus and after  corneal surgery Correspondence: ilse eMa Mol Department of Ophthalmology, erasmus  Medical Center, gravendijkwal 230,  3015 Ce rotterdam, the netherlands Tel +31 10 704 0135 Fax +31 10 703 3692 email i.mol@erasmusmc.n l ilse eMa Mol1,2 Bart Th Van Dooren1,2 1Department of Ophthalmology,   amphia hospital, Breda, 2Department  of Ophthalmology, erasmus Medical  Center, rotterdam, the netherlandsPurpose:  To describe the results of cataract extraction with toric intraocular lens (IOL)  implantation in patients with preexisting astigmatism from three corneal conditions (keratoconus,  postkeratoplasty, and postpterygium surgery).",Non-OADS,/arxiv_data1/oa_pdf/3c/95/opth-10-1153.PMC4922777.pdf
"Furthermore, irregular astigmatism seems to be  a relative contraindication for toric IOL implantation.7 We performed this study to evaluate the visual and refractive outcomes of toric  IOL implantation in cataract patients with topographically stable, although sometimes Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Mol and Van Dooren Running head recto: Toric intraocular lenses for corneal astigmatism correction DOI: http://dx.doi.org/10.2147/OPTH.S107305",Non-OADS,/arxiv_data1/oa_pdf/3c/95/opth-10-1153.PMC4922777.pdf
Available  from: http://amoeasy.com/cal c  16.,Non-OADS,/arxiv_data1/oa_pdf/3c/95/opth-10-1153.PMC4922777.pdf
Available  from: http://www.zeiss.com/iolmaster-onlin e 17.,Non-OADS,/arxiv_data1/oa_pdf/3c/95/opth-10-1153.PMC4922777.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/3c/95/opth-10-1153.PMC4922777.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/3c/95/opth-10-1153.PMC4922777.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/40/c1/vhrm-12-279.PMC4922778.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/40/c1/vhrm-12-279.PMC4922778.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Vascular Health and Risk Management  2016:12 279–286Vascular Health and Risk Management Dovepress submit your manuscript | www.dovepress.com Dovepress  279 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/VHRM.S107874Association between perceived lifetime risk of  cardiovascular disease and calculated risk in a  male population in Brazil Mário Maciel de Lima Jr1,2  Glaciane Rocha da Silva3  Sebastião Salazar Jensem  Filho2  Fabiana Granja3 1Department of Urology, Coronel  Mota Hospital, Roraima, 2Cathedral  College, 3Biodiversity Research  Center, Federal University of Roraima  (CBio/UFRR), Roraima, BrazilAim: Cardiovascular disease is the major cause of morbidity and mortality across the world.",Non-OADS,/arxiv_data1/oa_pdf/40/c1/vhrm-12-279.PMC4922778.pdf
"3,4 Given that a number of  these factors, such as smoking and high cholesterol, are modifiable, these have become Correspondence: Mário Maciel de Lima Jr   Rua Levindo Inácio de Oliveira, 1547  Bairro Paraviana, Boa Vista, Roraima, Brazil Tel +55 95 99123 0778   Fax +55 95 3623 0174   Email mmljr@uol.com.brJournal name: Vascular Health and Risk Management  Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 12Running head verso: de Lima Jr et alRunning head recto: Risk of cardiovascular diseaseDOI: http://dx.doi.org/10.2147/VHRM.S107874",Non-OADS,/arxiv_data1/oa_pdf/40/c1/vhrm-12-279.PMC4922778.pdf
Available from: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf.,Non-OADS,/arxiv_data1/oa_pdf/40/c1/vhrm-12-279.PMC4922778.pdf
"Vascular Health and Risk Management  2016:12submit your manuscript | www.dovepress.com Dovepress Dovepress Vascular Health and Risk Management  Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/vascular-health-and-risk-management-journal Vascular Health and Risk Management is an international, peer- reviewed journal of therapeutics and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes.",Non-OADS,/arxiv_data1/oa_pdf/40/c1/vhrm-12-279.PMC4922778.pdf
Visit http://www.dovepress.com/   testimonials.php to read real quotes from published authors.Dovepress 286 de Lima Jr et al,Non-OADS,/arxiv_data1/oa_pdf/40/c1/vhrm-12-279.PMC4922778.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/8d/05/ppa-10-1121.PMC4922779.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Patient Preference and Adherence 2016:10 1121–1129Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1121OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S10875 7 Persistence and compliance with newly initiated  antihypertensive drug treatment in patients with  chronic kidney disease Viet Thanh Truong1,2 Jocelyne Moisan1,2 edeltraut Kröger1–3 serge langlois4 Jean-Pierre grégoire1,2 1Faculty of Pharmacy, laval University,   2chair on Adherence to Treatments,   Population health and Optimal  Practices in health research Unit,   chU de Québec research center,   3center of excellence on Aging of  Québec, 4Faculty of Medicine, laval  University, Quebec, canadaBackground:  Patients with chronic kidney disease initiating an antihypertensive drug (AH)  treatment must persist and comply with it to slow disease progression and benefit from the  reduction of cardiovascular morbidity and mortality.",Non-OADS,/arxiv_data1/oa_pdf/8d/05/ppa-10-1121.PMC4922779.pdf
"Good adherence to AH treatment has  been associated with a lower risk of acute cardiovascular events,4 a reduction in the  risk of chronic heart failure events5 and end-stage renal disease,5,6 and with lower  health care costs.7correspondence: Jean-Pierre grégoire chair on Adherence to Treatments,  Population health and Optimal Practices  in health research Unit, chU de  Québec research center, 1050 chemin  sainte-Foy, Québec, canada g1s 4l8 Tel +1 418 682 7511 ext 84664 Fax +1 418 682 7949 email jean-pierre.gregoire@pha.ulaval.c a Journal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Truong et al Running head recto: Antihypertensive drug treatment persistence and compliance DOI: http://dx.doi.org/10.2147/PPA.S108757",Non-OADS,/arxiv_data1/oa_pdf/8d/05/ppa-10-1121.PMC4922779.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/8d/05/ppa-10-1121.PMC4922779.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/a0/82/ndt-12-1477.PMC4922780.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 1477–1487Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1477OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S10627 0 comparison of treatment outcomes in severe  personality disorder patients with or without  substance use disorders: a 36-month prospective  pragmatic follow-up study Fernando lana1–3 carmen sánchez-gil1–3 Núria D adroher4,5 Víctor Pérez1–4 guillem Feixas6 Josep Martí-Bonany1–3 Marta T orrens1–4 1institute of Neuropsychiatry and  addictions ( iNaD), centre emili  Mira and hospital del Mar, Parc de  salut Mar, Barcelona, spain; 2Mental  health research Networking  center (ciBersaM), Madrid,   spain; 3Department of Psychiatry,   autonomous University of Barcelona,   Barcelona, spain; 4iMiM (hospital  del Mar Medical research institute),   Barcelona, spain; 5Public health and  epidemiology research Networking  center (ciBeresP), Madrid, spain;   6Department of clinical Psychology  and Psychobiology, Faculty of  Psychology, University of Barcelona,   Barcelona, spainBackground:  Concurrent personality disorder (PD) and substance use disorder (SUD) are  common in clinical practice.",Non-OADS,/arxiv_data1/oa_pdf/a0/82/ndt-12-1477.PMC4922780.pdf
"Conversely, among individuals  in the general population with PD, ~7%–16% are believed to have concurrent SUD.1 correspondence: Fernando lana institute of Neuropsychiatry and  addictions (iNaD), emili Mira center,  Parc de salut Mar de Barcelona, c/Prat de  la riba, 171 santa coloma de gramenet,  Barcelona es-08921, spain Tel +34 93 462 8900 Fax +34 93 468 3742 email 25018@parcdesalutmar.ca t Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Lana et al Running head recto: Comparison of treatment outcomes in personality disorders DOI: http://dx.doi.org/10.2147/NDT.S106270",Non-OADS,/arxiv_data1/oa_pdf/a0/82/ndt-12-1477.PMC4922780.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/a0/82/ndt-12-1477.PMC4922780.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/a0/82/ndt-12-1477.PMC4922780.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/6e/28/ott-9-3791.PMC4922781.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3791–3797OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3791Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S9770 2Prognostic significance of metastatic lymph node  ratio in squamous cell carcinoma of the cervix chen li1 Wenhui liu2 Yufeng Cheng1 1Department of Radiation Oncology,   QiLu Hospital of Shandong University,   2School of Public Health, Shandong  University, Jinan, Shandong, People’s  Republic of ChinaPurpose:  Metastatic lymph node ratio (MLNR) was reported to be an important prognostic  factor in several tumors.",Non-OADS,/arxiv_data1/oa_pdf/6e/28/ott-9-3791.PMC4922781.pdf
"It has been reported that cervical cancer patients with meta - static lymph nodes, compared to node-negative patients, have worse prognosis after  operation.4 In addition, cervical cancer staging clinically depends on the International Correspondence: Yufeng Cheng Department of Radiation Oncology,  QiLu Hospital of Shandong University,  107 West Wenhua Road, Jinan 250012,  Shandong, People’s Republic of China email qlcyfsdu@163.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Li et al Running head recto: Prognostic significance of MLNR in SCC DOI: http://dx.doi.org/10.2147/OTT.S97702",Non-OADS,/arxiv_data1/oa_pdf/6e/28/ott-9-3791.PMC4922781.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/6e/28/ott-9-3791.PMC4922781.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/6e/28/ott-9-3791.PMC4922781.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/8a/32/copd-11-1335.PMC4922782.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 1335–1341International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1335OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S10551 6 Chronic bronchitis is an independently associated  factor for more symptom and high-risk groups Joon Y oung Choi,1 hyoung  Kyu Y oon,2 seoung Ju Park,3  Y ong Bum Park,4 Kyeong- Cheol shin,5 Ju Ock na,6  Kwang ha Y oo,7 Ki-suck  Jung,8 Y oung Kyoon Kim,1  Chin Kook rhee1 1Division of Pulmonary, allergy and  Critical Care Medicine, Department  of Internal Medicine, seoul st Mary’s  hospital, 2Division of Pulmonary and  Critical Care Medicine, Department of  Internal Medicine, Yeouido st Mary’s  hospital, College of Medicine, The  Catholic University of Korea, seoul,   3Division of Pulmonary, allergy, and  Critical Care Medicine, Department of  Internal Medicine, Chonbuk national  University Medical school, Jeonju,   4Division of Pulmonary, allergy, and  Critical Care Medicine, Department of  Internal Medicine, hallym University  Kangdong sacred heart hospital, seoul,   5regional Center for respiratory  Disease, Yeungnam University Medical  Center, Yeungnam University College of  Medicine, Daegu, 6Division of Pulmonary  and Critical Care Medicine, Department  of Internal Medicine, soonchunhyang  University Cheonan hospital, Cheonan,   7Division of Pulmonary, allergy and  Critical Care Medicine, Department of  Internal Medicine, Konkuk University  school of Medicine, seoul, 8Division of  Pulmonary, allergy and Critical Care  Medicine, Department of Internal  Medicine, hallym University Medical  Center, hallym University College of  Medicine, anyang, republic of KoreaBackground:  The chronic bronchitis (CB) phenotype has been associated with poor quality of  life and an increased risk of disease in patients with COPD.",Non-OADS,/arxiv_data1/oa_pdf/8a/32/copd-11-1335.PMC4922782.pdf
"However, most  individuals have both characteristics.2,9 The definition of CB has been variable but it  is classically defined as the presence of a chronic cough and sputum for 3 months per  year over a duration of 2 consecutive years.10,11 The prevalence of CB is reported to Correspondence: Young Kyoon Kim;  Chin Kook rhee Division of Pulmonary, allergy and Critical  Care Medicine, Department of Internal  Medicine, seoul st Mary’s hospital, College  of Medicine, The Catholic University of  Korea, 222 Banpodaero, seochogu, seoul  06591, republic of Korea Tel +82 2 2258 6059; +82 2 2258 6067 Fax +82 2 599 3589; +82 2 599 3589 email youngkim@catholic.ac.k r;   chinkook@catholic.ac.k rJournal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Choi et al Running head recto: CB is poor prognostic factor DOI: http://dx.doi.org/10.2147/COPD.S105516",Non-OADS,/arxiv_data1/oa_pdf/8a/32/copd-11-1335.PMC4922782.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/8a/32/copd-11-1335.PMC4922782.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/8a/32/copd-11-1335.PMC4922782.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/43/08/ppa-10-1131.PMC4922783.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Patient Preference and Adherence 2016:10 1131–1150Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1131Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S10392 7 Prevalence and severity of pain in adult end-stage  renal disease patients on chronic intermittent  hemodialysis: a systematic review T onci Brkovic1 eliana Burilovic2 Livia Puljak3 1Department of internal Medicine,   Division of Nephrology, 2Department  of Psychiatry, University Hospital Split,   3Department of Anatomy, Histology  and embryology, Laboratory for Pain  Research, University of Split School of  Medicine, Split, CroatiaObjectives:  Understanding the epidemiology of pain in patients on hemodialysis (HD) is  crucial for further improvement in managing pain.",Non-OADS,/arxiv_data1/oa_pdf/43/08/ppa-10-1131.PMC4922783.pdf
"ESRD is defined as loss of renal function requiring renal replacement therapy  with any form of chronic dialysis or transplantation or occasionally conservative Correspondence: Livia Puljak Laboratory for Pain Research,  University of Split School of Medicine,  Šoltanska 2, 21000 Split, Croatia Tel +385 21 557 807 Fax +385 21 557 811 email livia@mefst.h r Journal name: Patient Preference and Adherence Article Designation: Review Y ear: 2016 Volume: 10 Running head verso: Brkovic et al Running head recto: Pain in hemodialysis DOI: http://dx.doi.org/10.2147/PPA.S103927",Non-OADS,/arxiv_data1/oa_pdf/43/08/ppa-10-1131.PMC4922783.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/43/08/ppa-10-1131.PMC4922783.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/72/f1/ott-9-3753.PMC4922784.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3753–3762OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3753Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10655 7 small interfering rna targeting s100a4 sensitizes  non-small-cell lung cancer cells (a549) to  radiation treatment ruixue Qi  Tiankui Qiao  Xibing Zhuang Department of Oncology, affiliated  Jinshan hospital, Fudan University,   shanghai, People’s republic of china Objective:  This study aimed to investigate the impact of S100A4-small interfering RNA  (S100A4-siRNA) on apoptosis and enhanced radiosensitivity in non-small-cell lung cancer  (A549) cells.",Non-OADS,/arxiv_data1/oa_pdf/72/f1/ott-9-3753.PMC4922784.pdf
"Hence, enhancing the radiosensitivity of  resistant tumor cells is a common strategy in the clinical application of radiotherapy.5correspondence: Tiankui Qiao  Department of Oncology, Affiliated  Jinshan hospital, Fudan University,  longhang road 1508, Jinshan District,  shanghai, People’s republic of china Tel +86 189 3077 8786 email qiaotk@163.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Qi et al Running head recto: siRNA sensitizes NSCLC cells to radiation treatment DOI: http://dx.doi.org/10.2147/OTT.S106557",Non-OADS,/arxiv_data1/oa_pdf/72/f1/ott-9-3753.PMC4922784.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/72/f1/ott-9-3753.PMC4922784.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/72/f1/ott-9-3753.PMC4922784.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/0e/35/ott-9-3671.PMC4922786.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3671–3681OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3671Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S9843 5 radiological response and survival in locally  advanced non-small-cell lung cancer patients  treated with three-drug induction chemotherapy  followed by radical local treatment laura Bonanno,1 giulia  Zago,1 giuseppe Marulli,2  Paola Del Bianco,3 Marco  schiavon,2 giulia Pasello,1  Valentina Polo,1,4 Fabio  canova,1 Fabrizio T onetto,5  lucio loreggian,5 Federico  rea,2 PierFranco conte,1,4  adolfo Favaretto1 1Medical Oncology Unit 2, Veneto  institute of Oncology iOV-irccs,   2Thoracic surgery Department,   University of Padova, 3clinical  Trials and Biostatistics Unit, Veneto  institute of Oncology iOV-irccs,   4Department of surgery, Oncology  and gastroenterology, University of  Padova, 5radiotherapy Unit, Veneto  institute of Oncology iOV-irccs,   Padova, italyObjectives:  If concurrent chemoradiotherapy cannot be performed, induction chemotherapy  followed by radical-intent surgical treatment is an acceptable option for non primarily resectable  non-small-cell lung cancers (NSCLCs).",Non-OADS,/arxiv_data1/oa_pdf/0e/35/ott-9-3671.PMC4922786.pdf
"The term refers to a heterogeneous group of nonprimar - ily resectable tumors due to local invasion of vital structure or the degree of nodal  involvement.1 In recent years, no major improvement in the outcome of locally advanced correspondence: laura Bonanno Medical Oncology Unit 2, istituto  Oncologico Veneto irccs, Via  gattamelata 64, 35128 Padova, italy  Tel +39 049 821 5931 Fax +39 049 821 5932 email laura.bonanno@ioveneto.i t Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Bonanno et al Running head recto: Multimodality treatment in the management of stage III NSCLC DOI: http://dx.doi.org/10.2147/OTT.S98435",Non-OADS,/arxiv_data1/oa_pdf/0e/35/ott-9-3671.PMC4922786.pdf
Available from: https://www.nccn.org/professionals/physician_gls/   f_guidelines .asp.,Non-OADS,/arxiv_data1/oa_pdf/0e/35/ott-9-3671.PMC4922786.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/0e/35/ott-9-3671.PMC4922786.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/0e/35/ott-9-3671.PMC4922786.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/32/90/opth-10-1161.PMC4922787.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 1161–1165Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1161Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S10759 4 T welve-month outcomes in patients with retinal  vein occlusion treated with low-frequency  intravitreal ranibizumab Y oshihito sakanishi ami lee ayumi Usui-Ouchi rei ito nobuyuki ebihara Department of Ophthalmology,   Juntendo University Urayasu hospital,   Urayasu City, Chiba, JapanPurpose:  The purpose of this study was to determine the clinical efficacy of low-frequency  intravitreal ranibizumab to treat macular edema due to retinal vein occlusion (RVO).",Non-OADS,/arxiv_data1/oa_pdf/32/90/opth-10-1161.PMC4922787.pdf
"We used one injection and pro re nata (PRN), instead of Correspondence: Yoshihito sakanishi Department of Ophthalmology,  Juntendo University Urayasu hospital,  2-1-1 Tomioka, Urayasu City, Chiba,  279-0021 Japan Tel +81 47 353 3111 email yossy1950@hotmail.co m Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Sakanishi et al Running head recto: Ranibizumab for RVO DOI: http://dx.doi.org/10.2147/OPTH.S107594",Non-OADS,/arxiv_data1/oa_pdf/32/90/opth-10-1161.PMC4922787.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/32/90/opth-10-1161.PMC4922787.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/32/90/opth-10-1161.PMC4922787.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/e5/4d/dddt-10-2041.PMC4922788.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 2041–2046Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  2041Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S10615 3 Fondaparinux vs warfarin for the treatment  of unsuspected pulmonary embolism in cancer  patients Bruno amato1,2,* rita compagna1,2,* aldo rocca2 T ommaso Bianco2 Marco Milone2 luigi sivero2 gabriele Vigliotti2 Maurizio amato2 Michele Danzi2 giovanni aprea2 luca gallelli3,* stefano de Franciscis1,4,* raffaele serra1,4,* 1interuniversity center of  Phlebolymphology, international  research and educational Program  in clinical and experimental  Biotechnology, University Magna  graecia of catanzaro, Viale europa,   catanzaro, 2Department of clinical  Medicine and surgery, University  of naples “Federico ii”, naples,   3Department of health sciences,   4Department of Medical and surgical  sciences, University of catanzaro,   catanzaro, italy *These authors contributed equally  to this workIntroduction:  In cancer patients, the chest computer tomography (CT) can be used to identify  asymptomatic pulmonary embolism (APE).",Non-OADS,/arxiv_data1/oa_pdf/e5/4d/dddt-10-2041.PMC4922788.pdf
"In these patients, the detection of unsuspected pulmonary embolism  (UPE) related to asymptomatic pulmonary embolism (APE) has become increasingly  common,3,4 with an increase in health cost.5,6 In most cases, these patients are treated with anticoagulant drugs (eg, warfarin)  for at least 3 months, since the American College of Chest Physicians recommends  to consider these patients as patients with symptomatic PE.7correspondence: raffaele serra Department of Medical and surgical  sciences, University of catanzaro,   Viale europa, catanzaro 88100, italy Tel +39 961 364 7380 email rserra@unicz.i t Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Amato et al Running head recto: Fondaparinux vs warfarin in UPE DOI: http://dx.doi.org/10.2147/DDDT.S106153",Non-OADS,/arxiv_data1/oa_pdf/e5/4d/dddt-10-2041.PMC4922788.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/e5/4d/dddt-10-2041.PMC4922788.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/e5/4d/dddt-10-2041.PMC4922788.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p  and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/da/74/imcrj-9-155.PMC4922789.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Upper eyelid granuloma: a rare delayed-onset  complication secondary to cosmetic filler  injection on forehead Shu-I Pao1 Shih-Min Lin1,2 Yun-Hsiang Chang1 Shang-Yi Chiang1 1Department of Ophthalmology, Tri- Service General Hospital, National  Defense Medical Center, Taipei,   2Department of Ophthalmology,   Kaohsiung Armed Forces General  Hospital, Kaohsiung Correspondence: Shang-Yi Chiang   Department of Ophthalmology,   Tri-Service General Hospital, National  Defense Medical Center   325/2, Cheng Gong Rd, Taipei 114,   Taipei, Taiwan   T el +886 2 8792 7163   Fax +886 2 8792 7164   Email csy2001@gmail.co mAbstract:  A 72-year-old Taiwanese woman had the history of cosmetic cryopreserved   autologous fat injection on her forehead ∼21 years ago and was referred to our oculoplastic  clinic and presented with multiple painless mass, which she had for 4 years, on both upper  eyelids.",Non-OADS,/arxiv_data1/oa_pdf/da/74/imcrj-9-155.PMC4922789.pdf
"International Medical Case Reports Journal Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-medical-case-reports-journal-journa lThe International Medical Case Reports Journal is an international,  peer-reviewed open-access journal publishing original case reports  from all medical specialties.",Non-OADS,/arxiv_data1/oa_pdf/da/74/imcrj-9-155.PMC4922789.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/da/74/imcrj-9-155.PMC4922789.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/11/ac/cia-11-777.PMC4922790.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2016:11 777–786Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  777ORIGINAL RESEARCHopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S10550 5 Efficacies of globus pallidus stimulation and  subthalamic nucleus stimulation for advanced  Parkinson’s disease: a meta-analysis of randomized  controlled trials Zhi-Gang Tan Qian Zhou Tao Huang Yugang Jiang Department of Neurosurgery, The  Second Xiangya Hospital of Central  South University, Changsha, Hunan,   People’s Republic of ChinaObjectives:  Deep brain stimulation (DBS) is the surgical procedure for patients with advanced  Parkinson’s disease.",Non-OADS,/arxiv_data1/oa_pdf/11/ac/cia-11-777.PMC4922790.pdf
"Keywords:  advanced Parkinson’s disease, deep brain stimulation, globus pallidus internus,  subthalamic nucleusCorrespondence: Yugang Jiang Department of Neurosurgery, The  Second Xiangya Hospital of Central South  University, 139, Renming RD, Changsha,  Hunan 410011, People’s Republic  of China Tel +86 731 8529 5810 Fax +86 731 8553 3525 Email csu0018@126.co m Journal name: Clinical Interventions in Aging Article Designation: ORIGINAL RESEARCH Y ear: 2016 Volume: 11 Running head verso: Tan et al Running head recto: A general comparison of GPi DBS and STN DBS DOI: http://dx.doi.org/10.2147/CIA.S105505",Non-OADS,/arxiv_data1/oa_pdf/11/ac/cia-11-777.PMC4922790.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/11/ac/cia-11-777.PMC4922790.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/11/ac/cia-11-777.PMC4922790.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/40/f6/ijn-11-2935.PMC4922791.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 2935–2952International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  2935RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJN.S10238 5 A comparison of immunotoxic effects of  nanomedicinal products with regulatory  immunotoxicity testing requirements Christina Giannakou1,2 Margriet vDZ Park1 wim H de Jong1 Henk van Loveren1,2 Rob J vandebriel1 Robert e Geertsma1 1Centre for Health Protection,   National Institute for Public  Health  and the environment (RIvM),   Bilthoven, 2Department of  T oxicogenomics, Maastricht University,   Maastricht, the Netherlands Abstract:  Nanomaterials (NMs) are attractive for biomedical and pharmaceutical applications  because of their unique physicochemical and biological properties.",Non-OADS,/arxiv_data1/oa_pdf/40/f6/ijn-11-2935.PMC4922791.pdf
"Expectations for the benefits of these so-called nanomedicinal products  (NMPs) are high.3,4 NMPs can have a great impact in health care, including a reduction Correspondence: Christina Giannakou Centre for Health Protection,  National Institute for Public Health  and environment (RIvM), PO Box 1,  3720 BA, Bilthoven, the Netherlands Tel +31 30 274 4172 email christina.giannakou@rivm.n l Journal name: International Journal of Nanomedicine Article Designation: Review Y ear: 2016 Volume: 11 Running head verso: Giannakou et al Running head recto: NMPs: immunotoxic effects and regulatory testing requirements DOI: http://dx.doi.org/10.2147/IJN.S102385",Non-OADS,/arxiv_data1/oa_pdf/40/f6/ijn-11-2935.PMC4922791.pdf
Available  from: http://www.esf.org /.,Non-OADS,/arxiv_data1/oa_pdf/40/f6/ijn-11-2935.PMC4922791.pdf
"Available from: http://www.nano.gov/ nanotech-101/nanotechnology-fact s. Accessed October 20, 2015.",OADS,/arxiv_data1/oa_pdf/40/f6/ijn-11-2935.PMC4922791.pdf
Available from: http://www.ema.europa.eu/ema/index.,Non-OADS,/arxiv_data1/oa_pdf/40/f6/ijn-11-2935.PMC4922791.pdf
"Available  from: http://www.hc-sc.gc.ca/sr-sr/pubs/nano/pol-eng.ph p. Accessed  October 20, 2015.",Non-OADS,/arxiv_data1/oa_pdf/40/f6/ijn-11-2935.PMC4922791.pdf
Available  from: http://www.ambisome.com.,Non-OADS,/arxiv_data1/oa_pdf/40/f6/ijn-11-2935.PMC4922791.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/40/f6/ijn-11-2935.PMC4922791.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/40/f6/ijn-11-2935.PMC4922791.pdf
Available from:  http://www.ema.europa.eu/ema/index.jsp?curl =pages/regulation/ general/general_content_000564.jsp&mid =WC0b01ac05806403e 0.,Non-OADS,/arxiv_data1/oa_pdf/40/f6/ijn-11-2935.PMC4922791.pdf
Available from: http://ncl.cancer.gov /.,Non-OADS,/arxiv_data1/oa_pdf/40/f6/ijn-11-2935.PMC4922791.pdf
Available from: http://www.marina-fp7.eu /.,Non-OADS,/arxiv_data1/oa_pdf/40/f6/ijn-11-2935.PMC4922791.pdf
"Available  from: http://www.nanosafetycluster.eu/eu-nanosafety-cluster-projects/ seventh-framework-programme-projects/nanommune.htm l. Accessed  April 12, 2016.",Non-OADS,/arxiv_data1/oa_pdf/40/f6/ijn-11-2935.PMC4922791.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/53/c8/opth-10-1145.PMC4922796.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 1145–1151Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1145Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S10208 2long-term follow-up of vitrectomy, with or without  360° encircling buckle, for rhegmatogenous retinal  detachment due to inferior retinal breaks hamouda hamdy  ghoraba1,2 adel galal Zaky3 amin Faisal ellakwa3 1Ophthalmology Department,   Faculty of Medicine, Tanta University,   Tanta, 2Opthalmology Department,   el Magrabi eye hospital, Tanta,   3Ophthalmology Department, Faculty  of Medicine, Menoufia University,   Cairo, egyptObjective:  The aim of this study was to report and compare the anatomic and functional results  of primary vitrectomy with and without 360 ° encircling scleral buckle (SB) for the treatment of  rhegmatogenous retinal detachment (RRD) due to inferior retinal break(s).",Non-OADS,/arxiv_data1/oa_pdf/53/c8/opth-10-1145.PMC4922796.pdf
"However,   a significant number of vitreoretinal surgeons seem to be moving away from straight Correspondence: amin Faisal ellakwa  Ophthalmology Department, Faculty of  Medicine, Menoufia University, Yasen  abd al ghafar street from gamal abd  al naser, 32511, Cairo, egypt Tel +20 48 226 3959 email ellakwa@yahoo.co m Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Ghoraba et al Running head recto: Vitrectomy with or without scleral buckle DOI: http://dx.doi.org/10.2147/OPTH.S102082",Non-OADS,/arxiv_data1/oa_pdf/53/c8/opth-10-1145.PMC4922796.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/53/c8/opth-10-1145.PMC4922796.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/53/c8/opth-10-1145.PMC4922796.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/e1/92/ndt-12-1489.PMC4922799.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 1489–1497Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1489OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S10976 8 effects of perpetrator identity on suicidality  and nonsuicidal self-injury in sexually victimized  female adolescents gulsen Unlu Burcu cakaloz Department of child and adolescent  Psychiatry, Faculty of Medicine,   Pamukkale University, Denizli, T urkeyPurpose:  Child sexual abuse and sexual dating violence victimization are common problems  that are known to have long-term negative consequences.",Non-OADS,/arxiv_data1/oa_pdf/e1/92/ndt-12-1489.PMC4922799.pdf
"Sexual contact between a teenager and a younger  child can also be abusive if there is a significant incongruity in age, development,  or size.1 A meta-analysis research exhibited an estimated prevalence of child sexual abuse  (CSA) of 8%–31% for girls and 3%–17% for boys.2 Although sexual abuse is reported to correspondence: gulsen Unlu Department of child and adolescent  Psychiatry, Faculty of Medicine,  Pamukkale University, University street,  20070, Kinikli, Denizli, Turkey Tel +90 258 296 6000 ext 4519 Fax +90 258 296 6001 email gulsenu@pau.edu.t r Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Unlu and Cakaloz Running head recto: Sexual abuse and perpetrator identity DOI: http://dx.doi.org/10.2147/NDT.S109768",Non-OADS,/arxiv_data1/oa_pdf/e1/92/ndt-12-1489.PMC4922799.pdf
Available from: http://c.ymcdn.com/sites/www.,Non-OADS,/arxiv_data1/oa_pdf/e1/92/ndt-12-1489.PMC4922799.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/e1/92/ndt-12-1489.PMC4922799.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/e1/92/ndt-12-1489.PMC4922799.pdf
"Available  from: http://www.mevzuat.gov.tr/MevzuatMetin/1.5.5237.pd f.  Accessed March 31, 2016.",Non-OADS,/arxiv_data1/oa_pdf/e1/92/ndt-12-1489.PMC4922799.pdf
"Available from: http://www.tuik.gov.tr/ ilGostergeleri/iller/DENIZLI.pd f. Accessed March 31, 2016.",Non-OADS,/arxiv_data1/oa_pdf/e1/92/ndt-12-1489.PMC4922799.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/0c/cc/dddt-10-2015.PMC4922801.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 2015–2020Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  2015Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/DDDT .S10464 2 Position and enforcement practice of the People’s  Republic of China’s pharmaceutical data  exclusivity protection Na Li1 Xiang Yu2 Michael Pecht3 1School of Law, Ningbo University,   Ningbo, People’s Republic of China;   2School of Law and Politics, Ningbo  institute of T echnology, Zhejiang  University, Ningbo, People’s Republic  of China; 3Center for Advanced Life  Cycle engineering, University of  Maryland, College Park, MD, USAAbstract:  The concept of pharmaceutical data exclusivity protection comes from the West.",Non-OADS,/arxiv_data1/oa_pdf/0c/cc/dddt-10-2015.PMC4922801.pdf
"Those pharmaceutical companies who owned drugs pat - ents, when applying for the marketing approval, could also request the government  to protect their pharmaceutical experimental data.5 During this period, unauthorized Correspondence: Xiang Yu School of Law and Politics, Ningbo  institute of Technology, Zhejiang  University, 1 Xuefu Rd, Yinzhou, Ningbo  315100, People’s Republic of China email nityuxiang@126.co mJournal name: Drug Design, Development and Therapy Article Designation: Review Y ear: 2016 Volume: 10 Running head verso: Li et al Running head recto: People’s Republic of China’s pharmaceutical data exclusivity protection DOI: http://dx.doi.org/10.2147/DDDT.S104642",Non-OADS,/arxiv_data1/oa_pdf/0c/cc/dddt-10-2015.PMC4922801.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/0c/cc/dddt-10-2015.PMC4922801.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/0c/cc/dddt-10-2015.PMC4922801.pdf
"Available from: http://omaha.sanofi.com/ Images/22810_20F_2010.pd f. Accessed June 30, 2015.",Non-OADS,/arxiv_data1/oa_pdf/0c/cc/dddt-10-2015.PMC4922801.pdf
"Available from: http://www.schiffhardin.com/Templates/Media/ files/publications/PDF/ohly-Hatch_Waxman_Prescriptions-42010.pd f.  Accessed June 30, 2015.",Non-OADS,/arxiv_data1/oa_pdf/0c/cc/dddt-10-2015.PMC4922801.pdf
Available  from: http://hdl.handle.net/1807/3229 6.,Non-OADS,/arxiv_data1/oa_pdf/0c/cc/dddt-10-2015.PMC4922801.pdf
Avail - able from SSRN: http://ssrn.com/abstract =93426 9.,Non-OADS,/arxiv_data1/oa_pdf/0c/cc/dddt-10-2015.PMC4922801.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/c0/95/ndt-12-1517.PMC4922802.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 1517–1523Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1517OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S10691 5 Monitoring intracranial pressure utilizing a novel  pattern of brain multiparameters in the treatment  of severe traumatic brain injury hong-tao sun1,* Maohua Zheng2,* Yanmin Wang1 Yunfeng Diao1 Wanyong Zhao1 Zhengjun Wei1 1sixth Department of Neurosurgery,   affiliated hospital of logistics  University of People’s armed Police  Force, Tianjin, 2Department of  Neurosurgery, The First hospital of  lanzhou University, lanzhou, People’s  republic of china *These authors contributed equally  to this workAbstract:  The aim of the study was to evaluate the clinical value of multiple brain parameters  on monitoring intracranial pressure (ICP) procedures in the therapy of severe traumatic brain  injury (sTBI) utilizing mild hypothermia treatment (MHT) alone or a combination strategy with  other therapeutic techniques.",Non-OADS,/arxiv_data1/oa_pdf/c0/95/ndt-12-1517.PMC4922802.pdf
"Cerebral  monitoring parameters mainly include ICP, CPP, transcranial Doppler, brain tissue partial correspondence: hong-tao sun sixth Department of Neurosurgery,  Affiliated Hospital of Logistics University  of People’s armed Police Force,  220 chenglin road, hedong District,  Tianjin 300162, People’s republic  of china Tel/fax +86 22 6057 7142 email sunhongtao2016@163.co m Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Sun et al Running head recto: Monitoring intracranial pressure using multiparameters for sTBI DOI: http://dx.doi.org/10.2147/NDT.S106915",Non-OADS,/arxiv_data1/oa_pdf/c0/95/ndt-12-1517.PMC4922802.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/c0/95/ndt-12-1517.PMC4922802.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/c0/95/ndt-12-1517.PMC4922802.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/89/fa/ott-9-3739.PMC4922803.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3739–3752OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3739Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OTT .S8677 4 The evolution of combined molecular targeted  therapies to advance the therapeutic efficacy  in melanoma: a highlight of vemurafenib and  cobimetinib Theresa M Medina Karl D Lewis Cutaneous Oncology Program,   Division of Medical Oncology, School  of Medicine, University of Colorado –  Anschutz Medical Campus, Aurora,   CO, USAAbstract:  Metastatic melanoma is an aggressive, rapidly progressive disease which historically  had very few effective treatment options.",Non-OADS,/arxiv_data1/oa_pdf/89/fa/ott-9-3739.PMC4922803.pdf
"This is in part due to the increased understanding of the pathogenesis of mela - noma, especially with the discovery that the MAPK pathway is the key signaling pathway Correspondence: Theresa M Medina;  Karl D Lewis Cutaneous Oncology Program, Division  of Medical Oncology, School of Medicine,  University of Colorado – Anschutz  Medical Campus, 12801 east 17th  Avenue, Mail Stop 8117, Aurora,   CO 80045, USA Tel +1 720 848 2480; +1 720 848 0584 email theresa.medina@ucdenver.ed u;  karl.lewis@ucdenver.ed u Journal name: OncoTargets and Therapy Article Designation: Review Y ear: 2016 Volume: 9 Running head verso: Medina and Lewis Running head recto: Evolution of combined molecular targeted therapies DOI: http://dx.doi.org/10.2147/OTT.S86774",Non-OADS,/arxiv_data1/oa_pdf/89/fa/ott-9-3739.PMC4922803.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/89/fa/ott-9-3739.PMC4922803.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/89/fa/ott-9-3739.PMC4922803.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/d1/85/copd-11-1359.PMC4922805.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 1359–1365International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1359OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S10567 1 Vitamin D should be supplemented more actively  in elderly patients with coronary heart disease  combined with COPD ling Zhang1 Qiao-ying Yuan2 1Department of Out-patient  Clinic, 2Department of nutriology,   southwest hospital, The Third Military  Medical University, Chongqing,   People’s republic of ChinaObjective:  It is not clear whether vitamin D should be actively supplemented in elderly patients  suffering from an acute attack of COPD (AECOPD) and coronary heart disease (CHD).",Non-OADS,/arxiv_data1/oa_pdf/d1/85/copd-11-1359.PMC4922805.pdf
"However, researchers also found that taking large doses Correspondence: Qiao-ying Yuan Department of nutriology, southwest  hospital, The Third Military Medical  University, gao Tan Yan street, sha Ping  Ba District, Chongqing 400038, People’s  republic of China Tel/fax +86 23 6875 4340 email yuanqiao7843@163.co mJournal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Zhang and Yuan Running head recto: Vitamin D supplementation in elderly patients with COPD DOI: http://dx.doi.org/10.2147/COPD.S105671",Non-OADS,/arxiv_data1/oa_pdf/d1/85/copd-11-1359.PMC4922805.pdf
Available from:  http://www.goldcopd.org /.,Non-OADS,/arxiv_data1/oa_pdf/d1/85/copd-11-1359.PMC4922805.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/d1/85/copd-11-1359.PMC4922805.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/85/copd-11-1359.PMC4922805.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/d0/81/cpaa-8-051.PMC4922806.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",OADS,/arxiv_data1/oa_pdf/d0/81/cpaa-8-051.PMC4922806.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).A randomized, double-blind, placebo-, and  positive-controlled clinical pilot study to evaluate  the efficacy and tolerability of standardized  aqueous extracts of Terminalia chebula  and  Terminalia bellerica  in subjects with hyperuricemia Pingali Usharani1 Chandrasekhar Nutalapati1 Venkata Kishan Pokuri1 Chiranjeevi Uday Kumar1 Gangadhar Taduri2 1Department of Clinical Pharmacology  and Therapeutics, 2Department  of Nephrology, Nizam’s Institute  of Medical Sciences, Panjagutta,   Hyderabad, India Correspondence: P Usharani   Department of Clinical Pharmacology and  Therapeutics, Nizam’s Institute of Medical  Sciences, Panjagutta, Hyderabad 500082,  India  T el +91 40 2348 9211   Email ushapingali@yahoo.co mObjectives:  To evaluate the efficacy and tolerability of standardized aqueous extracts of   Terminalia chebula  and Terminalia bellerica  versus febuxostat and placebo on reduction in  serum uric acid levels in subjects with hyperuricemia.",Non-OADS,/arxiv_data1/oa_pdf/d0/81/cpaa-8-051.PMC4922806.pdf
"Clinical Pharmacology: Advances and Applications Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-pharmacology-advances-and-applications-journa lClinical Pharmacology: Advances and Applications is an international,  peer-reviewed, open access journal publishing original research, reports,  reviews and commentaries on all areas of drug experience in humans.",Non-OADS,/arxiv_data1/oa_pdf/d0/81/cpaa-8-051.PMC4922806.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d0/81/cpaa-8-051.PMC4922806.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/80/1a/ijwh-8-213.PMC4922807.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Women’s Health 2016:8 213–223International Journal of Women’s Health Dove press submit your manuscript | www.dovepress.co m Dove press  213RevIeWopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJWH.S8281 6Contralateral prophylactic mastectomy: current  perspectives Katharine Yao1 Mark Sisco2 Isabelle Bedrosian3 1Division of Surgical Oncology,   Department of Surgery, 2Division  of Plastic Surgery, Department of  Surgery, NorthShore University  HealthSystem, evanston, IL,   3Department of Surgery, MD  Anderson Cancer Center,   Houston,  TX, USAAbstract:  There has been an increasing trend in the use of contralateral prophylactic mastectomy  (CPM) in the United States among women diagnosed with unilateral breast cancer, particularly  young women.",Non-OADS,/arxiv_data1/oa_pdf/80/1a/ijwh-8-213.PMC4922807.pdf
"Additionally, physicians  are now ordering more preoperative diagnostic tests and consultations to provide Correspondence: Katharine Yao Division of Surgical Oncology,  Department of Surgery, NorthShore  University HealthSystem, 2650 Ridge  Avenue, evanston, IL 60201, USA Tel +1 847 570 1327 Fax +1 847 570 3695 email kyao@northshore.or g Journal name: International Journal of Women’s Health Article Designation: Review Y ear: 2016 Volume: 8 Running head verso: Y ao et al Running head recto: Current perspectives for CPM DOI: http://dx.doi.org/10.2147/IJWH.S82816",Non-OADS,/arxiv_data1/oa_pdf/80/1a/ijwh-8-213.PMC4922807.pdf
"International Journal of Women’s Health Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-womens-health-journa lThe International Journal of Women’s Health is an international, peer- reviewed open-access journal publishing original research, reports,  editorials, reviews and commentaries on all aspects of women’s  healthcare including gynecology, obstetrics, and breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/80/1a/ijwh-8-213.PMC4922807.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/80/1a/ijwh-8-213.PMC4922807.pdf
Available from: http://www.nccn.org/ professionals /physician_gls/f_guidelines.asp#sit e. Accessed 2015.,Non-OADS,/arxiv_data1/oa_pdf/80/1a/ijwh-8-213.PMC4922807.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/a7/d2/dddt-10-2029.PMC4922808.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2016:10 2029–2039Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  2029Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S10818 5 enhanced oral bioavailability of acetylpuerarin by  poly(lactide- co-glycolide) nanoparticles optimized  using uniform design combined with response  surface methodology Deqing sun1,2 aiying Xue3 Bin Zhang1 Xia Xue1 Jie Zhang1 Wenjie liu1 1Department of Pharmacy, the second  hospital of shandong University,   Jinan, People’s republic of china;   2school of Pharmaceutical sciences,   shandong University, Jinan, People’s  republic of china; 3Department of  cardiology, the second hospital of  shandong University, Jinan, People’s  republic of chinaAbstract:  Acetylpuerarin (AP), an acetylated derivative of puerarin, shows brain-protective  effects in animals.",Non-OADS,/arxiv_data1/oa_pdf/a7/d2/dddt-10-2029.PMC4922808.pdf
"To enhance oral bioavailability, some novel drug delivery systems have been  designed, including micelles, microspheres, liposomes, nanoemulsions, nanoparticles correspondence: Deqing sun Department of Pharmacy, the second  hospital of shandong University, 247  Beiyuan street, Jinan 250033, People’s  republic of china Tel +86 531 8587 5290 email sundq0405@126.co m Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Sun et al Running head recto: Enhanced oral bioavailability of AP by PLGA NPs DOI: http://dx.doi.org/10.2147/DDDT.S108185",Non-OADS,/arxiv_data1/oa_pdf/a7/d2/dddt-10-2029.PMC4922808.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/a7/d2/dddt-10-2029.PMC4922808.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/a7/d2/dddt-10-2029.PMC4922808.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/66/e9/copd-11-1391.PMC4922809.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2016:11 1391–1401International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1391RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/COPD.S10600 9 Lung inflammation caused by inhaled toxicants: a   review John Wong Bruce e Magun Lisa J wood School of Nursing, MGH Institute of  Health Professions, Boston, MA, USAAbstract:  Exposure of the lungs to airborne toxicants from different sources in the environment  may lead to acute and chronic pulmonary or even systemic inflammation.",Non-OADS,/arxiv_data1/oa_pdf/66/e9/copd-11-1391.PMC4922809.pdf
"Although these toxicants belong to the  different classes of chemicals, they nevertheless may activate similar biochemical Correspondence: John Wong School of Nursing, MGH Institute of  Health Professions, 36, 1st Street,  Boston, MA 02129, USA Tel +1 617 724 3623 Fax +1 617 952 6060 email jwong1@mghihp.ed u Journal name: International Journal of COPD Article Designation: Review Y ear: 2016 Volume: 11 Running head verso: Wong et al Running head recto: Lung inflammation by toxins DOI: http://dx.doi.org/10.2147/COPD.S106009",Non-OADS,/arxiv_data1/oa_pdf/66/e9/copd-11-1391.PMC4922809.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/66/e9/copd-11-1391.PMC4922809.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/66/e9/copd-11-1391.PMC4922809.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p  and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/ad/87/ceor-8-287.PMC4922810.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).ClinicoEconomics and Outcomes Research 2016:8 287–291ClinicoEconomics and Outcomes Research Dove press submit your manuscript | www.dovepress.co m Dove press  287ORiginal REsEaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CEOR.S7121 8is the routine use of bevacizumab in the treatment   of women with advanced or recurrent cancer of  the cervix sustainable?",Non-OADS,/arxiv_data1/oa_pdf/ad/87/ceor-8-287.PMC4922810.pdf
"ClinicoEconomics and Outcomes Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinicoeconomics-and-outcomes-research-journa lClinicoEconomics & Outcomes Research is an international, peer- reviewed open-access journal focusing on Health Technology Assess - ment, Pharmacoeconomics and Outcomes Research in the areas of  diagnosis, medical devices, and clinical, surgical and pharmacological  intervention.",Non-OADS,/arxiv_data1/oa_pdf/ad/87/ceor-8-287.PMC4922810.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/ad/87/ceor-8-287.PMC4922810.pdf
Available from: http://www.cms.gov/ Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrug- AvgSalesPrice /.,Non-OADS,/arxiv_data1/oa_pdf/ad/87/ceor-8-287.PMC4922810.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/6e/9c/ndt-12-1457.PMC4922811.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 1457–1466Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1457OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S10307 9Psychometric properties of the spanish version  of the clinical Outcomes in routine evaluation –  Outcome Measure adriana Trujillo,1,2 guillem  Feixas,1,2 arturo Bados,1  eugeni garcía-grau,1 Marta  salla,1 Joan carles Medina,1  adrián Montesano,1,2 José  soriano,3 leticia Medeiros- Ferreira,4 Josep cañete,5  sergi corbella,6 antoni  grau,7 Fernando lana,8  chris evans9 1Department of Personality,   assessment and Psychological  Treatments, Faculty of Psychology,   2institute for Brain, cognition and  Behaviour, University of Barcelona,   3hospital of the holy cross and  saint Paul, 4Nou Barris Mental  health center, Barcelona, 5hospital  of Mataró, sanitary consortium of  Maresme, Mataró, 6FPcee, Blanquerna,   Universitat ramon llull, 7institute of  eating Disorders, Barcelona, 8Mar  health Park, caeM il, santa coloma  de gramenet, spain; 9east london  Nhs Foundation Trust, NPDDNet,   london, UKObjective:  The objective of this paper is to assess the reliability and validity of the Spanish  translation of the Clinical Outcomes in Routine Evaluation – Outcome Measure, a 34-item self- report questionnaire that measures the client’s status in the domains of Subjective well-being,  Problems/Symptoms, Life functioning, and Risk.",Non-OADS,/arxiv_data1/oa_pdf/6e/9c/ndt-12-1457.PMC4922811.pdf
"The CORE-OM measure is copyleft; that is, it can be reproduced without payment  of any license fee if it is not changed in any way.2 Translations were done following the correspondence: guillem Feixas Department of Personality, assessment  and Psychological Treatments,  Faculty of Psychology, University of  Barcelona, Passeig Vall d’hebron, 171,  08035 Barcelona, spain Tel +34 93 312 5100 email gfeixas@ub.ed u Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Trujillo et al Running head recto: The Spanish version of the CORE-OM DOI: http://dx.doi.org/10.2147/NDT.S103079",Non-OADS,/arxiv_data1/oa_pdf/6e/9c/ndt-12-1457.PMC4922811.pdf
Available from: http://www.coresystemtrust.org.uk/copyright.,Non-OADS,/arxiv_data1/oa_pdf/6e/9c/ndt-12-1457.PMC4922811.pdf
"Available from: http://www.coresystemtrust.org.u k. Accessed  March 18, 2016.",OADS,/arxiv_data1/oa_pdf/6e/9c/ndt-12-1457.PMC4922811.pdf
"Available from: http://www.ub.edu/terdep/cor e. Accessed March 18,  2016.",Non-OADS,/arxiv_data1/oa_pdf/6e/9c/ndt-12-1457.PMC4922811.pdf
"Available from: https://www.coresystemtrust.org.uk/ cst-translation-polic y. Accessed March 18, 2016.",Non-OADS,/arxiv_data1/oa_pdf/6e/9c/ndt-12-1457.PMC4922811.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/6e/9c/ndt-12-1457.PMC4922811.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/6e/9c/ndt-12-1457.PMC4922811.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/81/75/jpr-9-445.PMC4922812.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/81/75/jpr-9-445.PMC4922812.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Pain Research  2016:9 445–451Journal of Pain Research Dovepress submit your manuscript | www.dovepress.com Dovepress  445 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JPR.S105766Tampa Scale of Kinesiophobia for Heart  T urkish Version Study: cross-cultural adaptation,  exploratory factor analysis, and reliability Serap Acar1  Sema Savci1  Pembe Keskino ğlu2  Bahri Akdeniz3  Ebru Özpelit3  Buse Özcan Kahraman1  Didem Karadibak1  Can Sevinc4 1School of Physical Therapy and  Rehabilitation, 2Department of  Biostatistics, Faculty of Medicine,   3Department of Cardiology, Faculty  of Medicine, 4Department of Chest  Disease, Faculty of Medicine, Dokuz  Eylul University, İzmir, T urkeyPurpose: Individuals with cardiac problems avoid physical activity and exercise because they  expect to feel shortness of breath, dizziness, or chest pain.",Non-OADS,/arxiv_data1/oa_pdf/81/75/jpr-9-445.PMC4922812.pdf
"1 However, poor participation and adherence to the programs  are growing problems for this population because of limited daily life activities.2   Worsening disease symptoms cause fear of movement and avoidance, resulting in  activity limitation.3 Most pulmonary arterial hypertension and heart failure patients Correspondence: Serap Acar   School of Physical Therapy and  Rehabilitation, Dokuz Eylul University, 35340 İnciralti, İzmir, Turkey  Tel +90 505 493 3762   Fax +90 232 412 4946   Email acarserap2@gmail.comJournal name: Journal of Pain Research  Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 9Running head verso: Acar et alRunning head recto: Tampa Scale of Kinesiophobia for Heart Turkish Version StudyDOI: http://dx.doi.org/10.2147/JPR.S105766",Non-OADS,/arxiv_data1/oa_pdf/81/75/jpr-9-445.PMC4922812.pdf
"Journal of Pain Research  2016:9submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Pain Research  Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/journal-of-pain-research-journal The Journal of Pain Research is an international, peer reviewed, open  access, online journal that welcomes laboratory and clinical findings   in the fields of pain research and the prevention and management of pain.",Non-OADS,/arxiv_data1/oa_pdf/81/75/jpr-9-445.PMC4922812.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 451 Tampa Scale of Kinesiophobia for Heart T urkish Version Study Disclosure The authors report no conflicts of interest in this work.,Non-OADS,/arxiv_data1/oa_pdf/81/75/jpr-9-445.PMC4922812.pdf
The full terms of this license are available at https://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/5b/e9/vhrm-12-269.PMC4922813.pdf
"com/terms.ph p and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/5b/e9/vhrm-12-269.PMC4922813.pdf
"For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Noninvasive FFR derived from coronary CT  angiography in the management of coronary  artery disease: technology and clinical update Rine Nakanishi Mathew J Budoff Los Angeles Biomedical Research  Institute, Harbor-UCLA Medical  Center, T orrance, CA, USA Correspondence: Mathew J Budoff   Los Angeles Biomedical Research  Institute, Harbor-UCLA Medical Center,  T orrance, CA 90502, USA   T el +1 310 222 4107   Fax +1 310 787 0448   Email mbudoff@labiomed.or gAbstract:  After a decade of clinical use of coronary computed tomographic angiography  (CCTA) to evaluate the anatomic severity of coronary artery disease, new methods of deriving  functional information from CCTA have been developed.",Non-OADS,/arxiv_data1/oa_pdf/5b/e9/vhrm-12-269.PMC4922813.pdf
"Vascular Health and Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/vascular-health-and-risk-management-journa lVascular Health and Risk Management is an international, peer- reviewed journal of therapeutics and risk management, focusing on  concise rapid reporting of clinical studies on the processes involved  in the maintenance of vascular health; the monitoring, prevention and  treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes.",Non-OADS,/arxiv_data1/oa_pdf/5b/e9/vhrm-12-269.PMC4922813.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/5b/e9/vhrm-12-269.PMC4922813.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p  and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/e7/be/ceor-8-293.PMC4922814.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).A structured review of health utility measures and  elicitation in advanced/metastatic breast cancer Yanni Hao1 Verena Wolfram2 Jennifer Cook2 1Novartis Pharmaceuticals, East  Hanover, NJ, USA; 2Adelphi Values,   Bollington, UK Correspondence: Jennifer Cook   Adelphi Values, Adelphi Mill, Bollington,  Macclesfield, Cheshire SK10 5JB, UK   T el +44 1625 577 256   Fax +44 1625 577 328   Email jennifer.cook@adelphivalues.co mBackground:  Health utilities are increasingly incorporated in health economic evaluations.",Non-OADS,/arxiv_data1/oa_pdf/e7/be/ceor-8-293.PMC4922814.pdf
"ClinicoEconomics and Outcomes Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinicoeconomics-and-outcomes-research-journa lClinicoEconomics & Outcomes Research is an international, peer- reviewed open-access journal focusing on Health Technology Assess - ment, Pharmacoeconomics and Outcomes Research in the areas of  diagnosis, medical devices, and clinical, surgical and pharmacological  intervention.",Non-OADS,/arxiv_data1/oa_pdf/e7/be/ceor-8-293.PMC4922814.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/e7/be/ceor-8-293.PMC4922814.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/c2/b7/ott-9-3705.PMC4922815.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3705–3710OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3705Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10046 0 correlation of primary middle and distal esophageal  cancers motion with surrounding tissues using  four-dimensional computed tomography Wei Wang1 Jianbin li1 Yingjie Zhang1 Qian shao1 Min Xu1 Bing guo1 Dongping shang2 1Department of radiation Oncology,   2Department of Big Bore cT room,   shandong cancer hospital affiliated  to shandong University, shandong  academy of Medical sciences, Jinan,   shandong, People’s republic of chinaPurpose:  To investigate the correlation of gross tumor volume (GTV) motion with the structure  of interest (SOI) motion and volume variation for middle and distal esophageal cancers using  four-dimensional computed tomography (4DCT).",Non-OADS,/arxiv_data1/oa_pdf/c2/b7/ott-9-3705.PMC4922815.pdf
"correspondence: Jianbin li Department of radiation Oncology  (chest section), shandong cancer  Hospital Affiliated to Shandong  University, shandong academy of Medical  sciences, road Jiyan 440, Jinan 250117,  shandong, People’s republic of china Tel/fax +86 531 6762 6130 email lijianbin@msn.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Wang et al Running head recto: Breathing motion and dosimetric impact DOI: http://dx.doi.org/10.2147/OTT.S100460",Non-OADS,/arxiv_data1/oa_pdf/c2/b7/ott-9-3705.PMC4922815.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/c2/b7/ott-9-3705.PMC4922815.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/c2/b7/ott-9-3705.PMC4922815.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/81/4b/ott-9-3683.PMC4922816.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3683–3694OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3683ORIGINAL RESEARCHopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OTT .S10515 8 Can GSTM1  and GSTT1  polymorphisms predict  clinical outcomes of chemotherapy in gastric and  colorectal cancers?",Non-OADS,/arxiv_data1/oa_pdf/81/4b/ott-9-3683.PMC4922816.pdf
"Unfortunately, many patients Correspondence: Wei Shi Office of Medical Statistics Cangzhou  Central Hospital, No 16 Xinhua West  Road, Yunhe District, Cangzhou 061001,  People’s Republic of China Tel +86 136 6317 8789 Email drweishi@163.co m  Lianli Zhao Human Resource Department, Cangzhou  Central Hospital, No 16 Xinhua West  Road, Yunhe District, Cangzhou 061001,  People’s Republic of China Tel +86 139 3272 1618 Email drllzhao@163.co m Journal name: OncoTargets and Therapy Article Designation: ORIGINAL RESEARCH Y ear: 2016 Volume: 9 Running head verso: Liu et al Running head recto: GSTs  polymorphisms and chemotherapy in gastrointestinal cancers DOI: http://dx.doi.org/10.2147/OTT.S105158",Non-OADS,/arxiv_data1/oa_pdf/81/4b/ott-9-3683.PMC4922816.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/81/4b/ott-9-3683.PMC4922816.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/81/4b/ott-9-3683.PMC4922816.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/53/34/ott-9-3799.PMC4922817.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 3799–3805OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  3799Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S9699 2expression of cD40 is a positive prognostic  factor of diffuse large B-cell lymphoma treated  with r-chOP (rituximab, cyclophosphamide,  doxorubicin, vincristine, and prednisone) guoqi song1 huiyun ni1 linqing Zou2 shukui Wang3 Fuliang Tian4 hong liu1 William c cho5 1Department of hematology, affiliated  hospital of nantong University,   nantong, 2Department of human  anatomy, nantong University,   nantong, 3central laboratory of  nanjing First hospital, nanjing  Medical University, nanjing,   4Maternal and child health hospital  of lianyungang, lianyungang,   Jiangsu, People’s republic of china;   5Department of clinical Oncology,   Queen elizabeth hospital, Kowloon,   hong KongObjectives:  The objective of this study was to investigate the expression level of CD40 and  its role in the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) who were  treated with rituximab-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and  prednisone).",Non-OADS,/arxiv_data1/oa_pdf/53/34/ott-9-3799.PMC4922817.pdf
"The IPI score is no longer considered to be the strongest prognostic indicator  in rituximab (R)-CHOP-treated patients, and a recent analysis revealed that it failed correspondence: hong liu Department of Hematology, Affiliated  hospital of nantong University,  room 6506, 5/F, 20 Xishi road, nantong,  Jiangsu, People’s republic of china Tel +86 187 6171 3399 Fax +86 512 8116 0506 email hongliu1963@163.co m  William c cho Department of clinical Oncology,  Queen elizabeth hospital, room 1305,  13/F, Block r, 30 gascoigne road,  Kowloon, hong Kong Tel +852 3506 5441 Fax +852 3506 5455 email williamcscho@gmail.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Song et al Running head recto: CD40 as a prognostic factor for DLBCL patients DOI: http://dx.doi.org/10.2147/OTT.S96992",Non-OADS,/arxiv_data1/oa_pdf/53/34/ott-9-3799.PMC4922817.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/53/34/ott-9-3799.PMC4922817.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/53/34/ott-9-3799.PMC4922817.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/5a/3c/prom-7-081.PMC4922818.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/5a/3c/prom-7-081.PMC4922818.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Patient Related Outcome Measures 2016:7 81–92Patient Related Outcome Measures Dovepress submit your manuscript | www.dovepress.com Dovepress 81 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PROM.S102647 Cultural adaptation: translatability  assessment and linguistic validation of the  patient‑reported outcome instrument for  irritable bowel syndrome with diarrhea Leticia Delgado ‑Herrera1 Kathryn Lasch2 Ana Popielnicki3 Akito Nishida4 Rob Arbuckle5 Benjamin Banderas6 Susan Zentner1 Ingrid Gagainis1 Bernhardt Zeiher1 1Astellas Pharma Global  Development, Northbrook, IL,   2Pharmerit International, Newton,   MA, USA; 3TransPerfect,  Linguistic  Validation Group, Boston, MA, USA;   4Development Project Management,   Astellas Pharma Inc, T okyo, Japan;   5Patient‑Centered Outcomes Adelphi  Values, Bollington, UK; 6Patient‑ Centered Outcomes Adelphi Values,   Boston, MA, USABackground and objective: Following a 2009 US Food and Drug Administration guidance,  a new patient-reported outcome (PRO) instrument was developed to support end points in  multinational clinical trials assessing irritable bowel syndrome with diarrhea (IBS-D) symptom  severity.",Non-OADS,/arxiv_data1/oa_pdf/5a/3c/prom-7-081.PMC4922818.pdf
"Keywords: stool consistency, stool-form scale, translatability, IBS-D PRO instrument Introduction Irritable bowel syndrome (IBS) is typically diagnosed using symptom-based diagnostic  criteria, such as the Rome III criteria for IBS.1,2 Upon diagnosis, IBS is often subtyped  into one of four categories, based on the predominant stool pattern: IBS with diarrhea Correspondence: Leticia  Delgado‑HerreraAstellas Pharma Global Development, 1 Astellas Way, Northbrook, IL 60062, USATel +1 224 205 5485Fax +1 224 205 5921Email Leticia.Delgado‑Herrera@astellas.comJournal name: Patient Related Outcome Measures Article Designation: ORIGINAL RESEARCHY ear: 2016V olume: 7Running head verso: Delgado-Herrera et alRunning head recto: Linguistic validation of PRO instrument for IBS-DDOI: http://dx.doi.org/10.2147/PROM.S102647",Non-OADS,/arxiv_data1/oa_pdf/5a/3c/prom-7-081.PMC4922818.pdf
Available from: http://www.romecriteria   .org/assets/pdf/19_RomeIII_apA_885-898.pdf.,Non-OADS,/arxiv_data1/oa_pdf/5a/3c/prom-7-081.PMC4922818.pdf
"Patient Related Outcome Measures 2016:7submit your manuscript | www.dovepress.com Dovepress Dovepress Patient Related Outcome Measures Publish your work in this journal Submit your manuscript here: http://www.dovepress.com/patient‑related‑outcome‑measures‑journalPatient Related Outcome Measures is an international, peer-reviewed,  open access journal focusing on treatment outcomes specifically relevant to patients.",Non-OADS,/arxiv_data1/oa_pdf/5a/3c/prom-7-081.PMC4922818.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/5a/3c/prom-7-081.PMC4922818.pdf
Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf.,Non-OADS,/arxiv_data1/oa_pdf/5a/3c/prom-7-081.PMC4922818.pdf
Available from: http://www.theguardian.com/us-news/2015/jun/29/us-second-biggest-spanish-speaking-country.,Non-OADS,/arxiv_data1/oa_pdf/5a/3c/prom-7-081.PMC4922818.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/5c/ca/cmar-8-077.PMC4922819.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/5c/ca/cmar-8-077.PMC4922819.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Cancer Management and Research 2016:8 77–82Cancer Management and Research Dovepress submit your manuscript | www.dovepress.com Dovepress  77 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CMAR.S93620Fosaprepitant dimeglumine for the management  of chemotherapy-induced nausea and vomiting:  patient selection and perspectives Nellowe Candelario Marvin Louis Roy Lu Department of Medicine, Einstein  Medical Center, Philadelphia, PA, USAAbstract:  Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of  antineoplastic agents.",Non-OADS,/arxiv_data1/oa_pdf/5c/ca/cmar-8-077.PMC4922819.pdf
"3,6 The introduction of neurokinin inhibi- tors has greatly improved the ability to prevent and treat persistent CINV in patients Correspondence: Nellowe Candelario Department of Medicine, Einstein Medical Center, 5501 Old York Road, Philadelphia, PA 19141, USATel +1 267 858 5508Email candelan@einstein.eduJournal name: Cancer Management and Research Article Designation: REVIEWY ear: 2016V olume: 8Running head verso: Candelario and LuRunning head recto: Fosaprepitant for the management of CINVDOI: http://dx.doi.org/10.2147/CMAR.S93620",Non-OADS,/arxiv_data1/oa_pdf/5c/ca/cmar-8-077.PMC4922819.pdf
Available from: http://cdc.gov/.,OADS,/arxiv_data1/oa_pdf/5c/ca/cmar-8-077.PMC4922819.pdf
"Cancer Management and Research 2016:8submit your manuscript | www.dovepress.com Dovepress Dovepress Cancer Management and Research Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/cancer-management-and-research-journalCancer Management and Research is an international, peer-reviewed  open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/5c/ca/cmar-8-077.PMC4922819.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 82 Candelario and Lu  3.,Non-OADS,/arxiv_data1/oa_pdf/5c/ca/cmar-8-077.PMC4922819.pdf
